AUTHOR INDEX

Aapro MS, *see* Hesketh PJ
Aarhus Lung Cancer Group, *see* Work E
Aaronson NK, *see* Sneeuw KCA
Abate M, *see* Carella AM
Abbruzzese JL, *see* Lenzi R
— *see* Pazdur R
— *see* Rich TA
— *see* Spitz FR
Abbruzzese MC, *see* Lenzi R
Abe S, *see* Oshita F
Abigerges D, *see* Merrouche Y
Abramson N, *see* Fisher B
Abratt RP, Bezwoda WR, Goedhals L, Hacking DJ. Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non–small-cell lung cancer, 744
Abu-Ghazaleh S, *see* Loprinzi CL
Abu-Zahra H, *see* Pritchard KI
Acimovic L, *see* Jeremic B
Acuña JR, *see* Lacava JA
Acuña LR, *see* Lacava JA
Adamkiewicz BB, *see* Livingston RB
Adamo V, *see* Crinò L
Adams G, *see* Connors JM
Adams H-P, *see* Beyermann B
Adams T, *see* Kurzrock R
Adamson PC, Reaman G, Finklestein JZ, Feusner J, Berg SL, Blaney SM, O'Brien M, Murphy RF, Balis FM. Phase I trial and pharmacokinetic study of all-*trans*-retinoic acid administered on an intermittent schedule in combination with interferon-α2a in pediatric patients with refractory cancer, 3330
— *see* Blaney SM
— *see* Widemann BC
Adenis A, *see* Rougier P
Adkins D, *see* Brown RA
Adkins DR, Brown RA, DiPersio JF. Granulocyte-macrophage colony-stimulating factor with induction treatment of acute myelogenous leukemia (letter), 862
Aghajanian C, *see* Fennelly D
Ahlert T, Sauerbrei W, Bastert G, Ruhland S, Bartik B, Simiantonaki N, Schumacher J, Häker B, Schumacher M, Schirrmacher V. Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer, 1354
Ahmed T, *see* Seiter K
— *see* Vose JM
AIDS Clinical Trials Group Oncology Committee, *see* Krown SE
Aisner J, *see* Maurer LH
Aisner SC, *see* Loehrer PJ Sr
Akerley W. Two doses of paclitaxel and statistical analysis: Try, try, try again (letter), 408
— *see* Safran H
Akiba S, *see* Imazono Y
Akiyama H, *see* Kajiyama Y
Akiyama S-I, *see* Imazono Y
Akporiaye ET, *see* Stopeck AT
Alba E, *see* Rueda A
Alberti D, *see* Berlin J
— *see* Robins HI
Albitar M, *see* Jung FA
Alessandroni P, *see* Cascinu S
Alexanian R, *see* Giralt S
Allegra CJ, *see* Pestalozzi BC
— *see* Takimoto CH
Allen-Mersh TG, *see* Earlam S
Allman DS, *see* Kris MG
Allred DC, *see* Elledge RM
Alpaugh RK, *see* Giantoni BJ
Al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, Cooper J, Byhardt R, Davis L, Emami B. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: An Intergroup study, 277
Altavilla G, *see* Crinò L
Altehoefer C, Blum U, Bathmann J, Wüstenberg C, Uhrmeister P, Laubenberger J, Lange W, Schwarzkopf J, Moser E, Langer M. Comparative diagnostic accuracy of magnetic resonance imaging and immunoscintigraphy for detection of bone marrow involvement in patients with malignant lymphoma, 1754
Altenhein E, *see* Safran H
Althausen AF, *see* Kachnic LA
Alvarez RD, *see* O'Reilly S
Amato S, *see* Lacava JA
Amaya H, *see* Tanigawa N
Amaya S, *see* Omura K
American Society of Clinical Oncology. The physician and unorthodox cancer therapies, 401
Amess J, *see* Slater S
Amylon MD, *see* Kusnierz-Glaz CR
Andersen J, *see* Burris HA III
Andersen JE, *see* Jakobsen A
Andersen JW, *see* Clark JR
Anderson B, *see* Omura GA
Anderson J, *see* Tempero M
Anderson JE, *see* Vose JM
Anderson JR, *see* Bierman PJ
— *see* Bishop MR
— *see* Raney RB
Anderson S, *see* Fisher B
— *see* McQuaker IG
— *see* Murren JR
Andersson B, *see* Giralt S
Andolenko P, *see* Ganem G
Andreeff M, *see* Kornblau SM
— *see* Younes A
Andreola S, *see* Pastorino U
Andrieu J-M, *see* Colonna P
Andrykowski MA, Lightner R, Studts JL, Munn RK. Hereditary cancer risk notification and testing: How interested is the general population? 2139
Angelini F, *see* Nicoletto MO
Angelucci E, *see* Locatelli F
Ansell SM, Habermann TM, Kurtin PJ, Witzig TE, Chen MG, Li CY, Inwards DJ, Colgan JP. Predictive capacity of the international prognostic factor index in patients with peripheral T-cell lymphoma, 2296

AUTHOR INDEX

Aapro MS, *see* Hesketh PJ
Aarhus Lung Cancer Group, *see* Work E
Aaronson NK, *see* Sneeuw KCA
Abate M, *see* Carella AM
Abbruzzese JL, *see* Lenzi R
— *see* Pazdur R
— *see* Rich TA
— *see* Spitz FR
Abbruzzese MC, *see* Lenzi R
Abe S, *see* Oshita F
Abigerges D, *see* Merrouche Y
Abramson N, *see* Fisher B
Abratt RP, Bezwoda WR, Goedhals L, Hacking DJ. Weekly gemcitabine with monthly cisplatin: Effective chemotherapy for advanced non–small-cell lung cancer, 744
Abu-Ghazaleh S, *see* Loprinzi CL
Abu-Zahra H, *see* Pritchard KI
Acimovic L, *see* Jeremic B
Acuña JR, *see* Lacava JA
Acuña LR, *see* Lacava JA
Adamkiewicz BB, *see* Livingston RB
Adamo V, *see* Crinò L
Adams G, *see* Connors JM
Adams H-P, *see* Beyermann B
Adams T, *see* Kurzrock R
Adamson PC, Reaman G, Finklestein JZ, Feusner J, Berg SL, Blaney SM, O'Brien M, Murphy RF, Balis FM. Phase I trial and pharmacokinetic study of all-*trans*-retinoic acid administered on an intermittent schedule in combination with interferon-α2a in pediatric patients with refractory cancer, 3330
— *see* Blaney SM
— *see* Widemann BC
Adenis A, *see* Rougier P
Adkins D, *see* Brown RA
Adkins DR, Brown RA, DiPersio JF. Granulocyte-macrophage colony-stimulating factor with induction treatment of acute myelogenous leukemia (letter), 862
Aghajanian C, *see* Fennelly D
Ahlert T, Sauerbrei W, Bastert G, Ruhland S, Bartik B, Simiantonaki N, Schumacher J, Häker B, Schumacher M, Schirrmacher V. Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer, 1354
Ahmed T, *see* Seiter K
— *see* Vose JM
AIDS Clinical Trials Group Oncology Committee, *see* Krown SE
Aisner J, *see* Maurer LH
Aisner SC, *see* Loehrer PJ Sr
Akerley W. Two doses of paclitaxel and statistical analysis: Try, try, try again (letter), 408
— *see* Safran H
Akiba S, *see* Imazono Y
Akiyama H, *see* Kajiyama Y
Akiyama S-I, *see* Imazono Y
Akporiaye ET, *see* Stopeck AT
Alba E, *see* Rueda A
Alberti D, *see* Berlin J
— *see* Robins HI
Albitar M, *see* Jung FA
Alessandroni P, *see* Cascinu S
Alexanian R, *see* Giralt S
Allegra CJ, *see* Pestalozzi BC
— *see* Takimoto CH
Allen-Mersh TG, *see* Earlam S
Allman DS, *see* Kris MG
Allred DC, *see* Elledge RM
Alpaugh RK, *see* Giantoni BJ
Al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, Cooper J, Byhardt R, Davis L, Emami B. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: An Intergroup study, 277
Altavilla G, *see* Crinò L
Altehoefer C, Blum U, Bathmann J, Wüstenberg C, Uhrmeister P, Laubenberger J, Lange W, Schwarzkopf J, Moser E, Langer M. Comparative diagnostic accuracy of magnetic resonance imaging and immunoscintigraphy for detection of bone marrow involvement in patients with malignant lymphoma, 1754
Altenhein E, *see* Safran H
Althausen AF, *see* Kachnic LA
Alvarez RD, *see* O'Reilly S
Amato S, *see* Lacava JA
Amaya H, *see* Tanigawa N
Amaya S, *see* Omura K
American Society of Clinical Oncology. The physician and unorthodox cancer therapies, 401
Amess J, *see* Slater S
Amylon MD, *see* Kusnierz-Glaz CR
Andersen J, *see* Burris HA III
Andersen JE, *see* Jakobsen A
Andersen JW, *see* Clark JR
Anderson B, *see* Omura GA
Anderson J, *see* Tempero M
Anderson JE, *see* Vose JM
Anderson JR, *see* Bierman PJ
— *see* Bishop MR
— *see* Raney RB
Anderson S, *see* Fisher B
— *see* McQuaker IG
— *see* Murren JR
Andersson B, *see* Giralt S
Andolenko P, *see* Ganem G
Andreeff M, *see* Kornblau SM
— *see* Younes A
Andreola S, *see* Pastorino U
Andrieu J-M, *see* Colonna P
Andrykowski MA, Lightner R, Studts JL, Munn RK. Hereditary cancer risk notification and testing: How interested is the general population? 2139
Angelini F, *see* Nicoletto MO
Angelucci E, *see* Locatelli F
Ansell SM, Habermann TM, Kurtin PJ, Witzig TE, Chen MG, Li CY, Inwards DJ, Colgan JP. Predictive capacity of the international prognostic factor index in patients with peripheral T-cell lymphoma, 2296

Antin JH, *see* Collins RH Jr
Antman KH, Rowlings PA, Vaughan WP, Pelz CJ, Fay JW, Fields KK, Freytes CO, Gale RP, Hillner BE, Holland HK, Kennedy MJ, Klein JP, Lazarus HM, McCarthy PL Jr, Saez R, Spitzer G, Stadtmauer EA, Williams SF, Wolff S, Sobocinski KA, Armitage JO, Horowitz MM. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America, 1870
Apolinario RM, van der Valk P, de Jong JS, Deville W, van Ark-Otte J, Dingemans A-MC, van Mourik JC, Postmus PE, Pinedo HM, Giaccone G. Prognostic value of the expression of p53, *bcl*-2, and *bax* oncoproteins, and neovascularization in patients with radically resected non–small-cell lung cancer, 2456
Appelbaum FR, *see* Demirer T
Arai Y, Kawakita M, Okada Y, Yoshida O. Sexuality and fertility in long-term survivors of testicular cancer, 1444
Aranguren PN, *see* Pavlovsky S
Arbuck SG, *see* Pazdur R
— *see* Takimoto CH
Ardaiz MC, *see* Pavlovsky S
Ardiet J-M, *see* Romestaing P
Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, Giaccone G, Schaefer B, Wanders J, Verweij J for the European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease, 2090
Aricò M, Masera G. Cytoreduction and prognosis in childhood acute lymphoblastic leukemia (letter), 1285
Aricó M, *see* Conter V
Arikian S, *see* McGuire W
Ariniello PD, *see* Lynch TJ Jr
Armand J-P, *see* Merrouche Y
Armata J, *see* Balwierz W
Armitage GR, *see* Pritchard KI
Armitage JO, *see* Antman KH
— *see* Bierman PJ
— *see* Bishop MR
— *see* Pavletic ZS
Armitage R, *see* Younes A
Armstrong DK, *see* O'Reilly S
Arribas R, Capellà G, Tórtola S, Masramon L, Grizzle WE, Perucho M, Peinado MA. Assessment of genomic damage in colorectal cancer by DNA fingerprinting: Prognostic applications, 3230
Arroyo A, *see* Lacava JA
Arthur DC, *see* Byrd JC
— *see* Slack JL
— *see* Stock W
Aruga A, *see* Chang AE
Arzoomanian RZ, *see* Berlin J
— *see* Robins HI
Aschele C, *see* Sobrero AF
Ascunce N, *see* Viladiu P
Ash RC, *see* Szydlo R
Ashley S, *see* Shankar AG
Ashour AA, Verschraegen CF, Kudelka AP, Kavanagh JJ. Paraneoplastic syndromes of gynecologic neoplasms, 1272
Asmar L, *see* Rahman ZU
— *see* Raney RB
Asou N, *see* Ohno R
Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Groups, *see* Conter V
Atiba JO, Meyskens FL Jr. Correction—Malignant glioma (letter), 1286
Atkins CD. Guidelines for the use of carcinoembryonic antigen in colorectal cancer (letter), 863
Atkins JN, *see* Fisher B
Atkins MB, *see* Du Bois JS
— *see* Hillner BE
Attal M, *see* Moreau P
August D, *see* Merajver SD
Augustine S, *see* Tempero M
Australian-New Zealand Breast Cancer Trials Group, *see* Byrne MJ
Avalos BR, *see* Copelan EA
Avet-Loiseau H, *see* Rubie H
Avramis VI, *see* Dinndorf PA
Awada A, *see* Piccart MJ
Ayash L, *see* Shapiro CL
Ayoub J-P, North L, Greer J, Cabanillas F, Younes A. Pulmonary changes in patients with lymphoma who receive paclitaxel (letter), 2476

Bacchini P, *see* Picci P
Bacci G, *see* Picci P
Bach FH, *see* Szydlo R
Bacus S, *see* Levine EA
Baer D, *see* Horning SJ
Baer MR, *see* Byrd JC
— *see* Wetzler M
Bagshawe KD, *see* Bower M
Bagwell C, *see* Heyn R
— *see* Raney RB
Bailey FA, *see* Isaacs C
Bajorin DF, Bosl GJ. Bleomycin in germ cell tumor therapy: Not all regimens are created equal (editorial), 1717
— *see* McCaffrey JA
— *see* Motzer RJ
— *see* Xiao H
Bajorunas DR, *see* Petrek JA
Baker SD, *see* O'Reilly S
Baker TW, *see* Kris MG
Bakker PJM, *see* Huizing MT
— *see* Rijks LJM
Balch CM, *see* Buzaid AC
Baldini E, *see* Conte PF
Baldisseri M, *see* Edwards RP
Balena R, *see* Delmas PD
Balis FM, *see* Adamson PC
— *see* Blaney SM
— *see* Widemann BC
Ballard WP, *see* Pazdur R
Balwierz W, Armata J, Skoczeń S, Strojny W. Can prophy-

lactic CNS radiotherapy be omitted in high-risk childhood acute lymphoblastic leukemia? (letter), 3024
Balzarotti M, *see* Bonfante V
Band RA, *see* Takimoto CH
Banerjee M, *see* Wood DP Jr
Baranda J, *see* Leichman CG
Baranzelli MC, *see* Rubie H
Barbieri E, *see* Picci P
Barbui T, *see* Vitolo U
Barcos M, *see* Budman DR
— *see* Wetzler M
Bardet E, *see* Ganem G
Bardonnet-Comte M, *see* Pujol J-L
Bardou VJ, *see* Stoppa AM
Barge R, *see* Pawson R
Bariffi F, *see* Castaldo G
Barlogie B, *see* Tricot G
Barnes P, *see* Forsyth PAJ
Barni S, *see* Cascinu S
Barosi G, *see* Liberato NL
Barr FG, *see* Kelly KM
Barra E, *see* Castaldo G
Barrett A, *see* Shankar AG
Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, Peiffert D, van Glabbeke M, Pierart M. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups, 2040
—, Rubens RD, van der Schueren E, Sylvester R. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: A European Organization for Research and Treatment of Cancer randomized phase III trial, 207
Bartels H, *see* Loeffler M
Bartik B, *see* Ahlert T
Barton C, Lemoine N. Antisense oligonucleotides targeting p53 (letter), 408
Basso G, *see* Conter V
— *see* De Zen L
— *see* Tonini GP
Bast RC Jr. In reply (letter), 864
— In reply (letter), 2175
Bastert G, *see* Ahlert T
Bastian AW, *see* Longo DL
Bastion Y, Blay J-Y, Divine M, Brice P, Bordessoule D, Sebban C, Blanc M, Tilly H, Lederlin P, Deconinck E, Salles B, Dumontet C, Brière J, Coiffier B. Elderly patients with aggressive non-Hodgkin's lymphoma: Disease presentation, response to treatment, and survival—A Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years, 2945
—, Sebban C, Berger F, Felman P, Salles G, Dumontet C, Bryon PA, Coiffier B. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients, 1587
— *see* Brice P
— *see* Haioun C
— *see* Österborg A
— *see* Thieblemont C
— *see* Warzocha K
Bathmann J, *see* Altehoefer C
Bauer C, *see* Nag S
Bauer J, *see* Leyvraz S
Bauer KS, *see* Kohn EC
Baum ES, *see* Provisor AJ
Bauman G, *see* Leighton C
Bay JO, *see* Legros M
Bayer R, *see* Stiff PJ
Bayerdörffer E, *see* Rudolph B
Beach KJ, *see* Isaacs C
Beard CJ, Propert KJ, Rieker PP, Clark JA, Kaplan I, Kantoff PW, Talcott JA. Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: A prospective multiinstitutional outcomes study, 223
Bechtel TP, *see* Copelan EA
Beck D, *see* Coze C
Beck T, *see* Hesketh PJ
Becouarn Y, *see* Rougier P
Becton DL, *see* Stine KC
Bedenne L, *see* de Gramont A
Bedikian A, *see* Buzaid AC
Begent RHJ, *see* Bower M
Béhar C, *see* Coze C
Behm FG, *see* Rubnitz JE
— *see* Weiner MA
Beidler D, *see* Murren JR
Beijnen JH, *see* Huizing MT
Beinfield M, *see* Haffty BG
Belinson J, *see* Markman M
Bella MA, *see* Passalacqua R
Belliveau D, *see* Murren JR
Belzile M, *see* Suarez-Almazor ME
Bénard J, *see* Rubie H
Benassi MS, *see* Picci P
Bender-Götze C, *see* Locatelli F
Benedetti FM, *see* Miller VA
Benedict WF, *see* Majlis A
Benjamin RS, *see* Buzaid AC
— *see* Patel SR
— *see* Pisters PWT
Bennett CL, *see* Waters TM
Benoit Y, *see* Thyss A
Bensinger WI, *see* Demirer T
Benson AB III, *see* Tepper JE
Bentz JS, *see* Faigel DO
Bentzen SM, *see* Work E
Benvenuto F, *see* Carella AM
Berardo M, *see* Elledge RM
Berd D, Maguire HC Jr, Schuchter LM, Hamilton R, Hauck WW, Sato T, Mastrangelo MJ. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases, 2359
Berg SL, *see* Adamson PC
— *see* Blaney SM
Bergan RC, *see* Dawson NA
Berger F, *see* Bastion Y
— *see* Thieblemont C

Berger MS, *see* Shaw DWW
Bergeron C, *see* Coze C
— *see* Rubie H
Berg-Johnsen J, *see* Lote K
Bergmann OJ, Mogensen SC, Ellermann-Eriksen S, Ellegaard J. Acyclovir prophylaxis and fever during remission-induction therapy of patients with acute myeloid leukemia: A randomized, double-blind, placebo-controlled trial, 2269
Berlin J, Tutsch KD, Hutson P, Cleary J, Rago RP, Arzoomanian RZ, Alberti D, Feierabend C, Wilding G. Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor, 781
Berlin-Frankfurt-Münster Study Group, *see* Beyermann B
Berman ML, *see* Omura GA
Bernard A, *see* Caillot D
Bernard JL, *see* Coze C
Bernasconi C, *see* Lazzarino M
Bernaudin F, *see* Michel G
Bernstein L, *see* Press MF
Bernstein SH, *see* Wetzler M
Berry C, *see* McKeage MJ
Bertelli G, *see* Del Mastro L
Bertelsen K, *see* Jakobsen A
Berthaud P, *see* Pujol J-L
Berthelot J-M, *see* Evans WK
Bertini M, *see* Vitolo U
Bertino J, *see* Kelsen DP
Bertino JR, *see* Sobrero AF
Bertoni F, *see* Picci P
Bertrand Y, *see* Thyss A
Besa EC. Is minimal residual disease in the peripheral-blood stem-cell transplantation of chronic myelogenous leukemia important? (letter), 3166
Bessell EM, *see* McQuaker IG
Betcher DL, *see* Provisor AJ
Betts E, *see* Stahel RA
Beveridge RA, *see* Chan DW
— *see* Vose JM
Beyermann B, Adams H-P, Henze G for the Berlin-Frankfurt-Münster Study Group. Philadelphia chromosome in relapsed childhood acute lymphoblastic leukemia; A matched-pair analysis, 2231
Bezwoda WR, *see* Abratt RP
— *see* Moreau P
Biadi O, *see* Conte PF
Bianchine JR, *see* Swain SM
Bichisao E, *see* Passalacqua R
Bienvenu J, *see* Warzocha K
Bierhorst FJ, *see* Huizing MT
Bierman PJ, Vose JM, Anderson JR, Bishop MR, Kessinger A, Armitage JO. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma, 445
— *see* Bishop MR
— *see* Pavletic ZS
— *see* Vose JM
Bignami P, *see* Costa A
Bigner S, *see* Slack JL
Bijnens L, *see* Clahsen PC
Birkhofer MJ, *see* Huizing MT
Biron P, *see* Haioun C
Bishop JF, *see* Millward MJ
Bishop MR, Tarantolo SR, Jackson JD, Anderson JR, Schmit-Pokorny K, Zacharias D, Pavletic ZS, Pirruccello SJ, Vose JM, Bierman PJ, Warkentin PI, Armitage JO, Kessinger A. Allogeneic-blood stem-cell collection following mobilization with low-dose granulocyte colony-stimulating factor, 1601
— *see* Bierman PJ
— *see* Iversen PL
— *see* Pavletic ZS
Bisogno G, *see* De Zen L
Blaise D, *see* Stoppa AM
Blake P, *see* Gore M
Blanc C, *see* Millward MJ
— *see* Pronk LC
Blanc M, *see* Bastion Y
Bland K, *see* Safran H
Blaney SM, Seibel NL, O'Brien M, Reaman GH, Berg SL, Adamson PC, Poplack DG, Krailo MD, Mosher R, Balis FM. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: A collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial, 1538
— *see* Adamson PC
Blanke CD, Kasimis B, Schein P, Capizzi R, Kurman M. Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer, 915
Blattler WA, *see* Lynch TJ Jr
Blay J-Y, *see* Bastion Y
Blazar BR, *see* Davies SM
Blessing JA, *see* Omura GA
Blijham GH, *see* Lalisang RI
Block AMW, *see* Wetzler M
Blomqvist C, *see* Saarto T
Bloomfield CD, *see* Byrd JC
— *see* Slack JL
— *see* Stock W
— *see* Wetzler M
Blum U, *see* Altehoefer C
Blume KG, *see* Kusnierz-Glaz CR
Blumenson L, *see* Wetzler M
Blumer JL, *see* Marx CM
Blumgart LH, *see* Fong Y
Bocchino ML, *see* Castaldo G
Bodis S, Kraus MD, Pinkus G, Silver B, Kadin ME, Canellos GP, Shulman LN, Tarbell NJ, Mauch PM. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease, 3060
Bodkin DJ, *see* Maloney DG
Boehn A, *see* Wendum D
Boer GJ, *see* Rijks LJM
Boerman OC, *see* Steffens MG
Boerrigter L, *see* Rodenhuis S
Bogliun G, *see* Cavaletti G
Böhling T, *see* Picci P
Bohnenstengel F, *see* Busse D
Bokemeyer C, Nowak P, Haupt A, Metzner B, Köhne H, Hartmann JT, Kanz L, Schmoll H-J. Treatment of brain metastases in patients with testicular cancer, 1449

Boku N, *see* Shirao K
Bolis G, Favalli G, Danese S, Zanaboni F, Mangili G, Scarabelli C, Tateo S, Valsecchi MG, Scarfone G, Richiardi G, Frigerio L, Melpignano M, Villa A, Parazzini F. Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer, 1938
— *see* ten Bokkel Huinink W
Bolliger C, *see* Levine EA
Bonadonna G, *see* Bonfante V
— *see* Gianni AM
— *see* Gianni L
Bonfante V, Santoro A, Viviani S, Devizzi L, Balzarotti M, Soncini F, Zanini M, Valagussa P, Bonadonna G. Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD, 528
—, Viviani S, Bonadonna G. In reply (letter), 3022
Boni L, *see* Tonini GP
Bonichon F, *see* Guillou L
Bonneterre J, *see* Rougier P
Bonnin A, *see* Caillot D
Bono B, *see* Witte RS
Bonomi AE, *see* Brady MJ
Bontenbal M, *see* Piccart MJ
Boogaerts MA, *see* Löwenberg B
— *see* Smith TJ
Bookman MA, *see* O'Reilly S
Borbas C, *see* Guadagnoli E
Bordessoule D, *see* Bastion Y
Bordigoni P, *see* Coze C
Bornstein RS, *see* Fisher B
Borowitz M, *see* Winick N
Bosch F-X, *see* Viladiu P
Bosco S, *see* De Zen L
Bosl GJ, *see* Bajorin DF
— *see* McCaffrey JA
— *see* Motzer RJ
— *see* Xiao H
Bosly A, *see* Haioun C
Bosset JF, *see* Bartelink H
Bosset J-F, *see* de Gramont A
Bostrom BC, *see* Uckun FM
Boswell W, *see* Leichman CG
Bottalico C, *see* De Lena M
Bottiglieri T, *see* Quinn CT
Botto B, *see* Vitolo U
Bouabdallah R, *see* Stoppa AM
— *see* Wendum D
Bouché O, *see* de Gramont A
Boutard P, *see* Thyss A
Bow EJ, Loewen R, Cheang MS, Shore TB, Rubinger M, Schacter B. Cytotoxic therapy–induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults, 2254
Bower M, Newlands ES, Holden L, Short D, Brock C, Rustin GJS, Begent RHJ, Bagshawe KD. EMA/CO for high-risk gestational trophoblastic tumors: Results from a cohort of 272 patients, 2636
— *see* Dark GG
Bowling K, *see* O'Reilly S
Bowman D, *see* Pritchard KI
Bowman WP, *see* Farrow AC
— *see* Winick N
Boyd N, *see* Pritchard KI
Boyett J, *see* Hudson MM
Boyett JM, *see* Gajjar A
— *see* Rubnitz JE
— *see* Wilimas JA
Brach del Prever A, *see* Picci P
Bracy D, *see* Tricot G
Bradley BA, *see* Szydlo R
Bradof JE, *see* Pazdur R
Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G. Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument, 974
Braman G, *see* Lynch TJ Jr
Bramwell VHC, *see* Pritchard KI
Brandi M, *see* De Lena M
Brandt DS, *see* Salloum E
Brasher P, *see* Forsyth PAJ
Brecher ML, *see* Weiner MA
Bregni M, *see* Gianni AM
Brehm T, *see* Meisenberg BR
Bremond A, *see* Delmas PD
Breneman JC, *see* Raney RB
Brennan M, *see* Giuliano AE
Brennan MF, *see* Casper ES
— *see* Fong Y
— *see* Heslin MJ
— *see* Lewis JJ
Brett C, *see* Scher HI
Brice P, Bastion Y, Lepage E, Brousse N, Haïoun C, Moreau P, Straetmans N, Tilly H, Tabah I, Solal-Céligny P for the Groupe d'Etude des Lymphomes de l'Adulte. Comparison in low–tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe D'Etude des Lymphomes Folliculaires, 1110
— *see* Bastion Y
— *see* Haioun C
Brière J, *see* Bastion Y
— *see* Haioun C
Brigato G, *see* Nicoletto MO
Brindle JS, *see* Al-Sarraf M
Broadwater GJL, *see* Halperin EC
Brock C, *see* Bower M
Brock P, *see* Thyss A
Brodowicz T, Kotz R, Wiltschke C, Zielinski CC, Ritschl P. Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial, 2174
Brodsky I, *see* Marks DI
Broom C, *see* Creemers GJ
— *see* ten Bokkel Huinink W
Brousse N, *see* Brice P
Brown A, *see* Fisher B
Brown BW, *see* Horning SJ
Brown JE, *see* Georgiadis MS

Brown R, Buckley R, Kelley M. Pancreatic panniculitis, 3418
Brown RA, Adkins D, Goodnough LT, Haug JS, Todd G, Wehde M, Hendricks D, Ehlenbeck C, Laub L, DiPersio J. Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies, 3067
— *see* Adkins DR
Brown S, *see* Rustin GJS
Brown TD, *see* Whitehead RP
Browne V, *see* Johansen MJ
Bruckner HW, *see* Kamthan AG
Bruera E, *see* Suarez-Almazor ME
Brundage MD, Davidson JR, Mackillop WJ. Trading treatment toxicity for survival in locally advanced non–small-cell lung cancer, 330
—, Groome PA, Feldman-Stewart D, Davidson JR, Mackillop WJ. Decision analysis in locally advanced non–small-cell lung cancer: Is it useful? 873
Brunet P, *see* Rougier P
Bruno R, *see* Millward MJ
— *see* Pronk LC
Bruno S, *see* Pavlovsky S
Bruzzi P, *see* Tonini GP
Bryon PA, *see* Bastion Y
Buchanan GR, *see* Farrow AC
— *see* Winick N
Buckley JD, *see* Van Tornout JM
Buckley R, *see* Brown R
Buckman RA, *see* Pritchard KI
Buckner CD, *see* Demirer T
Buckner JC, *see* Galanis E
Budd GT, *see* Russell CA
Budman DR, Petroni GR, Johnson JL, Cooper MR, Schlossman DM, Barcos M, Peterson BA. Phase II trial of docetaxel in non-Hodgkin's lymphomas: A study of the Cancer and Leukemia Group B, 3275
Bugat R, *see* Merrouche Y
— *see* Rougier P
Bugazia N, *see* Ippoliti C
Bui NB, *see* Guillou L
Buijs A, *see* Rubnitz JE
Buijs WCAM, *see* Steffens MG
Bukowski R, *see* Glaspy J
Bull C, *see* Sorensen K
Bunjes D, *see* Österborg A
Buonadonna A, *see* Frustaci S
Burdach S, *see* Locatelli F
Burger D, *see* Scheithauer W
Burgess MA, *see* Patel SR
Burghouts J, *see* Gregor A
Burghouts JTh, *see* Lalisang RI
Burki F, *see* Rougier P
Burnett A, *see* Muggia FM
Burns BF, *see* Connors JM
Burns CP, *see* Heckman KD
Burris HA, *see* Creemers GJ
Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial, 2403
Burstein HJ, Janicek MJ, Skarin AT. Hypertrophic osteoarthropathy, 2759
Burt M, Motzer R, Sheinfeld J. In reply (letter), 409
Burtness BA, *see* Murren JR
Busch FW, *see* Busse D
Buskirk SJ, *see* McGinnis WL
Busse D, Busch FW, Bohnenstengel F, Eichelbaum M, Fischer P, Opalinska J, Schumacher K, Schweizer E, Kroemer HK. Dose escalation of cyclophosphamide in patients with breast cancer: Consequences for pharmacokinetics and metabolism, 1885
Busse PM, *see* Clark JR
Buyse M, *see* Pastorino U
Buzaid AC. In reply (letter), 3026
—, Ross MI, Balch CM, Soong S-J, McCarthy WH, Tinoco L, Mansfield P, Lee JE, Bedikian A, Eton O, Plager C, Papadopoulos N, Legha SS, Benjamin RS. Critical analysis of the current American Joint Committee on Cancer Staging System for Cutaneous Melanoma and proposal of a new staging system, 1039
— *see* Jung FA
Buzdar AU, *see* Rahman ZU
Byhardt R, *see* Al-Sarraf M
Byhardt RW, *see* Pilepich MV
Byrd JC, Weiss RB, Arthur DC, Lawrence D, Baer MR, Davey F, Trikha ES, Carroll AJ, Tantravahi R, Qumsiyeh M, Patil SR, Moore JO, Mayer RJ, Schiffer CA, Bloomfield CD. Extramedullary leukemia adversely affects hematologic complete remission rate and overall survival in patients with t(8;21)(q22;q22): Results from Cancer and Leukemia Group B 8461, 466
Byrne J, *see* Zelter LK
Byrne MJ, Gebski V, Forbes J, Tattersall MHN, Simes RJ, Coates AS, Dewar J, Lunn M, Flower C, Gill PG, Stewart J for the Australian-New Zealand Breast Cancer Trials Group. Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: A phase III randomized trial, 3141
— *see* Pestalozzi BC

Cabanillas F, *see* Ayoub J-P
— *see* Majlis A
— *see* Younes A
Cabanillas FF, *see* Meistrich ML
Caceres W, Delgado L, Sanchez JR. Reed-Sternberg cells in spinal fluid, 3289
Cadiou M, *see* Zittoun R
Caggiano V, *see* Fisher B
Cai B, *see* Isaacs C
Caillot D, Casasnovas O, Bernard A, Couaillier J-F, Durand C, Cuisenier B, Solary E, Piard F, Petrella T, Bonnin A, Couillault G, Dumas M, Guy H. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery, 139
Cairncross G, *see* Leighton C
Cairncross JG, *see* Forsyth PAJ
— *see* Mason W

Calayag-Jung M, *see* Fossella FV
Callaghan M, *see* Meisenberg BR
Calzas J, *see* García-Carbonero R
Calzone KA, *see* Merajver SD
Camerlo J, *see* Stoppa AM
Cameron MJ, *see* Chang AE
Caminiti C, *see* Passalacqua R
Camoriano J, *see* Loprinzi CL
Canavese G, *see* Del Mastro L
Cancela MEA, *see* Pavlovsky S
Canellos GP. Changes in the JCO (editorial), 1
— CHOP may have been part of the beginning but certainly not the end: Issues in risk-related therapy of large-cell lymphoma (editorial), 1713
— Selection bias in trials of transplantation for metastatic breast cancer: Have we picked the apple before it was ripe? (editorial), 3169
— *see* Bodis S
— *see* Janicek M
Canis M, *see* Legros M
Cannistra SA. "Cancer defeated": Not if, but when—Introducing the *Biology of Neoplasia* series (editorial), 3297
Cantilena LR, *see* Takimoto CH
Cantor A, *see* Weiner MA
Cao S, *see* Rustum YM
Capellà G, *see* Arribas R
Capizzi R, *see* Blanke CD
Caplan R, *see* Pilepich MV
Capri G, *see* Gianni L
Carbone A, *see* Nicoletto MO
Cardella C, *see* Shepherd FA
Cardenal F, *see* Graus F
Carella AM, Corsetti MT, Frassoni F. In reply (letter), 3167
—, Cunningham I, Lerma E, Dejana A, Benvenuto F, Podestà M, Celesti L, Chimirri F, Abate M, Vassallo F, Figari O, Parodi C, Sessarego M, Valbonesi M, Carlier P, Prencipe E, Gatti AM, Van Den Berg D, Hoffman R, Frassoni F. Mobilization and transplantation of Philadelphia-negative peripheral-blood progenitor cells early in chronic myelogenous leukemia, 1575
Carey RW, *see* Choi NC
— *see* Maurer LH
Caride VJ, *see* Salloum E
Carli M, *see* De Zen L
Carlier P, *see* Carella AM
Carlton CE Jr, *see* Eastham JA
Carmichael J, *see* Ranson MR
— *see* ten Bokkel Huinink W
Carney W, *see* Yamauchi H
Carrasco H, *see* Patt YZ
Carrie C, *see* Romestaing P
Carroll AJ, *see* Byrd JC
— *see* Slack JL
Carroll D, *see* Marks DI
Carter G, *see* Vonderheide RH
Carter M, *see* Slater S
Cartoni C, *see* Loeffler M
Casadei R, *see* Picci P
Casale F, *see* Tonini GP
Casaretti R, *see* Frasci G
Casasnovas O, *see* Caillot D
Casasnovas R-O, *see* Wendum D
Cascino TL, *see* Ellison N
Cascinu S, Labianca R, Alessandroni P, Marcellini M, Silva RR, Pancera G, Testa E, Martignoni G, Barni S, Frontini L, Zaniboni A, Luporini G, Cellerino R, Catalano G. Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: A report from the Italian Group for the Study of Digestive Tract Cancer, 3313
Casey JR, *see* Graham ML
Casper ES, Schwartz GK, Sugarman A, Leung D, Brennan MF. Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma, 2111
— *see* Heslin MJ
Casper JT, *see* Szydlo R
Cassisi NJ, *see* Mendenhall WM
Castaldi J, *see* Lacava JA
Castaldo G, Tomaiuolo R, Sanduzzi A, Bocchino ML, Ponticiello A, Barra E, Vitale D, Bariffi F, Sacchetti L, Salvatore F. Lung cancer metastatic cells detected in blood by reverse transcriptase-polymerase chain reaction and dot-blot analysis, 3388
Castellsagué X, *see* Viladiu P
Castiglione M, *see* Senn HJ
Castiglione-Gertsch M, *see* Pestalozzi BC
Catalano G, *see* Cascinu S
Catimel G, *see* Merrouche Y
Catino A, *see* De Lena M
Catovsky D, *see* Österborg A
— *see* Pawson R
Cavaletti G, Bogliun G, Crespi V, Marzorati L, Zincone A, Marzola M, Rota S, Galli A, Tredici P, Tredici G. Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer, 199
Cavalli F, *see* Senn HJ
Cazals D, *see* Wendum D
Cazzola A, *see* Picci P
Cecchetto A, *see* Nicoletto MO
Celesti L, *see* Carella AM
Cella DF, *see* Brady MJ
Cellerino R, *see* Cascinu S
Cerutti I, *see* Pavlovsky S
Ceselski SK, *see* Copelan EA
Chabannon C, *see* Stoppa AM
Chaffee S, *see* Graham ML
Chamberlain D, *see* Evans WK
Chamberlain MC, Kormanik PA. Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas, 3427
Chambers JT, *see* Chambers SK
Chambers SK, Chambers JT, Davis CA, Kohorn EI, Schwartz PE, Lorber MI, Handschumacher RE, Pizzorno G. Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients, 1945
Champlin R, *see* Collins RH Jr
— *see* Giralt S

— *see* Ippoliti C
Champlin RE, *see* Johansen MJ
— *see* Rahman ZU
Chan DW, Beveridge RA, Muss H, Fritsche HA, Hortobagyi G, Theriault R, Kiang D, Kennedy BJ, Evelegh M. Use of truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease, 2322
Chang AE, Aruga A, Cameron MJ, Sondak VK, Normolle DP, Fox BA, Shu S. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2, 796
Chantraine J-M, *see* Thyss A
Chao NJ, *see* Kusnierz-Glaz CR
Chase J, *see* Patt YZ
Chassagne J, *see* Legros M
Chastagner P, *see* Rubie H
Chauvenet AR, *see* Weiner MA
Cheang MS, *see* Bow EJ
Cheever MA, *see* Disis ML
Chen AP, *see* Takimoto CH
Chen E, *see* Zelter LK
Chen G, *see* Kaste SC
Chen M, *see* Loehrer PJ Sr
Chen MG, *see* Ansell SM
Chen NP, *see* Pisters PWT
Chen T-L, *see* O'Reilly S
Chen Y-M, *see* Perng R-P
Cheng S-C, *see* Pisters PWT
Cheng YC, *see* Murren JR
Chéradame S, Etienne MC, Formento P, Schneider M, Dassonville O, Demard F, Milano G. Tumoral-reduced folates and clinical resistance to fluorouracil-based treatment in head and neck cancer patients, 2604
Chernoff SB, *see* Kris MG
Cheson BD, *see* Sorensen JM
Chessells J, *see* Sorensen K
Chesser MR, *see* Kamthan AG
Chetrit A, *see* Collins RH Jr
Cheung IY, *see* Cheung N-KV
Cheung N-KV, Heller G, Kushner BH, Liu C, Cheung IY. Detection of metastatic neuroblastoma in bone marrow: When is routine marrow histology insensitive? 2807
Chimirri F, *see* Carella AM
Chin C, *see* Lofters WS
Choi NC, Carey RW, Daly W, Mathisen D, Wain J, Wright C, Lynch T, Grossbard M, Grillo H. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non–small-cell lung cancer, 712
Chollet P, *see* Legros M
Chomy F, *see* Pujol J-L
Chomy P, *see* Pujol J-L
Choufi B, *see* Legros M
Chow W, *see* Somlo G
Choy H, *see* Safran H
Christophers E, *see* Gläser R
Chuang V, *see* Patt YZ
Chun HG, *see* Sorensen JM
Cicchetti G, *see* Safran H
Cima GP, *see* Nicoletto MO
Cinieri S, *see* Vitolo U
Ciocca D, *see* Elledge RM
Ciocci GH, *see* Graham ML
Clahsen PC, van de Velde CJH, Goldhirsch A, Rossbach J, Sertoli MR, Bijnens L, Sylvester RJ. Overview of randomized perioperative polychemotherapy trials in women with early-stage breast cancer, 2526
Clark GM, *see* Elledge RM
Clark JA, *see* Beard CJ
Clark JR, Busse PM, Norris CM Jr, Andersen JW, Dreyfuss AI, Rossi RM, Poulin MD, Colevas AD, Tishler RB, Costello R, Lucarini JW, Lucarini D, Thornhill L, Lackey M, Peters E, Posner MR. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: Long-term results, 3100
Clark P, *see* Shapiro CL
Clarke-Pearson DL, *see* Omura GA
Cleary J, *see* Berlin J
Cleary KR, *see* Spitz FR
Clerici M, *see* Crinò L
Clift R, *see* Demirer T
Clodi K, *see* Younes A
Coates AS, *see* Byrne MJ
Cobleigh M, *see* Brady MJ
Cocconi G, *see* Passalacqua R
Cody R, *see* Merajver SD
Cohen AM, *see* Fong Y
Coiffier B, *see* Bastion Y
— *see* Haioun C
— *see* Thieblemont C
— *see* Warzocha K
— *see* Wendum D
Coindre J-M, *see* Guillou L
Coit DG, *see* Fong Y
Colcher D, *see* Tempero M
Coldman AJ, *see* Olivotto IA
Cole E, *see* Shepherd FA
Coleman R, *see* Piccart MJ
— *see* Rustin GJS
— *see* ten Bokkel Huinink W
Coleman RE, *see* Vinholes J
Colevas AD, *see* Clark JR
Colgan JP, *see* Ansell SM
Colin P, *see* Ganem G
Collette L, *see* de Wit R
Collin F, *see* Guillou L
Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J. Donor leukocyte infusion in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation, 433
Collinson AR, *see* Lynch TJ Jr
Colombat P, *see* Moreau P
Colome M, *see* Giralt S
Colomer R, *see* García-Carbonero R
Colonello K, *see* Edwards RP
Colonna P, Andrieu J-M, Jais J-P. In reply (letter), 412

Comandone A, *see* Picci P
Comella G, *see* Frasci G
Comella P, *see* Frasci G
Condat P, *see* Legros M
Confravreux E, *see* Delmas PD
Congdon JE, *see* Russell CA
Connors JM, Klimo P, Adams G, Burns BF, Cooper I, Meyer RM, O'Reilly SE, Pater J, Quirt I, Sadura A, Shustik C, Skillings J, Sutcliffe S, Verma S, Yoshida S, Zee B. Treatment of advanced Hodgkin's disease with chemotherapy—Comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada Clinical Trials Group, 1638
— *see* Lee AYY
Conroy T, *see* Rougier P
Consoli U, *see* Kornblau SM
— *see* Younes A
Conte M, *see* Tonini GP
Conte PF, Baldini E, Gennari A, Michelotti A, Salvadori B, Tibaldi C, Danesi R, Innocenti F, Gentile A, Dell'Anna R, Biadi O, Mariani M, Del Tacca M. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: A regimen with high activity and low cardiotoxicity in advanced breast cancer, 2510
Conter V, Schrappe M, Aricó M, Reiter A, Rizzari C, Dördelmann M, Valsecchi MG, Zimmermann M, Ludwig W-D, Basso G, Masera G, Riehm H for the Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Groups. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone, 2786
Cook PA, *see* Horwich A
Cook S, *see* Lynch TJ Jr
Cooke E, *see* Tepper JE
Cooper DL, *see* Salloum E
Cooper I, *see* Connors JM
Cooper J, *see* Al-Sarraf M
Cooper MR, *see* Budman DR
— *see* Dawson NA
Cooperman A, *see* Kamthan AG
Copelan EA, Ceselski SK, Ezzone SA, Lasky LC, Penza SL, Bechtel TP, Klein JL, Hehmeyer DM, Scholl MD, Marshall DD, Elder PJ, Risley GL, Avalos BR. Mobilization of peripheral-blood progenitor cells with high-dose etoposide and granulocyte colony-stimulating factor in patients with breast cancer, non-Hodgkin's lymphoma, and Hodgkin's disease, 759
— *see* Vose JM
Copeland EM III, *see* Mendenhall WM
Coquard R, *see* Romestaing P
Coral F, *see* Lynch TJ Jr
Cordero di Montezemolo L, *see* De Zen L
Corn BW, *see* Rudoler SB
Cornelius E, *see* Salloum E
Cornfeld MJ. Claims-based 'report card' deserves failing grade (letter), 2761
Cornfield M, *see* Hudes GR
Corrado C, *see* Pavlovsky S
Corsetti MT, *see* Carella AM
Corstens FHM, *see* Steffens MG
Cortellazzo S, *see* Vitolo U
Cortés-Funes H, *see* García-Carbonero R
— *see* Pestalozzi BC
Cosolo W, *see* Millward MJ
Costa A, Doci R, Mochen C, Bignami P, Faranda A, Gennari L, Silvestrini R. Cell proliferation-related markers in colorectal liver metastases: Correlation with patient prognosis, 2008
Costa J, *see* Guillou L
Costa SD, von Minckwitz G, Gauwerky JFH, Kaufmann M, Diel IJ. Prospective randomized studies are needed to define the role of axillary lymph node dissection in primary breast cancer (letter), 3023
Costantini M, *see* Del Mastro L
Costello R, *see* Clark JR
Couaillier J-F, *see* Caillot D
Coughlin CT, *see* Pilepich MV
Couillault G, *see* Caillot D
Courbon-Collet B, *see* Rubie H
Coze C, Hartmann O, Michon J, Frappaz D, Dusol F, Rubie H, Plouvier E, Leverger G, Bordigoni P, Béhar C, Beck D, Mechinaud F, Bergeron C, Plantaz D, Otten J, Zucker JM, Philip T, Bernard JL. NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: A report from the French Society of Pediatric Oncology, 3433
— *see* Rubie H
Crawford ED, *see* Saxman SB
Crawford M, *see* Rustin GJS
Creaven PJ, *see* Soni N
Creemers GJ, Gerrits CJH, Eckardt JR, Schellens JHM, Burris HA, Planting AST, Rodriguez GI, Loos WJ, Hudson I, Broom C, Verweij J, Von Hoff DD. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors, 1087
Crespi V, *see* Cavaletti G
Creutzig MRU, *see* Schellong G
Crinò L, Scagliotti G, Marangolo M, Figoli F, Clerici M, De Marinis F, Salvati F, Cruciani G, Dogliotti L, Pucci F, Paccagnella A, Adamo V, Altavilla G, Incoronato P, Trippetti M, Mosconi AM, Santucci A, Sorbolini S, Oliva C, Tonato M. Cisplatin-gemcitabine combination in advanced non–small-cell lung cancer: A phase II study, 297
Cripps MC, *see* Burris HA III
Crisp M, *see* Miller VA
Crist W, *see* Raney RB
Crist WM, *see* Rubnitz JE
Crom DB, *see* Kaste SC
Cruciani G, *see* Crinò L
Cruz AB Jr, *see* Fisher B
Cuevas MA, *see* Lacava JA
Cuisenier B, *see* Caillot D
Culine S, *see* Rougier P
Cullen MH, *see* Horwich A
Cummings B, *see* Tepper JE
Cummings BJ, *see* Mackillop WJ
Cunningham D, *see* Webb A

Cunningham I, *see* Carella AM
Cure H, *see* Legros M
Curley S, *see* Patt YZ
Curran WJ Jr, *see* Rudoler SB
Cusack JD, *see* Seymour JF
Cusumano F, *see* Gianni AM
Cuthbertson DD, *see* Krischer JP

Daenen, SMGJ, *see* Löwenberg B
Dahut W, *see* Takimoto CH
Dakhil S, *see* Kaba SE
Dalesio O, *see* Gregor A
— *see* Huizing MT
Dalmau J, *see* Graus F
Dalrymple G, *see* Tempero M
Dalton J, *see* Kamthan AG
Dalton W, *see* Collins RH Jr
Daly W, *see* Choi NC
D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Tomaszewski JE, Wein A. Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer: The basis for an adjuvant therapy trial, 1465
Damon LE, *see* Smith GA
d'Amore ESG, *see* De Zen L
Danenberg K, *see* Leichman CG
Danenberg PV, *see* Leichman CG
Danese S, *see* Bolis G
Danesi R, *see* Conte PF
Daniels ER, *see* Howard OM
Daponte A, *see* Frasci G
Dark GG, Bower M, Newlands ES, Paradinas F, Rustin GJS. Surveillance policy for stage I ovarian germ cell tumors, 620
Darzynkiewicz Z, *see* Seiter K
Das Gupta TK, *see* Levine EA
Dassonville O, *see* Chéradame S
Dauplat J, *see* Legros M
Davey F, *see* Byrd JC
Davey FR, *see* Slack JL
Davidson JR, *see* Brundage MD
Davidson N, *see* ten Bokkel Huinink W
Davies M, *see* Earlam S
Davies SM, Wagner JE, Xiao-Ou-Shu, Blazar BR, Katsanis E, Orchard PJ, Kersey JH, Dusenbery KE, Weisdorf DJ, McGlave PB, Ramsay NKC. Unrelated donor bone marrow transplantation for children with acute leukemia, 557
Davis CA, *see* Chambers SK
Davis CS, *see* Heckman KD
Davis JM, *see* McQuaker IG
Davis L, *see* Al-Sarraf M
Davis PA, *see* Kohn EC
Dawson NA, Figg WD, Cooper MR, Sartor O, Bergan RC, Senderowicz AM, Steinberg SM, Tompkins A, Weinberger B, Sausville EA, Reed E, Myers CE. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer, 1470
De Bernardi B, *see* Tonini GP
de Boer-Dennert M, *see* Pronk LC
de Gramont A, Bosset J-F, Milan C, Rougier P, Bouché O, Etienne P-L, Morvan F, Louvet C, Guillot T, François E, Bedenne L. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup study, 808
de Haes, HJCJM, *see* Rinck GC
de Jong JS, *see* Apolinario RM
De Lena M, Lorusso V, Bottalico C, Brandi M, De Mitrio A, Catino A, Guida M, Latorre A, Leone B, Vallejo C, Gargano G. Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum, 3208
De Marinis F, *see* Crinò L
de Mascarel A, *see* Wendum D
De Mitrio A, *see* De Lena M
de Mulder PHM, *see* Horwich A
De Paoli A, *see* Frustaci S
De Potter P, *see* Rudoler SB
De Takats P, *see* Williams MV
de Wit R, Stoter G, Kaye SB, Sleiffer DTh, Jones WG, ten Bokkel Huinink WW, Rea LA, Collette L, Sylvester R. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group, 1837
— *see* Horwich A
De Zen L, Sommaggio A, d'Amore ESG, Masiero L, Cordero di Montezemolo L, Linari A, Madon E, Dominici C, Bosco S, Bisogno G, Carli M, Ninfo V, Basso G. Clinical relevance of DNA ploidy and proliferative activity in childhood rhabdomyosarcoma: A retrospective analysis of patients enrolled onto the Italian Cooperative Rhabdomyosarcoma study RMS88, 1198
Dean GE, *see* Quan WDY Jr
Dearnaley DP, *see* Horwich A
— *see* Lampe H
Deasy S, *see* Brady MJ
Debono DJ, Heilman DK, Einhorn LH, Donohue JP. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors, 1455
Debruyne FMJ, *see* Steffens MG
DeCillis A, *see* Fisher B
Deckers P, *see* Fisher B
Deconinck E, *see* Bastion Y
Dejana A, *see* Carella AM
Dekker AW, van't Veer MB, Sizoo W, Haak HL, van der Lelie J, Ossenkoppele G, Huijgens PC, Schouten HC, Sonneveld P, Willemze R, Verdonck LF, van Putten WLJ, Löwenberg B for the Dutch Hemato-Oncology Research Group. Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia, 476
Del Mastro L, Venturini M, Lionetto R, Garrone O, Melioli G, Pasquetti W, Sertoli MR, Bertelli G, Canavese G, Costantini M, Rosso R. Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia, 2715
del Muro JG, *see* Graus F

Del Tacca M, *see* Conte PF
Delasalle K, *see* Giralt S
Delattre O, *see* Rubie H
Delgado L, *see* Caceres W
Dell'Anna R, *see* Conte PF
Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study, 955
Delpassand ES, *see* Patt YZ
Demard F, *see* Chéradame S
Demeocq F, *see* Michel G
Demetri G, *see* Shapiro CL
— *see* Vonderheide RH
Demetri GD, *see* West DC
Demirer T, Buckner CD, Storer B, Lilleby K, Rowley S, Clift R, Appelbaum FR, Storb R, Bensinger WI. Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor, 684
Dempsey E, *see* Lofters WS
Denes AE. Chemotherapy with mitoxantrone in hormone-refractory prostate cancer (letter), 410
Depiero S, *see* Leighton C
Depisch D, *see* Scheithauer W
Desai A, *see* Swain SM
Desch CE, *see* Hillner BE
Desikan KR, *see* Tricot G
Detmar SB, *see* Sneeuw KCA
Devereux S, *see* Watts MJ
Deville W, *see* Apolinario RM
DeVita VT Jr. The war on cancer has a birthday, and a present (editorial), 867
— *see* Longo DL
Devizzi L, *see* Bonfante V
Dewar J, *see* Byrne MJ
Dezii CM, *see* McGuire W
Dezube BJ, *see* Northfelt DW
— *see* van den Brink MRM
Dhaliwal HS, *see* Ellison N
Di Costanzo F, *see* Passalacqua R
Di Leone L, *see* Schwartsmann G
di Montezemolo LC, *see* Tonini GP
Di Nicola M, *see* Gianni AM
Di Sarra S, *see* Passalacqua R
Di Stefano D, *see* Stoppa AM
Diaz-Canton E, *see* Pazdur R
Dibar E, *see* Pavlovsky S
Dick G, *see* Mitchell PLR
Diebold J, *see* Wendum D
Diehl V, *see* Loeffler M
Diel IJ, *see* Costa SD
Dimitrov N, *see* Fisher B
Dimitrov NV, *see* Fisher B
Dimopoulos M, *see* Giralt S
Dinarello C, *see* Du Bois JS
Dingemans, A-MC, *see* Apolinario RM
Dinndorf PA, Avramis VI, Wiersma S, Krailo MD, Liu-Mares W, Seibel NL, Sato JK, Mosher RB, Kelleher JF, Reaman GH. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: A report from the Children's Cancer Group, 2780
DiPersio J, *see* Brown RA
DiPersio JF, *see* Adkins DR
Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA. High-titer HER-2/*neu* protein-specific antibody can be detected in patients with early-stage breast cancer, 3363
Dispenzieri A, Loprinzi CL. Chemotherapy-induced insulin-dependent diabetes mellitus (letter), 1287
Dittadi R, *see* Disis ML
Divine M, *see* Bastion Y
Dixon P, *see* Mackillop WJ
Doci R, *see* Costa A
Dogliotti L, *see* Crinò L
Dohlsten M, *see* Giantoni BJ
d'Oleire F, *see* Robins HI
Dölken G, *see* Loeffler M
Dombernowsky P, *see* Ardizzoni A
— *see* Herrstedt J
Domingo JM, *see* Palomera L
Dominici C, *see* De Zen L
Donati D, *see* Passalacqua R
Donato H, *see* Pavlovsky S
Donehower RC, *see* O'Reilly S
Donohue JP, *see* Debono DJ
Doppman JL, *see* Sutliff VE
Dördelmann M, *see* Conter V
Doroshow JH, *see* Somlo G
Dorr FA, *see* Burris HA III
— *see* Stadler WM
Dorval T, *see* Leyvraz S
Dosik GM, *see* Northfelt DW
Douillard J-Y, *see* Ganem G
— *see* Pujol J-L
Douillard JY, *see* Rougier P
Downing JR, *see* Rubnitz JE
Doyle C, Stockler M, Pintilie M, Panesar P, Warde P, Sturgeon J, Oza AM. Resource implications of palliative chemotherapy for ovarian cancer, 1000
Doyle J, *see* McGuire W
Dreger P, *see* Smith TJ
Dreicer R, *see* Witte RS
Dresel S, Kirsch CM, Tatsch K, Zachoval R, Hahn K, Goldenberg DM. Detection of hepatocellular carcinoma with a new alpha-fetoprotein antibody imaging kit, 2683
Dreyfuss AI, *see* Clark JR
Drings P, *see* Gregor A
Drinkard LC, *see* Masters GA
Drobyski WR, *see* Collins RH Jr
Droste JHJ, *see* van Basten JPA
Drummond RG, *see* McGinnis WL
Du Bois JS, Trehu EG, Mier JW, Shapiro L, Epstein M, Klempner M, Dinarello C, Kappler K, Ronayne L, Rand W, Atkins MB. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin g chimera in patients with advanced melanoma and renal cell carcinoma, 1052

Dubray B, *see* Ganem G
Duffey PL, *see* Longo DL
Duggan D, *see* Shapiro CL
Dumas M, *see* Caillot D
Dummer R, *see* Keilholz U
DuMond C, *see* Northfelt DW
Dumontet C, *see* Bastion Y
— *see* Thieblemont C
— *see* Warzocha K
Duplay H, *see* Guillou L
Dupriez B, *see* Haioun C
Durand C, *see* Caillot D
Durie BGM, *see* Ludwig H
Dusenbery KE, *see* Davies SM
Dusol F, *see* Coze C
Dutch Hemato-Oncology Research Group, *see* Dekker AW
Dyer MJS, *see* Österborg A
— *see* Pawson R

Earlam S, Glover C, Davies M, Fordy C, Allen-Mersh TG. Effect of regional and systemic fluorinated pyrimidine chemotherapy on quality of life in colorectal liver metastasis patients, 2022
Earle CC, *see* Evans WK
Easlea D, *see* Mitchell PLR
Eastell R, *see* Vinholes J
Eastham JA, Kattan MW, Groshen S, Scardino PT, Rogers E, Carlton CE Jr, Lerner SP. Fifteen-year survival and recurrence rates after radiotherapy for localized prostate cancer, 3214
Eaton WL, *see* Maurer LH
Ebell W, *see* Locatelli F
Ebi N, *see* Kubota K
Eckardt JR, *see* Creemers GJ
Edwards CL, *see* Verschraegen CF
Edwards RP, Gooding W, Lembersky BC, Colonello K, Hammond R, Paradise C, Kowal CD, Kunschner AJ, Baldisseri M, Kirkwood JM, Herberman RB. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: Twenty-four–hour versus 7-day infusion, 3399
Egeland T, *see* Lote K
Eggermont AMM, Koops HS, Liénard D, Kroon BBR, van Geel AN, Hoekstra HJ, Lejeune FJ. In reply (letter), 2174
— *see* Keilholz U
Ehlenbeck C, *see* Brown RA
Eichelbaum M, *see* Busse D
Einhorn L, *see* Miller KD
Einhorn LH. Do all germ cell tumor patients with residual masses in multiple sites require postchemotherapy resections? (letter), 409
— In reply (letter), 3166
— *see* Debono DJ
— *see* Loehrer PJ Sr
— *see* Saxman SB
Elder PJ, *see* Copelan EA
Elem YL, *see* Lacava JA
Elias A, *see* Lynch TJ Jr
— *see* Shapiro CL
Elit LM, Gafni A, Levine MN. Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: An Ontario perspective, 632
Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, Pugh R, Ciocca D, Ravdin P, O'Sullivan J, Rivkin S, Martino S, Osborne CK. *bcl*-2, p53, and response to tamoxifen in estrogen receptor–positive metastatic breast cancer: A Southwest Oncology Group study, 1916
Ellegaard J, *see* Bergmann OJ
Ellermann-Eriksen S, *see* Bergmann OJ
Elliot V, *see* Tyc VL
Ellis GK, *see* Livingston RB
Ellis L, *see* Patt YZ
Ellison D, *see* Saven A
Ellison N, Loprinzi CL, Kugler J, Hatfield AK, Miser A, Sloan JA, Wender DB, Rowland KM, Molina R, Cascino TL, Vukov AM, Dhaliwal HS, Ghosh C. Phase III placebo-controlled trial of capsaicin cream in the management of surgical neuropathic pain in cancer patients, 2974
— *see* Loprinzi CL
El-Naggar A, *see* Press MF
Elomaa I, *see* Saarto T
Elson P, *see* Witte RS
Emami B, *see* Al-Sarraf M
Emanuel EJ, *see* Howard OM
Emmett E, *see* Pawson R
Ende K, *see* Verschraegen CF
Enk A, *see* Keilholz U
Enker WE, *see* Fong Y
Enzian J, *see* Loeffler M
Epstein M, *see* Du Bois JS
Epstein ML, *see* Krischer JP
Epstein S, *see* Krischer JP
Erder MH, *see* Smith TJ
Erdkamp FL, *see* Lalisang RI
Erland JB, *see* Hainsworth JD
Erlanger B, *see* Fetell MR
Ernst DS, *see* Moore MJ
Eschwege F, *see* Bartelink H
Escribà JM, *see* Viladiu P
Escudier B, *see* Thiesse P
Espina B, *see* Levine AM
Esseltine D, *see* Lynch TJ Jr
Estey E, Thall PF, Pierce S, Kantarjian H, Keating M. In reply (letter), 3021
—, Thall PF, Pierce S, Kantarjian H, Keating M. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine, 483
— *see* Kornblau SM
— *see* Kurzrock R
Estey EH. In reply (letter), 1710
Etienne MC, *see* Chéradame S
Etienne P-L, *see* de Gramont A
Eton O, *see* Buzaid AC
Ettinger LJ, *see* Provisor AJ
European Cancer Centre, *see* Huizing MT
European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative Group, *see* Thyss A

European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group, *see* Ardizzoni A
European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia, *see* Österborg A
European Working Group on Myelodysplastic Syndrome in Childhood, *see* Locatelli F
Evans DB, *see* Rich TA
— *see* Spitz FR
Evans H, *see* Rustin GJS
Evans WE, *see* Rubnitz JE
Evans WK, Newman T, Graham I, Rusthoven JJ, Logan D, Shepherd FA, Chamberlain D. Lung cancer practice guidelines: Lessons learned and issues addressed by the Ontario Lung Cancer Disease Site Group, 3049
—, Will BP, Berthelot J-M, Earle CC. Cost of combined modality interventions for stage III non–small-cell lung cancer, 3038
— *see* Stewart DJ
Evelegh M, *see* Chan DW
Ewer MS, *see* Swain SM
Ewings M, *see* Slater S
Extra J-M, *see* Ganem G
Extra JM, *see* Merrouche Y
— *see* Rougier P
Ezzone SA, *see* Copelan EA

Facon T, *see* Moreau P
Faigel DO, Ginsberg GG, Bentz JS, Gupta PK, Smith DB, Kochman ML. Endoscopic ultrasound-guided real-time fine-needle aspiration biopsy of the pancreas in cancer patients with pancreatic lesions, 1439
Fairclough DL, *see* Hayman JA
— *see* Howard OM
Falda M, *see* Vitolo U
Fallavollita A, *see* Sorensen JM
Faranda A, *see* Costa A
Farrow A, *see* Quinn CT
— *see* Winick N
Farrow AC, Buchanan GR, Zwiener RJ, Bowman WP, Winick NJ. Serum aminotransferase elevation during and following treatment of childhood acute lymphoblastic leukemia, 1560
Favalli G, *see* Bolis G
Favaro D, *see* Frustaci S
Favrot M, *see* Rubie H
Fay JW, *see* Antman KH
Fedele J, *see* Murren JR
Feierabend C, *see* Berlin J
— *see* Robins HI
Feig BW, *see* Pisters PWT
Feldman EJ, *see* Seiter K
Feldman-Stewart D, *see* Brundage MD
— *see* Mackillop WJ
Felman P, *see* Bastion Y
— *see* Thieblemont C
Fennelly D, Aghajanian C, Shapiro F, O'Flaherty C, McKenzie M, O'Connor C, Tong W, Norton L, Spriggs D. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer, 187
Fenoglio CJ, *see* Spitz FR
Ferguson BB, *see* Kris MG
Ferguson D, *see* Heimann R
Fernando IJ, *see* Kris MG
Ferrant A, *see* Smith TJ
— *see* Wendum D
Ferrara J, *see* Xiao H
Ferrari S, *see* Picci P
Ferraro A, *see* Picci P
Ferreyra R, *see* Lacava JA
Ferster A, *see* Thyss A
Fetell MR, Grossman SA, Fisher JD, Erlanger B, Rowinsky E, Stockel J, Piantadosi S for the New Approaches to Brain Tumor Therapy Central Nervous System Consortium. Preirradiation paclitaxel in glioblastoma multiforme: Efficacy, pharmacology, and drug interactions, 3121
Feusner J, *see* Adamson PC
Feusner JH, *see* Van Tornout JM
Fey MF, *see* Löwenberg B
Fibbe WE, *see* Pawson R
Fielding A, *see* Watts MJ
Fields KK, *see* Antman KH
Fields SC, *see* ten Bokkel Huinink W
Fiere D, *see* Moreau P
Figari O, *see* Carella AM
Figg WD, *see* Dawson NA
— *see* Kohn EC
Figoli F, *see* Crinò L
Findlay M, *see* Webb A
Fine S, *see* Pritchard KI
Finklestein JZ, *see* Adamson PC
Fiore F, *see* Frasci G
Fiorentino MV, *see* Nicoletto MO
Fischer D, *see* Haffty BG
Fischer JJ, *see* Haffty BG
Fischer P, *see* Busse D
Fischer R, *see* Loeffler M
Fisher B, Anderson S, Wickerham DL, DeCillis A, Dimitrov N, Mamounas E, Wolmark N, Pugh R, Atkins JN, Meyers FJ, Abramson N, Wolter J, Bornstein RS, Levy L, Romond EH, Caggiano V, Grimaldi M, Jochimsen P, Deckers P. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22, 1858
—, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18, 2483
— *see* Leighton C
Fisher C, *see* Verrill MW
Fisher ER, *see* Fisher B
Fisher JD, *see* Fetell MR
Fisher SG, *see* Stiff PJ

Fishman A, *see* Verschraegen CF
Fitch MI, *see* Liu G
Fleming GF, *see* O'Reilly S
Fleming MD, *see* Vonderheide RH
Fletcher J, *see* McQuaker IG
Fleury J, *see* Legros M
Flom KJ, *see* Press MF
Flomenberg N, *see* Szydlo R
Flower C, *see* Byrne MJ
Flynn SD, *see* Murren JR
Focaccia G, *see* Lacava JA
Fode K, *see* Work E
Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, Marrero AM, Prasad M, Blumgart LH, Brennan MF. Liver resection for colorectal metastases, 938
Fontanesi J, *see* Kaste SC
Forbes J, *see* Byrne MJ
Fordy C, *see* Earlam S
Foreman NK, *see* Yule SM
Forman SJ, *see* Somlo G
Formento P, *see* Chéradame S
Fornander T, *see* Gyenes G
Forsyth PAJ, Petrov E, Mahallati H, Cairncross JG, Brasher P, MacRae ME, Hagen NA, Barnes P, Sevick RJ. Prospective study of postoperative magnetic resonance imaging in patients with malignant gliomas, 2076
Fortin A, *see* Raybaud-Diogène H
Fortner JG, *see* Fong Y
Fosså SD, *see* Horwich A
Fossella FV, Lippman SM, Shin DM, Tarassoff P, Calayag-Jung M, Perez-Soler R, Lee JS, Murphy WK, Glisson B, Rivera E, Hong WK. Maximum-tolerated dose defined for single-agent gemcitabine: A phase I dose-escalation study in chemotherapy-naive patients with advanced non–small-cell lung cancer, 310
Fouillard L, *see* Vandenberghe E
Fox BA, *see* Chang AE
Franceschi S, *see* Nicoletto MO
François E, *see* de Gramont A
Frank AR, *see* McGinnis WL
Franklin J, *see* Loeffler M
Franssen E, *see* Liu G
Frappaz D, *see* Coze C
— *see* Rubie H
Fraschini F, *see* Passalacqua R
Frasci G, Comella P, Scoppa G, Guida C, Gravina A, Fiore F, Casaretti R, Daponte A, Parziale A, Comella G. Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non–small-cell lung cancer: A phase I study, 1409
Frassoni F, *see* Carella AM
Freedman RS, *see* Verschraegen CF
Freilone R, *see* Vitolo U
Freytes CO, *see* Antman KH
Friedman HS, *see* Graham ML
Friedrich W, *see* Locatelli F
Frigerio L, *see* Bolis G
Fritsche HA, *see* Chan DW
Fritz E, *see* Ludwig H
Frontini L, *see* Cascinu S
Frustaci S, Buonadonna A, Galligioni E, Favaro D, De Paoli A, Re GL, Sorio R, Tumolo S, Monfardini S. Increasing 4′-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A pilot study, 1418
Frye DK, *see* Rahman ZU
Fuchs CS. Chemotherapy for advanced gastric cancer: Where do we stand? (editorial), 3299
Fuchs R, *see* Loeffler M
Fujii T, *see* Shirao K
Fujita A, *see* Oshita F
Fukuda H, *see* Shirao K
Fuller LM, *see* Meistrich ML
Furukawa H, *see* Nakamori S

Gadner H, *see* Schellong G
Gafni A, *see* Elit LM
Gagliardi G, *see* Gyenes G
Gajewski J, *see* Giralt S
— *see* Ippoliti C
Gajewski JL, *see* Szydlo R
Gajjar A, Sanford RA, Heideman R, Jenkins JJ, Walter A, Li Y, Langston JW, Muhlbauer M, Boyett JM, Kun LE. Low-grade astrocytoma: A decade of experience at St Jude Children's Research Hospital, 2792
Galanis E, Buckner JC, Schomberg PJ, Hammack JE, Raffel C, Scheithauer BW. Effective chemotherapy for advanced CNS embryonal tumors in adults, 2939
Gale RP, *see* Antman KH
— *see* Szydlo R
Gallagher MJ, *see* Pilepich MV
Galli A, *see* Cavaletti G
Galligioni E, *see* Frustaci S
Gambacorta M, *see* Lazzarino M
Gams RA, *see* Swain SM
Gamucci T, *see* Ardizzoni A
Gandara D, *see* Hesketh PJ
Ganem G, Dubray B, Raoul Y, Colin P, Bardet E, Douillard J-Y, Goudier M-J, Hennequin C, Walter S, Michel-Langlet P, Martin P, Maron D, Morvan F, Andolenko P, Extra J-M. Concomitant chemoradiotherapy followed, where feasible, by surgery for cancer of the esophagus, 701
— *see* Rougier P
Garber J, *see* Hahn WC
Garcia A, *see* Muggia FM
García-Carbonero R, Hidalgo M, Paz-Ares L, Calzas J, Gómez H, Guerra JA, Hitt R, Hornedo J, Colomer R, Cortés-Funes H. Patient selection in high-dose chemotherapy trials: Relevance in high-risk breast cancer, 3178
Gargano G, *see* De Lena M
Gargantini L, *see* Lazzarino M
Garrison L, *see* Vose JM
Garrone O, *see* Del Mastro L
Gascoyne RD, *see* Lee AYY
Gastaut JA, *see* Stoppa AM
Gatti AM, *see* Carella AM
Gaulard P, *see* Haioun C
— *see* Wendum D
Gautier V, *see* Pujol J-L

Gauwerky JFH, *see* Costa SD
Gaynon PS, *see* Nachman J
— *see* Uckun FM
Gaßmann W, *see* Loeffler M
Gebhard F, *see* Michel G
Gebski V, *see* Byrne MJ
Gehan E, *see* Heyn R
Gehan EA, *see* Raney RB
Geilen W, *see* Loeffler M
Gelber RD, *see* Pestalozzi BC
Geller RB, *see* Vose JM
Gelman R, *see* Shapiro CL
— *see* Yamauchi H
Gennari A, *see* Conte PF
Gennari L, *see* Costa A
Gentile A, *see* Conte PF
Georgiadis MS, Schuler BS, Brown JE, Kieffer LV, Steinberg SM, Wilson WH, Takimoto CH, Kelley MJ, Johnson BE. Paclitaxel by 96-hour continuous infusion in combination with cisplatin: A phase I trial in patients with advanced lung cancer, 735
Georgii A, *see* Loeffler M
Gérard J-P, *see* Romestaing P
Gerber MC, *see* Swain SM
Gerdes H, *see* Pavlick AC
Gerhardt L, *see* Schwartsmann G
Gerhartz H, *see* Loeffler M
German-Austrian Pediatric Hodgkin's Disease Group, *see* Schellong G
Gerrits CJH, *see* Creemers GJ
Gerstner JB, *see* Loprinzi CL
Geueke A-M, *see* Keilholz U
Geyer JR, *see* Shaw DWW
Ghosh C, *see* Ellison N
— *see* Loprinzi CL
— *see* Pitot HC
Giaccone G, *see* Apolinario RM
— *see* Ardizzoni A
— *see* Gregor A
— *see* Huizing MT
Gianelli U, *see* Lazzarino M
Giani A, *see* Gianni L
Gianni AM, Siena S, Bregni M, Di Nicola M, Orefice S, Cusumano F, Salvadori B, Luini A, Greco M, Zucali R, Rilke F, Zambetti M, Valagussa P, Bonadonna G. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: Five-year results, 2312
Gianni L, Viganò L, Locatelli A, Capri G, Giani A, Tarenzi E, Bonadonna G. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer, 1906
Giantoni BJ, Alpaugh RK, Schultz J, McAleer C, Newton DW, Shannon B, Guedez Y, Kotb M, Vitek L, Persson R, Gunnarsson P-O, Kalland T, Dohlsten M, Persson B, Weiner LM. Superantigen-based immunotherapy: A phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin a recombinant fusion protein, in advanced pancreatic and colorectal cancer, 1994
Giantonio B, *see* Hudes GR
Gibril F, *see* Sutliff VE
Gieser PW, *see* Weiner MA
Giles F, *see* Levine AM
Gili M, *see* Viladiu P
Gill PG, *see* Byrne MJ
Gillet M, *see* Leyvraz S
Gillis W, *see* Robins HI
Ginsberg GG, *see* Faigel DO
Giralt S, Weber D, Colome M, Dimopoulos M, Mehra R, Van Besien K, Gajewski J, Andersson B, Khouri I, Przepiorka D, von Wolff B, Delasalle K, Korbling M, Seong D, Alexanian R, Champlin R. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue, 667
— *see* Collins RH Jr
— *see* Ippoliti C
Girault D, *see* Moreau P
Gisselbrecht C, *see* Haioun C
Gisselbrecht, C for the Groupe d'Etude des Lymphomes de l'Adulte, *see* Wendum D
Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer, 2345
Giusto M, *see* Nicoletto MO
Glantz MJ, *see* Lekos A
Gläser R, Rass K, Seiter S, Hauschild A, Christophers E, Tilgen W. Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: A clinical two-center study, 2818
Glasheen WP, *see* Hillner BE
Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S for the Procrit Study Group. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice, 1218
Glatstein E, *see* Longo DL
Glenat C, *see* Legros M
Glick JH, *see* Sparano JA
Glisson B, *see* Fossella FV
Glover C, *see* Earlam S
Gluckman E, *see* Michel G
— *see* Szydlo R
Gmür J, *see* Löwenberg B
Goebel MEM, *see* Stahel RA
Goedhals L, *see* Abratt RP
Goel V, *see* Olivotto IA
Goey SH, *see* Keilholz U
Goldberg RM, Hatfield AK, Kahn M, Sargent DJ, Knost JA, O'Connell MJ, Krook JE, Mailliard JA, Wiesenfeld M, Schaefer PL, Tirona MT, Moertel CG. Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the *l*-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer, 3320
— *see* Pitot HC
Goldenberg DM, *see* Dresel S
Goldhirsch A, *see* Clahsen PC

— *see* Pestalozzi BC
— *see* Spataro V
Goldman JM, *see* Szydlo R
Goldstein LJ, *see* Sparano JA
Goldstone AH, *see* Smith TJ
— *see* Vandenberghe E
— *see* Watts MJ
Goldstone AH, *see* Majolino I
Golomb HM, *see* Masters GA
Golouh R, *see* Pestalozzi BC
Gomella L, *see* Hudes GR
Gómez H, *see* García-Carbonero R
Gonin R, *see* Miller KD
Gonzalez DG, *see* Bartelink H
Gooding W, *see* Edwards RP
Goodman SA, *see* Collins RH Jr
Goodnough LT, *see* Brown RA
Goorin AM, *see* Krischer JP
Gordon A, *see* ten Bokkel Huinink W
Gordon AN, Stringer CA, Matthews CM, Willis DL, Nemunaitis J. Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: Rapid development of neurotoxicity is dose-limiting, 1965
Gore M, Shepherd J, Blake P, Wiltshaw E. In reply (letter), 864
— *see* ten Bokkel Huinink W
Goswitz MS, *see* Spitz FR
Goto K, *see* Kubota K
Goudier M-J, *see* Ganem G
Gouldon N, *see* Yule SM
Gradishar WJ, Jordan VC. Clinical potential of new antiestrogens, 840
Graham I, *see* Evans WK
Graham M, *see* Isaacs C
Graham MA, *see* Johnson CA
Graham ML, Herndon JE II, Casey JR, Chaffee S, Ciocci GH, Krischer JP, Kurtzberg J, Laughlin MJ, Longee DC, Olson JF, Paleologus N, Pennington CN, Friedman HS. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors, 1814
Graham S, *see* Pazdur R
Gralow JR, *see* Disis ML
— *see* Livingston RB
Granena A, *see* Vose JM
Granowetter L, *see* West DC
Granter S, *see* Vance E
Gratecos N, *see* Michel G
Gratwohl A, *see* Löwenberg B
Graus F, Dalmau J, Reñé R, Torà M, Malats N, Verschuuren JJ, Cardenal F, Viñolas N, del Muro JG, Vadell C, Mason WP, Rosell R, Posner JB, Real FX. Anti-Hu antibodies in patients with small-cell lung cancer: Association with complete response to therapy and improved survival, 2866
Gravina A, *see* Frasci G
Gray JR, *see* Hainsworth JD
Greco FA, *see* Hainsworth JD
— *see* Muggia FM
Greco M, *see* Gianni AM
Green MR, *see* Burris HA III
— *see* Maurer LH
Green S, *see* Elledge RM
Green SJ, *see* Russell CA
Greenberg R, *see* Hudes GR
Greenslade D, *see* Johnson CA
Greer J, *see* Ayoub J-P
Gregor A, Drings P, Burghouts J, Postmus PE, Morgan D, Sahmoud T, Kirkpatrick A, Dalesio O, Giaccone G. Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: A European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group study, 2840
Greig P, *see* Shepherd FA
Greiner R, *see* Scheithauer W
Grem JL, *see* Takimoto CH
Griener JC, *see* Quinn CT
Grier HE, *see* West DC
Griffin PP, *see* Kachnic LA
Grignani F, *see* Vitolo U
Grignon D, *see* Pilepich MV
Grillo H, *see* Choi NC
Grillo-López AJ, *see* Maloney DG
Grimaldi M, *see* Fisher B
Grimm EA, *see* Jung FA
Grizzle WE, *see* Arribas R
Grochow LB, *see* O'Reilly S
Grogan T, *see* Stopeck AT
Groome PA, *see* Brundage MD
— *see* Mackillop WJ
Groshen S, *see* Eastham JA
— *see* Leichman CG
— *see* Muggia FM
— *see* Quan WDY Jr
Gross TG, *see* Pavletic ZS
Grossbard M, *see* Choi NC
Grossman SA, Wharam M, Sheidler V, Kleinberg L, Zeltzman M, Yue N, Piantadosi S. Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma, 2596
— *see* Fetell MR
Grosveld G, *see* Rubnitz JE
Grote TH, *see* Kris MG
Groupe d'Etude des Lymphomes de l'Adulte, *see* Haioun C
Groupe d'Etude des Lymphomes de l'Adulte, *see* Brice P
Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer, *see* Thiesse P
Grunberg SM, *see* Hesketh PJ
Gruss HJ, *see* Younes A
Guadagnoli E, Shapiro C, Gurwitz JH, Silliman RA, Weeks JC, Borbas C, Soumerai SB. Age-related patterns of care: Evidence against ageism in the treatment of early-stage breast cancer, 2338
Guaspari A, *see* Masters GA
Guedez Y, *see* Giantoni BJ
Guerra JA, *see* García-Carbonero R
Guerrero E, *see* Viladiu P
Guevin RM, *see* Lofters WS

Guida C, *see* Frasci G
Guida M, *see* De Lena M
Guillot T, *see* de Gramont A
Guillou L, Coindre J-M, Bonichon F, Bui NB, Terrier P, Collin F, Vilain M-O, Mandard A-M, Le Doussal V, Leroux A, Jacquemier J, Duplay H, Sastre-Garau X, Costa J. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma, 350
Gunderson LL, *see* Tepper JE
Gunnarsson P-O, *see* Giantoni BJ
Gunton KE, *see* Soni N
Guo C-Y, *see* Vinholes J
Guo MD, *see* Zelter LK
Gupta E, Mick R, Ramirez J, Wang X, Lestingi TM, Vokes EE, Ratain MJ. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients, 1502
Gupta PK, *see* Faigel DO
Gurwitz JH, *see* Guadagnoli E
Gusterson BA, *see* Pestalozzi BC
Gutiérrez M, *see* Palomera L
Guy H, *see* Caillot D
Gyenes G, Gagliardi G, Lax I, Fornander T, Rutqvist LE. Evaluation of irradiated heart volumes in stage I breast cancer patients treated with postoperative adjuvant radiotherapy, 1348

Ha CS, *see* Meistrich ML
Haak HL, *see* Dekker AW
— *see* Moreau P
Haapasalo H, *see* Hirvikosi P
Haas N, *see* Hudes GR
Habermann TM, *see* Ansell SM
Hacking DJ, *see* Abratt RP
Haffty BG. In reply (letter), 3024
—, Son YH, Papac R, Sasaki CT, Weissberg JB, Fischer D, Rockwell S, Sartorelli AC, Fischer JJ. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: Results of the Yale mitomycin randomized trials, 268
—, Ward B, Pathare P, Salem R, McKhann C, Beinfield M, Fischer D, Reiss M. Reappraisal of the role of axillary lymph node dissection in the conservative treatment of breast cancer, 691
Hagemeister FB, *see* Meistrich ML
Hagen NA, *see* Forsyth PAJ
Hagen-Aukamp U, *see* Loeffler M
Hagenbeek A, *see* Löwenberg B
Hager B, *see* Lote K
Hagiwara A, *see* Kitamura K
Hahn K, *see* Dresel S
Hahn WC, Jones D, Leavitt P, Garber J, Stone R, Skarin AT. Leukemia cutis, 2170
Haigh LS, *see* Mendenhall WM
Haines DS, *see* Marks DI
Hainsworth J, *see* Lofters WS
Hainsworth JD, Erland JB, Kalman LA, Schreeder MT, Greco FA. Carcinoma of unknown primary site: Treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide, 2385
—, Gray JR, Stroup SL, Kalman LA, Patten JE, Hopkins LG, Thomas M, Greco FA. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: Comparison of sequential phase II trials using different dose-intensities, 3464
— *see* Hesketh PJ
— *see* Muggia FM
Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P, Bosly A, Dupriez B, Nouvel C, Tilly H, Lederlin P, Biron P, Brière J, Gaulard P, Reyes F for the Groupe d'Etude des Lymphomes de l'Adulte. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2, 1131
Haïoun C, *see* Brice P
Häker B, *see* Ahlert T
Halicka HD, *see* Seiter K
Haller DG, *see* O'Connell MJ
Halonen P, *see* Hirvikosi P
Halperin EC, Broadwater GJL. Are there sex biases in standardized tests of radiation oncology knowledge? 2722
Halvie M, *see* Merajver SD
Hamasaki V, *see* Somlo G
Hamilton JM, *see* Takimoto CH
Hamilton R, *see* Berd D
Hammack JE, *see* Galanis E
Hammer AM, *see* Loprinzi CL
Hammond GD, *see* Van Tornout JM
Hammond R, *see* Edwards RP
Hammond S, *see* Maurer LH
Hamoudi A, *see* Heyn R
Hamšíkova E, *see* Viladiu P
Hancock ML, *see* Rubnitz JE
Hancock SL, *see* Horning SJ
Handberg J, *see* Herrstedt J
Handschumacher RE, *see* Chambers SK
Hanks GE, *see* Lee WR
— *see* Pilepich MV
Hanlon A, *see* Lee WR
Hansen H, *see* Ardizzoni A
Hansen M, *see* Herrstedt J
Hantich B, *see* Keilholz U
Harari PM. Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice? 2050
Harbott J, *see* Schellong G
Hardouin C, *see* Delmas PD
Hardy P, *see* Delmas PD
Harker G, *see* Hesketh PJ
Harlan LC, *see* Muñoz KA
Harmer CL, *see* Verrill MW
Harold N, *see* Takimoto CH
Harousseau JL, *see* Moreau P
Harper P, *see* Webb A
Harrap KR, *see* McKeage MJ
Harris C, *see* Press MF
Harris DT, *see* Stopeck AT
Harris JR, *see* Hayman JA

Harrison K, *see* Tempero M
Harstrick A, *see* Rustum YM
Harteveld M, *see* Pronk LC
Hartman NR, *see* O'Reilly S
Hartmann JT, *see* Bokemeyer C
Hartmann O, *see* Coze C
— *see* Rubie H
Hasenclever D, *see* Loeffler M
Hasle H, *see* Locatelli F
Hatake K, *see* Ohno R
Hatfield AK, *see* Ellison N
— *see* Goldberg RM
— *see* Loprinzi CL
Hatta Y, *see* Yamada Y
Hatz R, *see* Rudolph B
Hauck WW, *see* Berd D
Haug JS, *see* Brown RA
Haupt A, *see* Bokemeyer C
Hauschild A, *see* Gläser R
Havsteen H, *see* Jakobsen A
Hayashi I, *see* Oshita F
Hayes D, *see* Shapiro CL
Hayes DF, *see* Yamauchi H
Hayman JA, Fairclough DL, Harris JR, Weeks JC. Patient preferences concerning the trade-off between the risks and benefits of routine radiation therapy after conservative surgery for early-stage breast cancer, 1252
Haynes AP, *see* McQuaker IG
Hays C, *see* Patel SR
Head DR, *see* Rubnitz JE
Heckman KD, Weiner GJ, Davis CS, Strauss RG, Jones MP, Burns CP. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/μL versus 20,000/μL, 1143
Hehmeyer DM, *see* Copelan EA
Heideman R, *see* Gajjar A
Heilman DK, *see* Debono DJ
Heimann R, Ferguson D, Powers C, Suri D, Weichselbaum RR, Hellman S. Race and clinical outcome in breast cancer in a series with long-term follow-up evaluation, 2329
Heineman M, *see* McCaffrey JA
Helin H, *see* Hirvikosi P
Heller G, *see* Cheung N-KV
Hellman S, *see* Heimann R
Helmerhorst TJM, *see* Huizing MT
Henderson IC, *see* Shapiro CL
Hendricks D, *see* Brown RA
Heney NM, *see* Kachnic LA
Hennequin C, *see* Ganem G
— *see* Maulard-Durdux C
Henslee-Downey PJ, *see* Szydlo R
Henze G, *see* Beyermann B
Hérait P, *see* Merrouche Y
Herait P, *see* Rougier P
Herberman RB, *see* Edwards RP
Hermann J, *see* Locatelli F
Herndon, JE II, *see* Graham ML
— *see* Maurer LH
Heron J-F, *see* ten Bokkel Huinink W
Herrstedt J, Sigsgaard T, Handberg J, Schousboe BMB, Hansen M, Dombernowsky P. Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer, 1690
Hersh EM, *see* Stopeck AT
Herskovic A, *see* Al-Sarraf M
Herzig GP, *see* Wetzler M
Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindley CM. Proposal for classifying the acute emetogenicity of cancer chemotherapy, 103
— *see* Safran H
Heslin M, *see* Lewis JJ
Heslin MJ, Lewis JJ, Nadler E, Newman E, Woodruff JM, Casper ES, Leung D, Brennan MF. Prognostic factors associated with long-term survival for retroperitoneal sarcoma: Implications for management, 2832
Hess K, *see* Kaba SE
Hess KR, *see* Lenzi R
Hess U, *see* Löwenberg B
Heyman R, *see* Miller VA
Heyn R, Newton WA, Raney RB, Hamoudi A, Bagwell C, Vietti T, Wharam M, Gehan E, Maurer HM. Preservation of the bladder in patients with rhabdomyosarcoma, 69
Hickish T, *see* Webb A
Hidalgo M, *see* García-Carbonero R
Hilkens PHE, *see* Pronk LC
Hill A, *see* Webb A
Hiller E, *see* Loeffler M
Hillner BE, Kirkwood JM, Atkins MB, Johnson ER, Smith TJ. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684, 2351
—, McDonald MK, Penberthy L, Desch CE, Smith TJ, Maddux P, Glasheen WP, Retchin SM. Measuring standards of care for early breast cancer in an insured population, 1401
— *see* Antman KH
— *see* Smith TJ
Hilton S, *see* McCaffrey JA
Hinds P, *see* Tyc VL
Hinkelbein H, *see* Loeffler M
Hinterberger W, *see* Loeffler M
Hirai H, *see* Yamada Y
Hirakata Y, *see* Yamada Y
Hiratsuka M, *see* Nakamori S
Hirsch J, *see* McCaffrey JA
— *see* Petrek JA
Hirschberg H, *see* Lote K
Hirvikosi P, Kumpulainen E, Virtaniemi J, Johansson R, Haapasalo H, Marin S, Halonen P, Helin H, Raitiola H, Pukander J, Kellokumpu-Lehtinen P, Kosma V-M. p53 expression and cell proliferation as prognostic factors in laryngeal squamous cell carcinoma, 3111
Hislop TG, *see* Olivotto IA
Hitt R, *see* García-Carbonero R
Ho M, *see* Petrek JA
Hoehn JL, *see* Fisher B

Hoekstra HJ, *see* Eggermont AMM
— *see* van Basten JPA
Hoffman MA, Janson D, Rose E, Rai KR. Treatment of hairy-cell leukemia with cladribine: Response toxicity, and long-term follow-up, 1138
Hoffman PC, *see* Masters GA
Hoffman R, *see* Carella AM
Hofmannová V, *see* Viladiu P
Hojo F, *see* Kubota K
Holcombe RF. The question remains: Oncology and primary care (letter), 1285
Holden L, *see* Bower M
Holland HK, *see* Antman KH
Hollis D, *see* Tepper JE
Hollis DR, *see* Maurer LH
Holmberg L, *see* Persson I
Holowaty E, *see* Mackillop WJ
Holowaty EJ, *see* Mackillop WJ
Holzmayer T, *see* Levine EA
Honegger H, *see* Stahel RA
Hong WK, *see* Fossella FV
Honold G, *see* Zippelius A
Hopkins LG, *see* Hainsworth JD
Hoppe RT, *see* Horning SJ
— *see* Torrey MJ
Hoque A, *see* Patt YZ
Hor JJ, *see* Pao CC
Hord M, *see* Verschraegen CF
Horne MK III, Mayo DJ. Low-dose urokinase infusions to treat fibrinous obstruction of venous access devices in cancer patients, 2709
Hornedo J, *see* García-Carbonero R
Horning SJ, Hoppe RT, Mason J, Brown BW, Hancock SL, Baer D, Rosenberg SA. Stanford-Kaiser permanente G1 study for clinical stage I to IIA Hodgkin's disease: Subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation, 1736
Horowitz IR, *see* O'Reilly S
Horowitz MM, *see* Antman KH
— *see* Szydlo R
Hortobagyi G, *see* Chan DW
Hortobagyi GN, *see* Rahman ZU
Horwich A, Sleiffer DT, Fosså SD, Kaye SB, Oliver RTD, Cullen MH, Mead GM, de Wit R, de Mulder PHM, Dearnaley DP, Cook PA, Sylvester RJ, Stenning SP. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer trial, 1844
— *see* Lampe H
Hösch S, *see* Yamauchi H
Hoskins P, *see* Lofters WS
Housset M, *see* Maulard-Durdux C
Howard OM, Fairclough DL, Daniels ER, Emanuel EJ. Physician desire for euthanasia and assisted suicide: Would physicians practice what they preach? 428
Howell A, *see* Ranson MR
Howes L, *see* Elledge RM
Hows JM, *see* Szydlo R
Hsieh A, *see* Masters GA
Hsieh C-c, *see* Savarese DMF
Hsueh S, *see* Pao CC
Hu W, *see* Collins RH Jr
Hu WW, *see* Kusnierz-Glaz CR
Huan S, *see* Moore MJ
Huang J, *see* Krown SE
Hubbard SM, *see* Longo DL
Hübner K, *see* Loeffler M
Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, Greenberg R, Gomella L, Litwin S, Ross E, Roethke S, McAleer C. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer, 3156
Hudgins LC, *see* Petrek JA
Hudson I, *see* Creemers GJ
— *see* ten Bokkel Huinink W
Hudson MM, Jones D, Boyett J, Sharp GB, Pui C-H. Late mortality of long-term survivors of childhood cancer, 2205
— *see* Tyc VL
Hughes M, *see* Webb A
Huijgens PC, *see* Dekker AW
— *see* Löwenberg B
Huizing MT, Giaccone G, van Warmerdam LJC, Rosing H, Bakker PJM, Vermorken JB, Postmus PE, van Zandwijk N, Koolen MGJ, ten Bokkel Huinink WW, van der Vijgh WJF, Bierhorst FJ, Lai A, Dalesio O, Pinedo HM, Veenhof CHN, Beijnen JH for the European Cancer Centre. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non–small-cell lung cancer, 317
—, van Warmerdam LJC, Rosing H, Schaefers MCW, Lai A, Helmerhorst TJM, Veenhof CHN, Birkhofer MJ, Rodenhuis S, Beijnen JH, ten Bokkel Huinink WW. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer, 1953
Humphrey SL, *see* McGinnis WL
Hung G, *see* Press MF
Hunter AE, *see* McQuaker IG
Hupperets PS, *see* Lalisang RI
Hurd D, *see* Shapiro CL
Hutchinson R, *see* Uckun FM
Hutson P, *see* Berlin J
Huvos AG, *see* Provisor AJ
Hyland K, *see* Quinn CT
Hynes HE, *see* Russell CA
Hyslop T, *see* Rudoler SB

Ihde DC, *see* Longo DL
Ikeda S, *see* Yamada Y
Imaoka S, *see* Nakamori S
Imazono Y, Takebayashi Y, Nishiyama K, Akiba S, Miyadera K, Yamada Y, Akiyama S-I, Ohi Y. Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma, 2570
Incarbone M, *see* Pastorino U
Incoronato P, *see* Crinò L
Innocenti F, *see* Conte PF

International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers, 594
Inwards DJ, *see* Ansell SM
Iolascon A, *see* Tonini GP
Ippoliti C, Champlin R, Bugazia N, Przepiorka D, Neumann J, Giralt S, Khouri I, Gajewski J. Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies, 3350
Iqbal A, *see* McQuaker IG
Irani J, *see* Merajver SD
Irimura T, *see* Nakamori S
Isaacs C, Robert NJ, Bailey FA, Schuster MW, Overmoyer B, Graham M, Cai B, Beach KJ, Loewy JW, Kaye JA. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin, 3368
Ishiguro S, *see* Nakamori S
Ishikawa O, *see* Nakamori S
Iversen PL, Bishop MR. In reply (letter), 408
Iveson T, *see* Webb A
Iwanaga T, *see* Nakamori S
Izarzugaza I, *see* Viladiu P
Izquierdo A, *see* Viladiu P

Jack W, *see* Kunkler I
Jackson JD, *see* Bishop MR
— *see* Pavletic ZS
Jacobs A, *see* Saven A
Jacobsen N, *see* Locatelli F
— *see* Szydlo R
Jacobson J, *see* Whitehead RP
Jacobson JA. Reaching to the choir: New voices in the end of life discussion (editorial), 413
Jacquemier J, *see* Guillou L
Jaeckle KA, *see* Kaba SE
Jaffe ES, *see* Longo DL
Jagannath S, *see* Tricot G
Jais J-P, *see* Colonna P
Jakobsen A, Bertelsen K, Andersen JE, Havsteen H, Jakobsen P, Moeller KA, Nielsen K, Sandberg E, Stroeyer I. Dose-effect study of carboplatin in ovarian cancer: A Danish Ovarian Cancer Group study, 193
Jakobsen P, *see* Jakobsen A
James R, *see* Millward MJ
Jamieson E, *see* Watts MJ
Jamil A, *see* Nag S
Janicek M, Kaplan W, Neuberg D, Canellos GP, Shulman LH, Shipp MA. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy, 1631
Janicek MJ, *see* Burstein HJ
Janjan NA, *see* Rich TA
— *see* Spitz FR
Janson D, *see* Hoffman MA
Janssen AGM, *see* Rijks LJM
Jaubert J, *see* Wendum D
Jeffers S, *see* Muggia FM
Jenkins JJ, *see* Gajjar A
Jensen RT, *see* Sutliff VE
Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: A randomized study, 893
Jiang H, *see* Kurzrock R
Jochimsen P, *see* Fisher B
Joffe JK, *see* Webb A
Johansen MJ, Madden T, Mehra RC, Wood JG, Rondon G, Browne V, Newman RA, Champlin RE. Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer, 1481
Johansson R, *see* Hirvikosi P
Johnson BE, *see* Georgiadis MS
Johnson CA, Kilpatrick D, von Roemeling R, Langer C, Graham MA, Greenslade D, Kennedy G, Keenan E, O'Dwyer PJ. Phase I trial of tirapazamine in combination with cisplatin in a single-dose every 3 weeks in patients with solid tumors, 773
Johnson D, *see* Loehrer PJ Sr
Johnson ER, *see* Hillner BE
Johnson J, *see* Rustin GJS
Johnson JL, *see* Budman DR
Johnson R, *see* Takvorian T
Johnson S, *see* Slater S
Johnston PG, *see* Pestalozzi BC
Jones D, *see* Hahn WC
— *see* Hudson MM
Jones DV Jr, *see* Patt YZ
Jones MP, *see* Heckman KD
Jones RC, *see* Giuliano AE
Jones SE, *see* Swain SM
Jones WG, *see* de Wit R
Jonker-Pool G, *see* van Basten JPA
Jordan VC, *see* Gradishar WJ
Jost LM, *see* Stahel RA
Jothy S, *see* Paraf F
Jouet JP, *see* Michel G
Jucgla A, Sais G. Hand-foot syndrome, 3164
Judson IR, *see* McKeage MJ
— *see* Verrill MW
Jung FA, Buzaid AC, Ross MI, Woods KV, Lee JJ, Albitar M, Grimm EA. Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients, 2826
Jungi WF, *see* Senn HJ

Kaba SE, Kyritsis AP, Hess K, Yung WKA, Mercier R, Dakhil S, Jaeckle KA, Levin VA. TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors, 1063
Kabuto T, *see* Nakamori S
Kachnic LA, Kaufman DS, Heney NM, Althausen AF, Griffin PP, Zietman AL, Shipley WU. Bladder preservation by combined modality therapy for invasive bladder cancer, 1022
Kadin ME, *see* Bodis S
Kaelin WG Jr, *see* Sellers WR

Kahanic SP, *see* McGinnis WL
Kahn M, *see* Goldberg RM
Kahn MJ, *see* O'Connell MJ
Kaizer L, *see* Osoba D
Kajita T, *see* Omura K
Kajiyama Y, Tsurumaru M, Udagawa H, Tsutsumi K, Kinoshita Y, Ueno M, Akiyama H. Prognostic factors in adenocarcinoma of the gastric cardia: Pathologic stage analysis and multivariate regression analysis, 2015
Kakinuma R, *see* Kubota K
Kalakun L, *see* Schwartsmann G
Kalland T, *see* Giantoni BJ
Kalman LA, *see* Hainsworth JD
Kamen BA, *see* Quinn CT
— *see* Winick N
Kameyama M, *see* Nakamori S
Kamihira S, *see* Yamada Y
Kamthan AG, Morris JC, Dalton J, Mandeli JP, Chesser MR, Leben D, Cooperman A, Bruckner HW. Combined modality therapy for stage II and stage III pancreatic carcinoma, 2920
Kanamaru A, *see* Ohno R
Kanehira E, *see* Omura K
Kantarjian H, *see* Estey E
— *see* Kornblau SM
Kantoff PW, *see* Beard CJ
Kanz L, *see* Bokemeyer C
Kaplan AL, *see* Verschraegen CF
Kaplan I, *see* Beard CJ
Kaplan L, *see* Levine AM
Kaplan S, *see* Ardizzoni A
Kaplan W, *see* Janicek M
Kappler K, *see* Du Bois JS
Karner J, *see* Scheithauer W
Kasimis B, *see* Blanke CD
Kaste SC, Chen G, Fontanesi J, Crom DB, Pratt CB. Orbital development in long-term survivors of retinoblastoma, 1183
— *see* Wilimas JA
Katsanis E, *see* Davies SM
Kattan MW, *see* Eastham JA
Kauffman WM, *see* Wilimas JA
Kaufman DS, *see* Kachnic LA
Kaufmann M, *see* Costa SD
Kaur JS, *see* Loprinzi CL
Kavanagh JJ, *see* Ashour AA
— *see* Verschraegen CF
Kawakami Y, *see* Oshita F
Kawakita M, *see* Arai Y
Kaye JA, *see* Isaacs C
Kaye SB, *see* de Wit R
— *see* Horwich A
Keating A, *see* Vose JM
Keating J, *see* Shapiro CL
Keating M, *see* Estey E
— *see* Kornblau SM
Keating MJ, *see* Kurzrock R
— *see* Seymour JF
Keenan E, *see* Johnson CA
Keilholz U, Goey SH, Punt CJA, Proebstle TM, Salzmann R, Scheibenbogen C, Schadendorf D, Liénard D, Enk A, Dummer R, Hantich B, Geueke A-M, Eggermont AMM. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group, 2579
Keizer HJ, *see* Steyerberg EW
Kelland LR, *see* McKeage MJ
Kelleher JF, *see* Dinndorf PA
Kelley M, *see* Brown R
Kelley MJ, *see* Georgiadis MS
Kellokumpu-Lehtinen P, *see* Hirvikosi P
Kelly KM, Womer RB, Sorensen PHB, Xiong Q-B, Barr FG. Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma, 1831
Kelly WK, *see* McCaffrey JA
— *see* Scher HI
Kelsen DP, Martin D, O'Neil J, Schwartz G, Saltz L, Sung MT, von Borstel R, Bertino J. Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer, 1511
Kennedy A, *see* Markman M
Kennedy BJ, *see* Chan DW
Kennedy G, *see* Johnson CA
Kennedy MJ, *see* Antman KH
Kerger C, *see* Stiff PJ
Kerr G, *see* Kunkler I
Kersey JH, *see* Davies SM
Kessinger A, *see* Bierman PJ
— *see* Bishop MR
— *see* Pavletic ZS
Khater C, *see* Hudes GR
Khouri I, *see* Giralt S
— *see* Ippoliti C
Kiang D, *see* Chan DW
Kibby MY, *see* Tyc VL
Kiche K-O, *see* Younes A
Kieback D, *see* Verschraegen CF
Kieffer LV, *see* Georgiadis MS
Kilpatrick D, *see* Johnson CA
Kim KM, *see* Loehrer PJ Sr
Kimura K, *see* Omura K
King DR, *see* Van Tornout JM
King TP, *see* Safran H
Kinoshita Y, *see* Kajiyama Y
Kinsella TJ, *see* Tannehill SP
Kinsen H, *see* Omura K
Kirchner H, *see* Loeffler M
Kirkpatrick A, *see* Gregor A
Kirkwood JM, *see* Edwards RP
— *see* Hillner BE
Kirsch CM, *see* Dresel S
Kirschling RJ, *see* Pitot HC
Kisker CT, *see* Provisor AJ
Kitamura K, Yamaguchi T, Sawai K, Nishida S, Yamamoto K, Okamoto K, Taniguchi H, Hagiwara A, Takahashi T. Chronologic changes in the clinicopathologic findings and survival of gastric cancer patients, 3471
Kitchin R, *see* Smith TJ
Kleijnen J, *see* Rinck GC
Klein EA, *see* Kupelian PA

Klein JL, *see* Copelan EA
Klein JP, *see* Antman KH
— *see* Szydlo R
Kleinberg L, *see* Grossman SA
Klempnauer J, Ridder GJ, von Wasielewski R, Werner M, Weimann A, Pichlmayr R. Resectional surgery of hilar cholangiocarcinoma: A multivariate analysis of prognostic factors, 947
Klempner M, *see* Du Bois JS
Klersy C, *see* Lazzarino M
Klijn J, *see* Piccart MJ
Klimo P, *see* Connors JM
— *see* Lee AYY
Klingebiel T, *see* Locatelli F
Kluin-Nelemans JC, *see* Pawson R
Knop R, *see* Witte RS
Knost JA, *see* Goldberg RM
— *see* Pitot HC
Knowling M, *see* Pritchard KI
Knudson AG. Hereditary cancer: Theme and variations, 3280
Kobayashi T, *see* Ohno R
Koch P, *see* Loeffler M
Kochman ML, *see* Faigel DO
Kodama T, *see* Kubota K
Kodera Y, *see* Ohno R
Koeffler HP, *see* Yamada Y
Koenders EB, *see* Steffens MG
Koh HK. Kids, cancer, and the Joe Camel connection (editorial), 2181
Kohn EC, Figg WD, Sarosy GA, Bauer KS, Davis PA, Soltis MJ, Thompkins A, Liotta LA, Reed E. Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: Pharmacokinetics, clinical outcome, and comparison of formulations, 1985
Köhne H, *see* Bokemeyer C
Kohorn EI, *see* Chambers SK
Kolb H-J, *see* Szydlo R
Kollath J, *see* Pavletic ZS
Köllermann MW, *see* Zippelius A
Kolvenbag G, *see* Scher HI
Kondo H, *see* Shirao K
Kong J, *see* Mitchell JM
Koolen MGJ, *see* Huizing MT
Koops HS, *see* Eggermont AMM
— *see* van Basten JPA
Korbling M, *see* Giralt S
Kormanik PA, *see* Chamberlain MC
Korn EL, *see* Smith MA
Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia, 1796
Kornek G, *see* Scheithauer W
Kosma V-M, *see* Hirvikosi P
Kostense PJ, *see* Smeele LE
Kosty MP, *see* Meisenberg BR
Kotb M, *see* Giantoni BJ
Kotz R, *see* Brodowicz T
Kovats E, *see* Scheithauer W
Kowal CD, *see* Edwards RP
Kraemer C, *see* Robins HI
Krailo MD, *see* Blaney SM
— *see* Dinndorf PA
— *see* Provisor AJ
— *see* Van Tornout JM
Kraus MD, *see* Bodis S
Kremens B, *see* Locatelli F
Kris MG. Lung cancer cure, care, and cost: Let the data be your guide (editorial), 3027
—, Pendergrass KB, Navari RM, Grote TH, Nelson AM, Thomas V, Ferguson BB, Allman DS, Pizzo BA, Baker TW, Fernando IJ, Chernoff SB. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone, 2135
— *see* Hesketh PJ
— *see* Miller VA
Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: The Pediatric Oncology Group experience, 1544
— *see* Graham ML
Kroemer HK, *see* Busse D
Kroener J, *see* Meisenberg BR
Kromfield M, *see* Schwartsmann G
Krook JE, *see* Goldberg RM
— *see* Lofters WS
Kroon BBR, *see* Eggermont AMM
Krown SE, Testa MA, Huang J for the AIDS Clinical Trials Group Oncology Committee. AIDS-related Kaposi's sarcoma: Prospective validation of the AIDS Clinical Trials Group staging classification, 3085
— *see* Northfelt DW
Krüger B, *see* Loeffler M
Kubota K, Nishiwaki Y, Kakinuma R, Hojo F, Matsumoto T, Ohmatsu H, Sekine I, Yokozaki M, Goto K, Ebi N, Kodama T. Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer, 292
Kudelka AP, *see* Ashour AA
— *see* Verschraegen CF
Kufer P, *see* Zippelius A
Kugler J, *see* Ellison N
— *see* Loprinzi CL
Kula J, *see* Olivotto IA
Kulp B, *see* Markman M
Kulvatunyou N, Schein M, Rucinski J. Delayed complication of Port-a-Cath: Perforation of the superior vena cava (letter), 865
Kumpulainen E, *see* Hirvikosi P
Kun LE, *see* Gajjar A
Kunkler I, Kerr G, Jack W. Intensity of surveillance after breast conservation (letter), 3420
Kunschner AJ, *see* Edwards RP
Kupelian PA, Kupelian VA, Witte JS, Macklis R, Klein EA. Family history of prostate cancer in patients with localized prostate cancer: An independent predictor of treatment outcome, 1478
Kupelian VA, *see* Kupelian PA
Kurita Y, *see* Oshita F

Kuriyama K, *see* Ohno R
Kurman M, *see* Blanke CD
Kürten H, *see* Loeffler M
Kurtin PJ, *see* Ansell SM
Kurtzberg J, *see* Graham ML
Kurz BW, *see* Marks DI
Kurzrock R, Strom SS, Estey E, O'Brien S, Keating MJ, Jiang H, Adams T, Talpaz M. Second cancer risk in hairy cell leukemia: Analysis of 350 patients, 1803
Kushner BH, *see* Cheung N-KV
Kusnierz-Glaz CR, Schlegel PG, Wong RM, Schriber JR, Chao NJ, Amylon MD, Hu WW, Negrin RS, Lee Y, Blume KG, Long GD. Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies, 18
Kutz M, *see* Robins HI
Kutzner K, *see* Loeffler M
Kuwert T, *see* Lerch H
Kuzel T, *see* Stadler WM
Kyle RA. Jan Gosta Waldenström (obituary), 1720
Kyritsis AP, *see* Kaba SE

Labianca R, *see* Cascinu S
Lacava JA, Leone BA, Machiavelli M, Romero AO, Pérez JE, Elem YL, Ferreyra R, Focaccia G, Suttora G, Salvadori MA, Cuevas MA, Acuña LR, Acuña JR, Langhi M, Amato S, Castaldi J, Arroyo A, Vallejo CT. Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma, 604
Lackey M, *see* Clark JR
Lagrange J-L, *see* Pujol J-L
Lai A, *see* Huizing MT
Laird J, *see* Millward MJ
Lake D, *see* Seiter K
Lalisang RI, Wils JA, Nortier HW, Burghouts JTh, Hupperets PS, Erdkamp FL, Schouten HC, Blijham GH. Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer, 1367
Lambert HE, *see* Rustin GJS
Lambert JM, *see* Lynch TJ Jr
Lampe H, Horwich A, Norman A, Nicholls J, Dearnaley DP. Fertility after chemotherapy for testicular germ cell cancers, 239
Lange M, *see* Vose JM
Lange W, *see* Altehoefer C
Langer C, *see* Johnson CA
Langer M, *see* Altehoefer C
Langhi M, *see* Lacava JA
Langston JW, *see* Gajjar A
Laporte JP, *see* Moreau P
Larson M, *see* Tannehill SP
Lasky LC, *see* Copelan EA
Lasset C, *see* Thiesse P
Lastiri F, *see* Pavlovsky S
Latorre A, *see* De Lena M
Latreille J, *see* Osoba D
Laub L, *see* Brown RA
Laubenberger J, *see* Altehoefer C
Lauer SJ, *see* Marks DI
Laughlin MJ, *see* Graham ML
Lavabre-Bertrand T, *see* Lazzarino M
Law M, *see* Loprinzi CL
Lawrence D, *see* Byrd JC
— *see* Slack JL
Lawton CA, *see* Pilepich MV
Lax I, *see* Gyenes G
Lazarus HM, *see* Antman KH
Lazzarino M, Orlandi E, Paulli M, Strätor J, Klersy C, Gianelli U, Gargantini L, Rousset MT, Gambacorta M, Morra E, Lavabre-Bertrand T, Magrini U, Manegold C, Bernasconi C, Möller P. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: A multicenter study of 106 patients, 1646
Le Beau MM, *see* Stock W
Le Chevalier T, *see* Pujol J-L
Le Doussal V, *see* Guillou L
Leavitt P, *see* Hahn WC
Leben D, *see* Kamthan AG
Lebsack ME, *see* Vose JM
LeClaire V, *see* Merajver SD
Lederlin P, *see* Bastion Y
— *see* Haioun C
Ledermann J, *see* Rustin GJS
Lee AYY, Connors JM, Klimo P, O'Reilly SE, Gascoyne RD. Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B, 1745
Lee J, *see* Somlo G
Lee JE, *see* Buzaid AC
— *see* Spitz FR
Lee JJ, *see* Jung FA
Lee JS, *see* Fossella FV
Lee RJ. Changing paradigms in the management of breast cancer (letter), 2476
Lee T, *see* Saven A
Lee WR, Hanks GE, Hanlon A. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: Clinical observations, 230
Lee Y, *see* Kusnierz-Glaz CR
Lees AW, *see* Fisher B
Legha SS, *see* Buzaid AC
Legros M, Dauplat J, Fleury J, Cure H, Suzanne F, Chassagne J, Bay JO, Sol C, Canis M, Condat P, Choufi B, Tavernier F, Glenat C, Chollet P, Plagne R. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: Long-term results, 1302
Lehingue Y, *see* Romestaing P
Lehn N, *see* Rudolph B
Leichman CG, Lenz H-J, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M, Danenberg PV. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin, 3223
Leichman L, *see* Al-Sarraf M
— *see* Leichman CG
Leichner P, *see* Tempero M
Leighton C, Cairncross G. Low-grade glioma—The Europeans are winning! (letter), 2761

—, Fisher B, Bauman G, Depiero S, Stitt L, Macdonald D, Cairncross G. Supratentorial low-grade glioma in adults: An analysis of prognostic factors and timing of radiation, 1294
Lejeune F, *see* Leyvraz S
Lejeune FJ, *see* Eggermont AMM
Lekos A, Glantz MJ. CNS metastases: One's too many, 3019
LeMaistre CF, *see* Vose JM
Lembersky BC, *see* Edwards RP
Lemerle J, *see* Rubie H
Lemež P. Delayed administration of dexrazoxane provides cardioprotection against anthracyclines in breast cancer or acute myeloid leukemia (letter), 3293
Lemoine N, *see* Barton C
Lenz H-J, *see* Leichman CG
Lenzi R, Hess KR, Abbruzzese MC, Raber MN, Ordoñez NG, Abbruzzese JL. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: Favorable subsets of patients with unknown-primary carcinoma? 2056
Leone B, *see* De Lena M
Leone BA, *see* Lacava JA
Leong L, *see* Somlo G
Lepage E, *see* Brice P
— *see* Haioun C
Lerch H, Schober O, Kuwert T, Saur H-B. Survival of differentiated thyroid carcinoma studied in 500 patients, 2067
Lerma E, *see* Carella AM
Lerner SA, *see* Seymour JF
Lerner SP, *see* Eastham JA
Leroux A, *see* Guillou L
Lestingi TM, *see* Gupta E
Leung D, *see* Casper ES
— *see* Heslin MJ
— *see* Lewis JJ
Leventhal B, *see* Weiner MA
Leverger G, *see* Coze C
— *see* Michel G
Levin A, *see* Merajver SD
Levin VA, *see* Kaba SE
Levine AM, Tulpule A, Tessman D, Kaplan L, Giles F, Luskey BD, Scadden DT, Northfelt DW, Silverberg I, Wernz J, Espina B, Von Hoff D. Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: Results from a multicenter phase II trial, 1094
Levine EA, Holzmayer T, Bacus S, Mechetner E, Mera R, Bolliger C, Roninson IB, Das Gupta TK. Evaluation of newer prognostic markers for adult soft tissue sarcomas, 3249
Levine MN, *see* Elit LM
— *see* Pritchard KI
Levine R, *see* Northfelt DW
Levis A, *see* Vitolo U
Levitt G, *see* Sorensen K
Levitt R, *see* Pitot HC
Levonian PJ, *see* Sorscher S
Levy G, *see* Shepherd FA
Levy L, *see* Fisher B
Levy R, *see* Maloney DG
Levy T, *see* Verschraegen CF
Lewis JJ, Leung D, Heslin M, Woodruff JM, Brennan MF. Association of local recurrence with subsequent survival in extremity soft tissue sarcoma, 646
— *see* Heslin MJ
Leyvraz S, Spataro V, Bauer J, Pampallona S, Salmon R, Dorval T, Meuli R, Gillet M, Lejeune F, Zografos L. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy, 2589
— *see* Senn HJ
Li CY, *see* Ansell SM
Li Y, *see* Gajjar A
Liang L-J, *see* Muggia FM
Liang MD, *see* Takimoto CH
Liberati AM, *see* Vitolo U
Liberato NL, Quaglini S, Barosi G. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia, 2673
Lichter A, *see* Merajver SD
Lieberman R, *see* Takimoto CH
Liebertz C, *see* Scher HI
Liénard D, *see* Eggermont AMM
— *see* Keilholz U
Lightner R, *see* Andrykowski MA
Liles T-M, *see* Maloney DG
Lilleby K, *see* Demirer T
Lin C-Y, *see* Pao CC
Lin W-C, *see* Perng R-P
Linari A, *see* De Zen L
Linch DC, *see* Smith TJ
— *see* Watts MJ
Lindley CM, *see* Hesketh PJ
Lindsley KL, *see* Shaw DWW
Lindtner J, *see* Pestalozzi BC
Link H, *see* Smith TJ
Link MP, *see* Marks DI
Linker CA, *see* Smith GA
Lionetto R, *see* Del Mastro L
Liotta LA, *see* Kohn EC
Lippman SM, *see* Fossella FV
Lipshultz LI, *see* Meistrich ML
Lipshultz SE, *see* Krischer JP
Lipton JH, Virro M, Solow H. Successful pregnancy after allogeneic bone marrow transplant with embryos isolated before transplant, 3347
List A, *see* Collins RH Jr
Lister TA, *see* Slater S
Litwin S, *see* Hudes GR
Liu C, *see* Cheung N-KV
Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy, 110
Liu-Mares W, *see* Dinndorf PA
Livingston R, *see* Loehrer PJ Sr
Livingston RB, Ellis GK, Gralow JR, Williams MA, White R, McGuirt C, Adamkiewicz BB, Long CA. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer, 1395
Llerena E, *see* Verschraegen CF
Llewellyn-Thomas HA, *see* Palda VA
Lloyd SR, *see* Brady MJ

Lo Cunsolo C, *see* Tonini GP
Locatelli A, *see* Gianni L
Locatelli F, Niemeyer C, Angelucci E, Bender-Götze C, Burdach S, Ebell W, Friedrich W, Hasle H, Hermann J, Jacobsen N, Klingebiel T, Kremens B, Mann G, Pession A, Peters C, Schmid H-J, Stary J, Suttorp , Uderzo C, van't Veer-Korthof ET, Vossen J, Zecca M, Zimmermann, M for the European Working Group on Myelodysplastic Syndrome in Childhood. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: A report from the European Working Group on myelodysplastic syndrome in childhood, 0566
Locatelli F, *see* Vitolo U
Lockhorst H, *see* Moreau P
Loeffler M, Diehl V, Pfreundschuh M, Rühl U, Hasenclever D, Nisters-Backes N, Sieber M, Tesch H, Franklin J, Geilen W, Bartels H, Cartoni C, Dölken G, Enzian J, Fuchs R, Gaßmann W, Gerhartz H, Hagen-Aukamp U, Hiller E, Hinkelbein H, Hinterberger W, Kirchner H, Koch P, Krüger B, Kürten H, Kutzner K, Loos U, Mende W, Müller H, Oertel W, Petsch S, Pfab R, Pflüger H, Rohloff R, Sauer R, Schalk K, Schick HD, Schoppe W, Szepesi S, Teichmann J, Worst P, Fischer R, Georgii A, Hübner K, Schwarze E-W. Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease, 2275
Loehrer PJ, *see* Miller KD
Loehrer PJ Sr, Chen M, Kim KM, Aisner SC, Einhorn LH, Livingston R, Johnson D. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: An Intergroup trial, 3093
Loehrer, PJ Sr, *see* Saxman SB
— *see* Witte RS
Loewen GR, *see* Miller VA
Loewen R, *see* Bow EJ
Loewy JW, *see* Isaacs C
Lofters WS, Pater JL, Zee B, Dempsey E, Walde D, Moquin J-P, Wilson K, Hoskins P, Guevin RM, Verma S, Navari R, Krook JE, Hainsworth J, Palmer M, Chin C. Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy, 2966
Logan D, *see* Evans WK
Long CA, *see* Livingston RB
Long GD, *see* Kusnierz-Glaz CR
Longee DC, *see* Graham ML
Longmire R, *see* Meisenberg BR
— *see* Saven A
Longo DL, Glatstein E, Duffey PL, Young RC, Ihde DC, Bastian AW, Wilson WH, Wittes RE, Jaffe ES, Hubbard SM, DeVita VT Jr. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease, 3338
Longo W, *see* Robins HI
— *see* Vose JM
Loos U, *see* Loeffler M
Loos WJ, *see* Creemers GJ
Lopez F, *see* Safran H
Loprinzi CL, Abu-Ghazaleh S, Sloan JA, vanHaelst-Pisani C, Hammer AM, Rowland KM Jr, Law M, Windschitl HE, Kaur JS, Ellison N. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer, 969
—, Ghosh C, Camoriano J, Sloan J, Steen PD, Michalak JC, Schaefer PL, Novotny PJ, Gerstner JB, White DF, Hatfield AK, Quella SK. Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy, 1235
—, Sloan J, Kugler J. Coumarin-induced hepatotoxicity (letter), 3167
— *see* Dispenzieri A
— *see* Ellison N
— *see* McGinnis WL
Lorber MI, *see* Chambers SK
Loret C, *see* Millward MJ
Lorusso V, *see* De Lena M
Lote K, Egeland T, Hager B, Stenwig B, Skullerud K, Berg-Johnsen J, Storm-Mathisen I, Hirschberg H. Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: A retrospective study in 379 patients, 3129
Louis DN, *see* Mason W
Louvet C, *see* de Gramont A
Lovisone E, *see* Vitolo U
Löwenberg B, Boogaerts MA, Daenen SMGJ, Verhoef GEG, Hagenbeek A, Vellenga E, Ossenkoppele GJ, Huijgens PC, Verdonck LF, van der Lelie J, Wielenga JJ, Schouten HC, Gmür J, Gratwohl A, Hess U, Fey MF, van Putten WLJ. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia, 3496
Lowenberg B, *see* Szydlo R
Löwenberg B, *see* Dekker AW
Lowy AM, *see* Spitz FR
Lozano R, *see* Patt YZ
Lucarini D, *see* Clark JR
Lucarini JW, *see* Clark JR
Ludwig H, Fritz E, Neuda J, Durie BGM. Patient preferences for interferon alfa in multiple myeloma, 1672
Ludwig W-D, *see* Conter V
Luini A, *see* Gianni AM
Lukens JN, *see* Nachman J
Lumley M, *see* McQuaker IG
Lunn M, *see* Byrne MJ
Luo X, *see* Wilimas JA
Luporini G, *see* Cascinu S
Luskey BD, *see* Levine AM
Lutz P, *see* Thyss A
Lymphoma Working Party of the European Group for Blood and Marrow Transplantation, *see* Majolino I
Lyn P, *see* Motzer RJ
Lynch T, *see* Choi NC
Lynch TJ Jr, Lambert JM, Coral F, Shefner J, Wen P, Blattler WA, Collinson AR, Ariniello PD, Braman G, Cook

S, Esseltine D, Elias A, Skarin A, Ritz J. Immunotoxin therapy of small-cell lung cancer: A phase I study of N901-blocked ricin, 723

Ma J, *see* Pronk LC
Ma Y, *see* Press MF
Macdonald D, *see* Leighton C
Macdonald JS, *see* O'Connell MJ
— *see* Tepper JE
— *see* Whitehead RP
Machiavelli M, *see* Lacava JA
Mackenzie RG, *see* Palda VA
Mackillop WJ, Groome PA, Zhang-Solomons J, Zhou Y, Feldman-Stewart D, Paszat L, Dixon P, Holowaty EJ, Cummings BJ. Does a centralized radiotherapy system provide adequate access to care? 1261
—, Zhang-Salomons, Groome PA, Paszat L, Holowaty E. Socioeconomic status and cancer survival in Ontario, 1680
— *see* Brundage MD
Macklis R, *see* Kupelian PA
MacRae ME, *see* Forsyth PAJ
Madden T, *see* Johansen MJ
— *see* Kornblau SM
Maddux P, *see* Hillner BE
Madon E, *see* De Zen L
Maeda T, *see* Yamada Y
Magnasco H, *see* Pavlovsky S
Magrini U, *see* Lazzarino M
Maguire HC Jr, *see* Berd D
Mahallati H, *see* Forsyth PAJ
Maher E, *see* Shepherd FA
Mahjoubi M, *see* Merrouche Y
— *see* Rougier P
Maibach R, *see* Senn HJ
Mailliard JA, *see* Goldberg RM
— *see* O'Connell MJ
— *see* Pitot HC
Maiolino A, *see* Spector N
Majlis A, Pugh WC, Rodriquez MA, Benedict WF, Cabanillas F. Mantle cell lymphoma: Correlation of clinical outcome and biologic features with three histologic variants, 1664
Majolino I, Pearce R, Taghipour G, Goldstone AH for the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: A new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data, 509
Mäkelä P, *see* Saarto T
Makley JT, *see* Provisor AJ
Malats N, *see* Graus F
Malavasi V, *see* Passalacqua R
Malfetano J, *see* ten Bokkel Huinink W
Malhotra D, *see* Stiff PJ
Malkowicz SB, *see* D'Amico AV
Malmström H, *see* ten Bokkel Huinink W
Maloney DG, Grillo-López AJ, Bodkin DJ, White CA, Liles T-M, Royston I, Varns C, Rosenberg J, Levy R. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma, 3266
Mamelle N, *see* Romestaing P
Mamelok RD, *see* Northfelt DW
Mamounas E, *see* Fisher B
Mancini AF, *see* Picci P
Mancuso AA, *see* Mendenhall WM
Mandard A-M, *see* Guillou L
Mandeli JP, *see* Kamthan AG
Manegold C, *see* Lazzarino M
Manfrini M, *see* Picci P
Mangili G, *see* Bolis G
Mangioni C. In reply (letter), 2762
Mann G, *see* Locatelli F
— *see* Schellong G
Mannino T, *see* Salloum E
Mans DRA, *see* Schwartsmann G
Mansfield P, *see* Buzaid AC
Mansi J, *see* Webb A
Marangolo M, *see* Crinò L
Maraninchi D, *see* Michel G
— *see* Stoppa AM
Marcellini M, *see* Cascinu S
Marchese N, *see* Tonini GP
Marcus RB, *see* Weiner MA
Marczell A, *see* Scheithauer W
Margolese RG, *see* Fisher B
Margolin K, *see* Somlo G
Marguerite G, *see* Thyss A
Mariani M, *see* Conte PF
Marin G, *see* Nicoletto MO
Marin S, *see* Hirvikosi P
Marino MT, *see* Takimoto CH
Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J. Simplified regimen for the prevention of paclitaxel-associated hypersensitivity reactions (letter), 3516
Marks DI, Kurz BW, Link MP, Ng E, Shuster JJ, Lauer SJ, Carroll D, Brodsky I, Haines DS. Altered expression of p53 and *mdm*-2 proteins at diagnosis is associated with early treatment failure in childhood acute lymphoblastic leukemia, 1158
Marmont F, *see* Vitolo U
Maron D, *see* Ganem G
Marrero AM, *see* Fong Y
Marshall DD, *see* Copelan EA
Martenson JA, *see* Tepper JE
Martignoni G, *see* Cascinu S
Martin D, *see* Kelsen DP
Martin P, *see* Ganem G
Martin-Algarra S, *see* Pavletic ZS
Martino S, *see* Elledge RM
— *see* Russell CA
Martínez-Monge R, *see* Nag S
Marty M, *see* Merrouche Y
— *see* Rougier P
Martz K, *see* Al-Sarraf M
— *see* Stewart DJ
Marx CM, Stein J, Tyler MK, Nieder ML, Shurin SB, Blumer JL. Ketamine-midazolam versus meperidine-midazo-

lam for painful procedures in pediatric oncology patients, 94
Marzola M, *see* Cavaletti G
Marzorati L, *see* Cavaletti G
Masaoka T, *see* Ohno R
— *see* Szydlo R
Masera G, *see* Aricò M
— *see* Conter V
Masiero L, *see* De Zen L
Mason J, *see* Horning SJ
Mason W, Louis DN, Cairncross JG. Chemosensitive gliomas in adults: Which ones and why? (editorial), 3423
Mason WP, *see* Graus F
Masramon L, *see* Arribas R
Masters GA, Hoffman PC, Hsieh A, Drinkard LC, Mick R, Samuels BL, Guaspari A, Golomb HM, Vokes EE. Phase I study of vinorelbine and ifosfamide in advanced non–small-cell lung cancer, 884
Mastrangelo MJ, *see* Berd D
Mathisen D, *see* Choi NC
Mathur K, *see* Meistrich ML
Matsuda S, *see* Ohno R
Matsuda T, *see* Oshita F
Matsumoto T, *see* Kubota K
Matsumura M, *see* Tanigawa N
Matthews CM, *see* Gordon AN
Mattox S, *see* Tricot G
Matutes E, *see* Pawson R
Mauch PM, *see* Bodis S
Maulard-Durdux C, Toubert ME, Hennequin C, Housset M. Serum tissue polypeptide antigen in bladder cancer as a tumor marker: A prospective study, 3446
Maurer HM, *see* Heyn R
— *see* Raney RB
Maurer LH, Herndon JE II, Hollis DR, Aisner J, Carey RW, Skarin AT, Perry MC, Eaton WL, Zacharski LL, Hammond S, Green MR. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: A Cancer and Leukemia Group B study, 3378
Mauriac L, *see* Piccart MJ
May P, *see* Yule SM
Mayer RJ. In reply (letter), 1286
— *see* Byrd JC
— *see* O'Connell MJ
— *see* Slack JL
Mayo DJ, *see* Horne MK III
Mazingue F, *see* Thyss A
Mazumdar M, *see* McCaffrey JA
— *see* Motzer RJ
— *see* Scher HI
— *see* Xiao H
Mazzocco K, *see* Tonini GP
McAleer C, *see* Giantoni BJ
— *see* Hudes GR
McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Heineman M, Hirsch J, Kelly WK, Scher HI, Bajorin DF. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma, 2449
—, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, Bajorin DF. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma, 1853
—, Mazumdar M, Bajorin DF, Bosl GJ, Vlamis V, Motzer RJ. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: Response and survival, 2559
McCarthy PL Jr, *see* Antman KH
McCarthy WH, *see* Buzaid AC
McDonald MK, *see* Hillner BE
McDowell HP, *see* Yule SM
McGinnis WL, Loprinzi CL, Buskirk SJ, Sloan JA, Drummond RG, Frank AR, Shanahan TG, Kahanic SP, Moore RL, Schild SE, Humphrey SL. Placebo-controlled trial of sucralfate for inhibiting radiation-induced esophagitis, 1239
McGlave PB, *see* Davies SM
McGuire W, Neugut AI, Arikian S, Doyle J, Dezii CM. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer, 640
McGuire WP III, *see* O'Reilly S
McGuirt C, *see* Livingston RB
McKeage MJ, Raynaud F, Ward J, Berry C, O'Dell D, Kelland LR, Murrer B, Santabárabara P, Harrap KR, Judson IR. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer, 2691
McKenzie M, *see* Fennelly D
McKhann C, *see* Haffty BG
McLaughlin P, *see* Meistrich ML
McMillan R, *see* Meisenberg BR
McQuaker IG, Haynes AP, Anderson S, Stainer C, Owen RG, Morgan GJ, Lumley M, Milligan D, Fletcher J, Bessell EM, Davis JM, Russell NH. Engraftment and molecular monitoring of $CD34^+$ peripheral-blood stem-cell transplants for follicular lymphoma: A pilot study, 2288
—, Hunter AE, Pacey S, Haynes AP, Iqbal A, Russell NH. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: Evidence for clinical and economic benefit, 451
McVie JG. Trial etiquette (letter), 2761
Mead GM, *see* Horwich A
Meadows AT, *see* Zelter LK
Mechetner E, *see* Levine EA
Mechinaud F, *see* Coze C
— *see* Michel G
— *see* Thyss A
Meehan KR, *see* Mitchell JM
Meehan M, *see* Webb A
Mehra R, *see* Giralt S
Mehra RC, *see* Johansen MJ
Mehta MP, *see* Tannehill SP
Meisenberg BR, Miller WE, McMillan R, Callaghan M, Sloan C, Brehm T, Kosty MP, Kroener J, Longmire R, Saven A, Piro LD. Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies, 11

Meisner LF, *see* Press MF
Meistrich ML, Wilson G, Mathur K, Fuller LM, Rodriguez MA, McLaughlin P, Romaguera JE, Cabanillas FF, Ha CS, Lipshultz LI, Hagemeister FB. Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease, 3488
Melioli G, *see* Del Mastro L
Mellstedt H, *see* Österborg A
Melpignano M, *see* Bolis G
Menard S, *see* Disis ML
— *see* Pastorino U
Mende W, *see* Loeffler M
Mendenhall WM, Parsons JT, Mancuso AA, Pameijer FJ, Stringer SP, Cassisi NJ. Definitive radiotherapy for T3 squamous cell carcinoma of the glottic larynx, 2394
—, Rout WR, Vauthey J-N, Haigh LS, Zlotecki RA, Copeland EM III. Conservative treatment of rectal adenocarcinoma with endocavitary irradiation or wide local excision and postoperative irradiation, 3241
Mera R, *see* Levine EA
Merajver SD, Weber BL, Cody R, Zhang D, Strawderman M, Calzone KA, LeClaire V, Levin A, Irani J, Halvie M, August D, Wicha M, Lichter A, Pierce LJ. Breast conservation and prolonged chemotherapy for locally advanced breast cancer: The University of Michigan experience, 2873
Mercier R, *see* Kaba SE
Mercuri M, *see* Picci P
Meropol NJ, *see* Soni N
Merritt JA, *see* Quan WDY Jr
Merrouche Y, Extra JM, Abigerges D, Bugat R, Catimel G, Suc E, Marty M, Hérait P, Mahjoubi M, Armand J-P. High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: A feasibility study, 1080
— *see* Rougier P
Mesic JB, *see* Pilepich MV
Metzger R, *see* Leichman CG
Metzner B, *see* Bokemeyer C
Meuli R, *see* Leyvraz S
Meyer LC, *see* Mitchell PLR
Meyer RM, *see* Connors JM
Meyers FJ, *see* Fisher B
Meyskens FL Jr, *see* Atiba JO
Michalak JC, *see* Loprinzi CL
Michel G, Socié G, Gebhard F, Bernaudin F, Thuret I, Vannier JP, Demeocq F, Leverger G, Pico JL, Rubie H, Mechinaud F, Reiffers J, Gratecos N, Troussard X, Jouet JP, Simonin G, Gluckman E, Maraninchi D. Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: The impact of conditioning regimen without total-body irradiation–A report from the Société Française de Greffe de Moelle, 2238
— *see* Thyss A
Michel-Langlet P, *see* Ganem G
Michelotti A, *see* Conte PF
Michiara M, *see* Passalacqua R
Michon J, *see* Coze C
— *see* Rubie H
Mick R, *see* Gupta E
— *see* Masters GA
Mier JW, *see* Du Bois JS
Milan C, *see* de Gramont A
Milanaccio C, *see* Tonini GP
Milano G, *see* Chéradame S
Milisavljevic S, *see* Jeremic B
Milito S, *see* Thomas CR Jr
Miller KD, Loehrer PJ, Gonin R, Einhorn L. Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma, 1427
Miller P, *see* Muggia FM
Miller VA, Benedetti FM, Rigas JR, Verret AL, Pfister DG, Straus D, Kris MG, Crisp M, Heyman R, Loewen GR, Truglia JA, Warrell RP Jr. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069, 790
Miller WE, *see* Meisenberg BR
Milleron B, *see* Pujol J-L
Milligan D, *see* McQuaker IG
Mills JL, *see* Zelter LK
Millward MJ, Zalcberg J, Bishop JF, Webster LK, Zimet A, Rischin D, Toner GC, Laird J, Cosolo W, Urch M, Bruno R, Loret C, James R, Blanc C. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer, 750
Milstein J, *see* Shaw DWW
Mine M, *see* Yamada Y
Ming-Liu J, *see* Perng R-P
Miramón J, *see* Rueda A
Miser A, *see* Ellison N
Miser JS, *see* Provisor AJ
Mitchell C, *see* Yule SM
Mitchell JM, Meehan KR, Kong J, Schulman KA. Access to bone marrow transplantation for leukemia and lymphoma: The role of sociodemographic factors, 2644
Mitchell MS, *see* Quan WDY Jr
Mitchell PLR, Morland B, Stevens MCG, Dick G, Easlea D, Meyer LC, Pinkerton CR. Granulocyte colony-stimulating factor in established febrile neutropenia: A randomized study of pediatric patients, 1163
Mitchell RB, *see* Smith TJ
Mittelman A, *see* Swain SM
Miura Y, *see* Ohno R
Miyadera K, *see* Imazono Y
Miyawaki S, *see* Ohno R
Mizukami Y, *see* Omura K
Mo F, *see* Brady MJ
Mochen C, *see* Costa A
Modiano MR, *see* Burris HA III
Moeller KA, *see* Jakobsen A
Moertel CG, *see* Goldberg RM
Mogensen SC, *see* Bergmann OJ
Molina A, *see* Somlo G
Molina R, *see* Ellison N
Möller P, *see* Lazzarino M
Monconduit M, *see* Moreau P
Monfardini S, *see* Frustaci S
Montbarbon X, *see* Romestaing P
Monteil RA, *see* Raybaud-Diogène H
Montello MJ, *see* Widemann BC

Mooi WJ, *see* Rodenhuis S
Moore JO, *see* Byrd JC
Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N. Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer, 3441
— *see* Burris HA III
Moore RL, *see* McGinnis WL
Moquin J-P, *see* Lofters WS
Morassut S, *see* Nicoletto MO
Moreau P, Fiere D, Bezwoda WR, Facon T, Attal M, Laporte JP, Colombat P, Haak HL, Monconduit M, Lockhorst H, Girault D, Harousseau JL. Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma, 660
— *see* Brice P
Morency R, *see* Raybaud-Diogène H
Moreo P, *see* Viladiu P
Morgan D, *see* Gregor A
Morgan GJ, *see* McQuaker IG
Morgan R Jr, *see* Somlo G
Morland B, *see* Mitchell PLR
Morra E, *see* Lazzarino M
Morris JC, *see* Kamthan AG
Morris MM, Powell SN. Irradiation in the setting of collagen vascular disease: Acute and late complications, 2728
Morris R, *see* Wilimas JA
Morrow CP, *see* Muggia FM
Morvan F, *see* de Gramont A
— *see* Ganem G
Mosconi AM, *see* Crinò L
Moser E, *see* Altehoefer C
Mosher R, *see* Blaney SM
Mosher RB, *see* Dinndorf PA
Motoyoshi K, *see* Ohno R
Motzer R, *see* Burt M
Motzer RJ, Mazumdar M, Bajorin DF, Bosl GJ, Lyn P, Vlamis V. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors, 2546
— *see* McCaffrey JA
— *see* Xiao H
Mousseau M, *see* Rougier P
Mrózek K, *see* Slack JL
— *see* Wetzler M
Muderspach L, *see* Muggia FM
Muggia FM. Salvage treatment of ovarian cancer (letter), 3420
—, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang L-J. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation, 987
Muhlbauer M, *see* Gajjar A
Müller H, *see* Loeffler M
Müller S, *see* Rudolph B
Munn RK, *see* Andrykowski MA
Muñoz KA, Harlan LC, Trimble EL. Patterns of care for women with ovarian cancer in the United States, 3408
Muñoz MT, *see* Viladiu P
Muñoz N, *see* Viladiu P
Munshi N, *see* Tricot G
Munzer M, *see* Thyss A
Murata K, *see* Yamada Y
Muro K, *see* Shirao K
Murphy M, *see* Slater S
Murphy RF, *see* Adamson PC
— *see* Widemann BC
Murphy WK, *see* Fossella FV
Murray N, *see* Moore MJ
Murren JR, Anderson S, Fedele J, Pizzorno G, Belliveau D, Zelterman D, Burtness BA, Tocino I, Flynn SD, Beidler D, Cheng YC. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer, 148
Murrer B, *see* McKeage MJ
Muss H, *see* Chan DW
Mutch DG, *see* Omura GA
Myers CE, *see* Dawson NA

Nachman J, Sather HN, Gaynon PS, Lukens JN, Wolff L, Trigg ME. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: A report from the Children's Cancer Group, 2222
Nachman J, *see* Uckun FM
Nachman JB, *see* Provisor AJ
Nadler E, *see* Heslin MJ
Nag S, Martínez-Monge R, Ruymann F, Jamil A, Bauer C. Innovation in the management of soft tissue sarcomas in infants and young children: High-dose-rate brachytherapy, 3075
Nagasato A, *see* Omura K
Nagler A, *see* Stahel RA
Nakabayashi T, *see* Oshita F
Nakamori S, Furukawa H, Hiratsuka M, Iwanaga T, Imaoka S, Ishikawa O, Kabuto T, Sasaki Y, Kameyama M, Ishiguro S, Irimura T. Expression of carbohydrate antigen sialyl Le`: A new functional prognostic factor in gastric cancer, 816
Nakashima H, *see* Takimoto CH
Namer M, *see* Rougier P
Nascimben O, *see* Nicoletto MO
Nasrati K, *see* Pavletic ZS
Nathan F, *see* Hudes GR
Nathanson L. Cutaneous melanoma, staging system (letter), 3026
Naucke S, *see* Tricot G
Navari R, *see* Lofters WS
Navari RM, *see* Kris MG
Navarro C, *see* Viladiu P
Naylor CD, *see* Palda VA
Negrier S, *see* Rougier P
Négrier S, *see* Thiesse P
Negrin RS, *see* Kusnierz-Glaz CR
Neidhardt-Berard E-M, *see* Warzocha K
Nelson AM, *see* Kris MG

Nelson R, *see* Burris HA III
Nelstrop AE, *see* Rustin GJS
Nemunaitis J, *see* Collins RH Jr
— *see* Gordon AN
Neubauer A, *see* Rudolph B
Neubauer B, *see* Rudolph B
Neuberg D, *see* Janicek M
— *see* Sparano JA
Neuda J, *see* Ludwig H
Neugut AI, *see* McGuire W
Neumann J, *see* Ippoliti C
Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique, *see* Rubie H
New Approaches to Brain Tumor Therapy Central Nervous System Consortium, *see* Fetell MR
Newlands ES, *see* Bower M
— *see* Dark GG
Newman E, *see* Heslin MJ
Newman RA, *see* Johansen MJ
— *see* Kornblau SM
Newman T, *see* Evans WK
Newton DW, *see* Giantoni BJ
Newton WA, *see* Heyn R
Newton WA Jr, *see* Raney RB
Ng E, *see* Marks DI
Nguyen HTB, *see* Pisters PWT
Nicholls J, *see* Lampe H
Nichols C, *see* Vose JM
Nicholson HS, *see* Zelter LK
Nicoletto MO, Tumolo S, Talamini R, Salvagno L, Franceschi S, Visonà E, Marin G, Angelini F, Brigato G, Scarabelli C, Carbone A, Cecchetto A, Prosperi A, Rosabian A, Giusto M, Cima GP, Morassut S, Nascimben O, Vinante O, Fiorentino MV. Surgical second look in ovarian cancer: A randomized study in patients with laparoscopic complete remission—A Northeastern Oncology Cooperative Group-Ovarian Cancer Cooperative Group study, 994
Nicolson M, *see* Webb A
Nieder ML, *see* Marx CM
Nielsen K, *see* Jakobsen A
Nielsen OS, *see* Work E
Niemeyer C, *see* Locatelli F
Ninfo V, *see* De Zen L
Nishida S, *see* Kitamura K
Nishikawa K, *see* Ohno R
Nishiwaki Y, *see* Kubota K
— *see* Oshita F
Nishiyama K, *see* Imazono Y
Nisters-Backes N, *see* Loeffler M
Noda K, *see* Oshita F
Noel D, *see* Soni N
Nonomura A, *see* Omura K
Nooij M, *see* Piccart MJ
Noorduyn LA, *see* Rijks LJM
Norman A, *see* Lampe H
— *see* Webb A
Normolle DP, *see* Chang AE
Norris BD, *see* Pritchard KI
Norris CM Jr, *see* Clark JR
North L, *see* Ayoub J-P
Northfelt DW, Dezube BJ, Thommes JA, Levine R, Von Roenn JH, Dosik GM, Rios A, Krown SE, DuMond C, Mamelok RD. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy, 653
— *see* Levine AM
Nortier HW, *see* Lalisang RI
Norton L, *see* Fennelly D
— *see* Thyss A
Nouvel C, *see* Haioun C
Novakovitch G, *see* Stoppa AM
Novotny PJ, *see* Loprinzi CL
Nowak P, *see* Bokemeyer C
Nozaki Y, *see* Omura K
Nucci M, *see* Spector N

Oates J, *see* Webb A
Oberneder R, *see* Zippelius A
Obrecht JP, *see* Senn HJ
O'Brien M, *see* Adamson PC
— *see* Blaney SM
— *see* Webb A
— *see* Widemann BC
O'Brien S, *see* Kurzrock R
O'Byrne K, *see* Ranson MR
O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, Wieand HS. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer, 246
— *see* Goldberg RM
— *see* Pitot HC
— *see* Tepper JE
O'Connor C, *see* Fennelly D
Oda Y, *see* Shirao K
O'Dell D, *see* McKeage MJ
Odom-Maryon T, *see* Somlo G
O'Dwyer PJ, *see* Johnson CA
Oertel W, *see* Loeffler M
O'Flaherty C, *see* Fennelly D
Ogawa S, *see* Yamada Y
Ognoskie N, *see* Collins RH Jr
Ohashi Y, *see* Ohno R
Ohi Y, *see* Imazono Y
Ohmatsu H, *see* Kubota K
Ohno R, Miyawaki S, Hatake K, Kuriyama K, Saito K, Kanamaru A, Kobayashi T, Kodera Y, Nishikawa K, Matsuda S, Yamada O, Omoto E, Takeyama H, Tsukuda K, Asou N, Tanimoto M, Shiozaki H, Tomonaga M, Masaoka T, Miura Y, Takaku F, Ohashi Y, Motoyoshi K. Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia: A double-blind controlled study, 2954
Ohtsu A, *see* Shirao K
Oka M, *see* Shirao K
Okada Y, *see* Arai Y
Okamoto K, *see* Kitamura K
Olave T, *see* Palomera L

Oliva C, *see* Crinò L
Oliver RTD, *see* Horwich A
Olivotto IA, Coldman AJ, Hislop TG, Trevisan CH, Kula J, Goel V, Sawka C. Compliance with practice guidelines for node-negative breast cancer, 216
Ollivier L, *see* Thiesse P
Olson JF, *see* Graham ML
Omoto E, *see* Ohno R
Omura GA, Blessing JA, Vaccarello L, Berman ML, Clarke-Pearson DL, Mutch DG, Anderson B. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: A Gynecologic Oncology Group study, 165
Omura K, Nagasato A, Kanehira E, Kinsen H, Amaya S, Kimura K, Kajita T, Nozaki Y, Mizukami Y, Nonomura A, Watanabe Y. Retinoblastoma protein and proliferating-cell nuclear antigen expression as predictors of recurrence in well-differentiated papillary thyroid carcinoma, 3458
O'Neil J, *see* Kelsen DP
O'Neill A, *see* Yamauchi H
Ono H, *see* Shirao K
Oosterhof GON, *see* Steffens MG
Oosterwijk E, *see* Steffens MG
Oosterwijk-Wakka JC, *see* Steffens MG
Opalinska J, *see* Busse D
Orchard PJ, *see* Davies SM
Ordoñez NG, *see* Lenzi R
Orefice S, *see* Gianni AM
O'Reilly S, Fleming GF, Baker SD, Walczak JR, Bookman MA, McGuire WP III, Schilder RJ, Alvarez RD, Armstrong DK, Horowitz IR, Ozols RF, Rowinsky EK. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: A Gynecologic Oncology Group study, 177
—, Grochow LB, Donehower RC, Chen T-L, Bowling K, Hartman NR, Struck RF, Rowinsky EK. Phase I and pharmacologic study of penclomedine, a novel alkylating agent, in patients with solid tumors, 1974
O'Reilly SE, *see* Connors JM
— *see* Lee AYY
Orlandi E, *see* Lazzarino M
Ortega JA, *see* Van Tornout JM
Osborne CK, *see* Elledge RM
— *see* Russell CA
Oshita F, Noda K, Nishiwaki Y, Fujita A, Kurita Y, Nakabayashi T, Tobise K, Abe S, Suzuki S, Hayashi I, Kawakami Y, Matsuda T, Tsuchiya S, Takahashi S, Tamura T, Saijo N. Phase II study of irinotecan and etoposide in patients with metastatic non–small-cell lung cancer, 304
Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L for the Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Determinants of postchemotherapy nausea and vomiting in patients with cancer, 116
Ossenkoppele G, *see* Dekker AW
Ossenkoppele GJ, *see* Löwenberg B
Oster W, *see* Rustin GJS
Österborg A, Dyer MJS, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H for the European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia, 1567
O'Sullivan J, *see* Elledge RM
— *see* Russell CA
Otten J, *see* Coze C
Otten J, *see* Thyss A
Otto P, *see* Rudolph B
Overmoyer B, *see* Isaacs C
Owen RG, *see* McQuaker IG
Oyen WJG, *see* Steffens MG
Oza AM, *see* Doyle C
Ozols RF. Treatment of recurrent ovarian cancer: Increasing options—"recurrent" results (editorial), 2177
— *see* O'Reilly S

Paccagnella A, *see* Crinò L
Pacey S, *see* McQuaker IG
Palda VA, Llewellyn-Thomas HA, Mackenzie RG, Pritchard KI, Naylor CD. Breast cancer patients' attitudes about rationing postlumpectomy radiation therapy: Applicability of trade-off methods to policy-making, 3192
Paleologus N, *see* Graham ML
Palmer JL, *see* Younes A
Palmer M, *see* Lofters WS
Palomera L, Domingo JM, Olave T, Romero S, Gutiérrez M. Sinus histiocytosis with massive lymphadenopathy: Complete response to low-dose interferon-α (letter), 2176
Palshof T, *see* Work E
Pameijer FJ, *see* Mendenhall WM
Pampallona S, *see* Leyvraz S
Pancera G, *see* Cascinu S
Pandite AN, *see* Vose JM
Panesar P, *see* Doyle C
Pangalis GA, *see* Österborg A
Pantel K, *see* Zippelius A
Pao CC, Hor JJ, Yang F-P, Lin C-Y, Tseng C-J. Detection of human papillomavirus mRNA and cervical cancer cells in peripheral blood of cervical cancer patients with metastasis, 1008
—, Tseng C-J, Lin C-Y, Yang F-P, Hor JJ, Yao D-S, Hsueh S. Differential expression of telomerase activity in human cervical cancer and cervical intraepithelial neoplasia lesions, 1932
Papac R, *see* Haffty BG
Papadopolous N, *see* Patel SR
Papadopoulos N, *see* Buzaid AC
Paradinas F, *see* Dark GG
Paradise C, *see* Edwards RP
Paradiso LJ, *see* Muggia FM
Paraf F, Jothy S, Van Meir EG. Brain tumor-polyposis syndrome: Two genetic diseases? 2744
Parazzini F, *see* Bolis G
Paridaens R, *see* Piccart MJ
Parmar M, *see* Williams MV
Parodi C, *see* Carella AM
Parsons JT, *see* Mendenhall WM

Parziale A, *see* Frasci G
Pasquetti W, *see* Del Mastro L
Passalacqua R, Cocconi G, Caminiti C, Silingardi V, Bella MA, Bichisao E, Michiara M, Malavasi V, Donati D, Di Costanzo F, Rocca A, Di Sarra S, Scaglione F, Fraschini F. Double-blind, multicenter, randomized trial to compare the effect of two doses of adrenocorticotropic hormone versus placebo in controlling delayed emesis after high-dose cisplatin in adult patients with cancer, 2467
Pastorino U, Andreola S, Tagliabue E, Pezzella F, Incarbone M, Sozzi G, Buyse M, Menard S, Pierotti M, Rilke F. Immunocytochemical markers in stage I lung cancer: Relevance to prognosis, 2858
Paszat L, *see* Mackillop WJ
Patel SR, Vadhan-Raj S, Papadopolous N, Plager C, Burgess MA, Hays C, Benjamin RS. High-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilot studies—dose-response and schedule dependence, 2378
— *see* Pisters PWT
Pater J, *see* Connors JM
— *see* Osoba D
Pater JL, *see* Lofters WS
Paterson AHG, *see* Pritchard KI
Pathare P, *see* Haffty BG
Patil SR, *see* Byrd JC
Patt YZ, Hoque A, Lozano R, Pazdur R, Chase J, Carrasco H, Chuang V, Delpassand ES, Ellis L, Curley S, Roh M, Jones DV Jr. Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon Alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin, 1432
Patten JE, *see* Hainsworth JD
Paul D, *see* Robins HI
Paul NA, *see* Pritchard KI
Paulli M, *see* Lazzarino M
Pavletic ZS, Bishop MR, Tarantolo SR, Martin-Algarra S, Bierman PJ, Vose JM, Reed EC, Gross TG, Kollath J, Nasrati K, Jackson JD, Armitage JO, Kessinger A. Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies, 1608
— *see* Bishop MR
Pavlick AC, Gerdes H, Portlock CS. Endoscopic ultrasound in the evaluation of gastric small lymphocytic mucosa-associated lymphoid tumors, 1761
Pavlovsky S, Schvartzman E, Lastiri F, Magnasco H, Corrado C, Raslawski E, Cancela MEA, Ardaiz MC, Cerutti I, Rosso A, Bruno S, Aranguren PN, Salvarezza A, Donato H, Dibar E, Zirone S. Randomized trial of CVPP for three versus six cycles in favorable-prognosis and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin's disease, 2652
Pawson R, Dyer MJS, Barge R, Matutes E, Thornton PD, Emmett E, Kluin-Nelemans JC, Fibbe WE, Willemze R, Catovsky D. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody, 2667
Paz-Ares L, *see* García-Carbonero R
Pazdur R, Diaz-Canton E, Ballard WP, Bradof JE, Graham S, Arbuck SG, Abbruzzese JL, Winn R. Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma, 2905
— *see* Patt YZ
Peace DJ, *see* Stiff PJ
Pearce R, *see* Majolino I
— *see* Vandenberghe E
— *see* Watts MJ
Peiffert D, *see* Bartelink H
Peinado MA, *see* Arribas R
Pellet J, *see* Tannehill SP
Pelz CJ, *see* Antman KH
Penberthy L, *see* Hillner BE
Pendergrass K, *see* Swain SM
Pendergrass KB, *see* Kris MG
Pendyala L, *see* Soni N
Pennington CN, *see* Graham ML
Penza SL, *see* Copelan EA
Perel Y, *see* Rubie H
Pérez JE, *see* Lacava JA
Perez-Soler R, *see* Fossella FV
Perng R-P, Chen Y-M, Ming-Liu J, Tsai C-M, Lin W-C, Yang K-Y, Whang-Peng J. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non–small-cell lung cancer in a phase II randomized study, 2097
Perrault D, *see* Pritchard KI
Perri P, *see* Tonini GP
Perry MC, *see* Maurer LH
Persson B, *see* Giantoni BJ
Persson I, Thurfjell E, Holmberg L. Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density, 3201
Persson R, *see* Giantoni BJ
Perucho M, *see* Arribas R
Pession A, *see* Locatelli F
— *see* Tonini GP
Pestalozzi BC, Peterson HF, Gelber RD, Goldhirsch A, Gusterson BA, Trihia H, Lindtner J, Cortés-Funes H, Simmoncini E, Byrne MJ, Golouh R, Rudenstam CM, Castiglione-Gertsch M, Allegra CJ, Johnston PG. Prognostic importance of thymidylate synthase expression in early breast cancer, 1923
Peters C, *see* Locatelli F
Peters E, *see* Clark JR
Peterson B, *see* Stock W
Peterson BA, *see* Budman DR
Peterson G, *see* Markman M
Peterson HF, *see* Pestalozzi BC
Petrek JA, Hudgins LC, Ho M, Bajorunas DR, Hirsch J. Fatty acid composition of adipose tissue, an indication of dietary fatty acids, and breast cancer prognosis, 1377
Petrella T, *see* Caillot D
Petroni GR, *see* Budman DR
— *see* Tepper JE
Petrov E, *see* Forsyth PAJ
Petsch S, *see* Loeffler M
Pettenati MJ, *see* Slack JL
Peyroulet MC, *see* Rubie H
Pezzella F, *see* Pastorino U

Pfab R, *see* Loeffler M
Pfister DG, *see* Miller VA
Pflüger H, *see* Loeffler M
Pfreundschuh M, *see* Loeffler M
Philip T, *see* Coze C
Philippe N, *see* Thyss A
Phillips RN, *see* Press MF
Piantadosi S, *see* Grossman SA
Piantadosi S, *see* Fetell MR
Piard F, *see* Caillot D
Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A, Van Glabbeke M. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: Final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer, 3149
Picci P, Böhling T, Bacci G, Ferrari S, Sangiorgi L, Mercuri M, Ruggieri P, Manfrini M, Ferraro A, Casadei R, Benassi MS, Mancini AF, Rosito P, Cazzola A, Barbieri E, Tienghi A, Brach del Prever A, Comandone A, Bacchini P, Bertoni F. Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities, 1553
Pichlmayr R, *see* Klempnauer J
Pico JL, *see* Michel G
Pidlich J, *see* Scheithauer W
Pierart M, *see* Bartelink H
Pierce LJ, *see* Merajver SD
Pierce S, *see* Estey E
Pierotti M, *see* Pastorino U
Pignard K, *see* Thiesse P
Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU, Grignon D. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group protocol 85-31, 1013
Pinedo HM, *see* Apolinario RM
— *see* Huizing MT
Pinkerton CR, *see* Mitchell PLR
— *see* Shankar AG
Pinkus G, *see* Bodis S
Pintilie M, *see* Doyle C
Piro L, *see* Saven A
Piro LD, *see* Meisenberg BR
Pirruccello SJ, *see* Bishop MR
Pisters PWT, Patel SR, Varma DGK, Cheng S-C, Chen NP, Nguyen HTB, Feig BW, Pollack A, Pollock RE, Benjamin RS. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: Long-term results from a single institution, 3481
— *see* Spitz FR
Pitot HC, Wender DB, O'Connell MJ, Schroeder G, Goldberg RM, Rubin J, Mailliard JA, Knost JA, Ghosh C, Kirschling RJ, Levitt R, Windschitl HE. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma, 2910
Piver MS. Systematic surgical staging: Stage I ovarian cancer (letter), 864
Pizzo BA, *see* Kris MG
Pizzorno G, *see* Chambers SK
— *see* Murren JR
Pizzuti M, *see* Vitolo U
Plager C, *see* Buzaid AC
— *see* Patel SR
Plagne R, *see* Legros M
Plantaz D, *see* Coze C
— *see* Rubie H
— *see* Thyss A
Planting AST, *see* Creemers GJ
— *see* Pronk LC
Plouvier E, *see* Coze C
— *see* Thyss A
Podestà M, *see* Carella AM
Poen JC, *see* Torrey MJ
Polin V, *see* Pujol J-L
Poljicak M, *see* Pritchard KI
Pollack A, *see* Pisters PWT
Pollera CF. More is better but . . . how is best: Are milligrams over hours better than grams over minutes? The case of gemcitabine (letter), 2172
Pollock RE, *see* Pisters PWT
— *see* Seymour JF
Ponticiello A, *see* Castaldo G
Poplack DG, *see* Blaney SM
Portenoy RK, *see* Burris HA III
Porter A, *see* Pilepich MV
Porter DL, *see* Collins RH Jr
Portlock CS, *see* Pavlick AC
Posner JB, *see* Graus F
Posner MR, *see* Clark JR
Postmus P, *see* Ardizzoni A
Postmus PE, *see* Apolinario RM
— *see* Gregor A
— *see* Huizing MT
Potkul RK, *see* Stiff PJ
Poulin MD, *see* Clark JR
Powell SN, *see* Morris MM
Powers C, *see* Heimann R
Prasad M, *see* Fong Y
Pratt CB, *see* Kaste SC
Prencipe E, *see* Carella AM
Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou J-Y, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR, Flom KJ. HER-2/*neu* gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas, 2894
Prince HM, Wirth A, Wolf M. Hodgkin's disease failures: Incorporating radiotherapy and high-dose treatment (letter), 3022
Pritchard KI, Paterson AHG, Fine S, Paul NA, Zee B, Shepherd LE, Abu-Zahra H, Ragaz J, Knowling M, Levine MN, Verma S, Perrault D, Walde PLD, Bramwell VHC, Poljicak M, Boyd N, Warr D, Norris BD, Bowman D, Armitage GR, Weizel H, Buckman RA the National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy

in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: A report of the National Cancer Institute of Canada Clinical Trials Group, 2302
Pritchard KI, *see* Palda VA
— *see* Stewart DJ
Proebstle TM, *see* Keilholz U
Prolla G, *see* Schwartsmann G
Pronk LC, Schellens JHM, Planting AST, van den Bent MJ, Hilkens PHE, van der Burg MEL, de Boer-Dennert M, Ma J, Blanc C, Harteveld M, Bruno R, Stoter G, Verweij J. Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors, 1071
Propert KJ, *see* Beard CJ
— *see* Saxman SB
Prosperi A, *see* Nicoletto MO
Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ, Huvos AG, Betcher DL, Baum ES, Kisker CT, Miser JS. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: A report from the Children's Cancer Group, 76
Przepiorka D, *see* Giralt S
— *see* Ippoliti C
Pucci F, *see* Crinò L
Pugh R, *see* Elledge RM
— *see* Fisher B
Pugh WC, *see* Majlis A
Pui C-H, *see* Hudson MM
— *see* Rubnitz JE
Pujol J-L, Douillard J-Y, Rivière A, Quoix E, Lagrange J-L, Berthaud P, Bardonnet-Comte M, Polin V, Gautier V, Milleron B, Chomy F, Chomy P, Spaeth D, Le Chevalier T. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: A multicenter randomized phase III study, 2082
Pukander J, *see* Hirvikosi P
Pulcheri W, *see* Spector N
Punt CJA, *see* Keilholz U
Pupa SM, *see* Disis ML
Purohit OP, *see* Vinholes J

Qu RP, *see* Robins HI
Quaglini S, *see* Liberato NL
Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group, *see* Osoba D
Quan WDY Jr, Dean GE, Spears L, Spears CP, Groshen S, Merritt JA, Mitchell MS. Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: A phase I/II trial of I-Mel-2 plus SAF-m, 2103
Quella SK, *see* Loprinzi CL
Quinn CT, Griener JC, Bottiglieri T, Hyland K, Farrow A, Kamen BA. Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer, 2800
Quinn JJ, *see* Van Tornout JM
Quirt I, *see* Connors JM
Qumsiyeh M, *see* Byrd JC
Quoix E, *see* Pujol J-L

Raber MN, *see* Lenzi R
Raderer M, *see* Scheithauer W
Radford M, *see* Shankar AG
Radie-Keane K, *see* Safran H
Raffel C, *see* Galanis E
Ragaz J, *see* Pritchard KI
Raghavan D, *see* Saxman SB
— *see* Stadler WM
Rago RP, *see* Berlin J
Rahman ZU, Frye DK, Buzdar AU, Smith TL, Asmar L, Champlin RE, Hortobagyi GN. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer, 3171
Rai KR, *see* Hoffman MA
Raimondi SC, *see* Rubnitz JE
Raitiola H, *see* Hirvikosi P
Ramirez J, *see* Gupta E
Ramsay NKC, *see* Davies SM
Ranada JMF, *see* Vose JM
Rand W, *see* Du Bois JS
Raney RB, Asmar L, Newton WA Jr, Bagwell C, Breneman JC, Crist W, Gehan EA, Webber B, Wharam M, Wiener ES, Anderson JR, Maurer HM. Ewing's sarcoma of soft tissues in childhood: A report from the Intergroup Rhabdomyosarcoma study, 1972 to 1991, 574
— *see* Heyn R
Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial, 3185
Rao KW, *see* Slack JL
Raoul Y, *see* Ganem G
Raschko J, *see* Somlo G
Raslawski E, *see* Pavlovsky S
Rass K, *see* Gläser R
Ratain MJ, *see* Gupta E
Ravdin P, *see* Elledge RM
Raybaud-Diogène H, Fortin A, Morency R, Roy J, Monteil RA, Têtu B. Markers of radioresistance in squamous cell carcinomas of the head and neck: A clinicopathologic and immunohistochemical study, 1030
Raynaud F, *see* McKeage MJ
Re GL, *see* Frustaci S
Rea LA, *see* de Wit R
Real FX, *see* Graus F
Reaman G, *see* Adamson PC
Reaman GH, *see* Blaney SM
— *see* Dinndorf PA
— *see* Uckun FM
Recht A. Preoperative chemotherapy and breast-conserving therapy: Why not everyone? (editorial), 2479
Reddy S, *see* Swain SM
Reed E, *see* Dawson NA
— *see* Kohn EC

Reed EC, *see* Pavletic ZS
Reiffers J, *see* Michel G
Reiss M, *see* Haffty BG
Reiter A, *see* Conter V
Renard N, *see* Warzocha K
Reñé R, *see* Graus F
Resbeut M, *see* Stoppa AM
Resegotti L, *see* Vitolo U
Retchin SM, *see* Hillner BE
Reyes F, *see* Haioun C
Rialland X, *see* Thyss A
Ribelles N, *see* Rueda A
Rich TA, Janjan NA, Abbruzzese JL, Evans DB. In reply (letter), 3292
— *see* Spitz FR
Richardson RR, *see* Witte RS
Richiardi G, *see* Bolis G
Ridder GJ, *see* Klempnauer J
Riehm H, *see* Conter V
Rieker PP, *see* Beard CJ
Ries CA, *see* Smith GA
Rietbroek RC, *see* Rijks LJM
Riethmüller G, *see* Zippelius A
Rieux C, *see* Thieblemont C
Rigas JR, *see* Miller VA
Rijks LJM, Bakker PJM, van Tienhoven G, Noorduyn LA, Boer GJ, Rietbroek RC, Taat CW, Janssen AGM, Veenhof CHN, van Royen EA. Imaging of estrogen receptors in primary and metastatic breast cancer patients with iodine-123–labeled Z-MIVE, 2536
Rilke F, *see* Gianni AM
— *see* Pastorino U
Rinck GC, van den Bos GAM, Kleijnen J, de Haes HJCJM, Schadé E, Veenhof CHN. Methodologic issues in effectiveness research on palliative cancer care: A systematic review, 1697
Rios A, *see* Northfelt DW
Rischin D, *see* Millward MJ
Risley GL, *see* Copelan EA
Ritschl P, *see* Brodowicz T
Ritter J, *see* Schellong G
Ritter M, *see* Rudolph B
Ritz J, *see* Lynch TJ Jr
Rivera E, *see* Fossella FV
Rivera GK, *see* Rubnitz JE
Rivière A, *see* Pujol J-L
Rivkin S, *see* Elledge RM
Rizzari C, *see* Conter V
Robert A, *see* Thyss A
Robert NJ, *see* Isaacs C
— *see* Sparano JA
Robidoux A, *see* Fisher B
Robins HI, Rushing D, Kutz M, Tutsch KD, Tiggelaar CL, Paul D, Spriggs D, Kraemer C, Gillis W, Feierabend C, Arzoomanian RZ, Longo W, Alberti D, d'Oleire F, Qu RP, Wilding G, Stewart JA. Phase I clinical trial of melphalan and 41.8°C whole-body hyperthermia in cancer patients, 158
Robinson RA, *see* Press MF
Robison LL, *see* Zelter LK
Rocca A, *see* Passalacqua R
Rockwell S, *see* Haffty BG
Rodenhuis S, Boerrigter L, Top B, Slebos RJC, Mooi WJ, van't Veer L, van Zandwijk N. Mutational activation of the K-*ras* oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: A prospective study, 285
— *see* Huizing MT
Rodriguez GI, *see* Creemers GJ
Rodriguez MA, *see* Meistrich ML
Rodriquez MA, *see* Majlis A
Roelofsen F, *see* Bartelink H
Roethke S, *see* Hudes GR
Rogers D, *see* Tonini GP
Rogers E, *see* Eastham JA
Roh M, *see* Patt YZ
Rohatiner AZS, *see* Slater S
Rohloff R, *see* Loeffler M
Romaguera JE, *see* Meistrich ML
Roman L, *see* Muggia FM
Romero AO, *see* Lacava JA
Romero S, *see* Palomera L
Romestaing P, Lehingue Y, Carrie C, Coquard R, Montbarbon X, Ardiet J-M, Mamelle N, Gérard J-P. Role of a 10-gy boost in the conservative treatment of early breast cancer: Results of a randomized clinical trial in Lyon, France, 963
Romond EH, *see* Fisher B
Ronayne L, *see* Du Bois JS
Rondon G, *see* Johansen MJ
Roninson IB, *see* Levine EA
Rosabian A, *see* Nicoletto MO
Rose E, *see* Hoffman MA
Rosell R, *see* Graus F
Rosen H, *see* Scheithauer W
Rosenberg J, *see* Maloney DG
Rosenberg SA, *see* Horning SJ
Rosing H, *see* Huizing MT
Rosito P, *see* Picci P
Rosmarin A, *see* Safran H
Ross E, *see* Hudes GR
Ross JS, *see* Press MF
Ross MI, *see* Buzaid AC
— *see* Jung FA
Rossbach J, *see* Clahsen PC
Rossi A, *see* Vitolo U
Rossi RM, *see* Clark JR
Rosso A, *see* Pavlovsky S
Rosso R, *see* Del Mastro L
Rota S, *see* Cavaletti G
Roth B, *see* Stadler WM
Rothenberg ML, *see* Burris HA III
Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P, Mahjoubi M. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy, 0251
Rougier P, *see* Bartelink H

— *see* de Gramont A
Rousset MT, *see* Lazzarino M
Rout WR, *see* Mendenhall WM
Rowinsky E, *see* Fetell MR
Rowinsky EK, *see* O'Reilly S
Rowland KM, *see* Ellison N
Rowland KM Jr, *see* Loprinzi CL
Rowley S, *see* Demirer T
Rowlings PA, *see* Antman KH
— *see* Szydlo R
Roy J, *see* Raybaud-Diogène H
Royston I, *see* Maloney DG
Rubens RD, *see* Bartelink H
Rubie H, Hartmann O, Michon J, Frappaz D, Coze C, Chastagner P, Baranzelli MC, Plantaz D, Avet-Loiseau H, Bénard J, Delattre O, Favrot M, Peyroulet MC, Thyss A, Perel Y, Bergeron C, Courbon-Collet B, Vannier J-P, Lemerle J, Sommelet D for the Neuroblastoma Study Group of the Société Française d'Oncologie Pédiatrique. N-*Myc* gene amplification is a major prognostic factor in localized neuroblastoma: Results of the French NBL 90 study, 1171
— *see* Coze C
— *see* Michel G
Rubin J, *see* Pitot HC
Rubinger M, *see* Bow EJ
Rubinstein L, *see* Smith MA
Rubnitz JE, Downing JR, Pui C-H, Shurtleff SA, Raimondi SC, Evans WE, Head DR, Crist WM, Rivera GK, Hancock ML, Boyett JM, Buijs A, Grosveld G, Behm FG. *TEL* gene rearrangement in acute lymphoblastic leukemia: A new genetic marker with prognostic significance, 1150
Rucinski J, *see* Kulvatunyou N
Rudenstam CM, *see* Pestalozzi BC
Rudoler SB, Shields CL, Corn BW, De Potter P, Hyslop T, Curran WJ Jr, Shields JA. Functional vision is improved in the majority of patients treated with external-beam radiotherapy for choroid metastases: A multivariate analysis of 188 patients, 1244
Rudolph B, Bayerdörffer E, Ritter M, Müller S, Thiede C, Neubauer B, Lehn N, Seifert E, Otto P, Hatz R, Stolte M, Neubauer A. Is the polymerase chain reaction or cure of *helicobacter pylori* infection of help in the differential diagnosis of early gastric mucosa-associated lymphatic tissue lymphoma? 1104
Rueda A, Alba E, Ribelles N, Sevilla I, Ruiz I, Miramón J. Six cycles of ABVD in the treatment of stage I and II Hodgkin's lymphoma: A pilot study, 1118
Ruggieri P, *see* Picci P
Rugo HS, *see* Smith GA
Rühl U, *see* Loeffler M
Ruhland S, *see* Ahlert T
Ruiz I, *see* Rueda A
Rushing D, *see* Robins HI
Russell CA, Green SJ, O'Sullivan J, Hynes HE, Budd GT, Congdon JE, Martino S, Osborne CK. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor–positive metastatic breast cancer: A Southwest Oncology Group phase III trial, 2494
Russell NH, *see* McQuaker IG
Rusthoven JJ, *see* Evans WK
Rustin GJS, Nelstrop AE, Crawford M, Ledermann J, Lambert HE, Coleman R, Johnson J, Evans H, Brown S, Oster W. Phase II trial of oral altretamine for relapsed ovarian carcinoma: Evaluation of defining response by serum CA125, 172
— *see* Bower M
— *see* Dark GG
Rustum YM, Harstrick A, Cao S, Vanhoefer U, Yin M-B, Wilke H, Seeber S. Thymidylate synthase inhibitors in cancer therapy: Direct and indirect inhibitors, 389
Rutqvist LE, *see* Gyenes G
Ruymann F, *see* Nag S

Saarto T, Blomqvist C, Välimäki M, Mäkelä P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients, 1341
Sacchetti L, *see* Castaldo G
Sadan S, *see* McCaffrey JA
Sadura A, *see* Connors JM
Saez R, *see* Antman KH
Safran H, King TP, Choy H, Hesketh PJ, Wolf B, Altenhein E, Sikov W, Rosmarin A, Akerley W, Radie-Keane K, Cicchetti G, Lopez F, Bland K, Wanebo HJ. Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: A phase I study, 901
Sahmoud T, *see* Gregor A
Saijo N, *see* Oshita F
Sais G, *see* Jucgla A
Saito D, *see* Shirao K
Saito K, *see* Ohno R
Salem G, *see* Scheithauer W
Salem R, *see* Haffty BG
Salles B, *see* Bastion Y
Salles G, *see* Bastion Y
— *see* Thieblemont C
— *see* Warzocha K
Salloum E, Brandt DS, Caride VJ, Cornelius E, Zelterman D, Schubert W, Mannino T, Cooper DL. Gallium scans in the management of patients with Hodgkin's disease: A study of 101 patients, 518
Salmon R, *see* Leyvraz S
Saltz L, *see* Kelsen DP
Salvadori B, *see* Conte PF
— *see* Gianni AM
Salvadori MA, *see* Lacava JA
Salvagno L, *see* Nicoletto MO
Salvarezza A, *see* Pavlovsky S
Salvati F, *see* Crinò L
Salvatore F, *see* Castaldo G
Salzmann R, *see* Keilholz U
Samuels BL, *see* Masters GA
Sanchez JR, *see* Caceres W
Sanchez-Williams G, *see* Kornblau SM
Sandberg E, *see* Jakobsen A
Sander E, *see* Schwartsmann G
Sanduzzi A, *see* Castaldo G

Sanford RA, *see* Gajjar A
Sangiorgi L, *see* Picci P
Santabárabara P, *see* McKeage MJ
Santoro A, *see* Bonfante V
Santucci A, *see* Crinò L
Sargent DJ, *see* Goldberg RM
Sarna S, *see* Saarto T
Sarosdy M, *see* Xiao H
Sarosy GA, *see* Kohn EC
Sarris AH. Prognostic factors in early-stage Hodgkin's disease (letter), 411
Sartor O, *see* Dawson NA
Sartorelli AC, *see* Haffty BG
Sasaki CT, *see* Haffty BG
Sasaki Y, *see* Nakamori S
Sastre-Garau X, *see* Guillou L
Sather HN, *see* Nachman J
— *see* Uckun FM
Sato JK, *see* Dinndorf PA
Sato T, *see* Berd D
Sauer R, *see* Loeffler M
Sauerbrei W, *see* Ahlert T
Saur H-B, *see* Lerch H
Sausville EA, *see* Dawson NA
Savarese DMF, Hsieh C-c, Stewart FM. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors, 2981
Savary J, *see* Thiesse P
Saven A, Lee T, Schlutz M, Jacobs A, Ellison D, Longmire R, Piro L. Major activity of cladribine in patients with de novo B-cell prolymphocytic leukemia, 37
— *see* Meisenberg BR
Sawai K, *see* Kitamura K
Sawka C, *see* Olivotto IA
Sawyer JR, *see* Stine KC
— *see* Tricot G
Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, Loehrer PJ Sr, Trump D. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study, 2564
—, Seitz D. Breast cancer associated with palmar fasciitis and arthritis, 3515
Saylors RL, *see* Stine KC
Scadden DT, *see* Levine AM
Scaglione F, *see* Passalacqua R
Scagliotti G, *see* Crinò L
Scarabelli C, *see* Bolis G
— *see* Nicoletto MO
— *see* ten Bokkel Huinink W
Scardino PT, *see* Eastham JA
Scarffe JH, *see* Webb A
Scarfone G, *see* Bolis G
Scaruffi P, *see* Tonini GP
Schacter B, *see* Bow EJ
Schacter LP, *see* Soni N
Schadé E, *see* Rinck GC
Schadendorf D, *see* Keilholz U
Schaefer B, *see* Ardizzoni A
Schaefer PL, *see* Goldberg RM
— *see* Loprinzi CL
Schaefers MCW, *see* Huizing MT
Schalk K, *see* Loeffler M
Scheibenbogen C, *see* Keilholz U
Schein M, *see* Kulvatunyou N
Schein P, *see* Blanke CD
Scheithauer BW, *see* Galanis E
Scheithauer W, Kornek G, Marczell A, Salem G, Karner J, Kovats E, Burger D, Greiner R, Pidlich J, Schneeweiss B, Raderer M, Rosen H, Depisch D. Fluorouracil plus racemic leucovorin versus fluorouracil combined with the pure *l*-isomer of leucovorin for the treatment of advanced colorectal cancer: A randomized phase III study, 908
Schellens JHM, *see* Creemers GJ
— *see* Pronk LC
Schellong G, Creutzig MRU, Ritter J, Harbott J, Mann G, Gadner H for the German-Austrian Pediatric Hodgkin's Disease Group. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease, 2247
Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, Kolvenbag G, Shapiro L, Schwartz M. Bicalutamide for advanced prostate cancer: The natural versus treated history of disease, 2928
— *see* McCaffrey JA
Schick HD, *see* Loeffler M
Schiffer CA, *see* Byrd JC
— *see* Slack JL
— *see* Stock W
Schild SE, *see* McGinnis WL
Schilder RJ, *see* O'Reilly S
Schildknecht O, *see* Senn HJ
Schiller D. Malignancy-associated microangiopathic hemolytic anemia, 2474
Schiller JH, *see* Tannehill SP
Schirrmacher V, *see* Ahlert T
Schlegel PG, *see* Kusnierz-Glaz CR
Schlimok G, *see* Zippelius A
Schlom J, *see* Tempero M
Schlossman DM, *see* Budman DR
Schluter SF, *see* Stopeck AT
Schlutz M, *see* Saven A
Schmid H-J, *see* Locatelli F
Schmit-Pokorny K, *see* Bishop MR
Schmitz N, *see* Smith TJ
Schmoll H-J, *see* Bokemeyer C
Schneeweiss B, *see* Scheithauer W
Schneider M, *see* Chéradame S
Schober O, *see* Lerch H
Scholl MD, *see* Copelan EA
Schomberg PJ, *see* Galanis E
Schoppe W, *see* Loeffler M
Schornagel JH, *see* Sneeuw KCA
Schousboe BMB, *see* Herrstedt J
Schouten HC, *see* Dekker AW
— *see* Lalisang RI
— *see* Löwenberg B
Schrappe M, *see* Conter V
Schreeder MT, *see* Hainsworth JD
Schriber JR, *see* Kusnierz-Glaz CR

Schroeder G, *see* Pitot HC
Schubert W, *see* Salloum E
Schuchter LM, *see* Berd D
Schuler BS, *see* Georgiadis MS
Schulman KA, *see* Mitchell JM
Schultz D, *see* D'Amico AV
Schultz J, *see* Giantoni BJ
Schumacher J, *see* Ahlert T
Schumacher K, *see* Busse D
Schumacher M, *see* Ahlert T
Schuster MW, *see* Isaacs C
— *see* Vose JM
Schvartzman E, *see* Pavlovsky S
Schwartsmann G, Sprinz E, Kromfield M, Kalakun L, Sander E, Prolla G, Di Leone L, Gerhardt L, Mans DRA. Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma with no prior exposure to cytotoxic therapy, 2118
Schwartz G, *see* Kelsen DP
Schwartz GK, *see* Casper ES
Schwartz L, *see* Scher HI
Schwartz M, *see* Scher HI
Schwartz PE, *see* Chambers SK
Schwarze E-W, *see* Loeffler M
Schwarzkopf J, *see* Altehoefer C
Schweizer E, *see* Busse D
Scoppa G, *see* Frasci G
Sebban C, *see* Bastion Y
— *see* Wendum D
Seeber S, *see* Rustum YM
Seibel NL, *see* Blaney SM
— *see* Dinndorf PA
Seifert E, *see* Rudolph B
Seiter K, Feldman EJ, Halicka HD, Traganos F, Darzynkiewicz Z, Lake D, Ahmed T. Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia, 44
Seiter S, *see* Gläser R
Seitz D, *see* Saxman SB
Seitz JF, *see* Rougier P
Sekine I, *see* Kubota K
Sellers WR, Kaelin WG Jr. Role of the retinoblastoma protein in the pathogenesis of human cancer, 3301
Seileslags J, *see* Piccart MJ
Senderowicz AM, *see* Dawson NA
Senn HJ, Maibach R, Castiglione M, Jungi WF, Cavalli F, Leyvraz S, Obrecht JP, Schildknecht O, Siegenthaler P. Adjuvant chemotherapy in operable breast cancer: Cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil—11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82, 2502
Sensel MG, *see* Uckun FM
Seong D, *see* Giralt S
Serrano J, *see* Sutliff VE
Sertoli MR, *see* Clahsen PC
— *see* Del Mastro L
Sessarego M, *see* Carella AM
Sevick RJ, *see* Forsyth PAJ
Sevilla I, *see* Rueda A
Seymour JF, Cusack JD, Lerner SA, Pollock RE, Keating MJ. Case/control study of the role of splenectomy in chronic lymphocytic leukemia, 52
Shah KV, *see* Viladiu P
Shanahan TG, *see* McGinnis WL
Shankar AG, Ashley S, Radford M, Barrett A, Wright D, Pinkerton CR. Does histology influence outcome in childhood Hodgkin's disease? Results from the United Kingdom Children's Cancer Study Group, 2622
Shannon B, *see* Giantoni BJ
Shapiro C, *see* Guadagnoli E
Shapiro CL, Ayash L, Webb IJ, Gelman R, Keating J, Williams L, Demetri G, Clark P, Elias A, Duggan D, Hayes D, Hurd D, Henderson IC. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients, 674
Shapiro F, *see* Fennelly D
Shapiro L, *see* Du Bois JS
— *see* Scher HI
Sharp GB, *see* Hudson MM
Shaw DWW, Geyer JR, Berger MS, Milstein J, Lindsley KL. Asymptomatic recurrence detection with surveillance scanning in children with medulloblastoma, 1811
Shaw E. Looking through the retrospectoscope in the era of evidence-based medicine (editorial), 1289
Shefner J, *see* Lynch TJ Jr
Sheidler V, *see* Grossman SA
Sheinfeld J, *see* Burt M
Shepherd FA. In reply (letter), 2173
—, Maher E, Cardella C, Cole E, Greig P, Wade JA, Levy G. Treatment of Kaposi's sarcoma after solid organ transplantation, 2371
— *see* Evans WK
— *see* Stewart DJ
Shepherd J, *see* Gore M
Shepherd LE, *see* Pritchard KI
Sher DA, *see* Stock W
Shibamoto Y, *see* Jeremic B
Shibata S, *see* Somlo G
Shields CL, *see* Rudoler SB
Shields JA, *see* Rudoler SB
Shimada Y, *see* Shirao K
Shimomatsuya T, *see* Tanigawa N
Shin DM, *see* Fossella FV
Shiomoto G, *see* Brady MJ
Shiozaki H, *see* Ohno R
Shipley WU, *see* Kachnic LA
— *see* Pilepich MV
Shipp MA, *see* Janicek M
Shirao K, Shimada Y, Kondo H, Saito D, Yamao T, Ono H, Yokoyama T, Fukuda H, Oka M, Watanabe Y, Ohtsu A, Boku N, Fujii T, Oda Y, Muro K, Yoshida S. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer, 921
Shore TB, *see* Bow EJ
Short D, *see* Bower M
Shpilberg O, *see* Collins RH Jr
Shu S, *see* Chang AE
Shulman LH, *see* Janicek M
Shulman LN, *see* Bodis S
Shurin SB, *see* Marx CM

Shurtleff SA, *see* Rubnitz JE
Shuster JJ, *see* Marks DI
— *see* Winick N
Shustik C, *see* Connors JM
Sieber M, *see* Loeffler M
Siegel D, *see* Tricot G
Siegenthaler P, *see* Senn HJ
Siena S, *see* Gianni AM
Sigsgaard T, *see* Herrstedt J
Sikov W, *see* Safran H
Silingardi V, *see* Passalacqua R
Silliman RA, *see* Guadagnoli E
Silva RR, *see* Cascinu S
Silver B, *see* Bodis S
Silver RT, *see* Stock W
Silverberg I, *see* Levine AM
Silvestrini R, *see* Costa A
Simes RJ, *see* Byrne MJ
Simiantonaki N, *see* Ahlert T
Simmoncini E, *see* Pestalozzi BC
Simon R, *see* Smith MA
Simonin G, *see* Michel G
Simpson J, *see* Somlo G
Singer S, *see* Vonderheide RH
Siu LL, Tannock IF. Chemotherapy dose escalation: Case unproven (editorial), 2765
Sizoo W, *see* Dekker AW
Skarin A, *see* Lynch TJ Jr
— *see* Takvorian T
— *see* Vance E
Skarin AT, *see* Burstein HJ
— *see* Hahn WC
— *see* Maurer LH
Skillings J, *see* Connors JM
Sklar J, *see* West DC
Sklaroff RB. Tumor marker guidelines (letter), 2175
Skoczeń S, *see* Balwierz W
Skullerud K, *see* Lote K
Slack JL, Arthur DC, Lawrence D, Mrózek K, Mayer RJ, Davey FR, Tantravahi R, Pettenati MJ, Bigner S, Carroll AJ, Rao KW, Schiffer CA, Bloomfield CD. Secondary cytogenetic changes in acute promyelocytic leukemia—Prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: A Cancer and Leukemia Group B study, 1786
Slamon DJ, *see* Press MF
Slater S, Rohatiner AZS, Murphy M, Amess J, Carter M, Lister TA, Johnson S, Ewings M. Treatment of acute myelogenous leukemia (letter), 1710
Slebos RJC, *see* Rodenhuis S
Sledge GW, *see* Sparano JA
Sleiffer DT, *see* Horwich A
— *see* Steyerberg EW
Sleiffer DTh, *see* de Wit R
— *see* van Basten JPA
Sloan C, *see* Meisenberg BR
Sloan J, *see* Loprinzi CL
Sloan JA, *see* Ellison N
— *see* Loprinzi CL
— *see* McGinnis WL
Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm, 382
Smeele LE, Kostense PJ, van der Waal I, Snow GB. Effect of chemotherapy on survival of craniofacial osteosarcoma: A systematic review of 201 patients, 363
Smith A, *see* Vose JM
Smith D, *see* Ranson MR
— *see* Stiff PJ
Smith DB, *see* Faigel DO
Smith GA, Damon LE, Rugo HS, Ries CA, Linker CA. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency, 833
Smith MA, Ungerleider RS, Korn EL, Rubinstein L, Simon R. Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute, 2736
Smith TJ, Hillner BE, Mitchell RB. Decision analysis in non–small-cell lung cancer: Not back to the modeling board, back to the bedside (editorial), 870
—, Hillner BE, Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Link H, Zander A, Yanovich S, Kitchin R, Erder MH. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and Non-Hodgkin's lymphoma, 5
— *see* Hillner BE
Smith TL, *see* Rahman ZU
Sneeuw KCA, Aaronson NK, Sprangers MAG, Detmar SB, Wever LDV, Schornagel JH. Value of caregiver ratings in evaluating the quality of life of patients with cancer, 1206
Snell V, *see* Kornblau SM
— *see* Younes A
Snow GB, *see* Smeele LE
Sobocinski KA, *see* Antman KH
Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer—A tale of two drugs: Implications for biochemical modulation, 368
Socié G, *see* Michel G
Soiffier RJ. Donor lymphocyte infusions: The door is open (editorial), 416
Sol C, *see* Legros M
Solal-Céligny P, *see* Brice P
Solary E, *see* Caillot D
Solbu G, *see* Thyss A
Solow H, *see* Lipton JH
Soltis MJ, *see* Kohn EC
Somlo G, Doroshow JH, Forman SJ, Odom-Maryon T, Lee J, Chow W, Hamasaki V, Leong L, Morgan R Jr, Margolin K, Raschko J, Shibata S, Tetef M, Yen Y, Simpson J, Molina A. High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: Prognostic indicators of progression-free and overall survival, 2882
Sommaggio A, *see* De Zen L
Sommelet D, *see* Rubie H
Son YH, *see* Haffty BG
Soncini F, *see* Bonfante V

Sondak VK, *see* Chang AE
Sondel PM, *see* Szydlo R
Soni N, Meropol NJ, Pendyala L, Noel D, Schacter LP, Gunton KE, Creaven PJ. Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer, 766
Sonneveld P, *see* Dekker AW
Soong S-J, *see* Buzaid AC
Sorbolini S, *see* Crinò L
Sorensen JM, Vena DA, Fallavollita A, Chun HG, Cheson BD. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: Five-year follow-up report, 458
— *see* Widemann BC
Sorensen K, Levitt G, Bull C, Chessells J, Sullivan I. Anthracycline dose in childhood acute lymphoblastic leukemia: Issues of early survival versus late cardiotoxicity, 61
Sorensen PHB, *see* Kelly KM
Sorio R, *see* Frustaci S
Sorscher S, Levonian PJ. BCRA 1 testing guidelines for high-risk patients (letter), 1711
Soumerai SB, *see* Guadagnoli E
Sozzi G, *see* Pastorino U
Spaeth D, *see* Pujol J-L
Spanczynski M, *see* ten Bokkel Huinink W
Sparano JA, Neuberg D, Glick JH, Robert NJ, Goldstein LJ, Sledge GW, Wood W. Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: An Eastern Cooperative Oncology Group study, 1880
Spataro V, Goldhirsch A. Breast cancer: Relevance of estrogen receptor determination (letter), 862
— *see* Leyvraz S
Spears CP, *see* Quan WDY Jr
Spears L, *see* Quan WDY Jr
Spector N, Pulcheri W, Nucci M, Maiolino A. Comparing an apple to a fruit salad (letter), 3021
Speyer J, *see* Swain SM
Spicer D, *see* Swain SM
Spicer J, *see* Xiao H
Spitz FR, Abbruzzese JL, Lee JE, Pisters PWT, Lowy AM, Fenoglio CJ, Cleary KR, Janjan NA, Goswitz MS, Rich TA, Evans DB. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas, 928
Spitzer G, *see* Antman KH
Sprangers MAG, *see* Sneeuw KCA
Spriggs D, *see* Fennelly D
— *see* Robins HI
Sprinz E, *see* Schwartsmann G
Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer, 3394
Stadtmauer EA, *see* Antman KH
Stahel RA, Jost LM, Honegger H, Betts E, Goebel MEM, Nagler A. Randomized trial showing equivalent efficacy of filgrastim 5 μg/kg/d and 10 μg/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas, 1730
Stahl S, *see* Stopeck AT
Stainer C, *see* McQuaker IG
Stary J, *see* Locatelli F
Statman R, *see* Giuliano AE
Steen PD, *see* Loprinzi CL
Stefano-Louineau DD, *see* Thiesse P
Steffens MG, Boerman OC, Oosterwijk-Wakka JC, Oosterhof GON, Witjes JA, Koenders EB, Oyen WJG, Buijs WCAM, Debruyne FMJ, Corstens FHM, Oosterwijk E. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250, 1529
Steger M, *see* Verschraegen CF
Stein J, *see* Marx CM
Steinberg D, *see* Glaspy J
Steinberg SM, *see* Dawson NA
— *see* Georgiadis MS
Steinherz PG, *see* Uckun FM
Stenning SP, *see* Horwich A
Stenwig B, *see* Lote K
Stephens CD, *see* Burris HA III
Stevens MCG, *see* Mitchell PLR
Stewart C, *see* Wetzler M
Stewart DJ. Socioeconomic status and cancer survival in Ontario (letter), 3516
—, Evans WK, Shepherd FA, Wilson KS, Pritchard KI, Trudeau ME, Wilson JJ, Martz K. Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: Superiority of doxorubicin, 1897
Stewart FM, *see* Savarese DMF
Stewart J, *see* Byrne MJ
Stewart JA, *see* Robins HI
Stewart S, *see* Ranson MR
Steyerberg EW, Keizer HJ, Sleiffer DT. Postchemotherapy surgery in nonseminoma (letter), 3165
Stiff PJ, Bayer R, Kerger C, Potkul RK, Malhotra D, Peace DJ, Smith D, Fisher SG. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: A multivariate analysis of survival for 100 consecutively treated patients, 1309
— *see* Vose JM
Stine KC, Saylors RL, Sawyer JR, Becton DL. Secondary acute myelogenous leukemia following safe exposure to etoposide, 1583
Stitt L, *see* Leighton C
Stock W, Westbrook CA, Peterson B, Arthur DC, Szatrowski TP, Silver RT, Sher DA, Wu D, Le Beau MM, Schiffer CA, Bloomfield CD. Value of molecular monitoring during the treatment of chronic myeloid leukemia: A Cancer and Leukemia Group B study, 26
Stockel J, *see* Fetell MR
Stockler M, *see* Doyle C
Stolte M, *see* Rudolph B
Stone R, *see* Hahn WC
Stopeck AT, Hersh EM, Akporiaye ET, Harris DT, Grogan T, Unger E, Warneke J, Schluter SF, Stahl S. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma, 341
Stoppa AM, Bouabdallah R, Chabannon C, Novakovitch G, Vey N, Camerlo J, Blaise D, Xerri L, Resbeut M, Di

Stefano D, Bardou VJ, Gastaut JA, Maraninchi D. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma, 1722
Storb R, *see* Demirer T
Storer B, *see* Demirer T
— *see* Tannehill SP
Storm-Mathisen I, *see* Lote K
Storniolo AM, *see* Burris HA III
Stoter G, *see* de Wit R
— *see* Pronk LC
Straetmans N, *see* Brice P
Strätor J, *see* Lazzarino M
Straus D, *see* Miller VA
Strauss RG, *see* Heckman KD
Strawderman M, *see* Merajver SD
Stringer CA, *see* Gordon AN
Stringer SP, *see* Mendenhall WM
Stroeyer I, *see* Jakobsen A
Strojny W, *see* Balwierz W
Strom SS, *see* Kurzrock R
Stroup SL, *see* Hainsworth JD
Struck RF, *see* O'Reilly S
Studts JL, *see* Andrykowski MA
Sturgeon J, *see* Doyle C
Suarez-Almazor ME, Belzile M, Bruera E. Euthanasia and physician-assisted suicide: A comparative survey of physicians, terminally ill cancer patients, and the general population, 418
Suc E, *see* Merrouche Y
— *see* Rougier P
Suciu S, *see* Thyss A
— *see* Zittoun R
Sugarman A, *see* Casper ES
Sugawara K, *see* Yamada Y
Sullivan AM, *see* Watts MJ
Sullivan I, *see* Sorensen K
Sung MT, *see* Kelsen DP
Suri D, *see* Heimann R
Sutcliffe S, *see* Connors JM
Sutliff VE, Doppman JL, Gibril F, Venzon DJ, Yu F, Serrano J, Jensen RT. Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns, 2420
Suttora G, *see* Lacava JA
Suttorp M, *see* Locatelli F
Suzanne F, *see* Legros M
Suzuki S, *see* Oshita F
Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR, Gams RA. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer, 1318
—, Whaley FS, Gerber MC, Ewer MS, Bianchine JR, Gams RA. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy, 1333
—, Whaley FS, Gams RA. In reply (letter), 3294
Swallow MM, *see* West DC
Sylvester R, *see* Bartelink H
— *see* de Wit R
Sylvester RJ, *see* Clahsen PC
— *see* Horwich A
Szatrowski TP, *see* Stock W
Szepesi S, *see* Loeffler M
Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH, Bradley BA, Casper JT, Flomenberg N, Gajewski JL, Gluckman E, Henslee-Downey PJ, Hows JM, Jacobsen N, Kolb H-J, Lowenberg B, Masaoka T, Rowlings PA, Sondel PM, van Bekkum DW, van Rood JJ, Vowels MR, Zhang M-J, Horowitz MM. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings, 1767

Taat CW, *see* Rijks LJM
Tabah I, *see* Brice P
Tabbara I, *see* Vose JM
Tafur L, *see* Viladiu P
Taghipour G, *see* Majolino I
— *see* Vandenberghe E
Tagliabue E, *see* Pastorino U
Takahashi S, *see* Oshita F
Takahashi T, *see* Kitamura K
Takaku F, *see* Ohno R
Takebayashi Y, *see* Imazono Y
Takeyama H, *see* Ohno R
Takimoto CH, Dahut W, Marino MT, Nakashima H, Liang MD, Harold N, Lieberman R, Arbuck SG, Band RA, Chen AP, Hamilton JM, Cantilena LR, Allegra CJ, Grem JL. Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients, 1492
— *see* Georgiadis MS
Takvorian T, Skarin A, Johnson R. Pyoderma gangrenosum, 407
Talamini R, *see* Nicoletto MO
Talcott JA, *see* Beard CJ
Talpaz M, *see* Kurzrock R
Tamura T, *see* Oshita F
Tan M, *see* Leichman CG
— *see* Muggia FM
Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T. Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma, 826
Taniguchi H, *see* Kitamura K
Tanimoto M, *see* Ohno R
Tannehill SP, Mehta MP, Larson M, Storer B, Pellet J, Kinsella TJ, Schiller JH. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non–small-cell lung cancer: Results of a phase II trial, 2850
Tannock I. In reply (letter), 410
— *see* Saxman SB
Tannock IF, *see* Moore MJ
— *see* Siu LL
Tantravahi R, *see* Byrd JC
— *see* Slack JL
Tarantolo SR, *see* Bishop MR
— *see* Pavletic ZS
Tarassoff P, *see* Burris HA III

— *see* Fossella FV
Tarbell NJ, *see* Bodis S
Tarenzi E, *see* Gianni L
Tateo S, *see* Bolis G
Tatsch K, *see* Dresel S
Tattersall MHN, *see* Byrne MJ
Tavernier F, *see* Legros M
Taylor C, *see* Glaspy J
Taylor SA, *see* Whitehead RP
Tchekmedyian S, *see* Glaspy J
Teichmann J, *see* Loeffler M
Tempero M, Leichner P, Dalrymple G, Harrison K, Augustine S, Schlom J, Anderson J, Wisecarver J, Colcher D. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: A phase I trial, 1518
ten Bokkel Huinink W, Gore M, Carmichael J, Gordon A, Malfetano J, Hudson I, Broom C, Scarabelli C, Davidson N, Spanczynski M, Bolis G, Malmström H, Coleman R, Fields SC, Heron J-F. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer, 2183
ten Bokkel Huinink WW, *see* de Wit R
— *see* Huizing MT
Tenney DY, *see* Yamauchi H
Tepper JE, O'Connell MJ, Petroni GR, Hollis D, Cooke E, Benson AB III, Cummings B, Gunderson LL, Macdonald JS, Martenson JA. Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: Initial results of Intergroup 0114, 2030
Ternberg JL, *see* Weiner MA
Terrier P, *see* Guillou L
Tesch H, *see* Loeffler M
Tessman D, *see* Levine AM
Testa E, *see* Cascinu S
Testa MA, *see* Krown SE
Tetef M, *see* Somlo G
Têtu B, *see* Raybaud-Diogène H
Thall PF, *see* Estey E
American Society of Clinical Oncology. 1997 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines, 3288
— Clinical practice guidelines for the treatment of unresectable non–small-cell lung cancer, 2996
— Criteria for facilities and personnel for the administration of parenteral systemic antineoplastic therapy, 3416
— Critical role of phase I clinical trials in cancer treatment, 853
— Recommended breast cancer surveillance guidelines, 2149
— Resource document for curriculum development in cancer genetics education, 2157
International Breast Cancer Study Group. Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients, 1385
Italian Group for Antiemetic Research. Ondansetron versus metoclopramide both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis, 124
National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group, *see* Pritchard KI
Theriault R, *see* Chan DW
Thieblemont C, Bastion Y, Berger F, Rieux C, Salles G, Dumontet C, Felman P, Coiffier B. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: Analysis of 108 patients, 1624
Thiede C, *see* Rudolph B
Thiesse P, Ollivier L, Stefano-Louineau DD, Négrier S, Savary J, Pignard K, Lasset C, Escudier B for the Groupe Français d'Immunothérapie of the Fédération Nationale des Centres de Lutte Contre le Cancer. Response rate accuracy in oncology trials: Reasons for interobserver variability, 3507
Thigpen JT. Dose-intensity in ovarian carcinoma: Hold, enough? (editorial), 1291
Thomas CR Jr, Milito S, Turrisi AT III. Hypofractionation, not rapid-fractionation (letter), 3291
Thomas EK, *see* Younes A
Thomas JM, *see* Verrill MW
Thomas M, *see* Hainsworth JD
Thomas PA, *see* Press MF
Thomas V, *see* Kris MG
Thommes JA, *see* Northfelt DW
Thompkins A, *see* Kohn EC
Thornhill L, *see* Clark JR
Thornton PD, *see* Pawson R
Thuret I, *see* Michel G
Thurfjell E, *see* Persson I
Thyss A, Suciu S, Bertrand Y, Mazingue F, Robert A, Vilmer E, Mechinaud F, Benoit Y, Brock P, Ferster A, Lutz P, Boutard P, Marguerite G, Plouvier E, Michel G, Plantaz D, Munzer M, Rialland X, Chantraine J-M, Norton L, Solbu G, Philippe N, Otten J, for the European Organization for Research and Treatment of Cancer Children's Leukemia Cooperative Group. Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia, 1824
Thyss A, *see* Rubie H
Tibaldi C, *see* Conte PF
Tienghi A, *see* Picci P
Tiggelaar CL, *see* Robins HI
Tilgen W, *see* Gläser R
Tilly H, *see* Bastion Y
— *see* Brice P
— *see* Haioun C
— *see* Wendum D
Tinoco L, *see* Buzaid AC
Tirona MT, *see* Goldberg RM
Tishler RB, *see* Clark JR
Tobise K, *see* Oshita F
Tocino I, *see* Murren JR
Todd G, *see* Brown RA
Tomaiuolo R, *see* Castaldo G
Tomaszewski JE, *see* D'Amico AV
Tomonaga M, *see* Ohno R
— *see* Yamada Y

Tompkins A, *see* Dawson NA
Tonato M, *see* Crinò L
Toner GC, *see* Millward MJ
Tong W, *see* Fennelly D
Tonini GP, Boni L, Pession A, Rogers D, Iolascon A, Basso G, di Montezemolo LC, Casale F, Pession A, Perri P, Mazzocco K, Scaruffi P, Lo Cunsolo C, Marchese N, Milanaccio C, Conte M, Bruzzi P, De Bernardi B. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: The Italian experience with 295 children, 85
Top B, *see* Rodenhuis S
Topolsky DL, *see* Vose JM
Torà M, *see* Graus F
Torrey MJ, Poen JC, Hoppe RT. Detection of relapse in early-stage Hodgkin's disease: Role of routine follow-up studies, 1123
Tórtola S, *see* Arribas R
Toubert ME, *see* Maulard-Durdux C
Traganos F, *see* Seiter K
Tran HT, *see* Kornblau SM
Tredici G, *see* Cavaletti G
Tredici P, *see* Cavaletti G
Trehu EG, *see* Du Bois JS
Trevisan CH, *see* Olivotto IA
Tricot G, Sawyer JR, Jagannath S, Desikan KR, Siegel D, Naucke S, Mattox S, Bracy D, Munshi N, Barlogie B. Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants, 2659
Trigg ME, *see* Nachman J
— *see* Uckun FM
Trihia H, *see* Pestalozzi BC
Trikha ES, *see* Byrd JC
Trimble EL, *see* Muñoz KA
Trippetti M, *see* Crinò L
Troussard X, *see* Michel G
Trudeau ME, *see* Stewart DJ
Truglia JA, *see* Miller VA
Trump D, *see* Saxman SB
Tsai C-M, *see* Perng R-P
Tseng C-J, *see* Pao CC
Tsuchiya S, *see* Oshita F
Tsukasaki K, *see* Yamada Y
Tsukuda K, *see* Ohno R
Tsurumaru M, *see* Kajiyama Y
Tsutsumi K, *see* Kajiyama Y
Tulpule A, *see* Levine AM
Tulsky DS, *see* Brady MJ
Tumolo S, *see* Frustaci S
— *see* Nicoletto MO
Turnbull AD, *see* Fong Y
Turrisi, AT III, *see* Thomas CR Jr
Tutsch KD, *see* Berlin J
— *see* Robins HI
Tyc VL, Hudson MM, Hinds P, Elliot V, Kibby MY. Tobacco use among pediatric cancer patients: Recommendations for developing clinical smoking interventions, 2194
Tyler MK, *see* Marx CM

Uckun FM, Gaynon PS, Sensel MG, Nachman J, Trigg ME, Steinherz PG, Hutchinson R, Bostrom BC, Sather HN, Reaman GH. Clinical features and treatment outcome of childhood t-lineage acute lymphoblastic leukemia according to the apparent maturational stage of t-lineage leukemic blasts: A Children's Cancer Group study, 2214
Udagawa H, *see* Kajiyama Y
Uderzo C, *see* Locatelli F
Ueno M, *see* Kajiyama Y
Uhrmeister P, *see* Altehoefer C
Underhill C, *see* Webb A
Unger E, *see* Stopeck AT
Ungerleider RS, *see* Smith MA
Urch M, *see* Millward MJ
Uziely B, *see* Muggia FM

Vaccarello L, *see* Omura GA
Vadell C, *see* Graus F
Vadhan-Raj S, *see* Patel SR
Vadhan-Raj, S for the Procrit Study Group, *see* Glaspy J
Vaitkevicius VK, *see* Al-Sarraf M
Valagussa P, *see* Bonfante V
— *see* Gianni AM
Valbonesi M, *see* Carella AM
Välimäki M, *see* Saarto T
Vallejo C, *see* De Lena M
Vallejo CT, *see* Lacava JA
Valsecchi MG, *see* Bolis G
— *see* Conter V
van Ark-Otte J, *see* Apolinario RM
van Basten JPA, Hoekstra HJ, van Driel MF, Koops HS, Droste JHJ, Jonker-Pool G, van de Wiel HBM, Sleiffer DTh. Sexual dysfunction in nonseminoma testicular cancer patients is related to chemotherapy-induced angiopathy, 2442
van Bekkum DW, *see* Szydlo R
Van Besien K, *see* Giralt S
van de Velde CJH, *see* Clahsen PC
van de Wiel HBM, *see* van Basten JPA
van den Bent MJ, *see* Pronk LC
Van Den Berg D, *see* Carella AM
van den Bos GAM, *see* Rinck GC
van den Brink MRM, Dezube BJ. AIDS-related Kaposi's sarcoma, 1283
van der Burg MEL, *see* Pronk LC
van der Lelie J, *see* Dekker AW
— *see* Löwenberg B
van der Schueren E, *see* Bartelink H
van der Valk P, *see* Apolinario RM
van der Vijgh WJF, *see* Huizing MT
van der Waal I, *see* Smeele LE
van Driel MF, *see* van Basten JPA
van Geel AN, *see* Eggermont AMM
van Glabbeke M, *see* Bartelink H
Van Glabbeke M, *see* Piccart MJ
Van Meir EG, *see* Paraf F
van Mourik JC, *see* Apolinario RM
van Putten WLJ, *see* Dekker AW
— *see* Löwenberg B
van Rood JJ, *see* Szydlo R
van Royen EA, *see* Rijks LJM
van Tienhoven G, *see* Rijks LJM

Van Tornout JM, Buckley JD, Quinn JJ, Feusner JH, Krailo MD, King DR, Hammond GD, Ortega JA. Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: A report from the Children's Cancer Group, 1190
Van Vreckem A, *see* Piccart MJ
van Warmerdam LJC, *see* Huizing MT
van Zandwijk N, *see* Huizing MT
— *see* Rodenhuis S
Vance E, Granter S, Skarin A. Sweet's syndrome, 860
Vandenberghe E, Pearce R, Taghipour G, Fouillard L, Goldstone AH. Role of a second transplant in the management of poor-prognosis lymphomas: A report from the European Blood and Bone Marrow Registry, 1595
vanHaelst-Pisani C, *see* Loprinzi CL
Vanhoefer U, *see* Rustum YM
Vannier JP, *see* Michel G
Vannier J-P, *see* Rubie H
van't Veer L, *see* Rodenhuis S
van't Veer MB, *see* Dekker AW
van't Veer-Korthof ET, *see* Locatelli F
Varma DGK, *see* Pisters PWT
Varns C, *see* Maloney DG
Vassallo F, *see* Carella AM
Vaughan WP, *see* Antman KH
Vauthey J-N, *see* Mendenhall WM
Veenhof CHN, *see* Huizing MT
— *see* Rijks LJM
— *see* Rinck GC
Velez-Garcia E, *see* Swain SM
Vellenga E, *see* Löwenberg B
Vena DA, *see* Sorensen JM
Venturini M, *see* Del Mastro L
Venzon DJ, *see* Sutliff VE
Verdonck LF, *see* Dekker AW
— *see* Löwenberg B
Verfaillie C, *see* Collins RH Jr
Verhoef GEG, *see* Löwenberg B
Verma S, *see* Connors JM
— *see* Lofters WS
— *see* Pritchard KI
Vermorken JB, *see* Huizing MT
Verret AL, *see* Miller VA
Verrill MW, Judson IR, Harmer CL, Fisher C, Thomas JM, Wiltshaw E. Ewing's sarcoma and primitive neuroectodermal tumor in adults: Are they different from Ewing's sarcoma and primitive neuroectodermal tumor in children? 2611
Verschraegen CF, Levy T, Kudelka AP, Llerena E, Ende K, Freedman RS, Edwards CL, Hord M, Steger M, Kaplan AL, Kieback D, Fishman A, Kavanagh JJ. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix, 625
— *see* Ashour AA
Verschuuren JJ, *see* Graus F
Verweij J, *see* Creemers GJ
— *see* Pronk LC
Verweij J, *see* Ardizzoni A
Vey N, *see* Stoppa AM
Viero P, *see* Vitolo U
Vietti T, *see* Heyn R
Viganò L, *see* Gianni L
Viladiu P, Bosch F-X, Castellsagué X, Muñoz N, Escribà JM, Hamšíkova E, Hofmannová V, Guerrero E, Izquierdo A, Navarro C, Moreo P, Izarzugaza I, Ascunce N, Gili M, Muñoz MT, Tafur L, Shah KV, Vonka V. Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer, 610
Vilain M-O, *see* Guillou L
Villa A, *see* Bolis G
Vilmer E, *see* Thyss A
Vinante O, *see* Nicoletto MO
Vinholes J, Guo C-Y, Purohit OP, Eastell R, Coleman RE. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy, 131
Viñolas N, *see* Graus F
Virro M, *see* Lipton JH
Virtaniemi J, *see* Hirvikosi P
Visonà E, *see* Nicoletto MO
Vitale D, *see* Castaldo G
Vitek L, *see* Giantoni BJ
Vitolo U, Cortellazzo S, Liberati AM, Freilone R, Falda M, Bertini M, Botto B, Cinieri S, Levis A, Locatelli F, Lovisone E, Marmont F, Pizzuti M, Rossi A, Viero P, Barbui T, Grignani F, Resegotti L. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma, 491
Viviani S, *see* Bonfante V
Vlamis V, *see* McCaffrey JA
— *see* Motzer RJ
— *see* Xiao H
Vogel C, *see* Swain SM
Vogelzang NJ, *see* Small EJ
Vokes EE, *see* Gupta E
— *see* Masters GA
von Borstel R, *see* Kelsen DP
Von Hoff D, *see* Levine AM
Von Hoff DD, *see* Burris HA III
— *see* Creemers GJ
von Minckwitz G, *see* Costa SD
von Roemeling R, *see* Johnson CA
Von Roenn JH, *see* Northfelt DW
von Wasielewski R, *see* Klempnauer J
von Wolff B, *see* Giralt S
Vonderheide RH, Fleming MD, Carter G, Singer S, Demetri G. Angiosarcoma, 1708
Vonka V, *see* Viladiu P
Vose JM, Pandite AN, Beveridge RA, Geller RB, Schuster MW, Anderson JE, LeMaistre CF, Ahmed T, Granena A, Keating A, Ranada JMF, Stiff PJ, Tabbara I, Longo W, Copelan EA, Nichols C, Smith A, Topolsky DL, Bierman PJ, Lebsack ME, Lange M, Garrison L. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: Results of a randomized double-blind trial, 1617

Vose JM, *see* Bierman PJ
— *see* Bishop MR
— *see* Pavletic ZS
— *see* Waters TM
Vossen J, *see* Locatelli F
Vowels MR, *see* Szydlo R
Vukov AM, *see* Ellison N

Wade JA, *see* Shepherd FA
Wadler S, *see* Swain SM
Wagner JE, *see* Davies SM
Wain J, *see* Choi NC
Walczak JR, *see* O'Reilly S
Walde D, *see* Lofters WS
Walde PLD, *see* Pritchard KI
Walter A, *see* Gajjar A
Walter S, *see* Ganem G
Wanders J, *see* Ardizzoni A
Wanebo HJ, *see* Safran H
Wang X, *see* Gupta E
Ward B, *see* Haffty BG
Ward J, *see* McKeage MJ
Warde P, *see* Doyle C
Wardley A, *see* Webb A
Warkentin PI, *see* Bishop MR
Warneke J, *see* Stopeck AT
Warner E, *see* Liu G
Warr D, *see* Osoba D
— *see* Pritchard KI
Warrell RP Jr, *see* Miller VA
Warzocha K, Salles G, Bienvenu J, Bastion Y, Dumontet C, Renard N, Neidhardt-Berard E-M, Coiffier B. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients, 499
Watanabe Y, *see* Omura K
— *see* Shirao K
Waters TM, Bennett CL, Vose JM. Economic analyses (editorial), 2
Watson M, *see* Webb A
Watts MJ, Sullivan AM, Jamieson E, Pearce R, Fielding A, Devereux S, Goldstone AH, Linch DC. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: An analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma, 535
Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, Hughes M, Mansi J, Findlay M, Hill A, Oates J, Nicolson M, Hickish T, O'Brien M, Iveson T, Watson M, Underhill C, Wardley A, Meehan M. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer, 261
Webb IJ, *see* Shapiro CL
Webber B, *see* Raney RB
Weber BL, *see* Merajver SD
Weber D, *see* Giralt S
Webster K, *see* Markman M
Webster LK, *see* Millward MJ
Weeks JC, *see* Guadagnoli E
— *see* Hayman JA
Wehde M, *see* Brown RA
Weichselbaum RR, *see* Heimann R
Weimann A, *see* Klempnauer J
Wein A, *see* D'Amico AV
Weinberger B, *see* Dawson NA
Weiner GJ, *see* Heckman KD
Weiner LM, *see* Giantoni BJ
Weiner MA, Leventhal B, Brecher ML, Marcus RB, Cantor A, Gieser PW, Ternberg JL, Behm FG, Wharam MD Jr, Chauvenet AR. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB IIIA2 IIIB, and IV Hodgkin's disease in pediatric patients: A Pediatric Oncology Group study, 2769
Weisberg S, *see* Swain SM
Weisdorf DJ, *see* Davies SM
Weiss GR, *see* Whitehead RP
Weiss R, *see* Zelter LK
Weiss RB, *see* Byrd JC
Weissberg JB, *see* Haffty BG
Weizel H, *see* Pritchard KI
Wen P, *see* Lynch TJ Jr
Wender DB, *see* Ellison N
— *see* Pitot HC
Wendum D, Sebban C, Gaulard P, Coiffier B, Tilly H, Cazals D, Boehn A, Casasnovas R-O, Bouabdallah R, Jaubert J, Ferrant A, Diebold J, de Mascarel A, Gisselbrecht C for the Groupe d'Etude des Lymphomes de l'Adulte. Follicular large-cell lymphoma treated with intensive chemotherapy: An analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma, 1654
Werner M, *see* Klempnauer J
Wernz J, *see* Levine AM
West DC, Grier HE, Swallow MM, Demetri GD, Granowetter L, Sklar J. Detection of circulating tumor cells in patients with Ewing's sarcoma and peripheral primitive neuroectodermal tumor, 583
Westbrook CA, *see* Stock W
Wetzler M, Baer MR, Bernstein SH, Blumenson L, Stewart C, Barcos M, Mrózek K, Block AMW, Herzig GP, Bloomfield CD. Expression of *c-mpl* mRNA, the receptor for thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with poor response to intensive chemotherapy, 2262
Wever LDV, *see* Sneeuw KCA
Whaley FS, *see* Swain SM
Whang-Peng J, *see* Perng R-P
Wharam M, *see* Grossman SA
— *see* Heyn R
— *see* Raney RB
Wharam MD Jr, *see* Weiner MA
White CA, *see* Maloney DG
White DF, *see* Loprinzi CL
White R, *see* Livingston RB
Whitehead RP, Jacobson J, Brown TD, Taylor SA, Weiss GR, Macdonald JS. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: A Southwest Oncology Group study, 2414
Whittington R, *see* D'Amico AV

Wicha M, *see* Merajver SD
Wickerham DL, *see* Fisher B
Widemann BC, Balis FM, Murphy RF, Sorensen JM, Montello MJ, O'Brien M, Adamson PC. Carboxypeptidase-G_2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction, 2125
Wieand HS, *see* O'Connell MJ
Wieand S, *see* Fisher B
Wielenga JJ, *see* Löwenberg B
Wiener ES, *see* Raney RB
Wiersma S, *see* Dinndorf PA
Wiesenfeld M, *see* Goldberg RM
Wilding G, *see* Berlin J
— *see* Robins HI
Wilimas JA, Kaste SC, Kauffman WM, Winer-Muram H, Morris R, Luo X, Boyett JM. Use of chest computed tomography in the staging of pediatric Wilms' tumor: Interobserver variability and prognostic significance, 2631
Wilke H, *see* Rustum YM
Will BP, *see* Evans WK
Willemze R, *see* Dekker AW
— *see* Pawson R
Williams L, *see* Shapiro CL
Williams MA, *see* Livingston RB
Williams MV, De Takats P, Parmar M. Survival benefit in melanoma (letter), 2172
Williams SF, *see* Antman KH
Willis DL, *see* Gordon AN
Wils JA, *see* Lalisang RI
Wilson G, *see* Meistrich ML
Wilson JJ, *see* Stewart DJ
Wilson K, *see* Lofters WS
Wilson KS, *see* Stewart DJ
Wilson WH, *see* Georgiadis MS
— *see* Longo DL
Wiltschke C, *see* Brodowicz T
Wiltshaw E, *see* Gore M
— *see* Verrill MW
Windschitl HE, *see* Loprinzi CL
— *see* Pitot HC
Winer-Muram H, *see* Wilimas JA
Winick N, Farrow A, Buchanan GR, Kamen BA, Shuster JJ, Bowman WP, Borowitz M. In reply (letter), 3025
Winick NJ, *see* Farrow AC
Winn R, *see* Pazdur R
Wirth A, *see* Prince HM
Wisecarver J, *see* Tempero M
Witjes JA, *see* Steffens MG
Witte JS, *see* Kupelian PA
Witte RS, Elson P, Bono B, Knop R, Richardson RR, Dreicer R, Loehrer PJ Sr. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma, 589
Wittes RE, *see* Longo DL
Witzig TE, *see* Ansell SM
Wolf B, *see* Safran H
Wolf M, *see* Prince HM
Wolff L, *see* Nachman J
Wolff S, *see* Antman KH
Wolff SN, *see* Collins RH Jr
Wolman SR, *see* Press MF
Wolmark N, *see* Fisher B
Wolter J, *see* Fisher B
Womer RB, *see* Kelly KM
Wong RM, *see* Kusnierz-Glaz CR
Wood DP Jr, Banerjee M. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival, 3451
Wood JG, *see* Johansen MJ
Wood W, *see* Sparano JA
Woodruff JM, *see* Heslin MJ
— *see* Lewis JJ
Woods KV, *see* Jung FA
Work E, Nielsen OS, Bentzen SM, Fode K, Palshof T for the Aarhus Lung Cancer Group. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer, 3030
Worst P, *see* Loeffler M
Wright C, *see* Choi NC
Wright D, *see* Shankar AG
Wu D, *see* Stock W
Wüstenberg C, *see* Altehoefer C

Xerri L, *see* Stoppa AM
Xiao H, Mazumdar M, Bajorin DF, Sarosdy M, Vlamis V, Spicer J, Ferrara J, Bosl GJ, Motzer RJ. Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin, 2553
Xiao-Ou-Shu, *see* Davies SM
Xiong Q-B, *see* Kelly KM

Yamada O, *see* Ohno R
Yamada Y, Hatta Y, Murata K, Sugawara K, Ikeda S, Mine M, Maeda T, Hirakata Y, Kamihira S, Tsukasaki K, Ogawa S, Hirai H, Koeffler HP, Tomonaga M. Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T-cell leukemia, 1778
— *see* Imazono Y
Yamaguchi T, *see* Kitamura K
Yamamoto K, *see* Kitamura K
Yamao T, *see* Shirao K
Yamauchi H, O'Neill A, Gelman R, Carney W, Tenney DY, Hösch S, Hayes DF. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/*c-neu* protein, 2518
Yang F-P, *see* Pao CC
Yang K-Y, *see* Perng R-P
Yanovich S, *see* Smith TJ
Yao D-S, *see* Pao CC
Ychou M, *see* Rougier P
Yen Y, *see* Somlo G
Yin M-B, *see* Rustum YM
Yokoyama T, *see* Shirao K
Yokozaki M, *see* Kubota K
York M, *see* Swain SM
Yoshida O, *see* Arai Y
Yoshida S, *see* Connors JM

— *see* Shirao K
Younes A, Consoli U, Snell V, Clodi K, Kiche K-O, Palmer JL, Gruss HJ, Armitage R, Thomas EK, Cabanillas F, Andreeff M. CD30 ligand in lymphoma patients with $CD30^+$ tumors, 3355
— *see* Ayoub J-P
Young RC, *see* Longo DL
Yu F, *see* Sutliff VE
Yue N, *see* Grossman SA
Yule SM, Foreman NK, Mitchell C, Gouldon N, May P, McDowell HP. High-dose cyclophosphamide for poor-prognosis and recurrent pediatric brain tumors: A dose-escalation study, 3258
Yung WKA, *see* Kaba SE
Yunis EJ, *see* Provisor AJ

Zacharias D, *see* Bishop MR
Zacharski LL, *see* Maurer LH
Zachoval R, *see* Dresel S
Zalcberg J, *see* Millward MJ
Zambetti M, *see* Gianni AM
Zanaboni F, *see* Bolis G
Zander A, *see* Smith TJ
Zaniboni A. Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: Impact on disease-free survival and overall survival, 2432
— *see* Cascinu S
Zanini M, *see* Bonfante V
Zecca M, *see* Locatelli F
Zee B, *see* Connors JM
— *see* Lofters WS
— *see* Osoba D
— *see* Pritchard KI
Zelter LK, Chen E, Weiss R, Guo MD, Robison LL, Meadows AT, Mills JL, Nicholson HS, Byrne J. Comparison of psychologic outcome in adult survivors of childhood acute lymphoblastic leukemia versus sibling controls: A cooperative Children's Cancer Group and National Institutes of Health study, 547
Zelterman D, *see* Murren JR
— *see* Salloum E
Zeltzman M, *see* Grossman SA
Zhang D, *see* Merajver SD
Zhang M-J, *see* Szydlo R
Zhang-Solomons J, *see* Mackillop WJ
Zhao S, *see* Kornblau SM
Zhou J-Y, *see* Press MF
Zhou Y, *see* Mackillop WJ
Zielinski CC, *see* Brodowicz T
Zietman AL, *see* Kachnic LA
Zimet A, *see* Millward MJ
Zimmermann M, *see* Conter V
— *see* Locatelli F
Zincone A, *see* Cavaletti G
Zippelius A, Kufer P, Honold G, Köllermann MW, Oberneder R, Schlimok G, Riethmüller G, Pantel K. Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow, 2701
Zirone S, *see* Pavlovsky S
Zittoun R, Cadiou M, Suciu S. In reply (letter), 863
Zlotecki RA, *see* Mendenhall WM
Zografos L, *see* Leyvraz S
Zucali R, *see* Gianni AM
Zucker JM, *see* Coze C
Zwiener RJ, *see* Farrow AC

SUBJECT INDEX

Acral paresthesia, associated with cisplatin-based chemotherapy, 2446
Actinomycin D, ifosfamide, vincristine regimen
for Ewing's sarcoma, 2612
for primitive neuroectodermal tumor, 2612
survival following, 2613-2617
Active specific immunotherapy, of metastatic melanoma, 2103-2110
Acute leukemia
childhood, unrelated donor BMT in, 557-565
topotecan, cytarabine regimen in, 44-51
Acute lymphoblastic leukemia
adult, consolidation chemotherapy in, 476-482
anthracyclines in, 61-68
augmented Berlin-Frankfurt-Munster therapy in, 2222-2230
childhood
aminotransferase elevations in, 1560-1566
intrathecal methotrexate in, 1824-1830
relapsed, Philadelphia-chromosome positive, 2231-2237
survivors of, negative mood in, 547-556
induction chemotherapy in, slow early response to, 2222-2230
T-lineage
leukemic cell maturation stage in, 2214-2221
treatment protocols for, 2215
without maintenance therapy, 476-482
Acute myeloblastic leukemia
busulfan, cyclophosphamide regimen in, 2238-2246
childhood, allogeneic BMT in, 2238-2246
Acute myelogenous leukemia
childhood, idarubicin, fludarabine, cytarabine regimen in, 2780-2785
dose-intense chemotherapy in, 2982
mitoxantrone, etoposide, PSC-833 regimen in, 1796-1802
relapsed or refractory, mitoxantrone, etoposide, PSC-833 regimen in, 1796-1802
secondary, following etoposide, 1583-1586
Acute myeloid leukemia
acyclovir prophylaxis in, 2269-2274
adult, cytotoxic therapy-induced D-xylose malabsorption in, 2254-2261
c-*mpl* mRNA in, as prognostic factor, 2262-2268
consolidation therapy in, M-CSF following, 2954-2965
GM-CSF in, 3496-3506
Acute promyelocytic leukemia
all-*trans* retinoic acid, idarubicin, mercaptopurine, vincristine, methotrexate, prednisone regimen in, 483-490
newly diagnosed, additional cytogenetic changes in, 1789
non-cytarabine therapy in, 483-490
secondary cytogenetic changes in, 1786-1795

Acyclovir, in prophylaxis, of acute myeloid leukemia, 2269-2274
Adenocarcinoma
  of gastric cardia
    prognostic factors in, 2015-2021
    surgical approaches in, 2017
  of lung, *ras* in, and drug resistance, 285-291
  of pancreas
    iodine-labeled CC49 localization of, 1523
    pre- and post-operative chemoradiotherapy for, 928-937
  of stomach, 818
  poorly differentiated, natural history of, 2056-2066
  rectal, endocavitary irradiation in, 3241-3248
Adenosine, molecular structure of, 459
Adipose tissue, fatty acid composition of, and breast cancer prognosis, 1377-1384
Adjuvant chemotherapy
  in breast cancer, practice guidelines for, 217
  in colon cancer, 246-250
  indications for, 220
  in prostate cancer, and prostate-specific antigen, 1465-1469
Adoptive immunotherapy, with vaccine-primed lymph node cells, 796-807
Adoptive transfer, 797
Adrenal gland, 3004
Adrenocorticotropic hormone, for delayed emesis, 2467-2473
Adult T-cell leukemia
  chronic, survival in, 1781
  p15-p16 gene deletion in, 1778-1785
  survival in, by p15-p16 genes, 1780
AFP-Scan, in hepatocellular cancer, 2683-2690
AG331, 391
Agarose gel electrophoresis, 585
Age
  autologous BMT and, 18-25
  care and, in breast cancer, 2338-2344
  distribution of, in glioma, 3131
  glioma survival and, 3129-3140
  hematologic malignancy relapse and, 20-21
  in Ewing's sarcoma diagnosis, 2611-2621
  in ovarian cancer, and patterns of care, 3408-3415
  peripheral-blood stem-cell transplantation and, 18-25
  in primitive neuroectodermal tumor diagnosis, 2611-2621
  survival advantage threshold and, 336
  survival by, following fludarabine, 462
  thymidine phosphorylase expression and, 2576
AIDS Clinical Trials Group staging classification, validation of, for Kaposi's sarcoma, 3085-3092
All-*trans* retinoic acid, 790-795
All-*trans* retinoic acid, idarubicin, mercaptopurine, vincristine, methotrexate, prednisone regimen, without cytarabine, 483-490
All-*trans*-retinoic acid, interferon regimen, phase I trial of, 3330-3337
Allogeneic bone marrow transplantation
  in childhood chronic myelomonocytic leukemia, 566-573
  late effects of, in childhood acute myeloblastic leukemia, 2238-2246
  in leukemia, 1767-1777
  relapse following, donor leukocytes for, 434-444
  successful pregnancy following, 3347-3349
Allogeneic histocompatibility antigen, in metastatic melanoma, 341-349
Allogeneic-blood stem-cell collection
  adverse effects following, 1603
  following G-CSF mobilization, 1601-1607
Allogeneic-blood stem-cell transplantation
  hematopoietic recovery following, 1608-1616
  hospitalization duration following, 1611-1612
Allotransplant, in breast cancer, 1871
Alopecia, doxorubicin-associated, 1897-1905
Alpha-fetoprotein immunoscintigraphy, in hepatocellular cancer, 2683-2690
Altretamine, for relapsed ovarian cancer, 172-176
Ambulatory chemotherapy, stem-cell infusion plus, in NHL, 1722-1729
American Board of Radiolgoy Written Radiation Oncology Board Examination, gender bias in, 2722-2727
American College of Radiology In-Training Examination in Radiation Oncology, gender bias in, 2722-2727
American Joint Committee on Cancer staging
  for cutaneous melanoma, 1039-1051
  1992, for cutaneous melanoma, 1040
American Society of Clinical Oncology
  recommendations of, in breast cancer surveillance, 2150
  statement of, on genetic testing, 2157-2159
Amifostine, cisplatin, vinblastine, radiotherapy regimen, in NSCLC, 2850-2857
9-Aminocamptothecin, 72-hour infusion of
  in colorectal cancer, 2905-2909
  pharmacokinetics of, 1492-1501
9-Aminocamptothecin carboxylate, 1493
9-Aminocamptothecin lactone, 1493
Aminoglutethimide, megestrol acetate, hydrocortisone regimen
  in breast cancer, 2494-2501
  toxicity of, 2498
Aminotransferase, elevations in, in acute lymphoblastic leukemia, 1560-1566
Amsacrine
  cardiotoxicity following, 1544-1552
  in combination chemotherapy, for acute lymphoblastic leukemia, 476-482
Anal cancer, radiochemotherapy in, 2040-2049
Analysis
  decision, in NSCLC, 870-872, 873-883
  economic, *see* Economic analysis
Androgen blockade
  combined, 382-388
  suramin plus, in prostate cancer, 1470-1477
Androgen suppression, adjuvant to radiotherapy, 1013-1021
Anemia
  drug-induced, erythropoietin prophylaxis in, 2715-2721
  malignancy-associated microangiopathic hemolytic, 2474-2475
  overview of, in cancer, 2715
Angiogenesis
  marker for, thymidine phosphorylase expression as, 2570-2578
  vascular endothelial growth factor expression and, 826-832
Angiopathy, chemotherapy-induced, in nonseminomatous testicular cancer, 2442-2448
Angiosarcoma, 1708-1709
Anti-CD20 monoclonal antibody, chimeric, in NHL, 3266-3274
Anti-CD3 monoclonal antibody, primed lymph node cells activated by, 796-807
Anti-Hu monoclonal antibody, as prognostic factor, in SCLC, 2866-2872

Antiestrogen
discovery of, 841-843
formula of, related to tamoxifen, 842
ideal, properties of, 841
new, clinical potential of, 840-852
published reports of, 848
pure, 846-847
targeted, 847-848
treatment opportunities with, 840-841
Antigen, allogeneic histocompatibility, in metastatic melanoma, 341-349
Antineoplastic therapy, parenteral systemic, facilities for, 3416-3417
Antineuronal antibody, as prognostic factor, in SCLC, 2866-2872
Apoptosis
data for, 48-49
leukemia cell, 44-51
Area-under-the-curve
of carboplatin, Calvert's fomula for, 193-198
for LGD1069, 793
of paclitaxel, per dose level, 190
Arthritis, breast cancer associated with, 3515
ASCO, *see* American Society of Clinical Oncology
Aspergillosis
early CT scan for, in neturopenics, 139-147
survival in, prognostic factors for, 144
Assisted suicide, euthanasia and, comparative study of, 418-427
Astrocytoma
high-grade, carmustine, cisplatin, radiotherapy regimen for, 2596-2603
pediatric low-grade, 2792-2799
Atropine, ketamine, midazolam regimen, meperidine, midazolam *v*, in childhood painful procedures, 94-102
Autologous Blood and Marrow Transplant Registry of North America, 1871
Autologous bone marrow transplantation
age and, 18-25
double, 1595-1600
economic analysis of, 5-10
5 *v* 10 microgram filgrastim dosing following, 1730-1735
in follicular low-grade NHL, 445-450
GM-CSF *v* PIXY 321 following, in NHL , 1617-1623
trials of, selection bias in, 3169-3170
Autologous bone marrow transplantation, carboplatin, etoposide, cyclophosphamide regimen
high-dose, in germ cell tumors, 2546-2552
toxicity of, 2549
Autologous bone marrrow transplantation, peripheral-blood stem-cell transplantation *v*, in lymphoma, 509-517
Autologous peripheral-blood stem-cell transplantation
combination chemotherapy plus, in ovarian cancer, 1302-1308
in diffuse large-cell lymphoma, 491-498
high-dose chemotherapy plus, in relapsed ovarian cancer, 1309-1317
outpatient, 11-17
Autotransplant
in breast cancer, 1870-1879
for metastatic breast cancer, 1875
ongoing trials of, in breast cancer, 1877
survival following, 1874, 1876
Axillary lymph node dissection, in breast cancer, 691-700
Axillary lymph node staging, with sentinel lymphadenectomy, in breast cancer, 2345-2350
Bax, in NSCLC, 2456-2466
bcl-2
in colorectal liver metastase, 2008-2014
in NSCLC, 2456-2466
as prognostic factor, in lung cancer, 2858-2865
tamoxifen response and, in breast cancer, 1916-1922
bcr gene rearrangement, quantitative Southern blot analysis for, 26-36
Berlin-Frankfurt-Munster therapy, augmented, in childhood acute lymphoblastic leukemia, 2222-2230
Bicalutamide
adverse effects of, 2934-2935
in prostate cancer, 2928-2938
libido and, 2934
Bilirubin level, following mitoxantrone, etoposide, PSC-833 regimen, 1799
Biochemical modulation
in colon cancer, 368-369
schedule-selective, 373-375
Biologic marker, as prognostic factor, in lung cancer, 2858-2865
Biology, of neoplasia, 3297-3298
Biomarker, in colorectal liver metastases, 2008-2014
Biopsy, tissue, following iodine-labeled CC49 radioimmunolocalization, 1523, 1524, 1525
Bisphosphonate risedronate, for chemotherapy-induced bone loss, 955-962
Bladder cancer
dose-intense chemotherapy in, 2986
serum tissue polypeptide antigen in, 3446-3450
transurethral resection, methotrexate, cisplatin, vinblastine, radiotherapy regimen for, 1022-1029
Bleomycin
in combination regimens, for germ cell tumor, 1717-1719
emetogenic potential of, 105
in germ cell tumor therapy, 1717-1719
tobacco use and, 2195
Bleomycin, carboplatin, etoposide regimen
in nonseminomatous germ cell cancer, 1844-1852
renal toxicity of, 1850
toxicity of, 1848
Bleomycin, cisplatin, etoposide regimen
in nonseminomatous germ cell cancer, 1844-1852
renal toxicity of, 1850
toxicity of, 1848
Bleomycin, cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, vinblastine, dacarbazine, radiation regimen, in HD, 2275-2287
Bleomycin, doxorubicin, vincristine regimen
following transplantation, 2371-2377
in Kaposi's sarcoma, 653-659
Bleomycin, etoposide, cisplatin regimen
etoposide, cisplatin regimen *v*, 1837-1843
relative dose intensity of, 1838
surgery following, 1840
survival following, 1840-1842
toxicity of, 1839-1840
Bleomycin, mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, vinblastine regimen, in HD, 1638-1645
Bleomycin, mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, vinblastine, dacarbazine regimen
in HD, 1638-1645

relapse following, 528-534
with total-nodal irradiation, 2769-2779
Bleomycin, mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, vinblastine, dacarbazine, radiotherapy regimen, 3338-3346
Bleomycin, methotrexate, cyclophosphamide, dactinomycin regimen, in osteosarcoma, 76-84
Bleomycin, methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone regimen, in late-relapse lymphoma, 1745-1753
Bleomycin, vinblastine, methotrexate regimen, with regional radiotherapy, for HD, 1736-1744
Bleomycin, vincristine regimen, in Kaposi's sarcoma, 653-659
Blood count, complete, in breast cancer surveillance, 2153-2154
BMT, *see* Bone marrow transplantation
Bone, sarcoma of, high-dose ifosfamide for, 2378-2384
Bone loss
associated with cyclophosphamide, methotrexate, FU regimen, 1341-1347
biochemical indices of, 959
chemotherapy-induced, prevention of, 955-962
clodronate for, 1341-1347
Bone marrow
metastasis detection in, by histology, 2807-2817
micrometastases of, prostate cancer, 3451-3457
reverse-transcriptase polymerase chain reaction analysis of, 2704
Bone marrow infiltration
immunoscintigraphy *v* MRI in, 1754-1760
multifocal, 1757
Bone marrow rescue
with cyclophosphamide plus melphalan, 1814-1823
with etoposide plus carboplatin, 1814-1823
with melphalan plus busulfan, 1814-1823
Bone marrow transplantation
access to, for leukemia, 2644-2651
allogeneic, *see* Allogeneic bone marrow transplantation
autologous, *see* Autologous bone marrow transplantation
haploidentical HLA-mismatched relative donors in, 1767-1777
HLA-identical sibling donors in, 1767-1777
HLA-matched and mismatched unrelated donors in, 1767-1777
for lymphoma, access and, 2644-2651
overview of, 2644-2645
peripheral-blood stem-cell transplantation *v*, 5-10
relapse following, by donor type, 1774
treatment failure following, by donor type, 1775
unrelated donor, in childhood acute leukemia, 557-565
with cyclophosphamide plus melphalan
patient outcome by, 1817
toxicity of, 1815-1816
with etoposide plus carboplatin
patient outcome by, 1817
toxicity of, 1815-1816
with melphalan plus busulfan
patient outcome by, 1817
toxicity of, 1815-1816
Bone mineral density, following cyclophosphamide, methotrexate, FU regimen, 1341-1347
Bone resorption marker, for hypercalcemia, of malignancy, 131-138
Bone scan, in breast cancer surveillance, 2154
Brachytherapy
high-dose-rate, for soft tissue sarcoma, 3075-3084
in tongue base, 3081
Brain, 3003-3004
metastasis to, thioguanine, procarbazine, dibromodulcitol, lomustine, FU, hydroxyurea regimen in, 1063-1070
Brain tumor
incidence of, 2596-2597
pediatric
cyclophosphamide for, 3258-3265
high-dose chemotherapy in, 1814-1823
Brain tumor-polyposis syndrome, 2744-2758
Breast, parenchymal density of, following hormone replacement therapy, 3201-3207
Breast cancer
adjuvant radiation therapy in, by referral, 219
advanced
adjuvant therapy in, 207-215
multiple-cycle cyclophosphamide, thiotepa, carboplatin, stem-cell, filgrastim regimen in, 674-683
survival duration in, 1900
allotransplant in, 1871
associated with arthritis, 3515
associated with palmar fasciitis, 3515
bcl-2 and, 1916-1922
biweekly cisplatin, paclitaxel regimen in, 1880-1884
cardioprotection in, dexrazoxane for, 1318-1332, 1333-1340
chemohormonal therapy in, 2873-2881
chlorambucil, methotrexate, FU regimen in, 2502-2509
conservative treatment of, axillary lymph node dissection in, 691-700
cyclophosphamide dose escalation in, 1885-1896
cyclophosphamide, FU, doxorubicin regimen in, 1897-1905
cyclophosphamide, FU, mitoxantrone regimen in, 1897-1905
cyclophosphamide, methotrexate, FU regimen in, 2502-2509
cyclophosphamide, methotrexate, melphalan regimen in, 2312-2321
docetaxel-induced fluid retention in, corticosteroids for, 3149-3155
dose-intense chemotherapy in, 2983-2985
doxorubicin-resistant, biweekly cisplatin, paclitaxel regimen in, 1880-1884
early-stage
age and, 2338-2344
HER-2-*neu* antibody in, 3363-3367
perioperative polychemotherapy in, 2526-2535
standards of care in, 1401-1408
thymidylate synthase expression and, 1923-1931
epirubicin, cyclophosphamide, G-CSF regimen in, 1367-1376
estrogen receptor-positive metastatic, 1916-1922
etoposide, G-CSF regimen in, for stem-cell mobilization, 759-765
functional assessment in, 975
guidelines for, compliance with, 216-222
high-dose chemotherapy in, with autologous stem-cell support, 1870-1879
high-risk
etoposide, cyclophosphamide, cisplatin regimen in, 2882-2893
etoposide, cyclophosphamide, doxorubicin regimen in, 2882-2893
patient selection in, 3178-3184
high-risk primary, 1872-1873
incidence of, 1871
intensified high-dose cyclophosphamide in, 1858-1869

iodine-labeled Z-MIVE estrogen receptor imaging in, 2536-2545
irradiated, hormonal therapy plus chemotherapy in, 207-215
irradiated heart volume in, 1348-1353
left-sided, Stockholm trial technique for, 1348-1353
locally advanced, breast conservation in, with prolonged neoadjuvant chemotherapy in, 2873-2881
measuring quality of life in, 974
metastatic, 1873
autotransplants for, 1875
epirubicin, paclitaxel regimen in, 2510-2517
megestrol acetate, aminoglutethimide, hydrocortisone regimen in, 2494-2501
vinorelbine, G-CSF regimen in, 1395-1400
neu-related protein in, as prognostic factor, 2518-2525
operable, preoperative chemotherapy in, 2483-2493
p53 and, 1916-1922
paclitaxel interaction with doxorubicin in, 1906-1915
paclitaxel-refractory metastatic, vinorelbine, G-CSF regimen in, 1395-1400
postmenopausal, chemoendocrine therapy for, 1385-1394
preoperative chemotherapy in, 2479-2482
pretransplant chemotherapy in, 1870-1879
primary, doxorubicin, cyclophosphamide regimen in, 1858-1869
prognosis in, fatty acids and, 1377-1384
recurrent, Truquant BR radioimmunoassay detection of, 2322-2328
sentinel lymphadenectomy in, 2345-2350
stem-cell transplantation in, with dose-intense chemotherapy, 2991-2992
survival duration in, prognostic factors for, 1900
survival in, overview of, 2329
tamoxifen in, with cyclophosphamide, methotrexate, FU regimen, 2302-2311
tamoxifen response in, 1916-1922
tamoxifen-resistant, medroxyprogesterone acetate in, 3141-3148
10-Gy irradiation boost in, 963-968
vaginal moisturizer in, 969-973
Breast cancer surveillance
ASCO recommendations for, 2150
guidelines for, 2149-2156
Breast conservation, hormonal synchronization and, 2873-2881
Breast-conserving therapy, patient selection for, 2479-2482
Breast density, mammographic, hormone replacement therapy and, 3201-3207
Breast self-examination, in breast cancer surveillance, 2152
Busulfan
emetogenic potential of, 105
tobacco use and, 2195
Busulfan, cyclophosphamide regimen, in acute myeloblastic leukemia, 2238-2246
Busulfan, melphalan, autologous marrow rescue regimen
in brain tumors, 1814-1823
patient outcome by, 1817
toxicity of, 1815-1816
BW1843 U 89, 391

C-*erb* B-2, as marker, of radioresistance, 1030-1038
C-*mpl* mRNA
as prognostic factor, in acute myeloid leukemia, 2262-2268
reverse-transcriptase polymerase chain reaction for, 2264, 2265
C-telopeptide region, 131-138
CA 15-3, in breast cancer surveillance, 2155
CA 27.29 antigen, in recurrent breast cancer detection, 2322-2328
CA242 antigen level, 1997, 2001
Caelyx, phase II trial of, 3185-3191
Calvert's formula, for carboplatin area-under-the-curve, 193-198
CAMPATH-1H
in chronic lymphocytic leukemia, 1567-1574
for T-cell prolymphocytic leukemia, 2667-2672
toxicity of, 2670
Camustine, in combination chemotherapy, for diffuse large-cell lymphoma, 491-498
Cancer
causes of, 3281
cloned genes of, 3281
DNA repair mutations and, 3285-3286
dominant inheritance of, 3280
hereditary, 3280-3287
inheritance patterns in, 3280-3282
predisposition to, 2158
proto-oncogene mutations and, 3284-3285
somatic mutations and, 3282-3284
therapy for, patient preference in, 110-115
Cancer genetics, education on, curriculum development for, 2157-2169
Cancer patient(s)
pediatric
smoking among, 2194-2204
smoking interventions in, 2199-2201
perceived vulnerability of, 2196
preferences of, in policy-making, 3192-3200
school-based tobacco use interventions and, 2197-2198
Cancer risk, hereditary, testing for, 2139-2148
Cancer therapy, unorthodox, 401-406
Capasaicin cream, for surgical neuropathic pain, 2974-2980
Capecitabine, 396
Carboplatin
area-under-the-curve of, 1960, 1961
in combination chemotherapy, with autologous stem-cell support, 1302-1308
cost attributable to, 1005
dose-effect study of, in ovarian cancer, 193-198
dosing of, in nonseminomatous germ cell cancer, 1847-1848
emetogenic potential of, 105
high-dose, with autologous stem-cell transplantation, 1309-1317
intraperitoneal, in ovarian cancer, 1945-1952
in ovarian cancer, 193-198
pharmacokinetic parameters of, 1960
Carboplatin, bleomycin, etoposide regimen
in nonseminomatous germ cell cancer, 1844-1852
renal toxicity of, 1850
toxicity of, 1848
Carboplatin, cyclophosphamide, thiotepa, stem-cell, filgrastim regimen, multiple-cycle, in breast cancer, 674-683
Carboplatin, cyclosporine regimen
intraperitoneal, in ovarian cancer, 1945-1952
toxicities of, 1950
Carboplatin, etoposide, autologous marrow rescue regimen
in brain tumors, 1814-1823
patient outcome by, 1817
toxicity of, 1815-1816
Carboplatin, etoposide, cyclophosphamide, autologous BMT regimen

high-dose, in germ cell tumors, 2546-2552
toxicity of, 2549
Carboplatin, paclitaxel regimen
clinical antitumor activity of, 1958
cumulative hematologic toxicity of, 1957
in NSCLC, 317-329
pharmacokinetic-pharmacodynamic relationships of, 1959-1961
pharmacokinetics of, 1958-1959, 317-329
pharmacologic study of, in ovarian cancer, 1953-1964
Carboplatin, paclitaxel, cyclophosphamide, stem-cell regimen, phase I trial of, 1481-1491
Carboplatin, paclitaxel, etoposide regimen
for carcinoma, of unknown primary site, 2385-2393
in SCLC, 3464-3470
toxicity of, 2389
Carboxyamidotriazole
gastroenterologic toxicity of, 784
hematologic toxicity of, 784
micronized formulation of, 1985-1993
molecular structure of, 789
neurotoxicity of, 784
oral, phase I trial of, 781-789
pharamcokinetic parameters of, 786
pharmacodynamic analysis of, 1989-1990
pharmacokinetics of, 1988-1989
phase I trial of, 1985-1993
plasma concentrations of, 785
in refractory solid tumors, 1985-1993
relative bioavailability of, 1989
response to, 785
toxicity of, 1987-1988
Carboxypeptidase-G2
pharmacokinetics of, 2128-2130
toxicity of, 2127-2128
Carboxypeptidase-G2, thymidine, folinic acid rescue, in methotrexate-induced nephrotoxicity, 2125-2134
Carcinoembryonic antigen, in breast cancer surveillance, 2155
Carcinoembryonic antigen mRNA
dot-blot detection of, in lung cancer, 3388-3393
RT-PCR detection of, in lung cancer, 3388-3393
Carcinoma
poorly differentiated, natural history of, 2056-2066
of unknown primary site, paclitaxel, carboplatin, etoposide regimen for, 2385-2393
Cardiac mechanics, following daunorubicin, 63
Cardioprotection, dexrazoxane for, 1318-1332, 1333-1340
Cardiotoxicity
definition of, 1544-1545
early anthracycline, 1544-1552
late, following anthracycline therapy, 61-68
relative risks for, 1549
Care coordination, in breast cancer surveillance, 2153
Carmustine
emetogenic potential of, 105
tobacco use and, 2195
Carmustine, cisplatin, radiotherapy regimen
for astrocytoma, 2596-2603
survival following, 2598-2601
toxicity of, 2601
Carmustine, etoposide, cytarabine, melphalan regimen, in lymphoma, 535-546
Catheter, fibrin sleeve occlusion of, 2709-2714
Cathetergram, 2713
CC49 mononclonal antibody, iodine-labeled
in gastrointestinal cancer, 1518-1528
nonhematopoietic toxicity associated with, 1526
CD4 count, as prognostic factor, in Kaposi's sarcoma, 3085-3092
CD30 ligand, in lymphoma, 3355-3362
CD-31, in NSCLC, 2460
CD34+ cell, number of, for rapid engraftment, 3067-3074
CD34+ selection, 2289
in peripheral-blood stem-cell transplantation, for follicular lymphoma, 2288-2295
CD52 antibody
for T-cell prolymphocytic leukemia, 2667-2672
toxicity of, 2670
CDR3 region, polymerase chain reaction and, in early gastric mucosa-associated lymphatic tissue lymphoma diagnosis, 1104-1109
Cell proliferation-related marker, in colorectal liver metastases, 2008-2014
Cervical cancer
advanced, vinorelbine, 604-609
cells of, in circulating blood, 1008-1012
cisplatin in, 165-171
cisplatin, mitolactol regimen in, 165-171
ifosfamide, cisplatin regimen in, 165-171
refractory, irinotecan in, 625-631
survival in, human papillomavirus and, 610-619
telomerase activity and, 1932-1937
Cervical intraeptithelial neoplasia lesion, telomerase activity and, 1932-1937
Chemistry studies, automated, in breast cancer surveillance, 2154
Chemoembolization, in ocular melanoma, 2589-2595
Chemoendocrine therapy, for postmenopausal breast cancer, 1385-1394
Chemohormonal therapy, in locally advanced breast cancer, 2873-2881
Chemoradiotherapy
accelerated *v* delayed hyperfractionated radiation in, for SCLC, 893-900
for brain metastases, of testicular cancer, 1449-1454
combination, *v* high-dose radiotherapy chemoradiotherapy trade-off, 333-335
in limited-stage thymoma, 3093-3099
in NSCLC, 1409-1417, 712-722
pre-and post-, plus surgery, in pancreatic cancer, 928-937
preoperative, in esophageal cancer, 709
radiotherapy *v*, in esophageal cancer, 277-284
in SCLC, 893-900
surgery plus
in esophageal cancer, 701-711
survival following, 706
toxicity of, 705
warfarin with, 3378-3387
Chemotherapy
adjuvant tamoxifen and, in node-positive breast cancer, 1385-1394
alternating *v* sequential, plus radiotherapy, in SCLC, 2840-2849
ambulatory, stem-cell infusion plus, in NHL, 1722-1729
combination, *see* Combination chemotherapy
consolidation, in acute lymphoblastic leukemia, 476-482

dose escalation in, 2765-2768
dose-intense, 2981-2995
with cytokines, 2987
emetogenicity of, 103-109
escalated, 2981-2995
fertility following, in testicular germ cell cancer, 239-245
high-dose, *see* High-dose chemotherapy
hormonal therapy plus, in irradiated breast cancer, 207-215
in craniofacial osteosarcoma, and survival, 363-367
in gastric cancer, 3299-3300
induction, in head and neck cancer, 2050-2055
intensive sequential, with stem-cell infusion, 1722-1729
nausea following, determinants of, 116-123
oral *v* IV, patient preference for, 110-115
palliative
costs of, in ovarian cancer, 1000-1007
oral *v* IV, 110-115
poly, *see* Polychemotherapy
preoperative, doxorubicin, cyclophosphamide regimen as, 2483-2493
prephase, in childhood acute lymphoblastic leukemia, 1824-1830
pretransplant, in breast cancer, 1870-1879
quality of life following, for liver metastases, 2022-2029
radiotherapy plus, *see* Chemoradiotherapy
role of, in NSCLC, 3005
for stem-cell collection, 684-690
use of, in breast cancer, 219
vomiting following, determinants of, 116-123
weekly, in gastric cancer, 3313-3319
Chemotherapy salvage regimen
with cisplatin-based regimen, for germ cell tumors, 2559-2563
with ifosfamide-based regimen, 2559
Chest, CT of
in relapsed SCLC, 731
in Wilms' tumor, 2631-2635
Chest roentgenography, in breast cancer surveillance, 2154
Childhood
acute leukemia in, unrelated donor BMT for, 557-565
acute lymphoblastic leukemia in
aminotransferase elevation in, 1560-1566
anthracycline therapy for, 61-68
augmented Berlin-Frankfurt-Munster therapy for, 2222-2230
early methotrexate use in, 1824-1830
Philadelphia chromosome status in, 2231-2237
acute myeloblastic leukemia in, allogeneic BMT in, 2238-2246
acute myelogenous leukemia in, idarubicin, fludarabine, cytarabine regimen for, 2780-2785
anthracycline therapy in, cardiotoxicity following, 1544-1552
brain tumor in, high-dose chemotherapy for, 1814-1823
cancer in, long-term survival and, 2205-2213
chronic myelomonocytic leukemia in, allogeneic BMT for, 566-573
extraosseous Ewing's sarcoma in, 574-582
HD in
histology and, 2622-2630
mechlorethamine elimination in, 2247-2253
intrathecal methotrexate for, 1824-1830
leukemia in, survivors of, negative mood in, 547-556
low-grade astrocyoma in, 2792-2799
medulloblastoma in, surveillance scanning following, 1811-1813
neuroblastoma in, MYCN oncogene amplification in, 85-93
one-hour docetaxel infusion in, phase I trial of, 1538-1543
painful procedures in, ketamine, atropine, idazolam *v* meperidine, midazolam regimen in, 94-102
rhabdomyosarcoma in, bladder preservation in, 69-75
smoking in, 2181-2182, 2194-2204
soft tissue sarcoma in, high-dose-rate brachytherapy for, 3075-3084
T-cell acute lymphoblastic leukemia in, cranial radiotherapy for, 2786-2791
T-lineage acute lymphoblastic leukemia in, leukemic cell maturation stage in, 2214-2221
Chlorambucil, emetogenic potential of, 105
Chlorambucil, methotrexate, FU regimen
in breast cancer, 2502-2509
toxicity of, 2506-2507
2-Chlorodeoxyadenosine, emetogenic potential of, 105
CHOP regimen, in large-cell lymphoma, 1713-1716
Chronic lymphocytic leukemia
CAMPATH-1H in, 1567-1574
human CD52 antibody in, 1567-1574
refractory, fludarabine in, 458-465
splenectomy in, 52-60
Chronic myelogenous leukemia
interferon alfa in, cost-effectiveness of, 2673-2682
Philadephia-negative peripheral-blood stem-cells in, 1575-1582
relapsed, donor leukocyte infusions in, 433-444
Chronic myeloid leukemia
molecular monitoring and, 26-36
Philadelphia chromosome and, 26
Chronic myelomonocytic leukemia, childhood, allogeneic BMT in, 566-573
Cisplatin
acral paresthesia associated with, 2446
in cervical cancer, 165-171
in combination chemotherapy
for breast cancer, 2318
for NHL, 1722-1729
for stem-cell collection, 684-690
with autologous stem-cell support, 1302-1308
cost attributable to, 1005
delayed emesis following, 124-130
adrenocorticotropic hormone for, 2467-2473
dexamethasone, metoclopramide regimen following, 124-130
emesis due to, dolasetron plus dexamethasone for, 2135-2138
emetogenic potential of, 105
fertility following, in testicular germ cell cancer, 239-245
lonidamine potentiation of, 3208-3213
monthly, with weekly gemcitabine, 744-749
neurotoxicity of, 168
ondansetron, dexamethasone regimen following, 124-130
pharmacokinetic parameters of, 778
preoperative, in esophageal cancer, 709
Raynaud's phenomenon associated with, 2446
sperm count recovery following, in combination chemotherapy, 242, 243
survival following, 169-170, 2566-2568
toxicity of, 1943
in urothelial cancer, 2564-2569
weekly, in ovarian cancer, for two months, 1938-1944
with continuous 96-hour paclitaxel infusion, 735-743
Cisplatin, amifostine, vinblastine, radiotherapy regimen, in NSCLC, 2850-2857

Cisplatin, bleomycin, etoposide regimen
etoposide, cisplatin regimen *v*, 1837-1843
in nonseminomatous germ cell cancer, 1844-1852
relative dose intensity of, 1838
renal toxicity of, 1850
surgery following, 1840
survival following, 1840-1842
toxicity of, 1839-1840, 1848
Cisplatin, carmustine, radiotherapy regimen
for astrocytoma, 2596-2603
survival following, 2598-2601
toxicity of, 2601
Cisplatin, cyclophosphamide regimen
cost attributable to, 1005
economic analysis of, in ovarian cancer, 632-639
neurotoxicity of, 199-206
ototoxicity of, 199-206
in ovarian cancer, for five months, 1938-1944
toxicity of, 1943
Cisplatin, cyclophosphamide, epidoxorubicin, etoposide, GM-CSF regimen, in SCLC, 2082-2089
Cisplatin, cyclophosphamide, vincristine, doxorubicon, etoposide, surgery regimen, in neuroblastoma, 3433-3440
Cisplatin, dactinomycin, doxorubicin regimen, in postoperative osteosarcoma, 76-84
Cisplatin, docetaxel regimen
granulocyte nadir duration following, 1075
hematologic toxicity of, 1074
nonhematologic toxicity of, 1074-1076
pharmacokinetic parameters of, 1076
phase I trial of, 1071-1079
Cisplatin, doxetaxel regimen
dosing of, in NSCLC, 753
hematologic toxicity of, 754
neutropenia of, 754
nonhematologic toxicity of, 755
in untreated NSCLC, 750-758
Cisplatin, doxorubicin, cyclophosphamide, radiotherapy regimen
in limited-stage thymoma, 3093-3099
survival following, 3097
toxicity of, 3096
Cisplatin, epirubicin, FU regimen
cost of, 264
in esophagogastric cancer, 261-267
response to, 263-264
survival following, 265
toxicity of, 264
Cisplatin, etoposide regimen
bleomycin, etoposide, cisplatin regimen *v*, 1837-1843
dose modification of, 1838
gemcitabine *v*, in NSCLC, 2097-2102
Indiana University Staging System for, 2556-2557
long-term follow-up of, 2553-2558
relative dose intensity of, 1838
surgery following, 1840
survival following, 1840-1842, 2555
toxicity of, 1839-1840
Cisplatin, etoposide, cyclophosphamide, stem-cell regimen, in breast cancer, 2882-2893
Cisplatin, FU, epi-doxorubicin, 6S-folinic acid, glutathione, filgrastim regimen
in gastric cancer, 3313-3319
survival following, 3316
toxicity of, 3316-3317
Cisplatin, FU, folinic acid regimen
in head and neck cancer, 3100-3110
major toxicities of, 3104
schematic design for, 3101
toxicity of, 3103-3104
Cisplatin, FU, radiotherapy regimen, in esophageal cancer, 277-284
Cisplatin, gemcitabine regime
hematologic toxicity of, 300
nonhematologic toxicity of, 300-301
in NSCLC, 297-303
Cisplatin, gemcitabine regimen
hematologic toxicity of, 747
nonhematologic toxicity of, 747
in NSCLC, 744-749
studies of, in NSCLC, 748
Cisplatin, ifosfamide regimen
in cervical cancer, 165-171
neurotoxicity of, 168
survival following, 169-170
Cisplatin, interferon alfa-2a, IL-2 regimen
in melanoma, 2579-2588
response to, 2582-2583
survival following, 2583-2587
toxicity of, 2581-2582
Cisplatin, irinotecan regimen
in gastric cancer, 921-927
objective response to, 925
toxicity of, 924
Cisplatin, methotrexate, vinblastine, doxorubicin regimen
survival following, 2566-2568
in transitional-cell carcinoma, 2449-2455
in urothelial cancer, 2564-2569
Cisplatin, methotrexate, vinblastine, radiotherapy, surgery regimen
for invasive bladder cancer, 1022-1029
protocol for, 1024
survival following, 1025-1026
Cisplatin, mitolactol regimen
in cervical cancer, 165-171
neurotoxicity of, 168
survival following, 169-170
Cisplatin, paclitaxel regimen
biweekly, in breast cancer, 1880-1884
clinical trials of, in breast cancer, 1883
economic analysis of, in ovarian cancer, 632-639
neurotoxicity of, 199-206
ototoxicity of, 199-206
in ovarian cancer, 1965-1973
Cisplatin, paclitaxel, G-CSF regimen
dosing of, 738
hematologic toxicity of, 739
in lung cancer, 735-743
nonhematologic toxicity of, 739
survival following, 739-740
Cisplatin, paclitaxel, radiotherapy regimen
hematologic toxicity of, 1413
nonhematologic toxicity of, 1414
in NSCLC, 1409-1417
survival following, 1414

Cisplatin, radiotherapy, FU, strepozocin, folinic acid regimen
in pancreas cancer, 2920-2927
survival following, 2924-2925
Cisplatin, tirapazamine regimen
antiemetic regimens used with, 776
nausea associated with, 776
phase I trial of, 773-780
vomiting associated with, 776
Cisplatin, vinblastine, ifosfamide regimen, in seminoma, 1427-1431
Cisplatin, vincristine, doxorubicin, etoposide regimen
in SCLC, 292-296
survival following, 294
worst toxicities of, 295
Cisplatin-based chemotherapy, results of, 2940
Cisplatin-based salvage regimen, for germ cell tumors, 2559-2563
Cis-11 beta-methoxy-17 alpha-iodovinylestradiol-17 beta, in estrogen receptor imaging, 2536-2545
Cladribine
in prolymphocytic leukemia, 37-43
response to, 39-41
therapy with, 38
toxicities of, 41-42
Classification
of chemotherapy emetogeneicity, 103-109
prognostic, in germ cell cancer, 594-603
Clinical trial(s)
of autotransplants, in breast cancer, 1877
end points in, for prostate cancer, 382-383
independent data-monitoring committee composition for, 2738-2739
National Cancer Institute-sponsored, 2736-2743
of paclitaxel, cisplatin regimen, in breast cancer, 1883
patient protection in, 2739-2740
response rate accuracy in, 3507-3514
Clodronate
bone loss and, 1341-1347
malignancy hypercalcemia and, 131-138
CNS, metastases to, 3019-3020
CNS embryonal tumor
cisplatin-based chemotherapy for, 2939-2944
nitrosourea-based chemotherapy for, 2939-2944
Collagen vascular disease, irradiation and, 2728-2735
Colon cancer, surgical adjuvant therapy in, 246-250
Colony-stimulating factor
overview of, 2954-2955
see also specific type
Colorectal cancer
adjuvant high-dose folinic acid in, 2432-2441
advanced
FU, folinic acid regimen in, 3320-3329
irinotecan in, 251-260
bolus *v* infusion FU in, 368-381
disseminated, overview of, 3223-3224
folinic acid, FU regimen in, 3223-3229, 808-815
genomic damage in, 3230-3240
irinotecan in, 251-260
liver metastases of
biomarkers in, 2008-2014
chemotherapy for, quality of life following, 2022-2029
FU, interferon alfa-2b regimen for, 1432-1438
resection for, 938-946
management of, 2910-2911
metastatic, irinotecan in, 2910-2919
pure folinic acid *l*-isomer, FU regimen in, 908-914
racemic folinic acid, FU regimen in, 908-914
72-hour continuous 9-aminocamptothecin infusion in, 2905-2909
trimetrexate, FU, folinic acid regimen in, 915-920
Combination chemotherapy
cisplatin-based, fertility following, 239-245
dose-intensive weekly, in SCLC, 292-296
emetogenicity of, algorithm defining, 106
for Kaposi's sarcoma, following organ transplantation, 2371-2377
in limited-stage thymoma, 3093-3099
for stem-cell collection, 684-690
stem-cell infusion plus, in NHL, 1722-1729
with G-CSF, in refractory cancer, 148-157
Combined androgen blockade, 382-388
new paradigm and, 384-387
old paradigm and, 383-384
Combined modality therapy
in bladder preservation, for invasive bladder cancer, 1022-1029
cost of, in NSCLC, 3038-3048
in limited-stage thymoma, 3093-3099
in NSCLC, 3038-3048
for pancreas cancer, 2920-2927
Complete remission, induction chemotherapy and, 2052-2053
Compliance, with breast cancer guidelines, 216-222
Computed tomography
of abdomen
in HD, 523, 524
in liver metastasis, 2106-2108
of axillary mass, 2391
in breast cancer surveillance, 2154-2155
of chest
in relapsed SCLC, 731
in Wilms' tumor, 2631-2635
early, for aspergillosis, in neutropenics, 139-147
of iodine-labeled CC49 radioimmunolocalization, in pancreas cancer, 1523
in mediastinal disease, 1635
pelvic, of sacrum, 2390
in retroperitoneal adenopathy, 1636
Conditioning regimen, busulfan plus cyclophosphamide as, in acute myeloblastic leukemia, 2238-2246
Consolidation chemotherapy, in acute lymphoblastic leukemia, 476-482
Corticosteroid(s)
in combination chemotherapy, for NHL, 1722-1729
for docetaxel-induced fluid retention, 3149-3155
Cost
of chemotherapy, 1004
of cisplatin, epirubicin, FU regimen, 264
of doxorubicin, methotrexate, FU regimen, 264
of drugs, 1005
of epirubicin, cisplatin, FU regimen, 264
of 5 *v* 10 microgram filgrastim dosing, 1730-1735
of FU, doxorubicin, methotrexate regimen, 264
of FU, epirubicin, cisplatin regimen, 264
inpatient, *v* outpatient, 1001
of methotrexate, doxorubicin, FU regimen, 264
of palliation, in ovarian cancer, 1000-1007
survival time and, 1005

Cost-effectiveness
of combined modality therapy, in NSCLC, 3038-3048
of interferon alfa, in chronic myelogneous leukemia, 2673-2682
of paclitaxel, in ovarian cancer, 640-645
Cranial irradiation, in T-cell acute lymphoblastic leukemia, 2786-2791
Craniofacial osteosarcoma, survival in, chemotherapy and, 363-367
Crosslaps region, 131-138
Curriculum development, in cancer genetics education, 2157-2169
Cutaneous melanoma
American Joint Committee on Cancer staging for, 1039-1051
lymph node size in, 1045-1048
microsatellites *v* macrosatellites in, 1045
new staging system for, 1039-1051
1992 American Joint Committee on Cancer staging for, 1040
nodal status in, 1043
satellites *v* in-transit metastases of, 1043-1044
satellites *v* local recurrence in, 1045
stage grouping of, 1049
stage I critique in, 1039-1042
stage II critique in, 1039-1042
stage III critique in, 1045-1048
survival following, 1041-1043
ulceration in, 1042-1043
Cyclin, 3305-3306
alterations of, in tumors, 3306
Cyclin D-1 staining, 1665
Cyclin-dependent kinase, 3305-3306
in tumors, 3306
inhibitors of, 3306
Cyclophosphamide
in Berlin-Frankfurt-Munster therapy, 2223
cardiotoxicity following, 1544-1552
in combination chemotherapy
for HD, 2247-2253
for NHL, 1722-1729
for stem-cell collection, 684-690
with autologous stem-cell support, 1302-1308
dexamethasone-modulated disposition of, 1885-1896
dose escalation of, 3258-3265
in breast cancer, 1885-1896
emetogenic potential of, 105
for pediatric brain tumors, 3258-3265
as prodrug, 1885-1896
for stem-cell collection, 684-690
high-dose
pharmacokinetics of, 1885-1896
with autologous stem-cell transplantation, 1309-1317
intensified high-dose, in breast cancer, 1858-1869
mean plasma concentration-time curve of, 1890
metabolic clearance of, 1891
metabolic pattern of, 1886
pharmacokinetics of, 1891, 3261, 3263
renal clearance of, 1891
response to, 3262
in stem-cell mobilization, for lymphoma, 535-546
systemic clearance of, 1891
thrombocytopenia due to, IL-11 in, 3368-3377
tobacco use and, 2195
toxicity of, 3260-3261
Cyclophosphamide, busulfan regimen, in acute myeloblastic leukemia, 2238-2246
Cyclophosphamide, carboplatin, etoposide, autologous BMT regimen
high-dose, in germ cell tumors, 2546-2552
toxicity of, 2549
Cyclophosphamide, carboplatin, paclitaxel, stem-cell regimen, phase I trial of, 1481-1491
Cyclophosphamide, cisplatin regimen
cost attributable to, 1005
economic analysis of, in ovarian cancer, 632-639
five months of, in ovarian cancer, 1938-1944
neurotoxicity of, 199-206
ototoxicity of, 199-206
toxicity of, 1943
Cyclophosphamide, cisplatin, doxorubicin, radiotherapy regimen
in limited-stage thymoma, 3093-3099
survival following, 3097
toxicity of, 3096
Cyclophosphamide, doxorubicin regimen
compliance with, 1863-1864
preoperative, in breast cancer, 2483-2493
Cyclophosphamide, doxorubicin, estrogen, methotrexate, FU, tamoxifen regimen, in breast cancer, 2873-2881
Cyclophosphamide, doxorubicin, etoposide regimen, radiotherapy plus, 2840-2849
Cyclophosphamide, doxorubicin, regimen
in breast cancer, 1858-1869
toxicity of, 1862-1863
Cyclophosphamide, doxorubicin, vincristine, prednisone regimen
early restaging gallium scan following, in NHL, 1631-1637
in large-cell lymphoma, 1713-1716
Cyclophosphamide, epidoxorubicin, etoposide, cisplatin, GM-CSF regimen, in SCLC, 2082-2089
Cyclophosphamide, epirubicin, G-CSF regimen
in breast cancer, 1367-1376
dose-intensification of, 1367-1376
Cyclophosphamide, etoposide, cisplatin, stem-cell regimen, in breast cancer, 2882-2893
Cyclophosphamide, etoposide, doxorubicin, stem-cell rescue regimen, in breast cancer, 2882-2893
Cyclophosphamide, FU, doxorubicin regimen
in breast cancer, 1897-1905
hematologic toxicity of, 1903
overall survival following, 1900, 1902
time to tumor progression following, 1903
toxicities of, 1904
Cyclophosphamide, FU, mitoxantrone regimen
in breast cancer, 1897-1905
hematologic toxicity of, 1903
overall survival following, 1900, 1902
time to tumor progression following, 1903
toxicities of, 1904
Cyclophosphamide, melphalan, autologous marrow rescue regimen
in brain tumors, 1814-1823
patient outcome by, 1817
toxicity of, 1815-1816
Cyclophosphamide, methotrexate, bleomycin, dactinomycin regimen, in osteosarcoma, 76-84
Cyclophosphamide, methotrexate, doxorubicin, vincristine, prednisone, bleomycin regimen, in late-relapse lymphoma, 1745-1753
Cyclophosphamide, methotrexate, FU regimen

bone loss associated with, 1341-1347
in breast cancer, 2502-2509
tamoxifen plus, in breast cancer, 1385-1394, 2302-2311
toxicity of, 2506-2507
Cyclophosphamide, methotrexate, melphalan regimen, in breast cancer, 2312-2321
Cyclophosphamide, teniposide, prednisone regimen
in aggressive NHL, 2945-2953
survival following, 2951
Cyclophosphamide, teniposide, prednisone, pirarubicin regimen
in aggressive NHL, 2945-2953
survival following, 2951
Cyclophosphamide, thiotepa, carboplatin, stem-cell, filgrastim regimen, multiple-cycle, in breast cancer, 674-683
Cyclophosphamide, topotecan regimen
hematologic toxicity of, 151-152
nonhematologic toxicity of, 151
pharmacokinetic studies of, 151-152
in refractory cancer, 148-157
Cyclophosphamide, vinblastine, procarbazine, prednisone regimen
in HD, 2652-2658
survival following, 2655-2656
Cyclophosphamide, vincristine regimen
fertility following, 2641
for gestational trophoblastic tumor, 2636-2643
second malignancy following, 2640
Cyclophosphamide, vincristine, dactinomycin regimen, in extraosseous Ewing's sarcoma, 574-582
Cyclophosphamide, vincristine, dactinomycin, doxorubicin regimen, in extraosseous Ewing's sarcoma, 574-582
Cyclophosphamide, vincristine, doxorubicn, cisplatin, etoposide, surgery regimen, in neuroblastoma, 3433-3440
Cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, dacarbazine, radiation regimen, in HD, 2275-2287
Cyclosporine
graft-versus-host disease and, in myeloma, 667-673
intraperitoneal, in ovarian cancer, 1945-1952
pharmacokinetics of, 1947, 1948
post-transplant, for autologous graft-versus-host disease, 667-673
Cyclosporine, carboplatin regimen
intraperitoneal, in ovarian cancer, 1945-1952
toxicities of, 1950
Cyclosporine, high-dose, with autologous stem-cell transplantation, 1309-1317
Cytarabine
in Berlin-Frankfurt-Munster therapy, 2223
in combination chemotherapy
for acute promyelocytic leukemia, 1786-1795
for diffuse large-cell lymphoma, 491-498
dosing of, in renal insufficiency, 833-839
elimination of, in acute lymphoblastic leukemia therapy, 476-482
emetogenic potential of, 105
high-dose
in renal insufficiency, 833
neurotoxicity and, 833-839
high-dose intensification of, in extramedullary leukemia, 466-475
tobacco use and, 2195
Cytarabine, amsacrine, mitoxantrone, etoposide, methotrexate regimen, as consolidation chemotherapy, 476-482
Cytarabine, carmustine, etoposide, melphalan regimen, in lymphoma, 535-546
Cytarabine, idarubicin, fludarabine regimen, in acute myelogenous leukemia, 2780-2785
Cytarabine, topotecan regimen
antileukemic activity of, 48
in acute leukemia, 44-51
nonhematologic toxicity of, 47
toxicity of, 47-48
Cytogenetic analysis
in chronic myeloid leukemia residual disease, 26
for prognosis, of multiple myeloma, 2659-2666
Cytokines, dose-intense chemotherapy with, 2987-2989

D-xylose malabsorption, cytotoxic therapy-induced, in acute myeloid leukemia, 2254-2261
Dacarbazine, cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, radiation regimen, in HD, 2275-2287
Dacarbazine, emetogenic potential of, 105
Dacarbazine, mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine regimen
relapse following, in HD, 528-534
with total-nodal irradiation, in HD, 2769-2779
Dacarbazine, mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, radiotherapy regimen, in HD, 3338-3346
Dacarbazine, vinblastine, mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin regimen, in HD, 1638-1645
Dactinomycin, doxorubicin, cisplatin regimen, in postoperative osteosarcoma, 76-84
Dactinomycin, etoposide, methotrexate regimen
fertility following, 2641
for gestational trophoblastic tumor, 2636-2643
second malignancy following, 2640
Dactinomycin, methotrexate, bleomycin, cyclophosphamide regimen, in osteosarcoma, 76-84
Dactinomycin, methotrexate, doxorubicin regimen, in postoperative osteosarcoma, 76-84
Dactinomycin, vincristine, cyclophosphamide regimen, in extraosseous Ewing's sarcoma, 574-582
Dactinomycin, vincristine, cyclophosphamide, doxorubicin regimen, in extraosseous Ewing's sarcoma, 574-582
Data-monitoring committee, independent, and NCI clinical trials, 2736-2743
Daunomycin, cardiotoxicity following, 1544-1552
Daunorubicin
in acute lymphoblastic leukemia, 61-68
cardiac mechanics following, 63
in combination chemotherapy, for acute lymphoblastic leukemia, 476-482
late cardiotoxicity following, 61-68
left ventricular end-systolic wall stress following, 62-66
left ventricular performance following, 63-65
tobacco use and, 2195
velocity of circumferential fiber shortening following, 62-66
Decision analysis
model development in, 874-880
in NSCLC, 870-872, 873-883
Decision making
in cancer therapy, 110-115
survival advantage threshold and, 336

Deoxycoformycin, second malignancy risk following, 1803-1810
Deoxypyridinoline, 131-138
Dexamethasone
  in Berlin-Frankfurt-Munster therapy, 2223
  in combination chemotherapy, for diffuse large-cell lymphoma, 491-498
  in cyclophosphamide disposition, 1885-1896
  following cisplatin, tirapazamine regimen, 776
Dexamethasone, dolasetron regimen, for emesis, 2135-2138
Dexamethasone, dolasetron, ondansetron regimen, in emesis, 2966-2973
Dexamethasone, metoclopramide regimen
  adverse events following, 128
  ondansetron, dexamethasone *v*, in delayed emesis, 124-130
Dexrazoxane, for cardioprotection, 1318-1332, 1333-1340
Diarrhea
  associated with graft-versus-host disease, octreotide for, 3350-3354
  following paclitaxel, 1965-1973
  following topotecan, 1087-1093
  loperamide for, 2910-2919
  treatment for, 1081
Dibromodulcitol, thioguanine, procarbazine, lomustine, FU, hydroxyurea regimen
  for brain metastases, 1063-1070
  response to, 1065
  survival following, 1066
  toxicity of, 1067
  treatment scheme for, 1064
Diet, fatty acids in, and breast cancer prognosis, 1377-1384
Differentiated thyroid carcinoma
  death in, causes of, 2071
  classification of, mortality by, 2071
  local infiltration in, 2073
  overall mortality in, 2070
  therapeutic protocol for, 2068
Diffuse large B-cell lymphoma, follicular large-cell lymphoma *v*, 1654-1663
Diffuse large-cell lymphoma, high-dose chemotherapy in, with autologous stem-cell transplantation, 491-498
Dinitrophenyl vaccine
  hapten, in melanoma, 2359-2370
  treatment schedule for, 2361
Diphenhydramine, following cisplatin, tirapazamine regimen, 776
DNA content, nondiploid, in adult sarcoma, 3249-3257
DNA fingerprinting, in colorectal cancer, 3230-3240
DNA ploidy, in colorectal liver metastases, 2008-2014
Docetaxel
  delivery of, 3152
  emetogenic potential of, 105
  fluid retention due to, corticosteroids for, 3149-3155
  in NHL, 3275-3279
  one-hour infusion of, phase I trial of, 1538-1543
  pharmacokinetics of, 756
  phase II trial of, in transitional-cell cancer, 1853-1857
  side effects due to, 3153
  toxicity of, 1855-1856
  in transitional-cell cancer, 1853-1857
Docetaxel, cisplatin regimen
  granulocyte nadir duration following, 1075
  hematologic toxicity of, 1074
  nonhematologic toxicity of, 1074-1076
  pharmacokinetic parameters of, 1076
  phase I trial of, 1071-1079
  in untreated NSCLC, 750-758
Dolasetron, dexamethasone regimen, for emesis, 2135-2138
Dolasetron, ondansetron, dexamethasone regimen, in emesis, 2966-2973
Dose-intensity
  escalation of, in chemotherapy, 2765-2768
  of paclitaxel, carboplatin, etoposide regimen, in SCLC, 3464-3470
Dot-blot analysis, in lung cancer metastatic cell detection, 3388-3393
Doxetaxel, cisplatin regimen
  dosing of, in NSCLC, 753
  hematologic toxicity of, 754
  neutropenia of, 754
  nonhematologic toxicity of, 755
Doxorubicin
  alopecia associated with, 1897-1905
  in Berlin-Frankfurt-Munster therapy, 2223
  cardiotoxicity following, 1544-1552
  in combination chemotherapy
    for acute lymphoblastic leukemia, 476-482
    for NHL, 1722-1729
  dexrazoxane following, 1318-1332, 1333-1340
  emetogenic potential of, 105
  high-dose, clinical trials of, selection bias in, 3172
  liposomal, *see* Liposomal doxorubicin
  main pharmacokinetic parameters of, 1911
  paclitaxel interaction with, 1906-1915
  pegylated-liposomal, in Kaposi's sarcoma, 653-659
  preoperative chemotherapy with, for soft tissue sarcoma, 3481-3487
  sequence impact on, 1909
  thrombocytopenia due to, IL-11 in, 3368-3377
  tobacco use and, 2195
Doxorubicin, bleomycin, vincristine regimen
  following transplantation, 2371-2377
  in Kaposi's sarcoma, 653-659
Doxorubicin, cisplatin, cyclophosphamide, radiotherapy regimen
  in limited-stage thymoma, 3093-3099
  survival following, 3097
  toxicity of, 3096
Doxorubicin, cisplatin, vincristine, etoposide regimen
  in SCLC, 292-296
  survival following, 294
  worst toxicities of, 295
Doxorubicin, cyclophosphamide regimen
  in breast cancer, 1858-1869
  compliance with, 1863-1864
  preoperative, in breast cancer, 2483-2493
  toxicity of, 1862-1863
Doxorubicin, cyclophosphamide, estrogen, methotrexate, FU, tamoxifen regimen, in breast cancer, 2873-2881
Doxorubicin, cyclophosphamide, etoposide regimen, plus radiotherapy, 2840-2849
Doxorubicin, cyclophosphamide, FU regimen
  in breast cancer, 1897-1905
  hematologic toxicity of, 1903
  overall survival following, 1900, 1902
  time to tumor progression following, 1903

toxicities of, 1904
Doxorubicin, cyclophosphamide, vincristine, cisplatin, etoposide, surgery regimen, in neuroblastoma, 3433-3440
Doxorubicin, cyclophosphamide, vincristine, dactinomycin regimen, in extraosseous Ewing's sarcoma, 574-582
Doxorubicin, cyclophosphamide, vincristine, prednisone regimen
early restaging gallium scan following, in NHL, 1631-1637
in large-cell lymphoma, 1713-1716
Doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, bleomycin, vinblastine, dacarbazine, radiation regimen, in HD, 2275-2287
Doxorubicin, dactinomycin, cisplatin regimen, in postoperative osteosarcoma, 76-84
Doxorubicin, etoposide, cyclophosphamide, stem-cell rescue regimen, in breast cancer, 2882-2893
Doxorubicin, mechlorethamine, vincristine, procarbazine, prednisone, bleomycin, vinblastine regimen, in HD, 1638-1645
Doxorubicin, mechlorethamine, vincristine, procarbazine, prednisone, bleomycin, vinblastine, dacarbazine regimen
in HD, 1638-1645
relapse following, in HD, 528-534
with total-nodal irradiation, in HD, 2769-2779
Doxorubicin, mechlorethamine, vincristine, procarbazine, prednisone, bleomycin, vinblastine, dacarbazine, radiotherapy regimen, in HD, 3338-3346
Doxorubicin, methotrexate, cyclophosphamide, vincristine, prednisone, bleomycin regimen, in late-relapse lymphoma, 1745-1753
Doxorubicin, methotrexate, dactinomycin regimen, in postoperative osteosarcoma, 76-84
Doxorubicin, methotrexate, FU regimen
cost of, 264
in esophagogastric cancer, 261-267
response to, 263-264
survival following, 265
toxicity of, 264
Doxorubicin, methotrexate, vinblastine, cisplatin regimen
survival following, 2566-2568
in transitional-cell carcinoma, 2449-2455
in urothelial cancer, 2564-2569
Doxorubicin, vincristine, prednisone, etoposide, radiotherapy regimen
in HD, 2652-2658
survival following, 2655-2656
Doxorubicin, vincristine, procarbazine, prednisone, procarbazine regimen, in HD, 2247-2253
Droloxifene
formula of, 842
history of, 844-845
Drug resistance, *ras* and, in NSCLC, 285-291

E6 gene, 1008-1012
E7 gene, 1008-1012
Economic analysis
of cyclophosphamide, cisplatin regimen, in ovarian cancer, 632-639
guidelines for, of clinical trial, 3
of interferon alfa-2b, in high-risk melanoma, 2351-2358
of low-dose filgrastim, following stem-cell transplantation, 451-457
of paclitaxel, in ovarian cancer, 632-639
of paclitaxel, cisplatin regimen, in ovarian cancer, 632-639
of peripheral-blood stem-cell transplantation, 2-4
of peripheral-blood stem-cell transplantation *v* autologous BMT, 5-10
Education, survival advantage threshold and, 336
Effectiveness research, on palliative care, 1697-1707
Elderly patient(s)
aggressive NHL in, 2945-2953
patterns of care in, with ovarian cancer, 3408-3415
Electrophoresis, agarosa gel, 585
Embryonal tumor
of CNS
cisplatin-based chemotherapy for, 2939-2944
nitrosourea-based chemotherapy for, 2939-2944
types of, 2939
Emesis
delayed
adrenocorticotropic hormone for, 2467-2473
following cisplatin, 124-130
dexamethasone, metoclopramide regimen for, 124-130
dolasetron, dexamethasone regimen for, 2135-2138
metopimazine, ondansetron regimen for, 1690-1697
ondansetron for, 1690-1697
ondansetron, dexamethasone regimen for, 124-130
Emetogenicity, of chemotherapy, 103-109
Emotional state, in childhood leukemia survivors, 547-556
End-systolic left ventricular, wall stress
following daunorubicin, 62-66
elevated, determinants of, 66
Endoscopic ultrasound
in small lymphocytic mucosa-associated lymphoid tumors, 1761-1766
real-time fine-needle aspiration biopsy guided by, in pancreatic lesions, 1439-1443
Engraftment, number of CD34+ cells for, 3067-3074
Epi-doxorubicin, FU, cisplatin, 6S-folinic acid, glutathione, filgrastim regimen
in gastric cancer, 3313-3319
survival following, 3316
toxicity of, 3316-3317
Epidermal growth factor receptor, as prognostic factor, in lung cancer, 2858-2865
Epidoxorubicin, cyclophosphamide, etoposide, cisplatin, GM-CSF regimen, in SCLC, 2082-2089
Epidoxorubicin, ifosfamide, GM-CSF regimen, in soft tissue sarcoma, 1418-1426
Epirubicin, emetogenic potential of, 105
Epirubicin, cisplatin, FU regimen
cost of, 264
in esophagogastric cancer, 261-267
response to, 263-264
survival following, 265
toxicity of, 264
Epirubicin, cyclophosphamide, G-CSF regimen
in breast cancer, 1367-1376
dose-intensification in, 1367-1376
Epirubicin, paclitaxel regimen
in breast cancer, 2510-2517
hematologic toxicity of, 2512-2513
nonhematologic toxicity of, 2513
Erythropoietin, in drug-induced anemia prophylaxis, 2715-2721

Esophageal cancer
chemoradiotherapy plus surgery in, 701-711
chemoradiotherapy *v* radiotherapy in, 277-284
Esophagogastric cancer
doxorubicin, methotrexate, FU regimen in, 261-267
epirubicin, cisplatin, FU regimen in, 261-267
Estradiol, formula of, 846
Estradiol-progestin replacement therapy, mammographic breast density following, 3201-3207
Estramustine, paclitaxel regimen
in prostate cancer, 3156-3163
toxicity of, 3158-3159
Estrogen receptor imaging, iodine-labeled Z-MIVE, in breast cancer, 2536-2545
Estrogen, doxorubicin, cyclophosphamide, methotrexate, FU, tamoxifen regimen, in breast cancer, 2873-2881
Ethics, phase I trial and, 855
Etoposide
adverse effects of, 2121
clinical response to, 2121
in combination chemotherapy
for diffuse large-cell lymphoma, 491-498
for NHL, 1722-1729
for stem-cell collection, 684-690
high-dose, followed by G-CSF, for stem-cell mobilization, 759-765
mean plasma concentrations of, 2123
oral, for AIDS-related Kaposi's sarcoma, 2118-2124
pharmacokinetic parameters of, 2122
calculations for, 2120
pharmacokinetics of, 2121
plasma concentrations of, measurement for, 2119-2120
preoperative, in esophageal cancer, 709
response to, 2121
secondary acute myelogenous leukemia following, 1583-1586
survival following, 2123
Etoposide phosphate
dose-limiting toxicity of, 769-770
pharmacokinetics of, 768
protracted infusion of, 766-772
response to, 768-769
stability of, 768
toxicity of, 768-769
Etoposide, bleomycin, cisplatin regimen
etoposide, cisplatin regimen *v*, 1837-1843
relative dose intensity of, 1838
surgery following, 1840
survival following, 1840-1842
toxicity of, 1839-1840
Etoposide, carboplatin, autologous marrow rescue regimen
in brain tumors, 1814-1823
patient outcome by, 1817
toxicity of, 1815-1816
Etoposide, carboplatin, bleomycin regimen
in nonseminomatous germ cell cancer, 1844-1852
renal toxicity of, 1850
toxicity of, 1848
Etoposide, carboplatin, cyclophosphamide, autologous BMT regimen
high-dose, in germ cell tumors, 2546-2552
toxicity of, 2549
Etoposide, carmustine, cytarabine, melphalan regimen, in lymphoma, 535-546
Etoposide, cisplatin regimen
bleomycin, etoposide, cisplatin regimen *v*, 1837-1843
dose modification of, 1838
gemcitabine *v*, in NSCLC, 2097-2102
Indiana University Staging System for, 2556-2557
long-term follow-up of, 2553-2558
relative dose intensity of, 1838
surgery following, 1840
survival following, 1840-1842, 2555
toxicity of, 1839-1840
Etoposide, cisplatin, bleomycin regimen
in nonseminomatous germ cell cancer, 1844-1852
renal toxicity of, 1850
toxicity of, 1848
Etoposide, cisplatin, vincristine, doxorubicin regimen
in SCLC, 292-296
survival following, 294
worst toxicities of, 295
Etoposide, cyclophosphamide, cisplatin, stem-cell regimen, in breast cancer, 2882-2893
Etoposide, cyclophosphamide, doxorubicin regimen, plus radiotherapy, 2840-2849
Etoposide, cyclophosphamide, doxorubicin, stem-cell rescue regimen, in breast cancer, 2882-2893
Etoposide, cyclophosphamide, epidoxorubicin, cisplatin, GM-CSF regimen, in SCLC, 2082-2089
Etoposide, cyclophosphamide, vincristine, doxorubicin, cisplatin, surgery regimen, in neuroblastoma, 3433-3440
Etoposide, cytarabine, amsacrine, mitoxantrone, methotrexate regimen, as consolidation chemotherapy, 476-482
Etoposide, doxorubicin, vincristine, prednisone, radiotherapy regimen
in HD, 2652-2658
survival following, 2655-2656
Etoposide, G-CSF regimen, in stem-cell mobilization, 759-765
Etoposide, ifosfamide regimen
for Ewing's sarcoma, 2612
for primitive neuroectodermal tumor, 2612
survival following, 2613-2617
Etoposide, irinotecan regimen, in NSCLC, 304-309
Etoposide, methotrexate, dactinomycin regimen
fertility following, 2641
for gestational trophoblastic tumor, 2636-2643
second malignancy following, 2640
Etoposide, mitoxantrone, PSC-833 regimen, in acute myelogenous leukemia, 1796-1802
Etoposide, paclitaxel, carboplatin regimen
for carcinoma, of unknown primary site, 2385-2393
in SCLC, 3464-3470
toxicity of, 2389
Euthanasia, assisted suicide and, comparative study of, 418-427
Evaluation committee, 3507-3514
Evidence-based recommendations, 3050
on adjuvant therapy, for stage II-IIIA NSCLC, 3055
development of, 3051-3052
number of, undertaken, 3057-3058
production of, 3053-3054
for resectable stage IIIA NSCLC, 3055
for unresected stage III NSCLC, 3054

Ewing's sarcoma
in adults, 2611-2621
chemotherapy-induced tumor necrosis in, as prognostic factor, 1553-1559
circulating tumor cell detection in, RT-PCR for, 583-588
diagnosis of, age at, 2611-2621
doxorubicin, vincristine, dactinomycin, cyclophosphamide regimen in, 574-582
extraosseous, in childhood, 574-582
histopathologic grading in, and clinical outcome, 1553-1559
ifosfamide, etoposide regimen for, 2612
ifosfamide, vincristine, actinomycin D regimen for, 2612
overview of, 1553-1554
of soft tissues, in childhood, 574-582
vincristine, dactinomycin, cyclophosphamide regimen in, 574-582
Excitatory amino acid neurotransmitters, methotrexate and, 2800-2806
Extended left lobectomy, in liver metastasis, 939
Extended right lobectomy, in liver metastasis, 939
Extended-field radiation, cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, dacarbazine regimen, 2275-2287
External-beam radiation therapy
beam arrangement for, 3076
complications following, 223-229
in early-stage prostate cancer, 223-229
expected morbidities with, 3081
gastrointestinal symptoms following, in prostate cancer, 226
genitourinary symptoms following, in prostate cancer, 226
in rectal adenocarcinoma, 3241-3248
sexual symptoms following, 227
in soft tissue sarcoma, 3075-3084
Extramedullary leukemia
high-dose cytarabine intensification in, 466
prognosis in, 466-475
Extremity sarcoma
local recurrence in, 646-652
stage IIB, preoperative chemotherapy for, 3481-3487

Facility, for parenteral systemic antineoplastic therapy, 3416-3417
Familial adenomatous polyposis kindred, 2744-2758
Fatigue, following cisplatin, tirapazamine regimen, 777
Fatty acids, breast cancer prognosis and, 1377-1384
Febrile neutropenia, M-CSF in, 2954-2965
Fertility
following chemotherapy, in testicular germ cell cancer, 239-245
in long-term testicular cancer survivors, 1444-1448
salvaging technique in, with in-vitro fertilized ova, 3347-3349
Fibrin sleeve
definition of, 2709
in catheter occlusion, 2709-2714
Filgrastim
daily bolus injection *v* continuous infusion of, 1730-1735
5 *v* 10 microgram dosing of, following autologous BMT, 1730-1735
following stem-cell transplantation, 451-457
low-dose, economic analysis of, 451-457
peripheral-blood stem-cell transplantation mobilized by, 5-10
see also Granulocyte colony-stimulating factor
Filgrastim, cyclophosphamide, thiotepa, carboplatin, stem-cell regimen, multiple-cycle, in breast cancer, 674-683
Filgrastim, FU, cisplatin, epi-doxorubicin, 6S-folinic acid, glutathione regimen
in gastric cancer, 3313-3319
survival following, 3316
toxicity of, 3316-3317
Fine-needle aspiration biopsy, endoscopic ultrasound-guided real-time, in pancreatic lesions, 1439-1443
Flow cytometric analysis, in direct gene transfer, 343
Fludarabine
in chronic lymphocytic leukemia, 458-465
emetogenic potential of, 105
molecular structure of, 459
survival following, by gender, 462
toxicity of, 463
Fludarabine, idarubicin, cytarabine regimen, in acute myelogenous leukemia, 2780-2785
Fluid retention, docetaxel-induced, steroids for, 3149-3155
Fluorescence in situ hybridization, HER-2-*neu* gene amplification by, 2894-2904
Fluorescent-activated cell sorter analysis, in acute myelogenous leukemia, 1800-1801
Fluorodeoxyuridine, 389-400
Fluorouracil, 389-400
adjuvant high-dose, in colorectal cancer, 2433
bolus, methotrexate modulation of, 370
bolus *v* infusion, in colorectal cancer, 368-381
continuous infusion, without modulation, 371
cytotoxicity of, dual mechanisms of, 373
degradation of, inhibition of, 396-397
dual nature of, 372-373
emetogenic potential of, 105
folinic acid
following surgery, 246-250
response to, 370
severe toxicities following, 248
folinic acid biomodulation of, 2433-2434
in head and neck cancer, and tumoral-reduced folates, 2604-2610
hepatic arterial infusion of, 1432-1438
hybrid regimens of, 375
pain improvement and, 2408
in pancreas cancer, 2403-2413
PN401 rescue and, 1511-1517
preoperative, in esophageal cancer, 709
schedule-selective biochemical modulation for, 373-375
scheduling of, and clincial dose-response curve, 369-370
sequential methotrexate and, 374
without modulation, 371
Fluorouracil, chlorambucil, methotrexate regimen
in breast cancer, 2502-2509
toxicity of, 2506-2507
Fluorouracil, cisplatin, epi-doxorubicin, 6S-folinic acid, glutathione, filgrastim regimen
in gastric cancer, 3313-3319
survival following, 3316
toxicity of, 3316-3317
Fluorouracil, cisplatin, folinic acid regimen
in head and neck cancer, 3100-3110
major toxicities of, 3104
schematic design for, 3101
toxicity of, 3103-3104
Fluorouracil, cisplatin, radiotherapy regimen, in esophageal cancer, 277-284

Fluorouracil, cyclophosphamide, doxorubicin regimen
in breast cancer, 1897-1905
hematologic toxicity of, 1903
overall survival following, 1900, 1902
time to tumor progression following, 1903
toxicities of, 1904
Fluorouracil, cyclophosphamide, methotrexate regimen
bone loss associated with, 1341-1347
in breast cancer, 2502-2509
tamoxifen plus, 1385-1394, 2302-2311
toxicity of, 2506-2507
Fluorouracil, cyclophosphamide, mitoxantrone regimen
in breast cancer, 1897-1905
hematologic toxicity of, 1903
overall survival following, 1900, 1902
time to tumor progression following, 1903
toxicities of, 1904
Fluorouracil, doxorubicin, cyclophosphamide, estrogen, methotrexate, tamoxifen regimen, in breast cancer, 2873-2881
Fluorouracil, doxorubicin, methotrexate regimen
cost of, 264
in esophagogastric cancer, 261-267
response to, 263-264
survival following, 265
toxicity of, 264
Fluorouracil, epirubicin, cisplatin regimen
cost of, 264
in esophagogastric cancer, 261-267
response to, 263-264
survival following, 265
toxicity of, 264
Fluorouracil, folinic acid regimen
adjuvant high-dose, in colorectal cancer, 2432-2441
adjuvant trials of, 2439
bimonthly *v* monthly dosing of, 808-815
in colorectal cancer, 3320-3329, 808-815
in disseminated colorectal cancer, 3223-3229
survival following, 811, 812
toxicity of, 811-812, 2435-2437
Fluorouracil, gallium nitrate regimen, in transitional-cell carcinoma, 2449-2455
Fluorouracil, interferon alfa-2b regimen, in liver metastases, 1432-1438
Fluorouracil, radiotherapy, folinic acid regimen
in rectal cancer, 2030-2039
toxicities of, 2033-2034, 2035, 2036
Fluorouracil, radiotherapy, levamisole regimen
in rectal cancer, 2030-2039
toxicities of, 2033-2034, 2035, 2036
Fluorouracil, radiotherapy, levamisole, folinic acid regimen
in rectal cancer, 2030-2039
toxicities of, 2033-2034, 2035, 2036
Fluorouracil, radiotherapy, strepozocin, cisplatin, folinic acid regimen
in pancreas cancer, 2920-2927
survival following, 2924-2925
Fluorouracil, thioguanine, procarbazine, dibromodulcitol, lomustine, hydroxyurea regimen
for brain metastases, 1063-1070
response to, 1065
survival following, 1066
toxicity of, 1067
treatment scheme for, 1064
Fluorouracil, trimetrexate, folinic acid regimen
in colorectal cancer, 915-920
hematologic toxicity of, 917
nonhematologic toxicity of, 917
survival following, 918
Flutamide, suramin, leuprolide regimen, in prostate cancer, 1470-1477
Folinic acid
adjuvant high-dose, in colorectal cancer, 2432-2441
FU plus
following surgery, 246-250
severe toxicities following, 248
intravenous, *l*-isomer of, 3320-3329
oral, 3320-3329
pure *l* isomer of, with FU, in colorectal cancer, 908-914
racemic, plus FU, in colorectal cancer, 908-914
6S-stereoisomer of, 3313-3319
Folinic acid, carboxypeptidase-G2, thymidine rescue, in methotrexate-induced nephrotoxicity, 2125-2134
Folinic acid, cisplatin, FU regimen
in head and neck cancer, 3100-3110
major toxicities of, 3104
schematic design for, 3101
toxicity of, 3103-3104
Folinic acid, FU regimen
adjuvant high-dose, in colorectal cancer, 2432-2441
adjuvant trials of, 2439
bimonthly *v* monthly dosing of, 808-815
in colorectal cancer, 3320-3329, 808-815
in disseminated colorectal cancer, 3223-3229
survival following, 811, 812
toxicity of, 2435-2437, 811-812
Folinic acid, FU, cisplatin, epi-doxorubicin, glutathione, filgrastim regimen
in gastric cancer, 3313-3319
survival following, 3316
toxicity of, 3316-3317
Folinic acid, levamisole, radiotherapy, FU regimen
in rectal cancer, 2030-2039
toxicities of, 2033-2034, 2035, 2036
Folinic acid, radiotherapy, FU regimen
in rectal cancer, 2030-2039
toxicities of, 2033-2034, 2035, 2036
Folinic acid, radiotherapy, FU, strepozocin, cisplatin regimen
in pancreas cancer, 2920-2927
survival following, 2924-2925
Folinic acid, trimetrexate, FU regimen
in colorectal cancer, 915-920
hematologic toxicity of, 917
nonhematologic toxicity of, 917
survival following, 918
Follicular large-cell lymphoma
diffuse large B-cell lymphoma *v*, 1654-1663
histopathology of, 1657
prognostic factors for, 1657-1658
Follicular lymphoma
CD34+ selection in, 2288-2295
interferon alfa-2b in, 1110-1117
overview of, 1587

peripheral-blood stem-cell transplantation in, 2288-2295
prednimustine in, 1110-1117
survival in, 1112, 1114
transformation of, 1587-1594
Fotemustine
hepatic intraarterial, in ocular melanoma, 2589-2595
survival following, 2593, 2594
French Federation of Cancer Centers Sarcoma Group system, in sarcoma grading, 350-362
FU, *see* Fluorouracil
Functional Assessment of Cancer Therapy-Breast
analysis of variance of, 980-981
descriptive statistics of, 977, 978
development of, 975
reliability of, 975-977
sensitivity of, 978-979
validation of, 974-986

G-CSF, see Granulocyte colony-stimulating factor
G250 monoclonal antibody, iodine-labeled chimeric
biodistribution of, 1533
in renal cell cancer, 1529-1537
Gallium nitrate, FU regimen, in transitional-cell carcinoma, 2449-2455
Gallium scan
of abdomen, in HD, 523
early restaging, in aggressive NHL, 1631-1637
in HD, 518-527
in mediastinal disease, 1635
of neck, in HD, 524
in retroperitoneal adenopathy, 1636
utility algorithm for, in HD, 525
Gastric cancer, 818
advanced, chemotherapy in, 3299-3300
chemoradiotherapy in, 901-907
chronologic changes in, 3471-3480
cumulative survival in, 2016, 2017, 2018, 2019
endoscopy of, 905
irinotecan, cisplatin regimen in, 921-927
KDR in, 826-832
paclitaxel, radiotherapy regimen in, 901-907
prognostic factors in, 2015-2021
sialyl Lea expression in, 816-825
surgical approaches in, 2017
survival in, 3471-3480
tumor depth invasion in, definition of, 2017
vascular endothelial growth factor in, 826-832
weekly filgrastim, FU, cisplatin, epi-doxorubicin, 6S-folinic acid, glutathione regimen in, 3313-3319
Gastrinoma, liver metastases in, 2420-2431
Gastrointestinal symptom, following external-beam irradiation, in prostate cancer, 226
Gemcitabine, 2172-2174
cisplatin, etoposide regimen *v*, in NSCLC, 2097-2102
emetogenic potential of, 105
hematologic toxicity of, 313
hepatic toxicity of, 313
maximum-tolerated dose of, 310-316
in NSCLC, 310-316
pain improvement and, 2408
for pancreas cancer, 2403-2413
phase II trial of, in urothelial cancer, 3394-3398
survival following, 312
toxicity of, 312-314
in urothelial cancer, 3441-3445
weekly, with monthly cisplatin, 744-749
Gemcitabine, cisplatin regime
hematologic toxicity of, 300
nonhematologic toxicity of, 300-301
in NSCLC, 297-303
Gemcitabine, cisplatin regimen
hematologic toxicity of, 747
nonhematologic toxicity of, 747
in NSCLC, 744-749
studies of, in NSCLC, 748
Gene fusion
as prognostic factor, 1831
in rhabdomyosarcoma, 1831-1836
Gene therapy, in metastatic melanoma, 341-349
Genetic marker, as prognostic factor, in rhabdomyosarcoma, 1831-1836
Genitourinary symptom, following external-beam irradiation, in prostate cancer, 226
Genomic damage
in colorectal cancer, 3230-3240
as prognostic factor, 3230
Germ Cell Consensus Classification, definition of, 600
Germ cell tumor
bleomycin regimens for, 1717-1719
chemotherapy in, fertility following, 239-245
cisplatin-based salvage regimen for, 2559-2563
disseminated nonseminomatous, postchemotherapy strategy in, 1455-1464
good-risk, etoposide, cisplatin regimen in, long-term follow-up of, 2553-2558
ifosfamide-based salvage regimen for, 2559-2563
International Consensus Prognostic Classification for, 2556
metastatic, International Consensus Prognostic Classification for, 2556
metastatic, prognostic factor-based staging in, 594-603
nonseminomatous, *see* Nonseminomatous testicular germ cell cancer
poor-risk, carboplatin, etoposide, cyclophosphamide, autologous BMT regimen in, 2546-2552
prognostic classification in, 594-603
stage I ovarian, surveillance policy in, 620-624
Germline mutation, in hereditary retinoblastoma, 3305
Gestational trophoblastic tumor, high-risk
cyclophosphamide, vincristine regimen in, 2636-2643
etoposide, methotrexate, dactinomycin regimen in, 2636-2643
Gilbert's syndrome, 1509
Gleason score, 1019-1020
Glioblastoma, pre-irradiation paclitaxel in, 3121-3128
Glioma
age distribution in, 3131
chemosensitive, 3423-3426
low-grade
radiation timing in, 1294-1301
survival factors in, 3129-3140
malignant, postoperative MRI in, 2076-2081
natural course of, 3129
prognostic factors in, 3135

Glottic larynx, carcinoma of, radiotherapy for, 2394-2402
Glutathione S transferase, as marker, of radioresistance, 1030-1038
Glutathione, FU, cisplatin, epi-doxorubicin, 6S-folinic acid, filgrastim regimen
in gastric cancer, 3313-3319
survival following, 3316
toxicity of, 3316-3317
GM-CSF, *see* Granulocyte-macrophage colony-stimulating factor
Goserelin
androgen suppression with, adjuvant to radiotherapy, 1013-1021
compliance with, 1015
Grading
histopathologic, in Ewing's sarcoma, 1553-1559
of soft tissue sarcomas, 350-362
Graft-versus-host disease
autologous induction of, in multiple myeloma, 667-673
chronic myelogenous leukemia relapse and, 433-444
diarrhea due to, octreotide for, 3350-3354
due to cyclosporine, in myeloma, 667-673
following unrelated donor BMT, 559-560
Graft-versus-leukemia, 433-444
Granulocyte colony-stimulating factor
for allogeneic-blood stem-cell collection, 1601-1607
CD34+ number and, 3067-3074
in combination chemotherapy
for diffuse large-cell lymphoma, 491-498
for NHL, 1722-1729
followed by high-dose etoposide, 759-765
liposomal doxorubicin plus, for sarcoma, 2111-2117
in stem-cell mobilization, for lymphoma, 535-546
with topotecan, in refractory cancer, 148-157
see also Filgrastim
Granulocyte colony-stimulating factor, epirubicin, cyclophosphamide regimen
in breast cancer, 1367-1376
dose-intensification in, 1367-1376
Granulocyte colony-stimulating factor, etoposide regimen, 759-765
Granulocyte colony-stimulating factor, ifosfamide regimen, for sarcoma, 2378-2384
Granulocyte colony-stimulating factor, paclitaxel regimen
in pancreatic cancer, 2414-2419
toxicity of, 2417
treatment with, 2415
Granulocyte colony-stimulating factor, paclitaxel, cisplatin regimen
dosing of, 738
hematologic toxicity of, 739
in lung cancer, 735-743
nonhematologic toxicity of, 739
survival following, 739-740
Granulocyte colony-stimulating factor, topotecan, paclitaxel regimen
antitumor activity of, 183
dose-escalation scheme for, 180
neutropenia following, 181
phase I trial of, in ovarian cancer, 177-186
thrombocytopenia following, 182
Granulocyte colony-stimulating factor, vinorelbine regimen, in breast cancer, 1395-1400
Granulocyte colony-stimulating factor, vinorelbine, ifosfamide regimen
in NSCLC, 884-892
survival following, 888-889
toxicity of, 887-888
Granulocyte-macrophage colony-stimulating factor
in acute myeloid leukemia therapy, 3496-3506
following high-dose melphalan, 660-666
PIXY 321 *v*, following autologous BMT, 1617-1623
in stem-cell mobilization, for lymphoma, 539-541
without stem-cell transplantation, 660-666
Granulocyte-macrophage colony-stimulating factor, cyclophosphamide, epidoxorubicin, etoposide, cisplatin regimen, in SCLC, 2082-2089
Granulocyte-macrophage colony-stimulating factor, epidoxorubicin, ifosfamide regimen, in soft tissue sarcoma, 1418-1426
Guidelines, *see* Practice guideline(s)

H-*ras*, 285
Hairy cell leukemia
characteristics of, 1803
second cancer risk in, 1803-1810
Hand-foot syndrome, 3164
Hapten-modified melanoma vaccine
autologous, 2359-2370
treatment schedule for, 2361
HD, *see* Hodgkin's disease
Head and neck cancer
advanced, induction chemotherapy for, 2050-2055
cisplatin, FU, folinic acid regimen in, 3100-3110
mitomycin in, 268-276
overview of, 3111-3112
radioresistance in, 1030-1038
tumoral-reduced folates in, and FU, 2604-2610
Health belief, perceived vulnerability as, 2196
Health care provider, tobacco use interventions by, 2201
Heat-shock protein-27, as marker, of radioresistance, 1030-1038
Helicobacter pylori, eradication of, and gastric mucosa-associated lymphatic tissue lymphoma diagnosis, 1104-1109
Heliobacter pylori infection, gastric, endoscopic ultrasound evaluation in, 1761-1766
Hematologic malignancy, relapse in, age and, 20-21
Hematologic toxicity, cumulative, of paclitaxel, carboplatin regimen, 1957
Hemolytic anemia, malignancy-associated microangiopathic, 2474-2475
Hepatic arterial chemotherapy, with fotemustine, in ocular melanoma, 2589-2595
Hepatic arterial infusion, of FU, 1432-1438
Hepatocellular cancer
AFP-Scan in, 2683
alpha-fetoprotein immunoscintigraphy in, 2683-2690
HER-2-*neu* antibody, in breast cancer, 3363-3367
HER-2-*NEU* gene amplification, by fluorescence in situ hybridization, 2894-2904
Hereditary cancer, 3280-3287
Hereditary cancer syndrome
selected, 2158
testing for, 2139-2148
Hereditary retinoblastoma, 3302
germline mutations in, 3305
Hexamethylmelamine
cost attributable to, 1005
emetogenic potential of, 105
High-dose chemotherapy

autologous stem-cell rescue with, 11-17
clinical trials with, selection bias in, 3171-3177
in follicular low-grade NHL, 445-450
patient selection in, 3178-3184
with G-CSF, plus autologous peripheral-blood stem-cell transplantation, 491-498
with stem-cell rescue, in breast cancer, 2882-2893
High-dose-rate brachytherapy, for soft tissue sarcoma, 3075-3084
Hilar cholangiocarcinoma, resected, prognosis of, 947-954
Histology
for bone marrow metastasis detection, 2807-2817
in childhood HD, 2622-2630
Histopathologic grading, in Ewing's sarcoma, and clinical outcome, 1553-1559
HLA-B7
detection of, 346
direct transfer of, in metastatic melanoma, 341-349
Hodgkin's disease
advanced, MOPP-ABV regimen in, 1638-1645
chemotherapy for, radiotherapy following, 2275-2287
childhood
histology in, 2622-2630
mechlorethamine elimination in, 2247-2253
vincristine, procarbazine, prednisone, doxorubicin, procarbazine regimen in, 2247-2253
cyclophosphamide, vinblastine, procarbazine, prednisone regimen in, 2652-2658
cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, dacarbazine, radiation regimen in, 2275-2287
doxorubicin, vincristine, prednisone, etoposide, radiotherapy regimen in, 2652-2658
etoposide, G-CSF regimen in, for stem-cell mobilization, 759-765
gallium scans in, 518-527
histologic subtypes in, 2623
lymphocyte-predominant, 3060-3066
mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, dacarbazine, radiotherapy regimen in, 3338-3346
mitoxantrone, vincristine, vinblastine, prednisone regimen in, 3488-3495
MOPP-ABVD regimen in, relapses following, 528-534
pediatric, MOPP-ABVD with total-nodal irradiation in, 2769-2779
peripheral-blood stem-cell transplantation *v* autologous BMT in, 5-10, 509-517
prognostic factors in, 411-412
second leukemia following, 2247-2253
stage I-IIA, 1736-1744
stem-cell transplantation in, with dose-intense chemotherapy, 2989-2991
therapy flowsheet in, 2276
vinblastine, methotrexate, bleomycin regimen in, with regional radiotherapy, 1736-1744
Homocysteine, methotrexate elevation of, 2800-2806
Hormonal therapy
chemotherapy plus, in irradiated breast cancer, 207-215
combination, in metastatic breast cancer, 2494-2501
second-line, in prostate cancer, 382-388
Hormone replacement therapy, impact of, on mammographic breast density, 3201-3207
Hormone therapy, *neu*-related protein and, in breast cancer, 2518-2525
Human antichimeric antibody, 1533-1534
Human antimouse antibody, 725
Human antiricin antibody, 725
Human CD52 antibody, phase II trial of, in chronic lymphocytic leukemia, 1567-1574
Human immunoglobulain G1 anti-CD52 monoclonal antibody, 1567-1574
Human leukocyte antigen testing, 2361
Human papillomavirus
cervical cancer survival and, 610-619
in circulating blood, 1008-1012
testing for, 611
Human papillomavirus 16 E7 proteins, antibodies to, and cervical cancer survival, 610-619
Humoral immune responses, 1997, 2001
Hydrocortisone, megestrol acetate, aminoglutethimide regimen
in breast cancer, 2494-2501
toxicity of, 2498
Hydroxyproline, 131-138
Hydroxyurea, emetogenic potential of, 105
Hydroxyurea, thioguanine, procarbazine, dibromodulcitol, lomustine, FU regimen
for brain metastases, 1063-1070
response to, 1065
survival following, 1066
toxicity of, 1067
treatment scheme for, 1064
Hypercalcemia, of malignancy, pamidronate *v* clodronate for, 131-138
Hyperthermia, melphalan with, in cancer, 158-164
Hypertrophic osteoarthropathy, 2759-2760

I-Mel-2, plus SAF-m, for metastatic melanoma, 2103-2110
ICI 164,384, formula of, 846
ICI 182,780, formula of, 846
Idarubicin
emetogenic potential of, 105
tobacco use and, 2195
Idarubicin, all-*trans* retinoic acid, mercaptopurine, vincristine, methotrexate, prednisone regimen, without cytarabine, 483-490
Idarubicin, fludarabine, cytarabine regimen, in acute myelogenous leukemia, 2780-2785
IDEC-C2B8, in NHL, 3266-3274
Idoxifene
formula of, 842
history of, 845-846
Ifosfamide
dose-response curve for, 2378-2384
emetogenic potential of, 105
high-dose, in sarcoma, 2378-2384
toxicity of, 591
in urothelial carcinoma, 589-593
Ifosfamide, cisplatin regimen
in cervical cancer, 165-171
neurotoxicity of, 168
survival following, 169-170
Ifosfamide, epidoxorubicin, GM-CSF regimen, in soft tissue sarcoma, 1418-1426
Ifosfamide, etoposide regimen

for Ewing's sarcoma, 2612
for primitive neuroectodermal tumor, 2612
survival following, 2613-2617
Ifosfamide, G-CSF regimen, for sarcoma, 2378-2384
Ifosfamide, vinblastine, cisplatin regimen, in seminoma, 1427-1431
Ifosfamide, vincristine, actinomycin D regimen
for Ewing's sarcoma, 2612
for primitive neuroectodermal tumor, 2612
survival following, 2613-2617
Ifosfamide, vinorelbine, G-CSF regimen
in NSCLC, 884-892
survival following, 888-889
toxicity of, 887-888
Ifosfamide-based salvage regimen, for germ cell tumors, 2559-2563
IL-2, *see* Interleukin-2
Iliac crest biopsy, in malignant lymphoma staging, 1754-1760
Immunoblotting, for thymidine phosphorylase, 2574
Immunocytochemical marker, as prognostic factor, in lung cancer, 2858-2865
Immunohistochemical analysis, of cytoplasmic *bcl*-2, 1917-1918
Immunohistochemical staining, in direct gene transfer, 343
Immunoscintigraphy, MRI *v*, in bone marrow infiltration, 1754-1760
Immunotherapy
active specific, of metastatic melanoma, 2103-2110
adoptive, 796-807
superantigen-based, 1994-2007
Immunotoxin therapy
of SCLC, 723-734
with N901-bR, 723-734
In vitro fertilization, following allogeneic BMT, 3347-3349
Income
cancer death and, 1687
cancer site distribution and, 1684
cancer survival by, 1685
relative death risk by, 1686, 1687
Indiana University Staging System, 2556
Induction chemotherapy, with cisplatin, FU, folinic acid regimen, in head and neck cancer, 3100-3110
Interferon alfa
adverse effects of, 1673
cost-effectiveness of, in chronic myelogneous leukemia, 2673-2682
in multiple myeloma, 1672-1679
patient profiles and, 1676
second malignancy risk following, 1803-1810
Interferon alfa, IL-2 regimen, posttransplant, 1575-1582
Interferon alfa-2a, IL-2 regimen
in melanoma, 2579-2588
response to, 2582-2583
survival following, 2583-2587
toxicity of, 2581-2582
Interferon alfa-2a, IL-2, cisplatin regimen
in melanoma, 2579-2588
response to, 2582-2583
survival following, 2583-2587
toxicity of, 2581-2582
Interferon alfa-2b
adjuvant, in high-risk melanoma, 2351-2358
in low-tumor burden follicular lymphoma, 1110-1117
survival in, 1112, 1114
Interferon alfa-2b, FU regimen, in liver metastases, 1432-1438
Interferon, all-*trans*-retinoic acid regimen, phase I trial of, 3330-3337
Interferon, isolated limb perfusion, tumor necrosis factor-alpha, melphalan regimen, in soft tissue sarcomas, 2174-2175
Interleukin-2
intraperitoneal, in ovarian cancer, 3399-3407
primed lymph node cells activated by, 796-807
therapy with, 797
with tumor necrosis factor receptor immunoglobulin G chimera, 1052-1062
weekly infusion of, 3399-3407
Interleukin-2, interferon alfa regimen, posttransplant, 1575-1582
Interleukin-2, interferon alfa-2a regimen
in melanoma, 2579-2588
response to, 2582-2583
survival following, 2583-2587
toxicity of, 2581-2582
Interleukin-2, interferon alfa-2a, cisplatin regimen
in melanoma, 2579-2588
response to, 2582-2583
survival following, 2583-2587
toxicity of, 2581-2582
Interleukin-3 fusion protein, GM-CSF *v*, following autologous BMT, 1617-1623
Interleukin-11, in chemotherapy-induced thrombocytopenia, 3368-3377
International Consensus Prognostic Classification, for metastatic germ cell tumor, 2556
International Germ Cell Cancer Collaborative Group Classification, 601
International Prognostic Factor Index, predictive capacity of, in peripheral T-cell lymphoma, 2296-2301
International Prognostic Index, 1713
Intestinal epithelium, cytotoxic therapy-induced damage to, in acute myeloid leukemia, 2254-2261
Intraperitoneal chemotherapy, in refractory ovarian cancer, 1945-1952
Intron 3 breakpoint, of promyelocytic leukemia gene, 1786-1795
Invasive pulmonary aspergillosis
early CT scan for, in neutropenics, 139-147
survival in, prognostic factors for, 144
Involved-field radiotherapy, doxorubicin, vincristine, prednisone, etoposide regimen
in HD, 2652-2658
survival following, 2655-2656
Iodine 123, for Z-MIVE labeling, in estrogen receptor imaging, 2536-2545
Iodine 131
chimeric monoclonal antibody G250 labeled with, in renal cell cancer, 1529-1537
monoclonal antibody CC49 labeled with, in gastrointestinal cancer, 1529-1537
Iodine-labeled Z-MIVE estrogen receptor imaging, in breast cancer, 2536-2545
Irinotecan
administration of, 253, 1081
antitumor activity of, 1083-1084
in colorectal cancer, 251-260, 2910-2919
delayed diarrhea following, 1083
feasibility study of, 1080-1086
hematologic toxicity following, 1083

high dose-intensity, every 3 weeks, 1080-1086
intestinal toxicity following, 1083
mortality following, 1083
pharmacokinetics of, 1502-1510
in refractory cervical cancer, 625-631
response to, 2915-2916
sequential metabolic pathway of, 1503
survival following, 2916
toxicity of, 2914-2915
Irinotecan, cisplatin regimen
in gastric cancer, 921-927
objective response to, 925
toxicity of, 924
Irinotecan, etoposide regimen, in NSCLC, 304-309
ISC92 regimen, 1722-1729
Isolated limb perfusion, tumor necrosis factor-alpha, interferon, melphalan regimen, in soft tissue sarcomas, 2174-2175

Japanese Classification of Gastric Carcinoma, 2016
JM216, phase I trial of, 2691-2700
Journal of Clinical Oncology, changes in, 1

K-*ras*, 285
mutational activity of, in NSCLC, 285-291
Kaposi's sarcoma
AIDS Clinical Trials Group staging classification for, validation of, 3085-3092
AIDS-related
oral etoposide for, 2118-2124
pegylated-liposomal doxorubicin in, 653-659
doxorubicin, bleomycin, vincristine regimen in, 653-659
post-transplant, treatment of, 2371-2377
presentation of, 2373
KDR, in gastric cancer, 826-832
Kendall's tau, 332, 336, 337
Ketamine, premedication regimen with, 94-102
Ketamine, atropine, midazolam regimen
adverse effects associated with, 100
behavioral reactions following, 98-99
meperidine, midazolam *v*, in childhood painful procedures, 94-102
recovery following, 98
safety of, 98
Ki-67 expression
in adult sarcoma, 3249-3257
in head and neck squamous cancer, 1033
as marker, of radioresistance, 1030-1038
Kinase, cyclin-dependent, 3305-3306

L-asparaginase, in Berlin-Frankfurt-Munster therapy, 2223
L-phenylalanine mustard, emetogenic potential of, 105
Laminin, as prognostic factor, in lung cancer, 2858-2865
Large-cell lymphoma
biologic markers in, 1749
diffuse, methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin regimen in, 1745-1753
late-relapse, management of, 1745-1753
methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin regimen in, 1745-1753
risk-related therapy of, 1713-1716
treated diffuse, late relapse in, 1745-1753
Large-field irradiation, amifostine, cisplatin, vinblastine regimen, in NSCLC, 2850-2857
Laryngeal cancer
p53 expression in, 3111-3120
prognostic factors in, 3111-3120
Left ventricular performance, following daunorubicin, 63-65
Legalization
of euthanasia, 418
of physician-assisted suicide, 418-427
Leucovorin, *see* Folinic acid
Leukemia, 44-51, 557-565
acute, 44-51
acute lymphoblastic, *see* Acute lymphoblastic leukemia
acute myeloblastic, 2238-2246
acute myelogenous, 1503-1506, 1796-1802, 2780-2785, 2982
acute myeloid, 2254-2261, 2262-2263, 2269-2274, 2954-2965
acute promyelocytic, 483-490, 1786-1795
adult T-cell, 1778-1785
alternative donor BMT in, 1767-1777
BMT in, access to, 2644-2651
childhood, survivors of, negative mood in, 547-556
childhood acute lymphoblastic, anthracyclines in, 61-68
chronic lymphocytic, 52-60, 458-465, 1567-1574
chronic myelogenous, 433-444, 1575-1582, 2673-2682
chronic myeloid, 26-36
chronic myelomonocytic, 566-573
de novo B-cell prolymphocytic, cladribine in, 37-43
extramedullary, prognosis in, 466-475
immunophenotyping in, 2215
second
following HD, 2247-2253
following mechlorethamine, 2247-2253
overview of, 2247-2248
see also specific type
Leukemia cutis, 2170-2171
Leukocyte, transfusion of, following allogeneic BMT relapse, 433-444
Leuprolide, suramin, flutamide regimen, in prostate cancer, 1470-1477
Levamisole, radiotherapy, FU regimen
in rectal cancer, 2030-2039
toxicities of, 2033-2034, 2035, 2036
Levamisole, radiotherapy, FU, folinic acid regimen
in rectal cancer, 2030-2039
toxicities of, 2033-2034, 2035, 2036
LGD1069
adverse effects of, 791-792
antitumor response to, 792-793
area-under-the-curve for, 793
pharmacokinetics of, 793
phase I trial of, 790-795
treatment plan for, 791
Libido, bicalutamide impact on, 2934
Liposomal doxorubicin
in ovarian cancer, 987-993
toxicity of, 989-991
Liposomal doxorubicin
pegylated-, in Kaposi's sarcoma, 653-659
in sarcoma, 2111-2117
Stealth, 3185-3191
sterically stabilized, 3185-3191

Liver, 3004
left lateral segmentectomy of, 939
left lobectomy of, 939
right lobectomy of, 939
segmental resection of, 939
ultrasound of, in breast cancer surveillance, 2154
Liver biopsy, following iodine-labeled CC49 radioimmunolocalization, 1523
Liver metastasis
chemotherapy for, quality of life following, 2022-2029
of colorectal cancer
biomarkers in, 2008-2014
FU, interferon alfa-2b regimen for, 1432-1438
resection for, 938-946
from gastrinoma, 2420-2431
Lomustine, tobacco use and, 2195
Lomustine, thioguanine, procarbazine, dibromodulcitol, FU, hydroxyurea regimen
in brain metastases, 1063-1070
response to, 1065
survival following, 1066
toxicity of, 1067
treatment scheme for, 1064
Lonidamine, cisplatin potentiating activity of, 3208-3213
Loperamide, as diarrhea therapy, 2910-2919
Lung, adenocarcinoma of, *ras* in, and drug resistance, 285-291
Lung cancer
advanced
diagnostic evaluation in, 3002-3004
paclitaxel, cisplatin, G-CSF regimen in, 735-743
children and, 2181-2182
management of, overview of, 3027-3029
metastatic cells of
dot-blot detection of, 3388-3393
RT-PCR detection of, 3388-3393
non-small-cell, *see* Non-small-cell lung cancer
paclitaxel, cisplatin, G-CSF regimen in, 735-743
practice guidelines for, 3049-3059
ras mutation in, 285-291
small-cell, *see* Small-cell lung cancer
stage I, immunocytochemical markers in, 2858-2865
LY231514, 391
Lymph node
precise classification of, 2016
size of, in cutaneous melanoma, 1045-1048
Lymph node cell
anti-CD3 activation of, 798-800
IL-2 activation of, 798-800
vaccine-primed, for adoptive immunotherapy, 796-807
Lymph node dissection, axillary, in breast cancer, 691-700
Lymphocyte proliferation assay, 1997
Lymphoid neoplasm, following hairy cell leukemia therapy, 1803-1810
Lymphoma
adult, dose-intense chemotherapy in, 2982
aggressive, in elderly patients, 2945-2953
BMT for, access to, 2644-2651
carmustine, etoposide, cytarabine, melphalan regimen in, 535-546
CD30 ligand in, 3355-3362
diffuse large-cell
autologous stem-cell transplantation in, 491-498
methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin regimen in, 1745-1753
double transplants in, 1595-1600
early gastric mucosa-associated lymphatic tissue, diagnosis of, 1104-1109
5 *v* 10 microgram filgrastim dosing in, 1730-1735
follicular, 1110-1117, 1587-1594, 2288-2295
large-cell, 1713-1716, 1745-1753
late relapse, management of, 1745-1753
low-tumor burden follicular, 1110-1117
malignant, 1754-1760
mantle cell, 1664-1671
mediastinal B-cell, 1646
methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin regimen in, 1745-1753
mucosa-associated lymphoid tissue
endoscopic ultrasound evaluation of, 1761-1766
gastrointestinal *v* nongastrointestinal outcome in, 1624-1630
non-Hodgkin's lymphoma, *see* Non-Hodgkin's lymphoma
peripheral-blood stem-cell transplantation in, adequacy of, 535-546
peripheral-blood stem-cell transplantation *v* autologous BMT in, 509-517
relapsed AIDS-related, mitoguazone in, 1094-1103
thymic B-cell, 1646
treated diffuse large-cell, late relapse in, 1745-1753
tumor necrosis factor ligand-receptor system in, 499-508
Lymphoma transformation, in follicular lymphoma, 1587-1594

M-CSF, *see* Macrophage colony-stimulating factor
M-V index, 3113
Macrophage colony-stimulating factor, following consolidation therapy, in acute myeloid leukemia, 2954-2965
Magnetic resonance imaging
immunoscintigraphy *v*, in bone marrow infiltration, 1754-1760
postoperative, in malignant glioma, 2076-2081
in Zollinger-Ellison syndrome, 2425, 2426
Malignant glioma, postoperative MRI in, 2076-2081
Malignant lymphoma
bone marrow infiltration in, immunoscintigraphy *v* MRI for, 1754-1760
staging in, diagnostic imaging for, 1754-1760
MALT, *see* Mucosa-associated lymphoid tissue
Mammography, in breast cancer surveillance, 2152-2153
Mandible, radiograph of, 3080
Mantle cell lymphoma
clinical response patterns of, 1664-1671
extranodal involvement in, 1668
treatment given in, 1666
Mantle-field radiotherapy, mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, dacarbazine regimen, 3338-3346
Marker(s)
bone resorption, for hypercalcemia, of malginancy, 131-138
prognostic, in adult sarcoma, 3249-3257
Markov decision model, 875-880
Marrow blast infiltrate, following mitoxantrone, etoposide, PSC-833 regimen, 1800
Mbr1, 2858-2865
Mbr8, 2858-2865
MDR-1, in adult sarcoma, 3249-3257

Mechlorethamine
emetogenic potential of, 105
second leukemia following, in HD, 2247-2253
Mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine regimen, 1638-1645
Mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, dacarbazine regimen
in HD, 1638-1645
relapse following, in HD, 528-534
with total-nodal irradiation, in HD, 2769-2779
Mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, dacarbazine, radiotherapy regimen, in HD, 3338-3346
Median household income, cancer survival and, 1680-1689
Mediastinal B-cell lymphoma, 1646-1653
Medroxyprogesterone acetate, in tamoxifen-resistant breast cancer, 3141-3148
Medulloblastoma
asymptomatic recurrence detection following, 1811-1813
metastatic, 2941
patients with, characteristics of, 1818
pediatric, surveillance scanning in, 1811-1813
Megestrol acetate, aminoglutethimide, hydrocortisone regimen
in breast cancer, 2494-2501
toxicity of, 2498
Melanoma
adoptive immunotherapy in, 796-807
autologous hapten-modified vaccine for, 2359-2370
circulating cells of, tyrosinase messenger RNA detection of, 2818-2825
cutaneous, 1039-1051
high-risk, interferon alfa-2b in, 2351-2358
IL-2 with tumor necrosis factor receptor immunoglobulin G chimera in, 1052-1062
interferon alfa-2b in, economic analysis of, 2351-2358
metastatic
active specific immunotherapy of, 2103-2110
gene therapy in, 341-349
interferon alfa-2a, IL-2 regimen in, 2579-2588
interferon alfa-2a, IL-2, cisplatin regimen in, 2579-2588
treatment overview for, 2579-2580
metastatic to lymph nodes, 2359
ocular, hepatic intraarterial fotemustine in, 2589-2595
overview of, 2103-2104
stage III, 2363-2365
survival benefit in, 2172
vaccine-primed lymph node cells in, 796-807
Melphalan
in combination chemotherapy
for diffuse large-cell lymphoma, 491-498
with autologous stem-cell support, 1302-1308
cost attributable to, 1005
high-dose
GM-CSF following, 660-666
with autologous stem-cell transplantation, 1309-1317
hyperthermia with, in cancer, 158-164
Melphalan, busulfan, autologous marrow rescue regimen
in brain tumors, 1814-1823
patient outcome by, 1817
toxicity of, 1815-1816
Melphalan, carmustine, etoposide, cytarabine regimen, in lymphoma, 535-546
Melphalan, cyclophosphamide, autologous marrow rescue regimen
in brain tumors, 1814-1823
patient outcome by, 1817
toxicity of, 1815-1816
Melphalan, cyclophosphamide, methotrexate regimen, in breast cancer, 2312-2321
Melphalan, isolated limb perfusion, tumor necrosis factor-alpha, interferon regimen, in soft tissue sarcomas, 2174-2175
Meperidine, midazolam regimen
adverse effects associated with, 100
behavioral reactions following, 98-99
ketamine-atropine-midazolam *v*, in childhood painful procedures, 94-102
recovery following, 98
safety of, 98
6-Mercaptopurine, in Berlin-Frankfurt-Munster therapy, 2223
6-Mercaptopurine, all-*trans* retinoic acid, idarubicin, vincristine, methotrexate, prednisone regimen, without cytarabine, 483-490
Mesna, in ifosfamide therapy, for urothelial cancer, 589-593
Methemoglobin, 2080
Methotrexate
aminotransferase following, 1560-1566
in Berlin-Frankfurt-Munster therapy, 2223
in combination chemotherapy, for HD, 2247-2253
complications of, overview of, 2800-2801
early, in childhood acute lymphoblastic leukemia, 1824-1830
emetogenic potential of, 105
excitatory amino acid neurotransmitters and, 2800-2801
homocysteine elevations by, 2800-2801
intensive, in childhood acute lymphoblastic leukemia, 1560-1566
intrathecal, in childhood acute lymphoblastic leukemia, 1824-1830
prephase, 1825
renal dysfunction induced by, carboxypeptidase-G2 in, 2125-2134
sequential, and fluorouracil, 374
tobacco use and, 2195
toxicity of, 2130-2132
Methotrexate, all-*trans* retinoic acid, idarubicin, mercaptopurine, vincristine, prednisone regimen, without cytarabine, 483-490
Methotrexate, bleomycin, cyclophosphamide, dactinomycin regimen, in osteosarcoma, 76-84
Methotrexate, chlorambucil, FU regimen
in breast cancer, 2502-2509
toxicity of, 2506-2507
Methotrexate, cisplatin, vinblastine, radiotherapy, surgery regimen
for invasive bladder cancer, 1022-1029
protocol for, 1024
survival following, 1025-1026
Methotrexate, cyclophosphamide, FU regimen
bone loss associated with, 1341-1347
in breast cancer, 2502-2509
tamoxifen plus, 1385-1394, 2302-2311
toxicity of, 2506-2507
Methotrexate, cyclophosphamide, melphalan regimen, in breast cancer, 2312-2321
Methotrexate, cytarabine, amsacrine, mitoxantrone, etoposide regimen, as consolidation chemotherapy, 476-482
Methotrexate, dactinomycin, doxorubicin regimen, in postoperative osteosarcoma, 76-84
Methotrexate, doxorubicin, cyclophosphamide, estrogen, FU, tamoxifen regimen, in breast cancer, 2873-2881

Methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin regimen, in late-relapse lymphoma, 1745-1753
Methotrexate, doxorubicin, FU regimen
  cost of, 264
  in esophagogastric cancer, 261-267
  response to, 263-264
  survival following, 265
  toxicity of, 264
Methotrexate, etoposide, dactinomycin regimen
  fertility following, 2641
  for gestational trophoblastic tumor, 2636-2643
  second malignancy following, 2640
Methotrexate, vinblastine, bleomycin regimen, with regional radiotherapy, for HD, 1736-1744
Methotrexate, vinblastine, doxorubicin, cisplatin regimen
  survival following, 2566-2568
  in transitional-cell carcinoma, 2449-2455
  in urothelial cancer, 2564-2569
Metoclopramide, following cisplatin, tirapazamine regimen, 776
Metopimazine, ondansetron regimen, following platinum-based chemotherapy, 1690-1697
Microangiopathic hemolytic anemia, malignancy-associated, 2474-2475
Micrometastatic cancer cell, detection of, 2701-2708
Microvessel density, thymidine phosphorylase expression and, 2576
Midazolam, atropine, ketamine regimen
  adverse effects associated with, 100
  behavioral reactions following, 98-99
  midazolam, meperidine *v*, in childhood painful procedures, 94-102
  recovery following, 98
  safety of, 98
Mitoguazone
  dosing of, 1097-1099
  in relapsed AIDS-related lymphoma, 1094-1103
  survival following, 1100-1101
  toxicities of, 1099-1100
Mitolactol, cisplatin regimen
  in cervical cancer, 165-171
  neurotoxicity of, 168
  survival following, 169-170
Mitomycin
  emetogenic potential of, 105
  in head and neck cancer, 268-276
  radiotherapy plus, in head and neck cancer, 268-276
Mitomycin, radiotherapy regimen
  in head and neck cancer, 268-276
  hematologic toxicity of, 271
  nonhematologic toxicity of, 271
  survival following, 272
Mitoxantrone
  cardiotoxicity following, 1544-1552
  in combination chemotherapy, for diffuse large-cell lymphoma, 491-498
  emetogenic potential of, 105
  high-dose, with autologous stem-cell transplantation, 1309-1317
  in hormone-refractory prostate cancer, 410-411
Mitoxantrone, cyclophosphamide, FU regimen
  in breast cancer, 1897-1905
  hematologic toxicity of, 1903
  overall survival following, 1900, 1902
  time to tumor progression following, 1903
  toxicities of, 1904
Mitoxantrone, cytarabine, amsacrine, etoposide, methotrexate regimen, as consolidation chemotherapy, 476-482
Mitoxantrone, etoposide, PSC-833 regimen
  in acute myelogenous leukemia, 1796-1802
  bilirubin level folowing, 1799
  marrow blast infiltrate following, 1800
Mitoxantrone, vincristine, vinblastine, prednisone regimen
  in HD, 3488-3495
  spermatogenesis following, 3488-3495
Mluc1, as prognostic factor, in lung cancer, 2858-2865
Model, for quality-adjusted life expectancy, 874
Molecular monitoring, chronic myeloid leukemia and, 26-36
Monoclonal antibody
  chimeric anti-CD20, in NHL, 3266-3274
  human immunoglobulain G1 anti-CD52, in chronic lymphocytic leukemia, 1567-1574
  I-Mel-2 type, for metastatic melanoma, 2103-2110
  iodine-labeled chimeric G250, in renal cell cancer, 1529-1537
Mood state, in childhood leukemia survivors, 547-556
MOPP-ABVD regimen, in HD, relapses following, 528-534
Mortality
  cancer, and income, 1687
  in lymphocyte-predominant HD, 3065
  late, of childhood cancer survivors, 2205-2213
MRI, *see* Magnetic resonance imaging
Mucosa-associated lymphoid tissue, small lymphocytic lymphoma of, endoscopic ultrasound evaluation of, 1761-1766
Mucosa-associated lymphoid tissue lymphoma
  gastrointestinal *v* nongastrointestinal, 1624-1630
  prognostic factors in, 1627-1628
  survival following, 1627
Multidisciplinary care, induction chemotherapy and, 2052-2053
Multidrug resistance gene 1
  expression of, 1801
  PSC-833 blockade of, 1796-1802
Multiple myeloma
  cyclosporine in, graft-versus-host disease due to, 667-673
  cytogenetic results in, 2662
  cytogenetics in, as prognostic factor, 2659-2666
  eliminating stem-cell transplantation in, 660-666
  GM-CSF in, without stem-cell transplantation, 660-666
  interferon alfa in, 1672-1679
  overview of, 1672, 2659-2660
  patient preferences in, and interferon alfa, 1672-1679
  stem-cell transplantation in, with dose-intense chemotherapy, 2991
Mutation, germline, in hereditary retinoblastoma, 3305
MYCN oncogene amplification, in neuroblastoma, 85-93
Myelosuppression
  dose-related, following iodine-labeled CC49 radioimmunolocalization, 1525
  drug sequencing and, 182

N-*ras*, 285
N-telopeptide region, 131-138
N901-bR
  cytotoxicity of, 726
  immunohistochemical technique for, 732

in vivo delivery of, 725
in SCLC, 723-734
serum concentrations of, 729
toxicity of, 728
National Cancer Institute, in sarcoma grading, 350-362
Nausea
dolasetron, ondansetron, dexamethasone regimen in, 2966-2973
irinotecan-induced, treatment of, 1081-1082
postchemotherapy, determinants of, 116-123
Neoadjuvant chemotherapy
definition of, 3001
for osteosarcoma, 76-84
prolonged, with breast conservation, 2873-2881
vinorelbine as, in advanced cervical cancer, 604-609
Neoplasia, biology of, 3297-3298
Neovascularization, in NSCLC, 2456-2466
Nephrotoxicity, methotrexate-induced, carboxypeptidase-G2 in, 2125-2134
Neu, as prognostic factor, in lung cancer, 2858-2865
Neuroblastoma
cerebral, 2941
childhood, MYCN oncogene amplification in, 85-93
cyclophosphamide, vincristine, doxorubicin, cisplatin, etoposide, surgery regimen in, 3433-3440
MYCN oncogene amplification in, 85-93
overview of, in childhood, 85-86
stage 4, NB87 induction protocol for, 3433-3440
Neuropathic pain, surgical, capasaicin cream for, 2974-2980
Neuropathy, of paclitaxel, 1965-1973
Neurotoxicity
asociated with mitolactol, cisplatin regimen, 168
associated with cisplatin, 168
associated with cisplatin, ifosfamide regimen, 168
associated with cyclophosphamide, cisplatin regimen, 199-206
high-dose cytarabine and, 833-839
associated with paclitaxel, 1965-1973
associated with paclitaxel, cisplatin regimen, 199-206
Neutropenia
febrile, M-CSF in, 2954-2965
following paclitaxel, topotecan regimen, 181
following paclitaxel, topotecan, G-CSF regimen, 181
Neu-related protein
as prognostic factor, in advanced breast cancer, 2518-2525
hormone therapy and, 2518-2525
Newcastle disease virus-modified irradiated tumor-cell vaccine, 1354-1366
NHL, *see* Non-Hodgkin's lymphoma
Nitrosourea-based chemotherapy, results of, 2940
Non-Hodgkin's lymphoma
aggressive
early restaging gallium scan in, 1631-1637
in elderly patients, 2945-2953
autologous BMT in, GM-CSF *v* PIXY 321 following, 1617-1623
centroblastic-centrocytic, 1759
docetaxel in, 3275-3279
dose-intense chemotherapy in, 2988
etoposide, G-CSF regimen in, for stem-cell mobilization, 759-765
follicular low-grade, transplantation in, 445-450
peripheral-blood stem-cell transplantation *v* autologous BMT in, 5-10, 509-517
relapsed, IDEC-C2B8 in, 3266-3274
stem-cell transplantation in, with dose-intense chemotherapy, 2989-2991
untreated poor-prognosis, chemotherapy plus stem-cell support in, 1722-1729
Nonseminoma, postchemotherapy strategy in, 1455-1464
Nonseminomatous testicular germ cell cancer
chemotherapy-induced angiopathy in, 2442-2448
chemotherapy-induced sexual dysfunction in, 2442-2448
carboplatin, bleomycin, etoposide regimen in, 1844-1852
cisplatin, bleomycin, etoposide regimen in, 1844-1852
disseminated, bleomycin, etoposide, cisplatin regimen in, 1837-1843
good-risk metastatic, carboplatin *v* cisplatin in, 1844-1852
postchemotherapy strategy in, 1455-1464
Non-small-cell histologies, definition of, 3001
Non-small-cell lung cancer
advanced, paclitaxel, cisplatin, radiotherapy regimen in, 1409-1417
amifostine, cisplatin, vinblastine, radiotherapy regimen in, 2850-2857
bax oncoprotein expression in, 2456-2466
bcl-2 protein expression in, 2456-2466
cisplatin, gemcitabine regimen in, 297-303
decision analysis in, 870-872, 873-883
decision analysis utility in, 880-881
doxetaxel, cisplatin regimen in, for untreated NSCLC, 750-758
drug selection in, 3006-3007
gemcitabine in, 310-316
gemcitabine, cisplatin regimen in, 744-749
gemcitabine *v* cisplatin, etoposide regimen in, 2097-2102
histology in, 3009
investigational agents in, 3009
irinotecan, etoposide regimen in, 304-309
locally advanced, decision analysis in, 873-874
neovascularization in, 2456-2466
p53 protein expression in, 2456-2466
paclitaxel, carboplatin regimen in, 317-329
quality of life in, 3006
radiotherapy in, 3009-3011
ras in, and drug resistance, 285-291
recurrent, lifestyle changes for, 3012-3013
second-line therapy in, 3008-3009
stage III, combined modality therapy in, 3038-3048
stage IIIA, chemoradiotherapy in, 712-722
stage IV, 3005-3006, 3008
surgery in, 3011
surveillance in, 3011-3012
treatment of, 3004-3011
treatment timing in, 3008
treatment toxicity in, *v* survival, 330-340
unresectable, treatment guidelines for, 2996-3018
unresectable stage III, 3005, 3007-3008
vinorelbine in, 885
vinorelbine, ifosfamide, G-CSF regimen in, 884-892
weekly gemcitabine in, with monthly cisplatin, 744-749
North America, breast cancer in, autotransplants for, 1870-1879
NSCLC, *see* Non-small-cell lung cancer
Nurse, tobacco use intervention by, 2198

Octreotide, for graft-versus-host disease-induced diarrhea, 3350-3354

Ocular melanoma
hepatic intraarterial fotemustine in, 2589-2595
incidence of, 2589
Oligodendroglioma, recurrent, paclitaxel for, 3427-3432
Oncologist(s)
attitude of, to euthanasia, 428-432
desire of, for assisted suicide legislation, 428-432
survey of, on assisted suicide and euthanasia, 418-427
Oncology
childhood, ketamine, atropine, midazolam *v* meperidine, midazolam regimen in, 94-102
outcomes analysis in, elements necessary for, 871
Oncology trial, response rate accuracy in, 3507-3514
Oncoprotein, 2459-2460
Ondansetron
following cisplatin, tirapazamine regimen, 776
following platinum-based chemotherapy, 1690-1697
Ondansetron, dexamethasone regimen
adverse events following, 128
metoclopramide, dexamethasone *v*, in delayed emesis, 124-130
Ondansetron, dolasetron, dexamethasone regimen, in emesis, 2966-2973
Ondansetron, metopimazine regimen, following platinum-based chemotherapy, 1690-1697
Organ preservation, induction chemotherapy and, 2052-2053
Organ transplantation, Kaposi's sarcoma following, treatment of, 2371-2377
Osteosarcoma
craniofacial, 363-367
dactinomycin, doxorubicin, cisplatin regimen in, 76-84
methotrexate, bleomycin, cyclophosphamide, dactinomycin regimen in, 76-84
methotrexate, dactinomycin, doxorubicin regimen in, 76-84
neoadjuvant treatment in, 76-84
patient outcome schematic in, 79
Ototoxicity
of cyclophosphamide, cisplatin regimen, 199-206
of paclitaxel, cisplatin regimen, 199-206
Outpatient therapy, with autologous stem-cell rescue, 11-17
Ovarian cancer
carboplatin in, 193-198
cisplatin in, lonidamine potentiation of, 3208-3213
cisplatin *v* cisplatin, cyclophophamide regimen in, 1938-1944
dose-intense chemotherapy in, 2985-2986
dose-intensity in, 1291-1293
doubled carboplatin dose-intensity in, 193-198
high-dose chemotherapy in, with autologous stem-cell support, 1302-1308
incidence of, 3408
intraperitoneal IL-2 in, 3399-3407
liposomal doxorubicin in, 987-993
overview of, 2183-2184
paclitaxel in
cost-effectiveness of, 640-645
economic analysis of, 632-639
paclitaxel, carboplatin regimen in, 1953-1964
paclitaxel, cisplatin regimen in, 1965-1973
paclitaxel, topotecan, G-CSF regimen in, 177-186
palliation in, costs of, 1000-1007
patterns of care in, 3408-3415
recurrent, treatment of, 2177-2180
refractory, intraperitoneal chemotherapy in, 1945-1952
relapsed
altretamine for, 172-176
high-dose chemotherapy in, 1309-1317
paclitaxel in, 187-192
stage I, surveillance policy in, 620-624
stage III-IV, paclitaxel, carboplatin regimen in, 1953-1964
surgery restaging in, 994-999
topotecan *v* paclitaxel in, 2183-2193

P-gp expression, in adult sarcoma, 3249-3257
p15-p16 gene deletion, in adult T-cell leukemia, 1778-1785
P16, alterations of, 3306
p53
in colorectal liver metastases, 2008-2014
as marker, of radioresistance, 1030-1038
in NSCLC, 2456-2466
as prognostic factor
in laryngeal cancer, 3111-3120
in lung cancer, 2858-2865
positive immunostaining for, 1033
retinoblastoma protein and, 3307
tamoxifen response and, in breast cancer, 1916-1922
Paclitaxel
cost attributable to, 1005
cost-effectiveness of, in ovarian cancer, 640-645
dose-limiting toxicity of, 3124
dosing of, 408-409, 903
doxorubicin interaction with, 1906-1915
economics of, in ovarian cancer, 632-639
emetogenic potential of, 105
high-dose, with autologous stem-cell transplantation, 1309-1317
in combination chemotherapy, for stem-cell collection, 684-690
in recurrent oligodendroglioma, 3427-3432
in relapsed ovarian cancer, 187-192
infusion of, effect of, 1910
main pharmacokinetic parameters of, 1911
maximum-tolerable dose of, 1965-1973
96-hour continuous infusion of, with cisplatin, 735-743
pharmacokinetic analysis of, in 96-hour continuous infusion, 739
pharmacokinetic parameters of, 183
phase I dose escalation of, in ovarian cancer, 1965-1973
plasma concentrations of, in 96-hour continuous infusion, 740
plasma levels of, 3125
pre-irradiation, in glioblastoma, 3121-3128
sequence impact on, 1909
survival following, 3125
topotecan *v*, in ovarian cancer, 2183-2193
toxicities of, per dose level, 189
tumor response to, 1970
weekly, phase I trial of, 187-192
Paclitaxel, carboplatin regimen
clinical antitumor activity of, 1958
cumulative hematologic toxicity of, 1957
in NSCLC, 317-329
pharmacokinetic-pharmacodynamic relationships of, 1959-1961
pharmacokinetics of, 317-329, 1958-1959
pharmacologic study of, in ovarian cancer, 1953-1964
Paclitaxel, carboplatin, cyclophosphamide, stem-cell regimen, phase I trial of, 1481-1491
Paclitaxel, carboplatin, etoposide regimen

for carcinoma, of unknown primary site, 2385-2393
in SCLC, 3464-3470
toxicity of, 2389
Paclitaxel, cisplatin regimen
biweekly, in breast cancer, 1880-1884
clinical trials of, in breast cancer, 1883
economic analysis of, in ovarian cancer, 632-639
neurotoxicity of, 199-206
ototoxicity of, 199-206
in ovarian cancer, 1965-1973
Paclitaxel, cisplatin, G-CSF regimen
dosing of, 738
hematologic toxicity of, 739
in lung cancer, 735-743
nonhematologic toxicity of, 739
survival following, 739-740
Paclitaxel, cisplatin, radiotherapy regimen
hematologic toxicity of, 1413
nonhematologic toxicity of, 1414
in NSCLC, 1409-1417
survival following, 1414
Paclitaxel, epirubicin regimen
in breast cancer, 2510-2517
hematologic toxicity of, 2512-2513
nonhematologic toxicity of, 2513
Paclitaxel, estramustine regimen
in prostate cancer, 3156-3163
toxicity of, 3158-3159
Paclitaxel, G-CSF regimen
in pancreas cancer, 2414-2419
toxicity of, 2417
treatment with, 2415
Paclitaxel, radiotherapy regimen
in gastric cancer, 901-907
hematologic toxicity of, 904
in pancreatic cancer, 901-907
Paclitaxel, topotecan regimen
antitumor activity of, 183
dose-escalation scheme for, 180
neutropenia following, 181
phase I trial of, in ovarian cancer, 177-186
thrombocytopenia following, 182
Paclitaxel, topotecan, G-CSF regimen
antitumor activity of, 183
dose-escalation scheme for, 180
neutropenia following, 181
phase I trial of, in ovarian cancer, 177-186
thrombocytopenia following, 182
Painful procedure, ketamine, atropine, midazolam *v* meperidine, midazolam regimen in, 94-102
Palliative care
effectiveness research on, 1697-1707
interventions in, 1703-1704
outcome assessment relevance in, 1704-1705
outcome measurement validity in, 1704-1705
trials of, enhancing quality of, 1706
Palliative chemotherapy, costs of, in ovarian cancer, 1000-1007
Palmar fasciitis, breast cancer associated with, 3515
Pamidronate, and hypercalcemia, of malignancy, 131-138
Pancreas
adenocarcinoma of, pre- and post-operative chemoradiotherapy for, 928-937
endoscopic ultrasound-guided real-time fine-needle aspiration biopsy of, 1439-1443
Pancreatic cancer
advanced, gemcitabine for, 2403-2413
angiogram in, 904
chemoradiotherapy in, 901-907
chemoradiotherapy plus surgery in, 928-937
FU in, 2403-2413
paclitaxel, G-CSF regimen in, 2414-2419
paclitaxel, radiotherapy regimen in, 901-907
stage II-III, combined modality therapy for, 2920-2927
Pancreatic panniculitis, 3418-3419
Pancreaticoduodenectomy, pre- and post-, chemoradiotherapy, for pancreatic cancer, 928-937
Panniculitis, pancreatic, 3418-3419
Patient(s)
cancer, 2194-2204, 3192-3200
characteristics of, and survival advantage thresholds, 336
elderly, 2945-2953, 3408-3415
perceived vulnerability of, 2196
survey of, on assisted suicide and euthanasia, 418-427
Patient education, in breast cancer surveillance, 2153
Patient history, in breast cancer surveillance, 2151-2152
Patient preference
for interferon alfa, in multiple myeloma, 1672-1679
for oral *v* IV chemotherapy, 110-115
in policy-making, 3192-3200
Patient selection, in high-risk breast cancer, 3178-3184
PAX3-FKHR, 1831-1836
PAX7-FKHR, 1831-1836
Penclomedine
chemical structure of, 1975
dose escalation scheme for, 1975
hematologic toxicity associated with, 1979
neurologic effects of, 1978
nonhematologic toxicity associated with, 1978
pharmacokinetic analysis of, 1976
pharmacokinetic parameters of, 1980
pharmacologic study of, in solid tumors, 1974-1984
plasma concentrations of, 1981
Perceived vulnerability, 2196
covariates of, 2196-2197
Performance status, definition of, 3001-3002
Peripheral primitive neuroectodermal tumor, circulating tumor cell detection of, RT-PCR for, 583-588
Peripheral T-cell lymphoma, 2296-2301
prognostic factors in, 2297
Peripheral-blood mononuclear cell, DNA fragmentation in, 154
Peripheral-blood stem-cell collection, 1723,1724, 3259-3260
chemotherapy for, 684-690
Peripheral-blood stem-cell infusion, combination chemotherapy plus, in NHL, 1722-1729
Peripheral-blood stem-cell mobilization, 2289
chemotherapy for, 684-690
collection methods for, 537
granulocyte recovery following, 763
in lymphoma, 535-546
Philadelphia-negative, in chronic myelogenous leukemia, 1575-1582
platelet recovery following, 763
prior radiotherapy and, 535-546

regimens for, 537
with etoposide, G-CSF regimen, 759-765
yield following, 762
Peripheral-blood stem-cell transplantation
adequacy of, in lymphoma, 535-546
age and, 18-25
allogeneic, 3067-3074
autologous
in diffuse large-cell lymphoma, 491-498
low-dose filgrastim following, 451-457
autologous BMT *v*, 5-10
in lymphoma, 509-517
CD34+ selection in, for follicular lymphoma, 2288-2295
dose-intense chemotherapy with, 2989-2992
double, 1595-1600
economic analyses of, 2-4, 5-10
filgrastim mobilization of, 5-10
in follicular low-grade NHL, 445-450
GM-CSF without 660-666
high-dose chemotherapy plus, 1303-1304
interferon alfa, IL-2 regimen following, 1575-1582
overview of, 3067-3068
Philadelphia-negative, in chronic myelogenous leukemia, 1575-1582
plus combination chemotherapy, in ovarian cancer, 1302-1308
see also Allogeneic-blood stem-cell transplantation
Peripheral-blood stem-cell transplantation, carboplatin, paclitaxel, cyclophosphamide regimen, phase I trial of, 1481-1491
Peripheral-blood stem-cell transplantation, cyclophosphamide, thiotepa, carboplatin, filgrastim regimen, in breast cancer, 674-683
Peripheral-blood stem-cell transplantation, etoposide, cyclophosphamide, cisplatin regimen, in breast cancer, 2882-2893
Peripheral-blood stem-cell transplantation, etoposide, cyclophosphamide, doxorubicin regimen, in breast cancer, 2882-2893
Peripheral-blood stem-cell, etoposide, carboplatin regimen
in brain tumors, 1814-1823
patient outcome by, 1817
toxicity of, 1815-1816
Peripheral-blood stem-cell, melphalan, busulfan regimen
in brain tumors, 1814-1823
patient outcome by, 1817
toxicity of, 1815-1816
Peripheral-blood stem-cell, melphalan, cyclophosphamide regimen
in brain tumors, 1814-1823
patient outcome by, 1817
toxicity of, 1815-1816
Personnel, for parenteral systemic antineoplastic therapy, 3416-3417
Pharmacoeconomics, of 5 *v* 10 microgram filgrastim dosing, 1730-1735
Pharmacokinetics
of cyclosporine, 1947
of high-dose cyclophosphamide, 1885-1896
of intrapertioneal cyclosporine, 1948
Phase I trial
of all-*trans*-retinoic acid, interferon regimen, 3330-3337
bearing costs of, 855
of carboplatin, paclitaxel, cyclophosphamide, stem-cell regimen, 1481-1491
of carboxyamidotriazole, in solid tumors, 1985-1993
common misconceptions regarding, 854-856
of continuous 96-hour paclitaxel infusion, with cisplatin, 735-743
critical role of, 853-859
of cyclosporine, in multiple myeloma, 667-673
of cyclosporine-induced autologous graft-versus-host disease, in myeloma, 667-673
decrease of, 856
definition of, 853-854
of direct gene transfer, in metastatic melanoma, 341-349
of docetaxel, cisplatin regimen, 1071-1079
for untreated NSCLC, 750-758
ethical questionability of, 855
in gastric cancer, of paclitaxel, radiotherapy regimen, 901-907
of gemcitabine, in NSCLC, 310-316
of IDEC-C2B8, in NHL, 3266-3274
of iodine-labeled CC49 monoconal antibody, in gastrointestinal cancer, 1518-1528
of LGD1069, 790-795
of liposomal doxorubicin, for sarcoma, 2111-2117
of melphalan, with hyperthermia, 158-164
misconceptions of, consequences of, 856-857
of one-hour docetaxel infusion, in children, 1538-1543
of oral carboxyamidotriazole, 781-789
of oral JM216, 2691-2700
of paclitaxel, in ovarian cancer, 187-192
of paclitaxel, carboplatin regimen, 1953-1964
of paclitaxel, cisplatin, G-CSF regimen, in lung cancer, 735-743
of paclitaxel, cisplatin, radiotherapy regimen, in NSCLC, 1409-1417
of paclitaxel, radiotherapy regimen, in pancreatic cancer, 901-907
of paclitaxel, topotecan regimen, 177-186
of paclitaxel, topotecan, G-CSF regimen, 177-186
of penclomedine, in solid tumors, 1974-1984
of PN401, 1511-1517
of PNU-214565, 1994-2007
proposed improvement in, 857-858
of protracted etoposide phosphate infusion, 766-772
public awareness of, 857
of staphylococcal enterotoxin A fusion protein, 1994-2007
as therapeutic trial, 854-855
of tirapazamine, cisplatin regimen, 773-780
of topotecan, cytarabine regimen, in acute leukemia, 44-51
toxicity expectations in, 855
of vinorelbine, ifosfamide, G-CSF regimen, in NSCLC, 884-892
of weekly paclitaxel, 187-192
Phase I-II trial
of I-Mel-2 plus SAF-m, for metastatic melanoma, 2103-2110
of idarubicin, fludarabine, cytarabine regimen, in acute myelogenous leukemia, 2780-2785
of irinotecan, cisplatin regimen, in gastric cancer, 921-927
Phase II trial
of alpha-fetoprotein immunoscintigraphy, in hepatocellular cancer, 2683-2690
of altretamine, for ovarian cancer, 172-176
of amifostine, cisplatin, vinblastine, radiotherapy regimen, in NSCLC, 2850-2857
of biweekly paclitaxel, cisplatin regimen, 1880-1884
of Caelyx, 3185-3191
of carmustine, cisplatin, radiotherapy regimen, for astrocytoma, 2596-2603
of cisplatin, gemcitabine regimen, in NSCLC, 297-303
of docetaxel

in NHL, 3275-3279
in transitional-cell cancer, 1853-1857
of FU, interferon alfa-2b regimen, in liver metastases, 1432-1438
of gallium nitrate, FU regimen, in transitional-cell carcinoma, 2449-2455
of gemcitabine, in urothelial cancer, 3394-3398
of gemcitabine *v* cisplatin, etoposide regimen, in NSCLC, 2097-2102
of high-dose ifosfamide, for sarcoma, 2378-2384
of human CD52 antibody, in chronic lymphocytic leukemia, 1567-1574
of ifosfamide, in urothelial carcinoma, 589-593
of irinotecan
in colorectal cancer, 251-260, 2910-2919
in refractory cervical cancer, 625-631
of irinotecan, etoposide regimen, for NSCLC, 304-309
of liposomal doxorubicin, in ovarian cancer, 987-993
of methotrexate, vinblastine, doxorubicin, cisplatin regimen, in transitional-cell carcinoma, 2449-2455
of mitoguazone, in relapsed AIDS-related lymphoma, 1094-1103
of oral etoposide, in AIDS-related Kaposi's sarcoma, 2118-2124
of paclitaxel, carboplatin, etoposide regimen, in SCLC, 3464-3470
of paclitaxel, estramustine regimen, in prostate cancer, 3156-3163
of 72-hour continuous 9-aminocamptothecin infusion, in colorectal cancer, 2905-2909
of sterically stabilized liposomal doxorubicin, 3185-3191
of suramin, leuprolide, flutamide regimen, in prostate cancer, 1470-1477
of tomudex, 395
of topotecan, in SCLC, 2090-2096
of trimetrexate, FU, folinic acid regimen, in colorectal cancer, 915-920
Phase III
of capasaicin cream, for surgical neuropathic pain, 2974-2980
of goserelin, in prostate cancer, 1013-1021
Phase III trial
of cisplatin, in urothelial cancer, 2564-2569
of dolasetron, ondansetron, dexamethasone regimen, in emesis, 2966-2973
of erythropoietin prophylaxis, in drug-induced anemia, 2715-2721
of hormonal therapy plus chemotherapy, in irradiated breast cancer, 207-215
of megestrol acetate, aminoglutethimide, hydrocortisone regimen in, 2494-2501
of methotrexate, vinblastine, doxorubicin, cisplatin regimen, in urothelial cancer, 2564-2569
of pure folinic acid *l*-isomer, FU regimen, in colorectal cancer, 908-914
of racemic folinic acid, FU regimen, in colorectal cancer, 908-914
of vaginal moisturizer, in breast cancer, 969-973
Philadelphia chromosome
chronic myeloid leukemia and, 26-36
-negative progenitors, in chronic myelogenous leukemia, 1575-1582
-positive, in acute lymphoblastic leukemia, 2231-2237
status of, as prognostic factor, in acute lymphoblastic leukemia, 2231-2237
Physical examination, in breast cancer surveillance, 2152
Physician
attitude of, to euthanasia, 428-432
desire of, for assisted suicide legislation, 428-432
survey of, on assisted suicide and euthanasia, 418-427
tobacco use interventions by, 2198
unorthodox cancer therapies and, 401-406
Physician-assisted suicide
euthanasia and, comparative study of, 418-427
overview of, 413-415
Pirarubicin, cyclophosphamide, teniposide, prednisone regimen
in aggressive NHL, 2945-2953
survival following, 2951
PIXY 321, GM-CSF *v*, following autologous BMT, 1617-1623
Platelet-derived endothelial cell growth factor, 2570-2578
Platinum, pharmacokinetics of, 756
Platinum-based regimen, definition of, 3001
PN401, phase I trial of, 1511-1517
PNU-214565
lymphocyte proliferation induced by, 2001-2003
phase I trial of, 1994-2007
plasma levels of, 2000-2001
Policy-making, patient preference in, 3192-3200
Polychemotherapy
in HD, 2275-2287
perioperative, in breast cancer, 2526-2535
trials of, in breast cancer, 2527
Polymerase chain reaction
arbitrarily primed, in colorectal cancer, 3230-3240
gastric MALT lymphoma diagnosis and, 1104-1109
reverse-transcriptase, *see* Reverse-transcriptase polymerase chain reaction analysis
Poorly differentiated adenocarcinoma, natural history of, 2056-2066
Poorly differentiated carcinoma, natural history of, 2056-2066
Population, survey of, on assisted suicide and euthanasia, 418-427
Practice guideline(s)
for breast cancer adjuvant systemic therapy, 217
in breast cancer surveillance, 2149-2156
for chemotherapy, in stage IV NSCLC, 3053
conflict resolution and, 3056-3057
development of, factors impacting on, 3058
evidence for, 2151
in lung cancer, 3049-3059
in NSCLC, 2996-3018
need for, 3050-3051
for node-negative breast cancer, compliance with, 216-222
overview of, 2149-2150
panel composition for, 2150-2151
for vinorelbine use, in stage IV NSCLC, 3053
Prednimustine
in low-tumor burden follicular lymphoma, 1110-1117
survival in, 1112, 1114
Prednisolone, in combination chemotherapy, for NHL, 1723
Prednisone, in Berlin-Frankfurt-Munster therapy, 2223
Prednisone, all-*trans* retinoic acid, idarubicin, mercaptopurine, vincristine, methotrexate regimen, without cytarabine, 483-490
Prednisone, cyclophosphamide, doxorubicin, vincristine regimen
in early restaging gallium scan following, in NHL, 1631-1637
in large-cell lymphoma, 1713-1716
Prednisone, cyclophosphamide, teniposide regimen
in aggressive NHL, 2945-2953
survival following, 2951
Prednisone, cyclophosphamide, teniposide, pirarubicin regimen
in aggressive NHL, 2945-2953

survival following, 2951
Prednisone, cyclophosphamide, vinblastine, procarbazine regimen
in HD, 2652-2658
survival following, 2655-2656
Prednisone, cyclophosphamide, vincristine, procarbazine, doxorubicin, bleomycin, vinblastine, dacarbazine, radiation regimen, 2275-2287
Prednisone, doxorubicin, vincristine, etoposide, radiotherapy regimen
in HD, 2652-2658
survival following, 2655-2656
Prednisone, mechlorethamine, vincristine, procarbazine, doxorubicin, bleomycin, vinblastine regimen, 1638-1645
Prednisone, mechlorethamine, vincristine, procarbazine, doxorubicin, bleomycin, vinblastine, dacarbazine regimen
in HD, 1638-1645
relapse following, 528-534
with total-nodal irradiation, 2769-2779
Prednisone, mechlorethamine, vincristine, procarbazine, doxorubicin, bleomycin, vinblastine, dacarbazine, radiotherapy regimen, 3338-3346
Prednisone, methotrexate, doxorubicin, cyclophosphamide, vincristine, bleomycin regimen, in late-relapse lymphoma, 1745-1753
Prednisone, mitoxantrone, vincristine, vinblastine regimen
in HD, 3488-3495
spermatogenesis following, 3488-3495
Prednisone, vincristine, procarbazine, doxorubicin, procarbazine regimen, 2247-2253
Pregnancy, following allogeneic BMT, 3347-3349
Prephase chemotherapy, in childhood acute lymphoblastic leukemia, 1824-1830
Primitive neuroectodermal tumor
in adults, 2611-2621
circulating tumor cell detection of, RT-PCR for, 583-588
diagnosis of, age at, 2611-2621
ifosfamide, etoposide regimen for, 2612
ifosfamide, vincristine, actinomycin D regimen for, 2612
Procarbazine, emetogenic potential of, 105
Procarbazine, cyclophosphamide, vinblastine, prednisone regimen 2652-2658
survival following, 2655-2656
Procarbazine, cyclophosphamide, vincristine, prednisone, doxorubicin, bleomycin, vinblastine, dacarbazine, radiation regimen, 2275-2287
Procarbazine, mechlorethamine, vincristine, prednisone, doxorubicin, bleomycin, vinblastine regimen, 1638-1645
Procarbazine, mechlorethamine, vincristine, prednisone, doxorubicin, bleomycin, vinblastine, dacarbazine regimen
in HD, 1638-1645
relapse following, 528-534
with total-nodal irradiation, 2769-2779
Procarbazine, mechlorethamine, vincristine, prednisone, doxorubicin, bleomycin, vinblastine, dacarbazine, radiotherapy regimen, 3338-3346
Procarbazine, thioguanine, dibromodulcitol, lomustine, FU, hydroxyurea regimen
for brain metastases, 1063-1070
response to, 1065
survival following, 1066
toxicity of, 1067
treatment scheme for, 1064
Procarbazine, vincristine, prednisone, doxorubicin, procarbazine regimen, in HD, 2247-2253
Procarbazine, vincristine, procarbazine, prednisone, doxorubicin regimen, in HD, 2247-2253
Prodrug, cyclophosphamide as, 1885-1896
Prognostic factor(s)
adipose tissue fatty acid composition as, in breast cancer, 1377-1384
in adult sarcoma, 3249-3257
anti-Hu antibody as, in SCLC, 2866-2872
associated with long-term retroperitoneal sarcoma survival, 2832-2839
c-*mpl* mRNA as, in acute myeloid leukemia, 2262-2268
CD4 count as, in Kaposi's sarcoma, 3085-3092
chemotherapy-induced tumor necrosis as, in Ewing's sarcoma, 1553-1559
in cutaneous melanoma, 1042
cytogenetics as, in multiple myeloma, 2659-2666
in early-stage HD, 411-412
in follicular large-cell lymphoma, 1657-1658
gene fusion as, in rhabdomyosarcoma, 1831-1836
genomic damage as, in colorectal cancer, 3230-3240
in glioma, 3135
histology as, in childhood HD, 2622-2630
human papillomavirus DNA as, in cervical cancer, 617
immunocytochemical markers as, in lung cancer, 2858-2865
International Index for, predictive capacity of, in peripheral T-cell lymphoma, 2296-2301
in laryngeal cancer, 3111-3120
lymph node size as, in cutaneous melanoma, 1045-1048
in MALT, 1627-1628
neu-related protein as, in breast cancer, 2518-2525
p15-p16 gene deletion as, in leukemia, 1788-1785
in peripheral T-cell lymphoma, 2297
Philadelphia chromosome status as, in acute lymphoblastic leukemia, 2231-2237
in primary mediastinal B-cell lymphoma, 1646-1653
proliferating-cell nuclear antigen expression as, in thyroid cancer, 3458-3463
in proximal gastric cancer, 2015-2021
in resected hilar cholangiocarcinoma, 947-954
retinoblastoma protein as, in thyroid cancer, 3458-3463
sialyl Lea as, in gastric cancer, 816-825
staging based on, in germ cell cancer, 594-603
for survival, in aspergillosis, 144
for survival duration, in breast cancer, 1900
thymidine phosphorylase expression as, in renal cell cancer, 2570-2578
thymidylate synthase expression as, in breast cancer, 1923-1931
tumor necrosis factor plama measurements as, in lymphoma, 499-508
Proliferating-cell nuclear antigen expression, as prognostic factor, in thyroid cancer, 3458-3463
Proliferation index, 3113
Proliferation index area, 3113
Prolymphocytic leukemia, de novo B-cell, cladribine in, 37-43
Promyelocytic leukemia gene, in three major breakpoint regions, 1787
Prophylaxis, with acyclovir, in acute myeloid leukemia, 2269-2274
Prostate cancer

bicalutamide in, 2928-2938
bone marrow micrometastases in, 3451-3457
external-beam irradiation in, 223-229
familial, 1478-1480
hormone-refractory
mitoxantrone in, 410-411
new paradigm in, 384-387
old paradigm in, 383-384
metastatic hormone-refractory, paclitaxel, estramustine regimen in, 3156-3163
natural history of, following radiotherapy, 230-238
paclitaxel, estramustine regimen in, 3156-3163
prostate-specific antigen in, and adjuvant therapy, 1465-1469
prostate-specific antigen mRNA in, 2705
radiotherapy in, 3214-3222
increasing prostate-specific antigen profile following, 230-238
second-line hormones in, 382-388
suramin plus androgen blockade in, 1470-1477
suramin, leuprolide, flutamide regimen in, 1470-1477
trials in, end points in, 382-383
unfavorable-prognosis, goserelin in, 1013-1021
Prostate-specific antigen
adjuvant therapy and, in prostate cancer, 1465-1469
early failure of, predictors of, 1467
increasing, following prostate cancer radiotherapy, 230-238
mRNA, 2705
Prostatectomy, bone marrow circulating prostate cells and, 3451-3457
PSC-833, in multidrug resistance gene blockade, 1796-1802
PSC-833, mitoxantrone, etoposide regimen, in acute myelogenous leukemia, 1796-1802
Public awareness, of phase I trials, 857
Publication bias, induction chemotherapy and, 2052-2053
Pulmonary aspergillosis, invasive
early CT scan for, in neutropenics, 139-147
survival in, prognostic factors for, 144
Pyoderma gangrenosum, 407
Pyridinoline, 131-138

Quality of life
following chemotherapy, for liver metastases, 2022-2029
following external-beam irradiation, in prostate cancer, 223-229
Quality-adjusted life expectancy model, 874, 876
Quality-of-life indicator, health-related, 228
Quality-of-life instrument, self-report, in breast cancer, 974-986

Race, breast cancer survival and, 2329-2337
Radiation
absorbed-dose, following iodine-labeled CC49 radioimmunolocalization, 1525
dosing of, in HD, 2279, 2280
Radiation oncology standardized test, sex bias in, 2722-2727
Radiochemotherapy
alternating *v* sequential, in SCLC, 2840-2849
in anal cancer, 2040-2049
in limited-stage thymoma, 3093-3099
Radioimmunoassay, Truquant BR, in recurrent breast cancer detection, 2322-2328
Radioimmunolocalization, iodine-labeled CC49 monoclonal antibody for, 1522
Radioresistance, markers of, in squamous cell carcinoma, 1030-1038

Radiotherapy
accelerated *v* delayed hyperfractionated, 893-900
androgen suppression adjuvant to, 1013-1021
chemoradiotherapy *v*, in esophageal cancer, 277-284
chemotherapy plus, *see* Chemoradiotherapy
in collagen vascular disease, 2728-2735
cranial, in T-cell acute lymphoblastic leukemia, 2786-2791
cyclophosphamide, doxorubicin, etoposide regimen plus, 2840-2849
different techniques for, comparison of, 3082
early *v* late, in SCLC, 893-900
endocavitary, in rectal adenocarcinoma, 3241-3248
extended- *v* involved-field, in HD, 1736-1744
external-beam, *see* External-beam radiation therapy
fields for, in HD, 2279
in glottic larynx cancer, 2394-2402
high-dose, *v* combination chemoradiotherapy trade-off, 333-335
increasing prostate-specific antigen profile following, in prostate cancer, 230-238
initial *v* late, with chemotherapy, in SCLC, 3030-3037
low- *v* high-dose, and trade-off results, 332-333
low-dose total-nodal, with MOPP-ABVD regimen, in HD, 2769-2779
mitomycin plus, in head and neck cancer, 268-276
in NSCLC, 3009-3011
postlumpectomy, patient preference in, 3192-3200
prior, stem-cell mobilization and, 535-546
in prostate cancer, 3214-3222
regional, with vinblastine methotrexate, bleomycin regimen, 1736-1744
subtotal lymphoid *v* regional, 1736-1744
10-Gy boost in, for breast cancaer, 963-968
timing of, in low-grade glioma, 1294-1301
tobacco use and, 2195
with external-beam irradiation, *see* External-beam irradiation
with tangential fields, in breast cancer, 1348-1353
Radiotherapy, carmustine, cisplatin regimen
for astrocytoma, 2596-2603
survival following, 2598-2601
toxicity of, 2601
Radiotherapy, cisplatin, doxorubicin, cyclophosphamide regimen
in limited-stage thymoma, 3093-3099
survival following, 3097
toxicity of, 3096
Radiotherapy, cisplatin, FU regimen, in esophageal cancer, 277-284
Radiotherapy, FU, folinic acid regimen
in rectal cancer, 2030-2039
survival following, 2035, 2036
toxicities of, 2033-2034
Radiotherapy, FU, levamisole regimen
in rectal cancer, 2030-2039
toxicities of, 2033-2034, 2035, 2036
Radiotherapy, FU, levamisole, folinic acid regimen
in rectal cancer, 2030-2039
toxicities of, 2033-2034, 2035, 2036
Radiotherapy, FU, streptozocin, cisplatin, folinic acid regimen
in pancreatic cancer, 2920-2927
survival following, 2924-2925
Radiotherapy, methotrexate, cisplatin, vinblastine, surgery regimen
for invasive bladder cancer, 1022-1029
protocol for, 1024

survival following, 1025-1026
Radiotherapy, mitomycin regimen
in head and neck cancer, 268-276
hematologic toxicity of, 271
nonhematologic toxicity of, 271
survival following, 272
Radiotherapy, paclitaxel regimen
in gastric cancer, 901-907
hematologic toxicity of, 904
in pancreatic cancer, 901-907
Radiotherapy, paclitaxel, cisplatin regimen
hematologic toxicity of, 1413
in NSCLC, 1409-1417
nonhematologic toxicity of, 1414
survival following, 1414
Raloxifene
formula of, 848
overview of, 847-848
ras, drug resistance and, in NSCL, 285-291
Raynaud's phenomenon, associated with cisplatin-based chemotherapy, 2446
RB-1 gene
cloning of, 3302
mutations of, 3305
Real-time fine-needle aspiration biopsy, ultrasound-guided, in pancreatic lesions, 1439-1443
Rectal adenocarcinoma, endocavitary irradiation in, 3241-3248
Rectal cancer, adjuvant postoperative therapy for, 2030-2039
Reed-Sternberg cell, in spinal fluid, 3289-3290
Renal cell cancer
adoptive immunotherapy in, 796-807
IL-2 with tumor necrosis factor receptor immunoglobulin G chimera in, 1052-1062
iodine-labeled chimeric monoclonal antibody G250 in, 1529-1537
thymidine phosphorylase expression in, 2570-2578
vaccine-primed lymph node cells in, 796-807
Renal dysfunction, methotrexate-induced, carboxypeptidase-G2 in, 2125-2134
Renal function, high-dose cytarabine and, 833-839
Replens, as vaginal moisturizer, in breast cancer, 969-973
Reproductive counseling, 3494
Residual disease
analysis of, in chronic myeloid leukemia, 34
gallium scan for, in HD, 518-527
Retinoblastoma
hereditary, 3302
historical perspective of, 3301-3304
pathway of, 3304-3307
sporadic, 3302
therapeutic implication in, 3307-3308
Retinoblastoma protein
alterations of, 3304-3305
in cancer pathogenesis, 3301-3312
function of, model for, 3302-3304
p53 and, 3307
phosphorylation of, 3303
as prognostic factor, in thyroid cancer, 3458-3463
Retinoblastoma-E2F pathway, 3304
Retinoic acid receptor, 790-795
Retinoid X receptor, 790-795
Retrospective study, in evidence-based medicine era, 1289-1290
Reverse-transcriptase polymerase chain reaction
of bone marrow, 2704
for bone marrow micrometastases, 3451-3457
for c-*mpl* mRNA, in leukemia blasts, 2264, 2265
in cervical cancer, 1008-1012
in chronic myeloid leukemia residual disease, 26
for circulating tumor cell detection, 583-588
in direct gene transfer, 343
in lung cancer metastatic cell detection, 3388-3393
in micromatestatic cancer cell detection, 2701-2708
of tyrosinase messenger RNA, 2818-2825, 2826-2831
Rhabdomyosarcoma
bladder preservation in, 69-75
of buccal mucosa, 3078
gene fusions in, 1831-1836
of tongue base, 3079
of vagina, 3078
Risedonate
adverse effects of, 958
for chemotherapy-induced bone loss, 955-962
Risk factor, cardiac, 1323
RT-PCR, *see* Reverse-transcriptase polymerase chain reaction

S-phase cell fraction
in acute leukemia, 50
in colorectal liver metastases, 2008-2014
SAF-m, plus I-Mel-2, for metastatic melanoma, 2103-2110
Salvage chemotherapy, with paclitaxel, for oligodendrogliomas, 3427-3432
Sarcoma(s)
adult, prognostic marker in, 3249-3257
Ewing's, *see* Ewing's sarcoma
of extremity, 646-652, 3481-3487
high-dose ifosfamide for, 2378-2384
ifosfamide, G-CSF regimen for, 2378-2384
isolated limb perfusion, tumor necrosis factor-alpha, interferon, melphalan regimen for, 2174-2175
Kaposi's, *see* Kaposi's sarcoma
liposomal doxorubicin in, 2111-2117
retroperitoneal, long-term survival in, 2832-2839
soft tissue
epidoxorubicin, ifosfamide, GM-CSF regimen in, 1418-1426
high-dose-rate brachytherapy in, 3075-3084
prognostic marker in, 3249-3257
Scientific evidence, levels of, for therapeutic interventions, 3050
SCLC, *see* Small-cell lung cancer
Second malignancy
acute myelogenous leukemia as, following etoposide, 1583-1586
following breast cancer therapy, 1873
following HD, 2247-2253
following lymphocyte-predominant HD therapy, 3064
following mechlorethamine, 2247-2253
mortality from, in long-term cancer survivors, 2211
overview of, 2247-2248
Second malignancy risk
following bleomycin, etoposide, cisplatin regimen, 1842
following deoxycoformycin therapy, 1803-1810
following etoposide, cisplatin regimen, 1842
following interferon alfa therapy, 1803-1810
following two-chlorodeoxyadenosine therapy, 1803-1810
in hairy cell leukemia, 1803-1810

incidence of, in hairy cell leukemia, 1803-1804
Selection bias, in clinical trials
of autologous BMT, 3169-3170
of high-dose chemotherapy, 3171-3177
Seminoma
clinical staging of, 597-598
recurrent, vinblastine, ifosfamide, cisplatin regimen in, 1427-1431
Sentinel lymphadenectomy, in breast cancer, 2345-2350
Sentinel node
in breast cancer, 2345-2350
metastases to, detection of, 2347
Sex
survival advantage threshold and, 336
survival by, following fludarabine, 462
Sex bias, in radiation oncology standardized tests, 2722-2727
Sexual dysfunction
chemotherapy-induced, in nonseminomatous testicular cancer, 2442-2448
literature review of, in testicular cancer, 2446
in long-term testicular cancer survivors, 1444-1448
Sexual function, bicalutamide impact on, 2934
Sexual symptom, following external-beam irradiation, in prostate cancer, 226-227
Sexuality, in long-term testicular cancer survivors, 1444-1448
Shipp regimen, 1727
Sialyl Lea
expression of, in gastric cancer, 816-825
as prognostic factor, 816
Single-photon emission computed tomography
of abdomen, in HD, 523
of iodine-labeled CC49 radioimmunolocalization, in pancreatic cancer, 1523
Sinus histiocytosis, with massive lymphadenopathy, 2176
Small-cell lung cancer
alternating *v* sequential radiochemotherapy in, 2840-2849
antineuronal antibodies in, 2866-2872
cyclophosphamide, doxorubicin, etoposide regimen in, plus radiotherapy, 2840-2849
cyclophosphamide, epidoxorubicin, etoposide, cisplatin, GM-CSF regimen in, 2082-2089
dose-intense chemotherapy in, 2985, 2986-2988
early *v* late radiotherapy in, 893-900
extensive-stage, high- *v* standard-dose chemotherapy in, 2082-2089
immunotoxin therapy of, 723-734
limited-stage
initial *v* late chest irradiation in, 3030-3037
warfarin in, 3378-3387
N901-bR therapy of, 723-734
paclitaxel, carboplatin, etoposide regimen in, 3464-3470
relapsed, cisplatin, vincristine, doxorubicin, etoposide regimen in, 292-296
stem-cell transplantation in, with dose-intense chemotherapy, 2992
topotecan in, 2090-2096
Smoking, among children, 2194-2204
SN-38, 1505
SN-38G, 1505
Sociodemographic factor, in BMT access, 2644-2651
Socioeconomic status, cancer survival and, 1680-1689
Soft tissue sarcoma
advanced, epidoxorubicin, ifosfamide, GM-CSF regimen in, 1418-1426
childhood, high-dose-rate brachytherapy in, 3075-3084
Ewing's, in childhood, 574-582
grading in, 350-362
high-dose ifosfamide for, 2378-2384
prognostic marker in, 3249-3257
retroperitoneal, long-term survival in, 2832-2839
stage IIB extremity, preoperative chemotherapy for, 3481-3487
Southern blot analysis
of adult T-cell leukemia cells, 1779
quantitative, for *bcr* gene rearrangements, 26-36
for therapy monitoring, 27
Spearman's rho, 332, 336, 337
Spermatogenesis
following chemotherapy, in testicular germ cell cancer, 239-245
following mitoxantrone, vincristine, vinblastine, prednisone regimen, 3488-3495
prognostic model for, in recovery, 244
recovery of, following cisplatin combination chemotherapy, 242, 243
Splenectomy
blood loss in, 54
in chronic lymphocytic leukemia, 52-60
complications following, 55
in cytopenic patients, and hematologic response, 56
hematologic response criteria for, 54
hematologic response following, 55
Rai stage IV of, survival in, 57
survival following, 56-57
Squamous cell cancer
of cervix, 165-171
cisplatin, FU, folinic acid regimen in, 3100-3110
of head and neck, 268-276
of larynx, p53 expression in, 3111-3120
radioresistance in, markers of, 1030-1038
stage T3, of glottic larynx, radiotherapy for, 2394-2402
Staging
cancer, overview of, 3085
prognostic, in germ cell cancer, 594-603
in Wilms' tumor, with chest CT, 2631-2635
Standard of care, in breast cancer, 1401-1408
Standard of practice, induction chemotherapy as, in head and neck cancer, 2050-2055
Staphylococcal enterotoxin A fusion protein, 1994-2007
laboratory assessment of, 1999-2000
toxicity of, 1999
Stealth liposome
overview of, 3185
phase II trial of, 3185-3191
Stem-cell collection, 3259-3260
see also Peripheral-blood stem-cell collection
Stem-cell transplantation, *see* Peripheral-blood stem-cell transplantation
Stomach
adenocarcinoma of, 818
MALT of, ultrasound evaluation of, 1761-1766
normal wall of, ultrasonography of, 1762
Streptozocin, emetogenic potential of, 105
Streptozocin, radiotherapy, FU, cisplatin, folinic acid regimen in pancreatic cancer, 2920-2927

survival following, 2924-2925
Subtotal outpatient transplantation, 11-17
Suicide, physician-assisted, and euthanasia, comparative study of, 418-427
Suramin, leuprolide, flutamide regimen, in prostate cancer, 1470-1477
Surgery
chemoradiotherapy plus
in esophageal cancer, 701-711
for pancreatic cancer, 928-937
survival following, 706
toxicity of, 705
in disseminated nonseminomatous germ cell tumor, following chemotherapy, 1455-1464
folinic acid plus FU following, in colon cancer, 246-250
Surgery, cyclophosphamide, vincristine, doxorubicin, cisplatin, etoposide regimen, in neuroblastoma, 3433-3440
Surgical second look, in ovarian cancer, 994-999
Surveillance, in stage I ovarian germ cell tumor, 620-624
Surveillance scanning, in medulloblastoma, 1811-1813
Survey(s)
of physician attitude, toward assisted suicide and euthanasia, 418-427
of physician-assisted suicide and euthanasia, 418-427
Survival
cancer, socioeconomic status and, 1680-1689
chemotherapy for, in craniofacial osteosarcoma, 363-367
cost and, 1005
by cytogenetic category, in promyelocytic leukemia, 1791
in differentiated thyroid carcinoma, 2067-2075
factors for, in low-grade glioma, 3129-3140
following autotransplants, 1874, 1876
following BMT, in leukemia, 1773
following medulloblastoma, and cyclophosphamide, 1819
following second malignancy, in hairy cell leukemia, 1807
in gastric cancer, 3471-3480
human papillomavirus16 E7 protein antibodies and, in cervical cancer, 610-619
in melanoma, 2172
long-term, in retroperitoneal sarcoma, 2832-2839
quality-adjusted life expectancy and, 874-875
race and, in breast cancer, 2329-2337
treatment toxicity *v*, in NSCLC, 330-340
Survival advantage threshold, 334-335, 337
patient characteristics and, 336
Survivor(s)
negative mood in, 547-556
late mortality of, 2205-2213
unintentional injuries in, 2210
Sweet's syndrome, 860-861

t(9;22)(q34;q11), as prognostic factor, in acute lymphoblastic leukemia, 2231-2237
T-cell acute lymphoblastic leukemia, childhood, cranial radiotherapy in, 2786-2791
T-cell prolymphocytic leukemia
CAMPATH-1H therapy in, 2667-2672
CD52 antibody therapy in, 2667-2672
overview of, 2667
T-cell receptor V-beta repertoire, analysis of, 1997-1998
Tamoxifen
adjuvant, referrals for, 220
adjuvant chemotherapy and, in node-positive breast cancer, 1385-1394
bcl-2 and, 1916-1922
in breast cancer, 2302-2311
cyclophosphamide, methotrexate, FU regimen plus, 1385-1394, 2302-2311
formula of, 842
response to, and p53, 1916-1922
use of, 219-220
Tamoxifen, doxorubicin, cyclophosphamide, estrogen, methotrexate, FU regimen, in breast cancer, 2873-2881
TAT-59
formula of, 842, 846
Taxol, *see* Paclitaxel
Taxotere, *see* Docetaxel
Telomerase, activity of, in cervical cancer, 1932-1937
Telomere repeat amplification protocol assay, in cervical cancer, 1932-1937
Teniposide, cyclophosphamide, prednisone regimen
in aggressive NHL, 2945-2953
survival following, 2951
Teniposide, cyclophosphamide, prednisone, pirarubicin regimen
in aggressive NHL, 2945-2953
survival following, 2951
Test-retest evaluation, 332, 336, 337
Testicular cancer
brain metastases of, chemoradiotherapy for, 1449-1454
chemotherapy for, fertility following, 239-245
dose-intense chemotherapy in, 2983, 2988
etoposide, cisplatin *v* bleomycin, etoposide, cisplatin regimen in, 1837-1843
good-prognosis, bleomycin combination chemotherapy in, 1837-1843
long-term survivors of, fertility in, 1444-1448
stem-cell transplantation in, with dose-intense chemotherapy, 2991
Thioguanine
in Berlin-Frankfurt-Munster therapy, 2223
emetogenic potential of, 105
Thioguanine, procarbazine, dibromodulcitol, lomustine, FU, hydroxyurea regimen
for brain metastases, 1063-1070
response to, 1065
survival following, 1066
toxicity of, 1067
treatment scheme for, 1064
Thiotepa, cyclophosphamide, carboplatin, stem-cells, filgrastim regimen, multiple-cycle, in breast cancer, 674-683
Thoracic large-field irradiation, with amifostine, cisplatin, vinblastine regimen, in NSCLC, 2850-2859
Thrombocytopenia, chemotherapy-induced, IL-11 in, 3368-3377
Thymic B-cell lymphoma, 1646-1653
Thymidine, toxicity of, 2127-2128
Thymidine phosphorylase expression
age and, 2576
microvessel density and, 2576
as prognostic factor, in renal cell cancer, 2570-2578
tumor size and, 2576
Thymidine, carboxypeptidase-G2, folinic acid rescue, in methotrexate-induced nephrotoxicity, 2125-2134

Thymidylate synthase expression
in early breast cancer, 1923-1931
intratumoral, quantitation of, 3223-3229
Thymidylate synthase inhibitor
antifolate, structure of, 391
basic characteristic of, 391
in cancer therapy, 389-400
direct, 390-396
indirect, 396-397
Thymoma
classification of, 3095
limited-stage, cisplatin, doxorubicin, cyclophosphamide, radiotherapy regimen in, 3093-3099
overview of, 3093-3094
Thyroid cancer
differentiated, 2067-2075
proliferating-cell nuclear antigen expression in, 3458-3463
recurrence in, retinoblastoma protein for, 3458-3463
Tirapazamine, pharmacokinetic parameters of, 777
Tirapazamine, cisplatin regimen
antiemetic regimens used with, 776
nausea associated with, 776
phase I trial of, 773-780
vomiting associated with, 776
Tissue biopsy, following iodine-labeled CC49 radioimmunolocalization, 1524
Tissue polypeptide antigen, serum, in bladder cancer, 3446-3450
Tobacco use
among pediatric cancer patients, 2194-2204
antineoplastic therapeutic drugs and, 2195
complications of, 2195-2196
comprehensive assessment of, 2200
health care provider-delivered interventions in, 2201
intervention barriers in, 2201
medical variables and, 2197
NCI interventions for, in childhood, 2198-2199
nurse-delivered interventions in, 2198
pediatric, smoking interventions in, 2199-2201
physician-delivered interventions in, 2198
psychosocial variables and, 2197
sociodemographic variables and, 2196-2197
Tomudex, 391
acquired resistance to, 393-394
clinical evaluation of, 395-396
DNA damage induced by, 392-393
in drug combination, 394-395
folinic acid impact on, 392
in vivo antitumor activity of, 394
phase II trials with, 395
thymidine impact on, 392
Topotecan
dosing of, 45
hematologic toxicity of, 1089
maximal-tolerated dose of, 149
nonhematologic toxicity of, 1089
oral, phase I trial of, 1087-1093
paclitaxel *v*, in ovarian cancer, 2183-2193
pharmacokinetic parameters of, 153, 183
pharmacokinetics of, 1089-1091
in SCLC, 2090-2096
twenty-one day twice-daily oral administration of, 1087-1093
Topotecan, cyclophosphamide regimen
hematologic toxicity of, 151-152
nonhematologic toxicity of, 151
pharmacokinetic studies of, 151-152
in refractory cancer, 148-157
Topotecan, cytarabine regimen
in acute leukemia, 44-51
antileukemic activity of, 48
nonhematologic toxicity of, 47
toxicity of, 47-48
Topotecan, paclitaxel regimen
antitumor activity of, 183
dose-escalation scheme for, 180
neutropenia following, 181
phase I trial of, in ovarian cancer, 177-186
thrombocytopenia following, 182
Topotecan, paclitaxel, G-CSF regimen
antitumor activity of, 183
dose-escalation scheme for, 180
neutropenia following, 181
phase I trial of, in ovarian cancer, 177-186
thrombocytopenia following, 182
Toremifene
formula of, 842
history of, 843-844
Total outpatient transplantation, 11-17
Total-nodal radiotherapy, with MOPP-ABVD regimen, in HD, 2769-2779
Toxicity
expectation of, in phase I trial participation, 855
of treatment, *v* survival, in NSCLC, 330-340
Trade-off technique
in breast cancer, 3192-3200
displacement-delay, 3194
recurrence risk-side effect, 3194
Transitional-cell carcinoma
docetaxel in, 1853-1857
gallium nitrate, FU regimen in, 2449-2455
methotrexate, vinblastine, doxorubicin, cisplatin regimen in, 2449-2455
Transplant-related mortality
in leukemia, 1772
relative risk of, by donor type, 1774
Transplantation
organ, Kaposi's sarcoma following, 2371-2377
subtotal outpatient, 11-17
total outpatient, 11-17
trials of, selection bias in, 3169-3170
Transurethral resection, for invasive bladder cancer, 1022-1029
Transurethral resection, methotrexate, cisplatin, vinblastine, radiotherapy regimen
for invasive bladder cancer, 1022-1029
protocol for, 1024
survival following, 1025-1026
Treatment trade-offf, in NSCLC, 330-340
Trimetrexate, FU, folinic acid regimen
in colorectal cancer, 915-920
hematologic toxicity of, 917
nonhematologic toxicity of, 917
survival following, 918
Truquant BR radioimmunoassay, in recurrent breast cancer detection, 2322-2328

Tumor marker(s)
guidelines for, 2175-2176
messenger RNA as, in melanoma, 2826-2831
serum tissue polypeptide antigen as, in bladder cancer, 3446-3450
Tumor necrosis factor
plasma measurement of, in lymphoma, 499-508
receptor immunoglobulin G chimera, with IL-2, 1052-1062
Tumor necrosis factor-alpha, isolated limb perfusion, interferon, melphalan regimen, in soft tissue sarcomas, 2174-2175
Tumor size, thymidine phosphorylase expression and, 2576
Tumor-node-metastasis system, definition of, 3001
Turcot's syndrome, 2744-2758
Two-chlorodeoxyadenosine, second malignancy risk following, 1803-1810
Two-hit hypothesis, 3301-3304
Tyrosinase, messenger RNA
for circulating melanoma cell detection, 2818-2825
as melanoma tumor marker, 2826-2831

Ulceration, in cutaneous melanoma, 1042-1043
Ultrasound, endoscopic, *see* Endoscopic ultrasound
Unknown primary tumor, natural history of, 2056-2066
Unorthodox cancer therapy, 401-406
government and, 402
physician abandonment and, 403
physician perceptions of, 402
physician responsibility and, 402-403
physician-patient dialogue and, 403
practitioners of, 402
prevalence of, 401
questionable methods in, 404-405
reliable information source and, 403-404
testimonials and, 404
users of, 402
Unresectable disease, definition of, 3001
Uracil-tegafur, 397
Uridine, in FU rescue, 1511-1517
Urinary bladder, preservation of
combined modality therapy for, 1022-1029
in rhabdomyosarcoma, 69-75
Urinary calcium, as bone resorption marker, 131-138
Urokinase
heparin plus, 2710
low-dose, in venous access device fibrinous obstruction, 2709-2714
Urothelial cancer
cisplatin in, 2564-2569
gemcitabine in, 3441-3445
phase II trial of, 3394-3398
methotrexate, vinblastine, doxorubicin, cisplatin regimen in, 2564-2569
previously treated advanced, ifosfamide in, 589-593
Urothelial tract, transitional-cell cancer of, docetaxel in, 1853-1857

Vaccine(s)
antiidiotype melanoma, 2103-2110
autologous hapten-modified melanoma, 2359-2370
cancer, autologous virus-modified, 1354-1366
combination therapy protocol for, 1355-1356
monotherapy protocol for, 1355
preparation of, 1356
purification of, efficiency of, 1357
Vaginal moisturizer, in breast cancer, 969-973
Vascular endothelial growth factor, in gastric cancer, 826-832
Velocity of circumferential fiber shortening, following daunorubicin, 62-66
Venous access device, obstruction of, urokinase for, 2709-2714
Vessel density, as prognostic factor, in lung cancer, 2858-2865
Vinblastine
emetogenic potential of, 105
preoperative, in esophageal cancer, 709
Vinblastine, amifostine, cisplatin, radiotherapy regimen, in NSCLC, 2850-2857
Vinblastine, cyclophosphamide, procarbazine, prednisone regimen
in HD, 2652-2658
survival following, 2655-2656
Vinblastine, cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, dacarbazine, radiation regimen, 2275-2287
Vinblastine, ifosfamide, cisplatin regimen, in seminoma, 1427-1431
Vinblastine, mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin regimen, 1638-1645
Vinblastine, mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, dacarbazine regimen
in HD, 1638-1645
relapse following, 528-534
with total-nodal irradiation, 2769-2779
Vinblastine, mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, dacarbazine, radiotherapy regimen, 3338-3346
Vinblastine, methotrexate, bleomycin regimen, with regional radiotherapy, 1736-1744
Vinblastine, methotrexate, cisplatin, radiotherapy, surgery regimen
for invasive bladder cancer, 1022-1029
protocol for, 1024
survival following, 1025-1026
Vinblastine, methotrexate, doxorubicin, cisplatin regimen
survival following, 2566-2568
in transitional-cell carcinoma, 2449-2455
in urothelial cancer, 2564-2569
Vinblastine, mitoxantrone, vincristine, prednisone regimen
in HD, 3488-3495
spermatogenesis following, 3488-3495
Vincristine
in Berlin-Frankfurt-Munster therapy, 2223
in combination chemotherapy
for breast cancer, 2318
for NHL, 1722-1729
emetogenic potential of, 105
Vincristine, all-*trans* retinoic acid, idarubicin, mercaptopurine, methotrexate, prednisone regimen, without cytarabine, 483-490
Vincristine, bleomycin regimen, in Kaposi's sarcoma, 653-659
Vincristine, cisplatin, doxorubicin, etoposide regimen
in SCLC, 292-296
survival following, 294
worst toxicities of, 295
Vincristine, cyclophosphamide regimen
fertility following, 2641
for gestational trophoblastic tumor, 2636-2643
second malignancy following, 2640
Vincristine, cyclophosphamide, doxorubicin, cisplatin, etoposide, surgery regimen, in neuroblastoma, 3433-3440

Vincristine, cyclophosphamide, doxorubicin, prednisone regimen
early restaging gallium scan following, in NHL, 1631-1637
in large-cell lymphoma, 1713-1716
Vincristine, cyclophosphamide, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, dacarbazine, radiation regimen, 2275-2287
Vincristine, dactinomycin, cyclophosphamide regimen, in extraosseous Ewing's sarcoma, 574-582
Vincristine, dactinomycin, cyclophosphamide, doxorubicin regimen, in extraosseous Ewing's sarcoma, 574-582
Vincristine, doxorubicin, bleomycin regimen
following transplantation, 2371-2377
in Kaposi's sarcoma, 653-659
Vincristine, doxorubicin, prednisone, etoposide, radiotherapy regimen
in HD, 2652-2658
survival following, 2655-2656
Vincristine, ifosfamide, actinomycin D regimen
for Ewing's sarcoma, 2612
for primitive neuroectodermal tumor, 2612
survival following, 2613-2617
Vincristine, mechlorethamine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine regimen, in HD, 1638-1645
Vincristine, mechlorethamine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, dacarbazine regimen
in HD, 1638-1645
relapse following, 528-534
with total-nodal irradiation, 2769-2779
Vincristine, mechlorethamine, procarbazine, prednisone, doxorubicin, bleomycin, vinblastine, dacarbazine, radiotherapy regimen, 3338-3346
Vincristine, methotrexate, doxorubicin, cyclophosphamide, prednisone, bleomycin regimen, in late-relapse lymphoma, 1745-1753
Vincristine, mitoxantrone, vinblastine, prednisone regimen
in HD, 3488-3495
spermatogenesis following , 3488-3495
Vincristine, procarbazine, prednisone, doxorubicin, procarbazine regimen, in HD, 2247-2253
Vinorelbine
dose escalation of, 887
emetogenic potential of, 105
as neoadjuvant therapy, in advanced cervical cancer, 604-609
in NSCLC, 885
practice guideline for, in stage IV NSCLC, 3053
toxicity of, 606
Vinorelbine, G-CSF regimen, in breast cancer, 1395-1400
Vinorelbine, ifosfamide, G-CSF regimen
in NSCLC, 884-892
survival following, 888-889
toxicity of, 887-888
Vomiting
dolasetron, ondansetron, dexamethasone regimen in, 2966-2973
irinotecan-induced, treatment of, 1081-1082
postchemotherapy, determinants of, 116-123

Wait time, maximal acceptable, 3196
Waldenström, Jan Gosta, 1720-1721
War on cancer, 867-869
Warfarin, in SCLC, 3378-3387
Wedge resection, of liver metastasis, 939
Whipple resection, in pancreatic cancer, 904
Whole-body hyperthermia
41.8:C, 158-164
melphalan with, in cancer, 158-164
Whole-body scan, following iodine-labeled chimeric G250 monoclonal antibody, 1532-1533, 1536
Whole-body scintigraphy, with Z-MIVE, in estrogen receptor-positive breast cancer, 2539
Wilms' tumor, pediatric, chest CT in, 2631-2635

Yttrium, future uses of, 1518-1528

Z-MIVE, iodine-123 labeling for, in estrogen receptor imaging, 2536-2545
Z-MIVE scintigraphy, in estrogen receptor-positive breast cancer, 2536-2545
Zollinger-Ellison syndrome, 2424
MRI in, 2425, 2426